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Summary
The pro-inflammatory anaphylatoxin C5a exerts its biological actions via the C5a receptor 
(C5aR), a G-protein-coupled-receptor (GPCR). Cholesterol, a crucial component of 
biological membranes, has previously been shown to regulate expression and function of 
numerous GPCRs. As statin therapy is widely used to reduce serum cholesterol levels, it 
was hypothesised that statins can exert anti-inflammatory effects by down regulation 
expression and/or function of the C5aR.
This thesis first investigated how basal human C5aR expression was regulated. It 
was shown that the majority of the -2Kbp promoter region is dispensable for transcription of 
the C5aR and that the main regulatory domains are localised in the first 200 bp of the 
promoter region. Furthermore CCAAT and NFAT motifs are important for the transcriptional 
control of the human C5aR, however the transcription factors which bind to these sites could 
not be identified.
A model system to measure C5aR expression and function was set up using two pro- 
monocytic U937 sub-cell lines, which demonstrated that dibutyryl-cyclic-AMP was the best 
inducer of the C5aR, but only in one of the cell lines. Induction of the C5aR made these cells 
more responsive to C5a induced intracellular calcium-release and IL-8 and MMP-9 secretion.
Investigating possible effects of cholesterol and modulation of cholesterol on C5aR 
expression and function showed that statins did not affect expression and function of basal 
levels of C5aR in monocytes or U937 cells, but reduced induced C5aR expression. 
Concomitantly C5a induced release of intracellular calcium and secretion of IL-8 reduced, 
however C5a induced MMP-9 secretion increased. This reduction was due to inhibition of 
isoprenoid biosynthesis rather than inhibition of cholesterol biosynthesis.
Using sucrose gradient floatation it was shown that the C5aR is unlikely to reside in a 
lipid raft region of the plasma membrane making it less likely to be susceptible to membrane 
cholesterol content.
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Regulation of C5aR expression and function: potential 
modulation by lipid-lowering drugs
Complement activation leads to the release of the potent pro-inflammatory anaphylatoxin 
C5a, which exerts its biological actions via the C5a receptor (C5aR), a G-protein coupled 
receptor. Over expression or under regulation of C5a and the C5aR has been implicated in a 
variety of pathologies, including ischaemia reperfusion injury. Cholesterol, a major risk factor 
for cardiovascular disease, is a crucial component of biological membranes. Furthermore 
cholesterol has been shown to regulate expression and function of numerous GPCRs. Statin 
therapy is the most widely used therapeutic strategy to lower serum cholesterol levels. 
Evidence suggests that statins also exert beneficial anti-inflammatory effects, thus further 
improving cardiovascular disease outcome. The principal aim of this thesis was to determine 
if the C5aR expression and function can be modulated by cholesterol. It is hypothesised that 
statins can exert anti-inflammatory effects by down regulation of expression and/or function 
of the receptor for the potent pro-inflammatory anaphylatoxin C5a, C5aR. pi
Chapter 1 
General Introduction
1.1 Complement system
Complement (C) is a crucial part of innate immunity. It was identified in the late nineteenth 
century as a heat labile fraction of serum which complemented the antibody-mediated killing 
of bacteria. Since then more than 30 soluble and cell surface proteins have been identified, 
which together interact in a tightly controlled manner to achieve its main physiological 
functions in host defence against infection, bridging the innate and adaptive immunity and 
waste disposal (Walport, 2001b, Walport, 2001a).
1.1.1 Complement activation
C activation can be achieved by three pathways: the classical pathway (CP), alternative 
pathway (AP) and lectin pathway (LP) (figure 1.1).
Activation of the CP is achieved by the recognition subunit C1q of the C1 complex. 
C1q contains six large globular heads, which bind to the Fc regions of immobilised antigen 
bound IgG or IgM antibodies. As well as being activated by immune complexes, C1q can 
also bind other ligands including fragments of cellular and subcellular membranes (e.g. 
mitochondria membrane), modified host proteins and phospholipids, and C-reactive protein 
and serum amyloid protein, of the pentraxin family (reviewed in (Kojouharova et al., 2010)).
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Activator binding to C1q induces a conformational change that triggers the activation of C1r2) 
which in turn cleaves C1s2 within the C1 complex.
Activation of the AP allows the rapid and spontaneous deposition of complement C3b 
on cell surfaces. This is achieved by the spontaneous hydrolysis of C3, which then binds to 
factor B to form the C3 convertase of the AP following cleavage by factor D. As activation of 
the AP lacks specificity, host cells are protected from C3b disposition by the expression of 
complement regulators, such as CR1, DAF and MCP, on their cell surface. However, foreign 
surfaces are unable to control C3b deposition due to the lack of these regulators, which 
results in the C3 positive feedback amplification loop.
The LP is the most recently discovered and least understood pathway. This pathway 
employs germline-encoded pattern recognition receptors, mannose-binding lectin (MBL) and 
ficolin, which bind to pathogen associated molecular patterns, such as simple carbohydrates 
and N-acetyl glucosamine groups, present on the pathogen cell surface (Dunkelberger and 
Song, 2010). Similarly to the CP activation, the LP activation results in the generation of 
C4bC2a on pathogen cell surfaces, however this is mediated via the MBL-associated serine 
protease (MASP) complex instead of the C1 complex (reviewed by (Gal et al., 2009)).
More recently it has also been suggested that complement activation could occur by 
the direct cleavage of either C3 or C5 by serum protease unrelated to complement such as 
kallikrein and thrombin (Huber-Lang et al., 2006, Dunkelberger and Song, 2010).
1.1.2 The complement cascade
Activation of the complement cascade leads to the proteolytic cleavage of inactive 
proenzymes to their active form (figure 1.1). Although C activation occurs via three distinct 
pathways, they all converge at the point of C3 activation by the C3 convertases.
The activation of complexes C1r2s2, via the CP, or MBL/MASP and ficolin/MASP, via 
the LP, leads to the cleavage of C4 and C2 to form the C3 convertase C4b2a and released 
fragments C4a and C2b.
The spontaneous formation of a single C3 convertase (C3(H20)Bb), via the AP, can 
lead to C3b deposition on activating surfaces by cleavage of C3. The deposition of C3b can 
lead to the formation of the predominant C3 convertase, C3bBb, of the AP when deposited in 
the presence of factor B and factor D. Furthermore this C3 convertase can be stabilised by 
properdin. Together both these C3 convertases would rapidly activate all C3 and factor B via 
this positive feedback amplification loop.
The formation of the C3 convertase C4b2a, via the CP or LP, or C3(H20)Bb and
C3bBb, via the AP, leads to the proteolytic cleavage of C3 to C3b and the released fragment
C3a. The addition of C3b to the C3 convertases leads to the formation of the C5
convertases; C4bC3bC2a of the CP and LP and C3bBbC3b of the AP. Both C5 convertases
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are able to cleave C5 into C5a and C5b to initiate the terminal pathway. The released 
fragment, C5a, serves as a potent anaphylatoxin and inflammatory mediator, as does C3a, 
although to a lesser extent.
1.1.3 The membrane attack complex
The terminal pathway ends by the formation of the transmembrane channel (the membrane 
attack complex, MAC) within the phospholipid bilayer of the target cell. Following the 
cleavage of C5, C5b binds to C6 to form C5b-6 and then to C7 to form C5b-7. Binding of 
C5b-7 to a membrane surface allows C8 to bind and becoming inserted into the membrane 
forming an unstable pore. Binding of C9 to C5b-8 initiates polymerisation of multiple C9 
molecules and incorporation to form the stable C5b-9n complex. The MAC disrupts the 
osmotic gradient across the membrane and thus results in a rapid influx of water which leads 
to swelling and lysis of the cell.
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Figure 1.1 The complement cascade. The complement cascade can be activated via three pathways. Activation leads to a series of proteolytic 
cleavages of individual components and formation of enzymatic complexes which eventually leads to the activation of the terminal pathway and formation of 
the membrane attack complex. Adapted from S A Law and K B M Reid, Complement in Focus 2nd edition, IRL press.
1.1.4 Biological activities of complement activation
The physiological activities of C can be divided into three main categories; defending the 
host against infection; acting as an interface between the innate and adaptive immunity; and 
the clearance of immune complexes and apoptotic cellular waste (Walport, 2001b).
C can defend against bacterial infections by several mechanisms. The opsonisation 
of bacteria with covalently bound fragments C3b and C4b results in their engulfment and 
destruction by the phagocytic cells via receptors CR1 and CR3. C can recruit leukocytes 
towards sites of infection via the pro-inflammatory anaphylatoxins (C3a, C4a and C5a) and 
their receptors (C3aR and C5aR) present on leukocytes cell surface. The anaphylatoxins 
can activate leukocytes causing them to increase their cytotoxicity by increasing expression 
of phagocytic receptors on their cell surface and increasing production of other inflammatory 
mediators and reactive oxygen metabolites. The anaphylatoxins C3a and C5a and their 
receptors C3aR and C5aR can cross talk with Toll-like receptors and the coagulation system; 
therefore further coordinate the innate immune response and preventing the spread of 
infection by amplifying coagulation (reviewed by (Ricklin et al., 2010)). The formation of the 
MAC is an essential mechanism for defence against Neisseria bacteria infections.
C activation can also serve as an important bridge between the innate and adaptive 
immunity. One mechanism by which this is achieved is by augmentation of humoral B cell 
immunity. Expression of the C3 receptors (CR1 and CR2) on B cells and antigen presenting 
cells (APC) lowers the activation threshold when they encounter antigen opsonised with C3 
fragments. Expression of CR2 by follicular dendritic cells is essential for long term B cell 
memory (Barrington et al., 2002). The anaphylatoxins and their receptors can regulate the 
humoral B cell response; for instance the C5aR can lower the threshold for Fey receptor 
(FcyR) activation by increasing expression of FcyRI and FcyRIII and down regulating the 
inhibitory FcyRIIB (Kumar et al., 2006, Shushakova et al., 2002). C can also regulate T cell 
immunity by its regulators DAF/CD55, MCP/CD46 and CD59, as well as the anaphylatoxins 
and their receptors (Ricklin et al., 2010). The anaphylatoxins can affect T cell differentiation 
partly due to their effects on APC but also due to cross talk with the TLR pathway.
The C system can also remove apoptotic cells and immune complexes from tissues 
via C1q of the CP, as well as opsonisation with C3 and C4 fragments.
1.1.5 Methods of regulating complement activation
As the C cascade involves a series of enzymatic steps its activation can rapidly be amplified 
and therefore must be tightly regulated to prevent detrimental damage to the host. 
Regulation is achieved by the expression of membrane bound and fluid phase regulators 
(figure 1.2), but also by intrinsic mechanisms such as; inactive precursor zymogens need to
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and a heavily glycosylated STP rich domain (Caras et al., 1987, Medof et al., 1987). Like 
MCP, C3b and C4b binding sites are located within the CCP repeats (Law and Reid, 1995).
CR1
Complement receptor 1 (CR1) is an integral membrane glycoprotein which acts as a cofactor 
for factor I mediating the cleavage of C3b to iC3b and C3f and further cleaving iC3b to C3c 
and C3dg (Morley and Walport, 2000). Furthermore, CR1 also acts as a cofactor for factor I 
mediated cleavage of C4b to C4c and C4d. CR1 can also accelerate decay of the C3 and 
C5 convertases (Medof et al., 1982). CR1 is found on all erythrocytes, B cells, neutrophils, 
monocytes, a small subset of T cells, follicular dendritic cells and glomerular podocytes 
(Morley and Walport, 2000).
CD59
CD59 another widely distributed GPI anchored membrane regulator. CD59 can prevent the 
formation of the MAC by binding to C8 in the C5b-8 complex, thus blocking the binding C9 
and formation of the MAC pore (Sugita et al., 1988).
1.1.5.2 Fluid phase regulators
C1 inhibitor
C1-inhibitor (C1-lnh) prevents over activation of the CP and LP. It does so by binding to 
active C1r and C1s and MASPs causing their displacement from the active complexes (Sim 
and Reboul, 1981). C1-lnh can also prevent the spontaneous activation of CP by binding 
reversibly to C1 in fluid phase. Other targets for C1-lnh include factors XIla, factor Xia, 
plasmin and kallikrein. The importance of C1-lnh can be seen in hereditary angioneurotic 
oedema (HANE) where there is a deficiency C1-lnh which is associated with attacks of 
increased vascular permeability.
Factor I
Factor I is a highly specific serine protease which regulates the C3/C5 convertase. It does 
so by cleaving the a  chain of C4b or C3b using co-factor activities from C4-binding protein 
(C4bp), CR1, DAF or factor H (Pangburn et al., 1977).
Factor H
Factor H is the main fluid phase regulator of the AP. It has a high affinity for the sialic acid 
residues attached to glycoproteins present on the host cell membranes compared with the 
pathogen membrane and thus allows the discrimination between self and non-self. Factor H 
protects the host from AP activation by attaching to C3b deposited on the host surface and 
then acting as a cofactor for factor I. The importance of factor H can be observed in fH
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deficiencies or impairments where unrestricted AP activation leads to C3 deficiency and 
predisposes to bacterial infections and conditions such as glomerulonephritis or hemolytic- 
uremic syndrome (HUS) and age related macular degeneration (AMD) (Ault, 2000, Zipfel et 
al., 2010).
C4 binding protein
Similar to factor H, C4bp can act as a cofactor for factor I causing the proteolytic inactivation 
of C4b and C3b. C4bp also contains decay accelerating activity and its principal aim is to 
decay the C3 convertase (Gigli et al., 1979, Daha and van Es, 1980).
Properdin
Properdin is a positive regulator of C activation via the AP. The binding of properdin to C3b 
results in (1) resistance to cleavage by factor I, (2) it increases C3b affinity for factor B and 
(3) it increases stability of the C3 convertase C3bBb (Fearon and Austen, 1975, Smith et al., 
1984).
S-protein
S-protein (vitronectin) can prevent the formation of MAC by binding up to three molecules 
C5b-7 and preventing the complex from binding to the cell surface. S-protein can also 
prevent C9 polymerisation (Podack et al., 1984).
Clusterin
Similarly to S-protein, clusterin can prevent MAC formation by binding to C5b-7 and 
preventing the complex from binding to the cell surface (Jenne and Tschopp, 1992).
C8p chain
The C protein C8, which is composed of three non-identical subunits (a, p and y), can also 
act as a fluid phase inhibitory protein. In the absence of membranes the C8p chain can bind 
to soluble SC5b-7 complex, bound by S protein, therefore rendering the complex inactive 
and membrane insertion cannot take place (Monahan and Sodetz, 1980).
Carboxypeptidase-N
The anaphylatoxins are very potent pro-inflammatory molecules whose activities need to be 
tightly controlled. The anaphylatoxins C5a, C3a and C4a are readily metabolised to their 
less active ‘des Arg' counter parts by serum and cell surface carboxypeptidase which remove 
the C-terminal arginine (Bokisch and Muller-Eberhard, 1970). Although C5a des Arg is less 
capable at binding to the C5aR than C5a, studies have found that C5a des Arg binds with a 
10-fold higher affinity to the receptor C5L2 which has led to the suggestion that one function
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of C5L2 is to remove circulating C5a des Arg, however, this remains controversial (see 
section 1.2.6) (Cain and Monk, 2002, Okinaga et al., 2003, Scola et al., 2009).
1.1.6 Complement in pathology
It is essential that the correct balance between C activation and regulation is achieved in 
order to protect the host from infection and aid the clearance of immune complexes and 
apoptotic cells, whilst ensuring that the activation is restricted to prevent its deleterious 
effects to the host (Walport, 2001b, Walport, 2001a). The importance of this balance is 
observed in pathology where attenuated activation can predispose to infections or to 
diseases such as systemic lupus erythematosus (SLE) where the delayed clearance of 
apoptotic cells due to deficiency of CP components triggers autoimmunity (Flierman and 
Daha, 2007). In contrast, uncontrolled activation of C can lead to excessive inflammation, 
which has implicated in numerous pathological inflammatory diseases such as rheumatoid 
arthritis (Guo and Ward, 2005).
1.2 C5a and its receptors
1.2.1 Biological functions of C5a
C5a is the most potent anaphylatoxin generated following C activation, being 20 times more 
potent than C3a at exerting its pro-inflammatory activities. Following the release of C5a from 
site of injury, smooth muscle cells lining the blood vessels contract increasing vasodilation 
and vascular permeability (Ember and Hugli, 1997). Although smooth muscle cell 
constriction is believed to be due the release of histamine from residential mast cells, 
secondary to C5a, the identification of C5aR expression on smooth muscle cells suggests a 
possible direct role (Haviland et al., 1995, Gasque et al., 1998, Zwirner et al., 1999). The 
released C5a also acts as a potent chemoattractant for neutrophils, monocytes and 
macrophages (Snyderman et al., 1971, Snyderman et al., 1975, Marder et al., 1985). The 
binding of C5a to the phagocytes promotes their adhesion to endothelial cells by up- 
regulating the expression of adhesion molecules on their cell surface, followed by their 
infiltration and chemotaxis up the C5a concentration gradient towards the site of C activation 
(Guo et al., 2002). C5a can enhance the phagocytic activities of activated leukocytes by 
increasing expression of phagocytic receptors and releasing reactive oxygen species, 
cytokines, chemokines and granule enzyme (Snyderman and Pike, 1984, Goldstein and 
Weissmann, 1974, Sacks etal., 1978).
In addition to these pro-inflammatory properties C5a also displays some immune
modulating functions. For instance it has been proposed that C5a plays an important role in
inhalation tolerance regulating Th2 lineage commitment of naive CD4+ Th lymphocytes
9
((Kohl et al., 2006); reviewed by (Kohl, 2006)). C5a can also effect T cell differentiation and 
lineage commitment via cross-talk with the TLR signalling pathways (reviewed (Ricklin et al., 
2010, Kohl, 2006)).
The discovery of the C5a receptor, C5aR, expression on non-myeloid cells suggested 
that the anaphylatoxin may function beyond its immuno-modulating and inflammation 
functions and roles in tissue regeneration, tissue fibrosis and in brain development have also 
been suggested (Strey et al., 2003, Mastellos et al., 2001, Hillebrandt et al., 2005, Osaka et 
al., 1999, Mukherjee and Pasinetti, 2000, Mukherjee and Pasinetti, 2001).
1.2.2 Binding of C5a to the C5aR
C5a binds to the seven transmembrane receptors C5aR and C5L2. Although both receptors 
are capable of binding to C5a, only the C5aR is functionally coupled to G proteins (Okinaga 
et al., 2003). Binding of C5a to the C5aR is more complex than other GPCR as binding 
occurs via two separate domains. The first domain is composed of acidic residues in the N- 
terminus of the C5aR which interacts with high affinity to the basic residues in the core of 
C5a (figure 1.3).
Using antibodies raised against N-terminal peptides of the C5aR, two separate
studies have demonstrated that blocking the N-terminus inhibits binding of C5a to the C5aR,
and anaphylatoxin mediated cellular activation (Oppermann et al., 1993, Morgan et al.,
1993). Furthermore, it was suggested that N-terminus of the C5aR, which is rich in
negatively charged residues, facilitates the interaction with the positively charged C5a ligand
(Oppermann et al., 1993). Removal of the N-terminal residues 2-22, resulted in a 600 fold
reduction in affinity of C5a for its receptor, while extending the deletion to residues 30 caused
a further 75 fold reduction in C5a binding (DeMartino et al., 1994). Using site directed
mutagenesis this study identified key aspartic acid residues (Asp 10, 15, 16, 18, 21 and 27)
at the N-terminus as being critical for the high affinity binding of C5a (DeMartino et al., 1994).
In contrast another study by Chen and co-workers (1998), using NMR, suggested that
residues 21-30 are crucial for the first binding domain of C5a to the receptor (Chen et al.,
1998b). Using yeast random saturation mutagenesis which exploits the fact that amino acid
residues most critical for receptor function are those that are most resistant to substitution,
Hagemann and co-workers found that residues 19-29 remained relatively conserved
suggesting their importance for C5a binding, but no single aspartate residue was critical
(Hagemann et al., 2006). Chimeric receptors of the human C3aR and C5aR also confirmed
that the C5aR N-terminus is required for the high affinity binding of the native C5a ligand,
however, the C5a analogue peptide (H-8315) was still able to bind to the receptor, therefore
confirming the two step binding model for the human C5aR (Crass et al., 1999). Sulphated
tyrosine residues at positions 11 and 14 in the C5aR, have also been identified as critical for
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the ability of C5aR to bind C5a and mobilise calcium (Farzan et al., 2001). Although 
Hagemann and colleagues were unable to support these findings in their yeast random 
saturation mutagenesis (Hagemann et al., 2006).
The second interaction occurs between the C-terminus of the C5a and a binding 
pocket formed by the hydrophobic residues in the transmembrane (TM) helices and charged 
residues at the base of the extracellular loops (ECLs) of the C5aR (Monk et al., 2007). 
Investigations of the ECLs using random saturation analysis has revealed that both the first 
and third ECLs are important for receptor activation but not ligand binding. However, ECL1 
is more resistant to amino acid substitution than ECL3, suggesting this loop contains more 
essential amino acid residues (Klco et al., 2006). Investigations of the second ECL revealed 
that this loop acts as a negative regulator for C5aR activation as the random mutagenesis 
resulted in ligand independent signalling (Klco et al., 2005).
As well as C5a, several other proteins have been found to bind to the C5aR. S19 
ribosomal dimers were first identified as a major monocyte specific chemotactic factor in 
rheumatoid arthritis synovial tissue (Nishiura et al., 1996). It has since been shown that the 
S19 ribosomal dimers are liberated by apoptotic HL-60 and AsPC-1 cells and it has therefore 
been suggested that this monocyte chemotactic factor plays an important role in phagocytic 
clearance of apoptotic cells (Nishiura et al., 1998, Shibuya et al., 2001). Skp, a periplasmic 
chaperone protein from E. coli, has also been shown to induce chemotactic responses of 
monocytes and polymorphonuclear leukocytes via the C5aR (Shrestha et al., 2004). Using 
receptor antagonising experiments Shrestha and co-workers showed that Skp is likely to bind 
to the C5aR in the same two-step mechanism as C5a and ribosomal S19 (Shrestha et al., 
2004). Chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) efficiently inhibits 
the activation of neutrophils and monocytes by C5a, and does so by binding to the N-terminal 
(residues 1-35) of the C5aR (Ippel et al., 2009). Ippel and co-workers found that sulphated 
tyrosines residues 11 and 14 are essential for the tight binding between C5aR and CHIPS 
(Ippel et al., 2009).
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1.2.3 Intracellular signalling of the C5aR
G protein coupled receptors activate signalling cascades via a heterotrimeric G protein
composed of a Ga, Gp and Gy subunits. It is believed that the C5aR is coupled primarily to
the pertussis toxin (PTX) sensitive Gai2 G protein; however several studies have also shown
that when C5aR is ectopically expressed in COS-7 and human kidney 293 cell lines, the
receptor only signals when co-transfected with the PTX insensitive Ga16 G protein (Vanek et
al., 1994, Sheth et al., 1991, Skokowa et al., 2005, Buhl et al., 1993, Amatruda et al., 1993).
It has also been shown that in the MonoMac6 cell line, differentiated with dibutyryl cAMP
(Bt2cAMP), to be coupled to PTX insensitive G proteins (Takabayashi et al., 2004).
The G protein subunits bind to the C5aR via the intracellular loops 1 and 2, which act
as a selective filter only allowing the correct G proteins to bind to the receptor. These loops
also contain essential residues for the activation of the G proteins (Matsumoto et al., 2007a,
Matsumoto et al., 2007b). Binding of C5a to the C5aR causes a conformational change
which allows Ga-GDP to be exchanged to Ga-GTP by guanine nucleotide exchange factor
(Matsumoto et al., 2007b). This exchange causes Ga-GTP to dissociate from the Gpy
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subunits, and then both Ga and G(3y can transmit the signal to downstream effectors 
molecules (figure 1.4).
As well as signalling via G-proteins, more recently it has also been suggested that the 
association of the activated C5aR with p-arrestins, which mediates receptor internalisation 
(see section 1.2.4.4), also results in the activation of ERK1/2 (Bamberg et al., 2010). 
Furthermore, it has been suggested that C5L2 can act as a negative intracellular receptor of 
C5aR/p-arrestin/ERK1/2 signalling via its association to p-arrestins (see section 1.2.6) 
(Bamberg et al., 2010).
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Figure 1.4 Schematic diagram illustrating the down stream signalling mechanisms of 
the C5aR following binding of C5a (adapted from (Monk et al., 2007, Rabiet et al., 2007)).
1.2.3.1 Activation o f phospholipase C p2
Following the binding of C5a to its receptor, phospholipase C p2 (PLCp2) has been shown to 
be activated by the dissociated Gpy subunits (Jiang et al., 1996, Camps et al., 1992). 
Activation of PLCp2 results in the hydrolysis of phosphoinositol-4,5-bisphosphate (PIP2) to 
diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 diffuses through the cytosol and 
binds to IP3 receptors present on the endoplasmic reticulum membrane which in turn causes 
the release of calcium from the intracellular stores. DAG remains within the plasma
13
membrane and together the interaction of DAG with protein kinase C (PKC) and rise in 
intracellular calcium concentrations results in the activation of PKC. PKC activity has been 
shown to be important for the C5a-induced priming of oxidative burst in phagocytes (Wrann 
et al., 2007).
1.2.3.2 Activation of phosphoinositol 3-kinase
The dissociated Gpy subunits have been found activate both p110p and p110y isoforms of 
phosphoinositol 3-kinase (PI3K) (Guillermet-Guibert et al., 2008, Stoyanov et al., 1995). 
PI3K can convert the membrane PIP2 into phosphoinositol-3,4,5-bisphosphate (PIP3) (Rabiet 
et al., 2007). PI3K also activates Akt which phosphorylates p38 MAPK, ERK and c-Jun N- 
terminal kinase (JNK) and causes C5a induced IL-12 reduction in human monocytes (la Sala 
et al., 2005). PI3K activity is critical for numerous leukocyte functions. Hirsch and co­
workers found that PI3Ky knockout mice have an impaired respiratory burst and chemotactic 
activity towards C5a (Hirsch et al., 2000). Another study by Wrann and co-workers has 
shown that inhibition of the PI3K results in a reduced C5a-induced phagocytic response 
(Wrann et al., 2007). Convergence of the PI3K/Akt and ERK signalling pathways leads to 
the activation of cAMP-response element-binding protein (CREB) (Perianayagam et al., 
2006). CREB, in turn, modulates the transcription of the anti-apoptotic molecule Bcl2 which 
has been proposed to be part of the mechanism by which C5a can delay neutrophil 
apoptosis (Perianayagam et al., 2002, Perianayagam et al., 2004). Signal transducer and 
activator of transcription (STAT3) has also been shown to become phosphorylated following 
C5a stimulation. In human erythroleukemia cells this is believed to be achieved via 
Ras/Raf/MEK/ERK and c-Src/JAK pathways, whereas in neutrophils it is believed to be only 
achieved by ERK pathway (Lo et al., 2003, Kuroki and O'Flaherty, 1999).
1.2.3.3 Activation of GTP-binding proteins
p21-activated kinase (PAK) has also been shown to be activated in neutrophils following 
stimulation of the C5aR (Huang et al., 1998). PAKs play an important role in regulation of 
the motility and cytoskeleton dynamics, as well as in the regulation of transcription factors, 
such as NFkB, through the MAPK cascade (Bokoch, 2003). A study by Li and colleagues 
found that the G protein Py subunits binds PAK1 and with the guanine nucleotide exchange 
factor PIXa, via PAK-associated. P IXa activates Cdc42, a low molecular weight GTP binding 
protein part of the Rho family, which in turns activates PAK1. They showed that this Gpy- 
PAK1/PIXa/Cdc42 pathway is essential for directional sensing and the persistent directional 
migration of chemotactic leukocytes (Li et al., 2003). PAK1/PAK2 can activate p38 MAPK, 
which in turn activates MAKP-activated protein kinase 2 (MAPKAP-K2). Macrophages from 
mice deficient in MAPKAP-K2 have an impaired chemotaxis towards C5a (Rousseau et al.,
2006). Activated Cdc42 has also been shown to bind to the Wiskott-Aldrich syndrome protein 
(WASP), which then promotes the association of WASP to the C-terminal cytoplasmic tail of 
the C5aR (Tardif et al., 2003). Tardif and co-workers suggested that this targeting of WASP 
to the plasma membrane following C5aR stimulation and Cdc42 activation might be one 
mechanism by which actin assembly is spatially controlled in cells moving towards C5a.
Activation of other guanine nucleotide exchange factors can lead to the activation of 
other GTP-binding proteins. pRexI activation has been shown to activate Rac, another 
member of the Rho family which can control leukocyte functions such as chemotaxis, 
phagocytosis and superoxide production (Welch et al., 2002a). RhoG has also been found 
to become activated in neutrophils following stimulation of the C5aR. RhoG knockout mice 
have an impaired reactive oxygen species generation in response to C5a (Condliffe et al., 
2006).
1.2.4 Regulation of C5aR function
Due to the potent pro-inflammatory nature of C5a-C5aR signalling, a crucial mechanism to 
limit its excessive activation is to regulate the C5aR function. Regulation of receptor 
activation can be achieved by receptor oligomerisation, clustering, phosphorylation and 
desensitization and internalisation.
1.2.4.1 Receptor oligomerisation
Only recently the idea that many GPCR form dimeric structures or higher order oligomeric 
complexes has become accepted (Milligan et al., 2003). It is believed that receptor 
oligomerisation may play an important role in receptor biosynthesis and the trafficking of the 
receptor to the plasma membrane (Rabiet et al., 2007).
A study by Floyd and co-workers found, by fluorescence resonance energy transfer 
(FRET) analysis, that the C5aR tagged with green fluorescent protein (GFP) forms receptor 
specific and constitutive dimers in vivo and by using S.cerevisiae expression system, they 
showed that this oligomerisation is not dependent on any accessory proteins (Floyd et al.,
2003). Subcellular fractionation studies suggest that oligomerisation occurs early in the 
biosynthesis of the receptor and is important for the transport to the plasma membrane 
(Rabiet et al., 2007, Floyd et al., 2003, Milligan et al., 2003).
It has been suggested that GPCR dimerisation is likely to occur through association 
of transmembrane helices 1 and 2 (Geva et al., 2000, Klco et al., 2003). A study by Klco and 
co-workers investigated the role of the lipid facing residues in C5aR oligomerisation. They 
found that these residues alone are not essential for oligomerisation and they proposed that 
it is likely that multiple residues within the transmembrane are responsible for dimerisation. 
However, they did find that these lipid facing residues are essential for the trafficking of the
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C5aR from the endoplasmic reticulum to the plasma membrane (Klco et al., 2009). Although 
C5aR homodimers do not undergo cross-phosphorylation, the stimulation and 
phosphorylation of only one monomer is enough to lead to the dimer internalisation (Rabiet 
et al., 2008). The C5aR has also been shown to form hetero-oligomers with the chemokine 
receptor 5 (CCR5) (Huttenrauch et al., 2005). In this study they found that G protein receptor 
kinases (GRK) as well as PKC, promote the cross-phosphorylation of these hetero-oligomers 
and that p-arrestin then mediated their internalisation.
1.2.4.2 Receptor clustering
Chemotaxis across a chemical gradient induces cell polarisation which results in 
asymmetrical distribution of the membrane. This asymmetrical distribution of the membrane 
can cause an enrichment of some chemoattractant receptors at the leading edge towards a 
point source. A study by Servant and co-workers (1999) found that C5aR forms clusters at 
the plasma membrane shortly after stimulation with C5a, however, this apparent increase in 
C5aR concentration reflects the increased relative abundance of plasma membrane rather 
then preferential accumulation of the receptor at the leading edge (Servant et al., 1999).
1.2.4.3 Receptor phosphorylation
Activation of GPCR leads to their rapid phosphorylation. Phosphorylation can occur by 
secondary messenger dependent kinases such as PKC or by GRK. Receptor 
phosphorylation can lead to desensitization of the receptor within milliseconds to minutes of 
agonist challenge (Pitcher et al., 1998). Desensitization is achieved by the binding of 
arrestins to the phosphorylated receptor, which causes the uncoupling from the G proteins 
and receptor internalisation (Rabiet et al., 2007).
The C5aR is primarily phosphorylated on serine residues (Ser-314, Ser-317, Ser-327, 
Ser-332, Ser-334, Ser-338), as well as threonine residues, all be it to a lesser extent 
(Giannini et al., 1995, Huttenrauch et al., 2005). Christophe and co-workers found that 
phosphorylation of either of the two serine pairs (Ser-332/-334 and Ser-334/-338) is a 
prerequisite for full receptor phosphorylation (Christophe et al., 2000). Phosphorylation of 
serine residues (Ser-327, Ser-334, Ser-338), allows p-arrestin 1 and 2 to associate with the 
activated receptor, however, internalisation requires a minimal level of phosphorylation of 
these key residues (Braun et al., 2003). As well as mediating the uncoupling of G proteins 
from the receptor, it has also been suggested that bound p-arrestins sterically interfere with 
further receptor phosphorylation and also protects phosphorylated residues by 
dephosphorylation by protein phosphatases (Pollok-Kopp et al., 2007). Several studies have 
shown that mutant C5aRs, which are not able to undergo phosphorylation, are not 
internalised following agonist binding and undergo a sustained intracellular calcium release
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and production of superoxide (Naik et al., 1997, Suvorova et al., 2008, Christophe et al.,
2000).
The exact nature of the kinases which phosphorylate the C5aR still remains 
controversial. The C5aR phosphorylation levels are likely to be regulated by GRK, as well as 
PKCp (Langkabel et al., 1999, Pollok-Kopp et al., 2007). Co-expression of GRK 2 and 3 with 
C5aR in human mast cells, led to the suggestion that these were likely to be the main GRK 
members involved in phosphorylation of the C5aR (Langkabel et al., 1999). However, when 
GRK2, as well as GRK6, were over expressed in COS-7 cells transfected with the C5aR, the 
agonist induced phosphorylation remained unchanged (Milcent et al., 1999).
1.2.4.4 Internalisation, intracellular trafficking and recycling
Following agonist binding some GPCR, but not all, are internalised via [3-arrestin-mediated 
pathway into early endosomes. Internalised receptors can either be recycled back to the 
plasma membrane or they can be targeted to lysosomes where they are then degraded. A 
rapid internalisation and recycling process may be critical for receptors whose primary 
function is to direct cell migration across a chemotactic gradient (Naik et al., 1997).
Within ten minutes of exposure to C5a, the C5aR can be detected within vesicles that 
cluster in the perinuclear region (Naik et al., 1997). The internalised receptors are rapidly 
recovered to the plasma membrane. The amount of C5aR re-expressed on the cell surface 
seems to depend on which cells are being studied; 73% of the C5aR has been found to be 
re-expressed on the cell surface of neutrophils compared with 90% in the stably transfected 
rat insulinoma cell line (Suvorova et al., 2005, Naik et al., 1997). Originally it was proposed 
that C5aR internalisation was mediated in an arrestin, dynamin and clathrin independent 
manner; however, more recent studies suggest that the C5aR is internalised via the classical 
clathrin-dependent pathway (Gilbert et al., 2001, Licht et al., 2003, Braun et al., 2003, 
Suvorova et al., 2005, Huttenrauch et al., 2005). Further investigations are needed in order 
to define the exact nature of the structural determinants involved in trafficking the C5aR to 
the lysosomes.
1.2.5 C5aR expression
C5aR expression was originally believed to be restricted to cells of myeloid origin, however it 
is now known to be expressed by numerous non-myeloid cell types. Summarised in table
1.1 is the non-myeloid cellular distribution of C5aR expression. This table highlights that 
some evidence for the expression of the C5aR in non-myeloid cells, such as the 
parenchymal cells of the lungs and kidney, remains controversial with several studies 
challenging the expression of the C5aR in these cells. A variety of techniques have been 
employed to detect C5aR; including measuring mRNA by techniques such as RT-PCR,
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northern blotting and in situ hybridisation; and measuring protein expression by flow 
cytometry, western blotting and immunofluorescence. However, traditional techniques of 
measuring binding of radio labelled C5a are no longer an accurate measure of C5aR 
expression due to the discovery of the second C5a receptor, C5L2, which can also bind C5a 
(Cain and Monk, 2002).
C5aR expression has been well documented in the literature to be up-regulated in the 
myeloblastic cell lines by stimuli including dibutyryl cAMP (Bt2cAMP), phorbol 12-myristate 
13-acetate (PMA) and Interferon-y (IFN-y) (table 1.2) (Chenoweth et al., 1984, Rubin et al., 
1986, Gavison et al., 1988, Gasque et al., 1998, Burg et al., 1996, Burg et al., 1995). These 
stimuli are therefore commonly used to investigate the C5aR. Other stimuli, such as 
forskolin, prostaglandin E2 and isoproterenol when combined with 1,25-(OH)2D3, IL-1 and 
TNFa, have also been reported to increase C5aR expression, however, these have been 
less well characterised (table 1.2) (Rubin et al., 1986, Rubin et al., 1991a, Takabayashi et al., 
2004, Gasque et al., 1998).
Despite numerous studies investigating the expression profile of the C5aR, relatively 
few studies have actually investigated how expression is regulated. Initial studies by Gerard 
and co-workers found that the gene encoding the human C5aR was located on chromosome 
19q13.3 within a chemotactic receptor gene cluster which also encodes the fMLP receptor 
(FPR) (Gerard et al., 1993). This study characterised the C5aR gene as a having a two exon 
structure, with the 5’ untranslated sequence and initiating methionine codon located within 
the first exon, which is then separated by a ~9Kbp intron from the second receptor encoding 
exon (figure 1.5).
1 kbp
Figure 1.5 Genomic structure o f C5aR. Two exons separated by a ~9 kbp intron sequence 
located between codon 1 and codon 2 (Gerard et al., 1993).
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Table 1.1 Non-myeloid distribution of the C5aR. LBS = ligand binding studies (using radio labelled C5a), IC = immunochemistry, WB = 
western blotting, RT-PCR = reverse transcriptase PCR, FC = flow cytometry, CHX = chemotaxis assay, ISH = in situ hybridisation and NB = 
northern blotting.
Loci Species Cell type Method of 
detection
C5aR
detected
Reference
Circulatory
system
Mouse Microvascular endothelial cells LBS, IC Y (Laudes et al., 2002)
CNS Human
Mouse
Microglia, reactive astrocytes 
Neural stem cells
IC, WB, RT- 
PCR 
ISH, IC
Y
Y
(Gasque et al., 1995, 
Gasque et al., 1997) 
(O'Barr et al., 2001)
Connective
tissue
Human Synoviocytes RT-PCR, 
FC, IC
Y (Yuan et al., 2003)
Endocrine Rat Anterior pituitary gland and pituitary cell lines RT-PCR, IC Y (Francis et al., 2008)
system
Immune Human CD3+ and Jurkat T cells FC, RT- Y (Nataf et al., 1999)
system PCR, CHX
Kidney Human
Mouse
Rat
Cultured human glomerular mesangial cells 
Tubular epithelial cells
Normal and inflamed renal tubular epithelial cells 
Tubular smooth muscle or endothelial cells 
Normal and inflamed renal tubular epithelial cells 
Normal and inflamed renal tubular epithelial cells
IC,FC,RT- 
PCR 
IC,ISH 
IC
NB,IC
IC
IC
Y
Y 
N 
N 
N 
N
(Braun and Davis, 
1998)
(Abeet al., 2001a) 
(Kiafard et al., 2007) 
(Zwirner et al., 1999) 
(Kiafard et al., 2007) 
(Kiafard et al., 2007)
Liver Human HepG2 cell line 
Liver parenchymal cells
Liver hepatocytes, bile duct epithelial cells, vascular smooth 
muscle and endothelial cells
NB, LBS
ISH, IC 
IC
Y
Y 
N
(Haviland et al.,
1995)
(Buchner et al., 1995) 
(Haviland et al.,
1995)
(Zwirner et al., 1999)
Lung Human Vascular smooth muscle, endothelial cells and bronchial and 
alveolar epithelial cells
Normal and inflamed bronchial epithelial and smooth muscle cells 
Inflamed pulmonary epithelial cells
Bronchial and alveolar epithelial, vascular smooth muscle or
IC
ISH,IC
ISH
IC
Y
Y 
N 
N
(Haviland et al.,
1995)
(Drouin et al., 2001) 
(Fayyazi et al., 1999) 
(Zwirner et al., 1999)
Mouse
Rat
endothelial cells
Normal and inflamed epithelial, endothelial and smooth muscle 
cells.
Normal and inflamed bronchial epithelial and smooth muscle cells 
Normal and inflamed epithelial, endothelial and smooth muscle 
cells.
IC
ISH.IC
IC
N
Y
N
(Tschernig et al., 
2007)
(Drouin et al., 2001) 
(Tschernig et al., 
2007)
Respiratory
tract
Human Normal or allergic nasal mucosa epithelial, vascular smooth 
muscle or endothelial cells
IC, WB N (Jun et al., 2008)
Skin Human Inflamed keratinocytes ISH Y (Fayyazi et al., 1999) 
(Zwirner et al., 1999)
Table 1.2 Stimuli reported to alter C5aR expression. Abbreviations; LBS = iigand binding studies; CHX chemotaxis assay; FC = flow 
cytometry; WB = western blotting; NB = northern blotting; RT-PCR = reverse transcriptase PCR; Q-PCR = quantitative PCR; IHC = 
immunohistochemistry.__________________________________________________________________________________ ________________________
Stimuli Cell type Conditions Methods of 
detection
Reference
Cigarette smoke 
extract
Human bronchial 
epithelial cells
5% cigarette smoke extract 2h incubation LBS, FC (Allen-Gipson et al., 
2005)
Dibutyryl cAMP 
(Bt2cAMP)
U937, MM6 and
HL-60
U937
72h Incubation 0.5mM Bt2cAMP 
72h Incubation 1mM Bt2cAMP
LBS, NB 
LBS, FC
(Burg et al., 1996, Burg 
et al., 1995)
(Chenoweth et al., 1984)
U937 72h Incubation 10mM Bt2cAMP CHX (Gavison et al., 1988)
co
'</>
U937
U937
72h Incubation 0.5mM Bt2cAMP 
96h Incubation 1mM Bt2cAMP
LBS, NB 
LBS
(Gerard and Gerard, 
1991)
(Rubin et al., 1986)
2Q.
X(1)
MM6 24h Incubation 0.5mM Bt2cAMP LBS, RT- 
PCR
(Takabayashi et al., 
2004)
cr(0to
Forskolin U937 72h Incubation 75 uM forskolin CHX (Shayoetal., 1997)
O
a></)m
2>oc
U937 96h Incubation 15 uM forskolin and 10'8M 1,25- 
(OH)2D3
LBS (Rubin et al., 1986, 
Brodsky et al., 1998)
Isoproterenol when 
combined with 
1,25-(OH)2D3
U937 96h Incubation 10'7-10'5M isoproterenol and 10' 
8M 1,25-(OH)2D3
LBS (Rubin et al., 1986)
Prostaglandin E2 
when combined 
with 1,25-(OH)2D3
U937 96h Incubation 10nM 1,25-(OH)2D3and 0..3uM 
Prostaglandin E2
LBS (Rubin et al., 1991a)
Phorbol 12- 
myristate 13- 
acetate (PMA)
U937, MM6 and 
HL-60
64h Incubation 10nM PMA
72h Incubation (THP-1), 48h Incubation (U937
LBS, NB 
FC, WB,
(Burg et al., 1996) 
(Gasque et al., 1995,
THP-1 and U937 10ng/m! PMA RT-PCR Gasque etal., 1998)
U937 24h IncubationlOOnM PMA NB (Gerard and Gerard, 
1991)
IL-1 (IL-a and IL-
1P)
MM6 24h Incubation, 20ng/ml IL-1 LBS (Takabayashi et al., 
2004)
IL-6 Mouse lung, liver, 
kidney and heart
During the development of sepsis in mice IHC, RT- 
PCR
(Riedemann et al., 2003)
IL-4 when 
combined with 
1,25-(OH)2D3
Monocyte-derived
DC
7 day Incubation
250U/ml followed by prostaglandin E2 1 ug/ml 
for 48h
FC,RT- 
PCR, Q- 
PCR
(Weinmann et al., 2003)
IFNy U937
U937, HL60 and 
MM6
48h Incubation 10,100,1000 lU/ml 
72h Incubation 1000U/ml rlNFy
FC, RT- 
PCR
LBS
(Gasque et al., 1998)
(Burg et al., 1996, Burg 
et al., 1995)
TNFa U937 48h Incubation 10IU/ml TNFa FC (Gasque et al., 1998)
D
ec
re
as
e
C
5a
R
IL-4 Human
monocytes and 
monocyte derived 
DC
24h Incubation 300 U/ml FC, RT- 
PCR
(Weinmann et al., 2003, 
Soruri et al., 2003)
Gerard and colleagues also investigated the promoter activity of a ~800bp fragment, 
using a chloramphenicol acetyltransferase (CAT) reporter, composed of ~-350bp upstream of 
the initiating methionine codon, exon 1 and ~450bp of the beginning of the intron, of the 
human C5aR gene (figure 1.6 A). Their results showed that this ~800bp fragment contained 
a c/s-acting element which is responsive to PMA, as treatment of the transfected rat 
basophilic leukemia (RBL-1) cells with PMA resulted in 2 fold increase in reporter CAT 
activity and they speculated that an AP-1 site could be responsible for this activity. Gerard 
and colleagues also found cell-type specific suppressor activity within -346bp and -225bp 
from the start codon which prevented transcription of the CAT gene when transfected into the 
neuroblastoma SK-N-SH cell line (Gerard et al., 1993) (figure 1.6 A).
Another study by Hunt and colleagues (2005) investigated the transcriptional 
regulation of the mouse C5aR gene. In this study they cloned a -2278bp fragment from the 
transcription start site and created a series of 5’deletions into the pGL2-Basic vector which 
allowed the promoter activity to be determined by performing luciferase assays (figure 1.6 B). 
By transfecting these constructs into the mouse macrophage (RAW 264.7) and endothelial 
(b.End3 and mHEVc) cell lines, which express C5aR mRNA, they found that the majority of 
the region cloned (-2278bp to -232bp) was dispensable for expression in these cells (Hunt et 
al., 2005). When they transfected the same constructs into the B16 melanoma cell line, 
which do not express C5aR mRNA, they found that the -2278bp to -232bp fragments 
contained a cell type specific suppressor element which resulted in minimal transcriptional 
activity of the luciferase gene in this cell line. Hunt and colleagues also showed that deletion 
of fragments between -232bp to -132bp and -132bp to -90bp, resulted in approximately 40%  
and 80% reduction in promoter activity respectively, in the RAW 264.7, b.End3 and mHEVc 
cell lines (figure 1.6 B). They identified the transcriptional regulatory site most critical for the 
promoter activity within the -132bp to -90bp is a putative CCAAT site, which specifically binds 
nuclear factor-Y (NF-Y). This NF-Y site was also shown to be predominately responsible for 
LPS induced up regulation of the C5aR, however, there was some contribution from a CP-2 
site at position -155bp (Hunt et al., 2005).
Further studies by the same group investigated the transcriptional control 
mechanisms of the mouse C5aR in glial cells of the central nervous system. They found that 
the mouse microglial (BV-2) and astrocyte (Ast2.1) cell lines and primary microglial cells 
contained strong CCAAT box DNA binding activity, however, only weak activity was 
observed in primary astrocytes. Supershift assays demonstrated that NF-YA protein is 
critical in formation of this DNA-protein complex. By using the luciferase reporter gene 
constructs Martin et al. (2007) showed that, contrary to results in murine macrophages, the 
CCAAT element has little activity in primary astrocytes. They then suggest that C5aR
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expression in astrocytes is regulated by additional control regions both 3’ and 5’ of the 
CCAAT box (Martin, 2007).
A novel single nucleotide polymorphism (SNP) in the promoter region of the human 
C5aR at position -245 (T/C) has also been identified (Barnes et al., 2004). This SNP was 
shown to have a higher frequency in the Afro-Caribbean population compared with the 
German and Tangier Island population, however, it had no association with asthma or atopy 
(Barnes et al., 2004). This study also found, using the 2711 bp sequence immediately 
upstream from the 5’UTR of the C5aR gene into the luciferase reporter gene plasmid, that 
the T to C substitution at position -245bp had no effect of reporter gene activity, when 
transfected into the U937 cell line, despite an AP-4 motif being disrupted. However, this 
study did not investigate the effects of this SNP on induced expression (Barnes et al., 2004).
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Figure 1.6 Schematic diagram of reporter studies carried out using human C5aR  
promoter region (A) or mouse C5aR promoter region (B). Results from Gerard et al 1993
(A). Results from Hunt et al 2005 and Martin et al 2007 (B). See text above for full description.
1.2.6 C5L2
As already mentioned, C5a can also bind to the seven transmembrane receptor C5L2, as 
well as, the C5aR. Although both receptors bind C5a with similar affinities, C5L2 has 10 
times higher affinity for C5a des Arg compared with the C5aR (Cain and Monk, 2002). 
Although both receptors are capable of binding to C5a, only the C5aR is functionally coupled 
to G proteins (Okinaga et al., 2003). Furthermore, binding of C5a to C5L2 does not induce
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MAP-kinase activation, intracellular Ca2+ flux, degranulation or chemotaxis; thus further 
suggesting a non-signalling role (Cain and Monk, 2002, Okinaga et al., 2003). However, the 
exact role for C5L2 still remains controversial. In rodents, deletion or blockade of the C5L2 
receptor was found to enhance the biological activities of C5a suggesting that its role is to 
limit the pro-inflammatory response to C5a (Gerard et al., 2005, Gao et al., 2005). However 
a study by Chen and co-workers found that C5L2 deficiency led to a reduction in C5a 
mediated inflammatory cell infiltration (Chen et al., 2007). Furthermore, in a mouse model of 
sepsis only blockade of both C5aR and C5L2 improved outcome (Rittirsch et al., 2008). 
Despite evidence suggesting a more positive regulatory role for C5L2 in C5a signalling in 
mice, the human C5L2 has been shown to act as negative regulator by removing and 
degrading active C5a fragments from the extracellular environment when transfected into the 
rat basophilic leukemia cell line (Scola et al., 2009). In human neutrophils antibody blockade 
of C5L2 resulted in a dramatic increase in C5a mediated chemotaxis and ERK- 
phosphorylation but C5aR endocytosis remained unchanged. Bamberg and co-workers also 
observed that following C5a stimulation both C5aR and C5L2 appeared to translocate to the 
same compartment, and that both receptors were found to associate with p-arrestins. These 
findings led the authors to suggest that C5L2 acts as a negatively regulate for C5aR ERK1/2 
signalling possibly via p-arrestin pathway in human neutrophils (Bamberg et al., 2010).
C5L2 is co-expressed with C5aR on many cell types including neutrophils, 
macrophages and immature dendritic cells (Ohno et al., 2000, Chen et al., 2007, Gerard et 
al., 2005), as well as, in the lung, liver, spleen, brain and heart (Kalant et al., 2005, Gao et 
al., 2005). Despite being co-expressed with the C5aR, the C5L2 mRNA transcript 
expression is approximately one-third of that of the C5aR (Gerard et al., 2005), and its actual 
protein expression is found mainly intracellular compared with the C5aR which is expressed 
mainly on the cell surface (Bamberg et al., 2010).
1.2.7 C5a and the C5aR in disease
Over production of C5a or increased C5aR expression has been implicated in pathogenesis
of many inflammatory conditions, autoimmune and neurodegenerative diseases (table 1.3).
Elevated plasma levels of C5a have been noted in humans with sepsis, and is believed to
cause neutrophil dysfunction which in turn contributes towards the cytokine storm and
multiple organ failure (Guo and Ward, 2005). In cecal ligation and puncture (CLP) induced
septic rats neutrophils displayed defective phagocytosis, chemotaxis and NADPH oxidase
assembly, which was prevented by blockade of C5a (Huber-Lang et al., 2002). Despite
down regulation of C5aR expression in neutrophils, which is probably due to increased
internalisation of the receptor following interaction with C5a, Riedemann and co-workers
have shown the receptor expression increases in the lungs, liver, kidney and heart in the
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mouse CLP septic model, which has been suggested to contribute towards multiple organ 
failure (Riedemann et al., 2002). In mouse CLP induced sepsis, Rittirsch and co-workers 
showed that only blockade of both C5aR and C5L2 improved survival rates suggesting that 
C5L2 may have some signalling role (Rittirsch et al., 2008). For information on the role of 
C5a/C5aR signalling in atherosclerosis and ischemic reperfusion injury please see sections 
1.4.4 and 1.4.5 respectively.
In some instances C5a/C5aR signalling has been shown to have a protective effect 
initially, however, once an inflammatory response has become established C5a generation 
exacerbates pathology. For instance in allergic asthma C5a/C5aR signalling can initially 
have a protective role in the allergen-sensitisation phase by regulating the dendritic cell/T cell 
interface, however, once allergen inflammation is established it drives Th2 mediated 
eosinophil and mast cell destruction (Kohl, 2006, Ricklin et al., 2010).
In autoimmune diseases, such as rheumatoid arthritis, C activation initiated by 
immune complex formation results in a C5a chemotactic gradient which attracts leukocytes 
to the site of C activation which in turn exacerbates the inflammatory response. Evidence 
from C5aR-/- mice suggest that the C5a gradient across the synovial joint is crucial for the 
recruitment and activation of neutrophils and monocytes into the synovium and synovial fluid 
(Grant et al., 2002). Furthermore, these activated neutrophils secrete pro-inflammatory 
cytokines TNFa and IL-1 p, which recruit additional inflammatory cell subsets and activate 
residential synovial fibroblasts, and therefore amplifying the inflammatory response and 
resulting in cartilage and bone degradation (Grant et al., 2002, Woodruff et al., 2002, 
Weissmann, 2004).
Due to the potentially destructive nature of C5a/C5aR signalling in disease, a C5aR 
antagonist would have huge therapeutic potential.
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Table 1.3 Pathologies associated with over production or under regulation of C5a or 
increased C5aR expression. Adapted from (Monk et al., 2007).
Disease Author
Rheumatoid arthritis (Grant et al., 2002, Woodruff et al., 2002, 
Neumann et al., 2002, Weissmann, 2004)
Respiratory distress syndrome (Hammerschmidtetal., 1980)
Inflammatory bowl disease (Woodruff et al., 2003)
Ischaemia reperfusion injury (Arumugam et al., 2003, Martin et al., 1988, 
Proctor et al., 2004, Woodruff et al., 2004, 
Arumugam et al., 2004a)
Chronic obstructive pulmonary disease (Marc et al., 2004)
Sepsis (Huber-Lang et al., 2002)
Asthma and allergy (Abe et al., 2001b, Baelder et al., 2005, Gerard 
and Gerard, 2002, Lambrecht, 2006)
Psoriasis (Kapp et al., 1985)
Atherosclerosis (Hammerschmidt et al., 1981, Speidl et al., 2005)
Tissue rejection (Gaca et al., 2006, Gueler et al., 2008)
Glomerulonephritis (Kondo et al., 2001, Welch et al., 2002b)
Pancreatitis (Bhatia, 2002)
Multiple sclerosis (Muller-Ladner etal., 1996)
Neurodegeneration and macular degeneration (Kijlstra et al., 2005, van Beek et al., 2003, Ager 
et al., 2010)
Cystic fibrosis (Fick et al., 1986)
Systemic lupus erythematosus (Hammerschmidt et al., 1980, Hopkins et al., 
1988)
Antiphospholipid syndrome (Girardi et al., 2003)
Anaphylactic and haemorrhagic shock (Harkin et al., 2004, Younger et al., 2001)
Burns (Piccolo et al., 1999)
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1.3 Role of cholesterol in GPCR function and expression
Cholesterol is an integral component of biological membranes. Its rigid ring structure allows 
it to insert between phospholipids present within the lipid bilayer, where it then regulates 
membrane fluidity and permeability (Pike, 2003). As well as its crucial role in membrane 
fluidity, cholesterol is now becoming recognised for its importance in the formation of 
cholesterol rich microdomains termed lipid rafts (Burger et al., 2000, Maxfield and Tabas,
2005). As GPCR are commonly found localised within these lipid raft microdomains or move 
in or out of such regions following their interaction with their ligand (table 1.4); their function 
and expression can often be regulated by cholesterol. Discussed below are the different 
mechanisms by which cholesterol can alter GPCR function and expression within the plasma 
membrane.
Table 1.4 Summary of the effects of agonist binding on G-protein coupled receptor 
membrane lipid raft localisation. (Adapted from (Pike, 2003)).
Moves into rafts Moves out of rafts Unaffected by agonist
Angiotensin II type 1 
(Ishizaka et al., 1998)
Adenosine A1 (Lasley et al., 
2000)
pi-Adrenergic (Rybin et al., 
2000)
m2 Muscarinic cholinergic 
(Feron et al., 1997)
p2-Adrenergic (Rybin et al., 
2000)
Endothelin (Chun et al., 
1994)
Bradykinin 1 (Sabourin et al., 
2002)
Rhodopsin (Seno et al., 
2001)
Bradykinin 2 (de Weerd and 
Leeb-Lundberg, 1997, 
Haasemann et al., 1998)
EDG-1 (Igarashi and Michel, 
2000)
1.3.1 Role of cholesterol in GPCR compartmentalisation into lipid rafts
The identification of lipid raft regions within the membrane has allowed the concept of
membrane sub-compartmentalisation (Lingwood and Simons, 2010). The
compartmentalisation of signalling components into lipid raft or non-lipid raft regions can act
as an important regulatory mechanism for the signalling cascade. For instance, the close
proximity of signalling components when localised all in one raft would allow a rapid and
efficiently signalling mechanism (Pike, 2003). Alternatively it could restrict the signalling flux
by physically separating different signalling components which would then be targeted to
each other upon activation (Pike, 2003).
Compartmentalisation and targeting of certain receptors to different regions of the
plasma membrane can also lead to a polarity of the cell. This cell polarity is crucial for
chemoattractant stimulated cells which display noticeable polarised phenotype where lipid
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rafts and associated proteins, such as chemokine receptors, are preferentially distributed 
towards the leading edge (Manes et al., 2001). Several studies have shown that chemotaxis 
of neutrophils and monocytes towards fMLP is reliant on membrane cholesterol levels (Bath 
et al., 1991, Dunzendorfer et al., 1997, Wolach et al., 1992). It has been show, using methyl- 
p-cyclodextrin (MpCD), which depletes membrane of cholesterol, that cholesterol is critical 
for the clustering and redistribution of the fMLP receptor (FPR), structurally homologous to 
the C5aR, into lipids rafts during the chemotaxis towards fMLP (Xue et al., 2004). Another 
study has also shown that although cholesterol was required for polarisation and 
redistribution of the FPR, cholesterol depletion had no effect on earlier signalling events such 
as intracellular Ca2+ flux (Rose et al., 2008). Furthermore a study by Dunzendorfer and co­
workers showed that treatment of neutrophils and monocytes with the statin pravastatin 
significantly decreased chemotaxis triggered by fMLP (Dunzendorfer et al., 1997). However, 
a study by Sitrin et al. contradicts these findings and suggests that the FPR is not located in 
lipid rafts neither does it require intact rafts for its signalling capacity (Sitrin et al., 2006). 
Although the FPR and the C5aR are often compared in the literature due to their structural 
similarities, evidence suggests that the C5aR is unlikely to form clusters at the membrane 
edge towards C5a. As already described in section 1.2.4.2, a study by Servant et al. found 
that although the C5aR appeared to cluster at the plasma membrane towards the C5a 
source, this was due to an increase in relative abundance of plasma membrane rather than 
preferential accumulation of the receptor at the leading edge (Servant et al., 1999). Despite 
this, a study by Nagao and co-workers found that cholesterol loading of mouse macrophages 
J774A.1 cells with cholesterol MpCD led to a significant decrease in transmigration towards 
C5a suggesting that the chemotactic functioning of the receptor is sensitive to membrane 
cholesterol (Nagao et al., 2007). However, this study did not investigate whether cholesterol 
loading had any effect on the clustering/membrane compartmentalisation of the C5aR, 
instead it found that cholesterol loading reduced activation of Rho A, a GTP binding protein 
involved in downstream signalling of the C5aR (Nagao et al., 2007).
1.3.2 Role of cholesterol on GPCR structural properties
Cholesterol within the plasma membrane can also affect the structural properties of proteins
and therefore their function. It does so by either a direct mechanism, where cholesterol can
bind directly to the protein, thereby altering its conformation, or indirectly, by influencing the
biophysical properties of the membrane lipid bilayer (Burger et al., 2000). The rhodopsin
receptor, for example, has been shown to be regulated by cholesterol content in both an
indirect and direct manner. Stimulation of this photoreceptor with light induces a
conformational change from its inactive to its active form. This change requires the receptor
to expand within the plane of the bilayer. In a high-cholesterol environment this transition is
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inhibited as the membrane becomes more rigid and therefore signalling is reduced (Albert 
and Boesze-Battaglia, 2005).
As lipid rafts are rich in cholesterol, GPCRs and their signalling components located 
in these regions tend to be sensitive to membrane cholesterol levels. For instance, 
experiments using neutrophils from neonates, which have more fluid plasma membranes due 
to lower cholesterol to phospholipid ratio, showed that slight rigidification of the plasma 
membrane using cholesteryl hemisuccinate enhanced the fMLP chemotactic function 
(Wolach et al., 1992). However, as described above 1.3.1, several studies have shown that 
membrane cholesterol is crucial for the redistribution of the FPR following its stimulation and 
to date no published studies have investigated whether cholesterol binds directly to the 
receptor. As very little is known about the membrane localisation of the C5aR it is difficult to 
speculate at this stage whether the structural properties of the receptor will be affected either 
directly or indirectly by cholesterol.
1.3.3 Effects of cholesterol on GPCR internalisation
Following stimulation of GPCR with their ligands many are desensitised by rapid 
phosphorylation and internalisation of the receptor. Where some GPCR are targeted to lipid 
raft regions following their activation, these microdomains can then facilitate receptor 
endocytosis as well as signal transduction (Pike, 2003). Although initially there were 
conflicting results as to whether C5aR internalisation was mediated by clathrin dependent or 
independent mechanism, it is now believed that following stimulation of the C5aR with C5a 
the receptor clusters into clathrin coated pits where it is then internalised in a p-arrestin, 
dynamin, and clathrin-dependent pathway (Gilbert et al., 2001, Licht et al., 2003, Braun et al., 
2003, Suvorova et al., 2005, Huttenrauch et al., 2005). However, as lipid raft dependent 
endocytosis is characterised by clathrin-independence, as well as cholesterol sensitivity, this 
would suggest that the C5aR is unlikely to be internalised in a lipid raft dependent manner, 
however it has not been investigated whether C5aR internalisation is dependent on 
cholesterol (Lajoie and Nabi, 2010).
Regulating GPCR internalisation by altering membrane cholesterol is another 
mechanism which cell surface expression can be regulated which will be discussed below in 
more detail.
1.3.4 Effects of cholesterol on GPCR expression
As cholesterol is a crucial component for maintaining membrane integrity, mammals have
developed several feedback regulation mechanisms to sustain cholesterol homeostasis
within the cell (see section 1.5) (Goldstein and Brown, 1990). Many genes that are involved
in cholesterol metabolism are regulated by sterol-regulatory-element-binding protein
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(SREBP), which allows the cell to sense cholesterol levels and regulate gene transcription of 
target genes accordingly. At high cholesterol levels, SREBP is trapped within the 
endoplasmic reticulum where it is bound to SREBP cleavage activator protein (SCAP) in its 
inactive form (Muller-Wieland et al., 1997, Maxfield and Tabas, 2005). Inactivation of 
SREBP leads to a reduction of cholesterol biosynthesis by reduction in gene transcription of 
HMG-CoA synthase and HMG-CoA reductase, as well as reducing uptake of LDL-cholesterol 
via down regulation of the LDL receptor gene. When cholesterol levels are low the SREBP- 
SCAP complex exits the endoplasmic reticulum and undergoes proteolytic cleavage to 
release SREBP. SREBP is translocated into the nucleus where it regulates the transcription 
of many genes such as HMG-CoA reductase, HMG-CoA synthase and LDL receptor gene 
(Muller-Wieland et al., 1997). Plasma LDL has also been shown to increase expression of 
the MCP-1 receptor CCR2, a GPCR, in the THP-1 cell line; furthermore its expression is 
dramatically increased on monocytes from hypercholesterolemic patients (Han et al., 1998). 
Later investigations found that in a mouse hypercholesterolemia model the CCR2 gene in 
circulating monocytes is under the transcriptional control of SREBP and PPARy within the 
promoter region (Chen et al., 2005, Han et al., 2005).
As cholesterol is an integral part of cellular membranes it can also affect expression 
of genes which encode cell surface molecules by affecting membrane fluidity and therefore 
the proper processing and targeting to plasma membrane. For instance simvastatin has 
been suggested to reduce surface expression of MHC-II molecules by disrupting the 
cholesterol-containing microdomains which are important for the transport and concentration 
of MHC-II at the cell surface (Kuipers et al., 2005).
1.4 Atherosclerosis
Atherosclerosis is the primary cause of heart disease in westernised societies. It is a highly 
complex disease where both environmental and genetic factors play an important role in its 
susceptibility and progression (table 1.5). Atherosclerosis is an inflammatory disease, 
initiated by endothelial dysfunction followed by chronic inflammation in the vessel wall (Ross, 
1999a). Atherosclerotic lesions are characterised by infiltrating immune cells (mainly 
monocytes, macrophages, T-cells and mast cells), chronic inflammation, lipid accumulation, 
cell-death and fibrosis. Unstable lesions may rupture causing thrombotic occlusions of the 
artery which can lead to serve clinical events such as myocardial infarction or ischaemic 
stroke (Libby, 2002).
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Table 1.5 Risk factors associated with cardiovascular disease. Adapted from (Lusis, 
2000).
Genetic risk factors Environmental risk factors
Elevated LDLA/LDL levels High fat diet
Reduced levels of HDL Smoking
Elevated levels of lipoprotein (a) Lack of exercise
Elevated blood pressure Infection agents
Elevated levels of homocysteine C Reactive protein
Family history
Diabetes and obesity
Elevated levels of haemostatic factors
Depression and other behavioural traits
Gender (male)
Systemic inflammation
Metabolic syndrome
1.4.1 Initiation of atherosclerosis
Early research, which focused on the link between hypercholesterolemia and the 
development of atherosclerosis, led to the lipid hypothesis model being proposed by Rudolf 
Virchow in 1856. However, simply reducing serum lipid levels did not prevent the 
development of the disease. In 1977 the response to injury hypothesis was proposed, which 
postulated that the lesions of atherosclerosis arise as a result of injury to the arterial 
endothelium (Ross et al., 1977). In response to endothelium injury, caused by mechanical, 
chemical or biochemical factors (table 1.5), inflammation and the formation of a 
fibroproliferative response begins, as a protective mechanism initally, however with time and 
continuing insult may become excessive (Ross, 1999b).
Endothelium dysfunction, thought to play a large role in the initial, progression and
complications of atherosclerosis, manifests itself by abnormal production of vasoactive
factors such as decreased nitric oxide production and adhesion molecule expression.
Disruption to the endothelial cells leads to an increased permeability that allows LDL to
diffuse within the vessel wall which may become retained by its interactions with matrix
proteoglycans (Boren et al., 1998). Trapped LDL can become modified by oxidation,
lipolysis, proteolysis and aggregation which in turn contributes towards the inflammatory
response and foam cell formation (Lusis, 2000). The recruitment of leukocytes, mainly
monocytes and T-cells, into the arterial intima represents an essential step in lesion initiation
and formation. Experimental evidence has shown that expression of adhesion molecules
VCAM-1 and P-selectin are increased on endothelium cells lining aortic plaques in rabbits
fed a high cholesterol diet, which is a prerequisite for recruitment of monocytes and T-
lymphocytes into the intima (Li et al., 1993, Cybulsky et al., 2001). Animal studies using
mice lacking chemokine MCP-1 and its receptor CCR2 have also shown that this
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chemotactic gradient is essential for the recruitment of monocytes into the arterial wall (Gu et 
al., 1998, Boring et al., 1998). A similar role has also been reported for IL-8 (Boisvert et al.,
1998). The recruitment of lymphocytes is achieved by a trio of IFNy inducible chemokines 
IP-10, Mig and l-TAC (Libby, 2002).
1.4.2 Atherosclerosis progression
Atherosclerosis develops slowly over many years (see figure 1.7 for schematic diagram of 
the different stages). The first observed stage in atheroma development is the formation of 
the fatty streak which can be seen in childhood (Stary, 2000). The formation of the fatty 
streak involves the activation of the recruited monocytes into macrophages by inflammatory 
cytokines such as TNFa or IFNy and macrophage colony-stimulating factor MCS-F. 
Activated macrophages rapidly take up oxidised LDL via scavenger receptors on their cell 
surface to become foam cells. The importance of scavenger receptors, SR-A and CD36, in 
formation of foam cells has been demonstrated in mice lacking these receptors, which show 
a modest reduction in atherosclerotic lesions (Suzuki et al., 1997, Febbraio et al., 2000). The 
accumulation of lipid-laden foam cells within the early lesion gives the appearance of fatty 
streak under the microscope hence its name.
Fatty streaks can progress into fibrous plaques by the proliferation and migration of 
vascular smooth muscle cells (VSMC) into the lesion, which is achieved by the secretion of 
growth factors and cytokines by macrophages and foam cells. Together the VSMC and 
leukocytes within the lesion secret extracellular matrix components, which give rise to the 
fibrous cap.
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1.4.3 Plaque rupture
As the atherosclerotic plaque develops, the lesion becomes overlaid with a fibrotic cap 
composed of collagen and elastin secreted by the VSMC (Rekhter, 1999). These more 
complex plaques contain a necrotic core which is rich in lipids and cellular debris from dead 
cells. At this point the plaques can restrict blood flow through the lumen of the artery; 
however the greatest danger is of plaque rupture and thrombus formation. Destabilisation of 
the fibrotic plaque occurs by the continual secretion of pro-inflammatory cytokines and matrix 
metalloproteinases (MMPs) by activated macrophages, T cells and mast cells, which in turn 
inhibit the proliferation of the VSMCs and reduce their collagen synthesis. Following plaque 
rupture prothrombotic lipids spill into the blood pool activating the coagulation cascade. 
Thrombus formation can cause occlusion of the artery leading to myocardial infarction (Ml), 
ischaemic reperfusion (l/R) injury or ischaemic stoke (Libby, 2002).
1.4.4 Complement in atherosclerosis
Atherosclerosis is a chronic inflammatory disease state, involving inflammation at all stages 
from initiation to destabilisation. The participation of C in the atherosclerotic process was 
first proposed over forty years ago by Geertinger and Sorensen who found that C6 deficient 
rabbits fed on high cholesterol diet had reduced atherosclerosis (Geertinger and Sorensen, 
1977). Although the C system has been well recognised for its pro-inflammatory role in 
atherosclerosis, it is now becoming clear that the C system is likely to have a role in 
protecting tissue from the accumulation of debris (Haskard et al., 2008).
C activation within atherosclerotic lesions occurs through activation of the CP and the 
AP (Torzewski et al., 1997, Vlaicu et al., 1985b). Potential triggers for C activation within the 
lesions include CRP (Torzewski et al., 1998a), auto-antibodies (Vlaicu et al., 1985c, Vlaicu et 
al., 1985b, Orekhov et al., 1991, Burnt et al., 2010) cholesterol crystals (Seifert and 
Kazatchkine, 1987), apoptotic cells, cellular debris and enzymatic modified LDL (Seifert et 
al., 1990, Torzewski et al., 1998b, Bhakdi et al., 1999, Klouche et al., 1999, Wieland et al.,
1999). Enzymatically modified LDL (E-LDL) represents the most abundant stimulus within 
the lesions and is capable of activating both the AP and the CP by the presence of circulating 
auto-antibodies against modified LDL (Seifert et al., 1990, Orekhov et al., 1991, Burut et al., 
2010).
Using immunohistochemistry several studies have identified evidence that C
components (C1q, C3c, C3d, C4, C9 and Bb) (Niculescu et al., 1987, Vlaicu et al., 1985a,
Vlaicu et al., 1985c, Vlaicu et al., 1985b, Vlaicu et al., 1985d), C receptors (CR1, CR3, C3aR
and C5aR) (Saito et al., 1992, Oksjoki et al., 2007) and C inhibitory proteins (DAF, factor H,
CD59, CR1 and clusterin) are present within atherosclerotic lesions (Niculescu et al., 1990,
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Seifert and Hansson, 1989a, Seifert and Hansson, 1989b, Seifert et al., 1992). C activation 
has also been demonstrated by formation of the terminal pathway complex C5b-9 within 
atherosclerotic lesions (Vlaicu et al., 1985a). Expression of C5b-9 was found to be higher in 
advanced fibrotic plaques compared with early lesions and fatty streaks, which led to the 
suggestion that there is a constant accumulation of these complexes within the lesion (Vlaicu 
et al., 1985a). In addition C5b-9 has been found to be co-localised with enzymatically 
modified E-LDL within early lesion, which has been suggested to induce foam cell formation 
(Seifert et al., 1990, Bhakdi et al., 1995, Torzewski et al., 1998b).
It has been suggested that the function of the C5b-9 complex within the 
atherosclerotic lesion is unlikely to involve complete lysis of the target cells due to the critical 
density required to achieve this but instead lower levels of disposition may be important for 
cellular signalling cascades and stimulate cell activation (Haskard et al., 2008). Several 
studies have shown that the sublytic assembly of C5b-9 on aortic SMC and endothelial cells 
induces their activation and proliferation (Niculescu and Rus, 1999). In SMC C5b-9 induced 
activation of ERK-1, c-Jun, JNK and p38-MAPK, resulting in an increased production of 
MCP-1, which may be important for the recruitment of monocytes during the initial stages of 
atherosclerosis (Niculescu and Rus, 1999, Torzewski et al., 1996). Furthermore, it was 
shown in endothelial cells that C5b-9 induces activation of the PI3K/Akt pathway, which was 
important for cell cycle progression and proliferation of the endothelial cells (Fosbrink et al.,
2006). To protect against formation of the C5b-9 complex on endothelial cells, Kinderlerer 
and colleagues have found that shear laminar stress can cause up-regulation of CD59 and 
therefore helps protect endothelial cells from activation (Kinderlerer et al., 2008).
C activation also leads to the generation of the anaphylatoxins C3a and C5a which in 
turn cause further inflammation (see sections 1.1.4 and 1.2.1). Both receptors C3aR and 
C5aR have been found to present within the human atherosclerotic plaques but not normal 
intimas by immunofluorescence and RT-PCR (Oksjoki et al., 2007). Furthermore, C5a has 
recently been suggested to contribute towards destabilising the lesions by increasing the 
secretion of MMP-1 and MMP-9 within the plaques (Speidl et al., 2011).
Several experimental models have been used to clarify the role of the C system in
vascular injury and atherosclerosis. Results from LdIR-/- C1qA-/- double knockout mice
suggest that activation of the CP has an anti-atherogenic role by removing apoptotic cells
from early lesions, as these mice had plaques three fold larger and more complex compared
to the control mice (Bhatia et al., 2007). Furthermore CP activation has been shown to
promote the phagocytosis of modified forms of LDL by human monocytes and monocyte
derived macrophages (Fraser and Tenner, 2010). The CP can also be activated by CRP
which can bind apoptotic cells and E-LDL aiding their phagocytosis in early lesions, however
at high concentrations of E-LDL the protective function of CP activation is overrun by
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potentially harmful accumulation of C5b-9 complexes (Bhakdi et al., 2004). Studies involving 
the LdIR-/- mice crossed with C3-/- mice found that these mice had greater plaque sizes 
compared with the control animals however the lesions did not advance beyond the fatty 
streak stage suggesting that a complete C system is essential for maturation of the plaques 
(Buono et al., 2002, Persson et al., 2004). LdIR-/- crossed with factor B -/- mice showed no 
significant difference in plaque size suggesting that the AP is not involved in atherogenesis 
(Persson et al., 2004).
Evidence from experimental animal models suggest that the terminal pathway has a 
pro-atherogenic role. Initial studies involving C6 deficient hypercholesterolemic rabbits 
showed that these rabbits contained significantly fewer lesion compared with C6 competent 
counterparts (Geertinger and Sorensen, 1977, Schmiedt et al., 1998). Similarly ApoE-/- C6- 
/- mice also showed significantly reduced plaque area and disease severity compared with 
control counter parts (Lewis et al., 2010). In agreement with the pro-atherogenic role of 
MAC, several studies have also found that CD59 -/- ApoE-/- mice have earlier death rate and 
larger plaque area with increased complexity (Lewis et al., 2010, Wu et al., 2009, An et al., 
2009). Interestingly a study by Patel and co-workers found C5-/- mice cross bred with ApoE- 
/- mice displayed no significant change in plaque size at the aortic root, however these 
studies were performed on mice fed a high fat diet for 22 weeks where disease is more likely 
to be in advanced stages (Patel et al., 2001).
1.4.5 Complement involvement in myocardial infarction
Following plaque rupture, thrombus formation can lead to occlusion of the artery and thereby 
causing ischaemic reperfusion (l/R) injury (Entman et al., 1991). The first phase of l/R injury, 
ischaemic phase, is mediated by anoxic injury caused by decreased mitochondrial ATP 
generation. The second phase, reperfusion phase, is an inflammatory process which further 
contributes to tissue injury beyond that generated already in the ischaemic phase (Szeplaki 
et al., 2009). It is believed that C activation induces cell damage and apoptosis and further 
amplifies the inflammatory response by up-regulation of adhesion molecules, activation and 
chemotaxis of polymorphonuclear cells (PMN), secretion of cytokines and reactive oxygen 
species via the generation of the anaphylatoxins and MAC (Szeplaki et al., 2009).
The C system was first implicated as an important mediator in the inflammatory 
reperfusion phase of l/R injury in 1971 by Hill and Ward who shown that C activation 
products were vital for the recruitment of neutrophils into Ml of rats (Hill and Ward, 1971). 
The importance of C activation has since been demonstrated by several studies that have 
shown that knock down or silencing of C3 is protective against l/R injury (Zhou et al., 2000, 
Zheng et al., 2006).
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Several studies involving the inhibition of C5 cleavage or blockade of C5a using 
antibodies have been shown to attenuate l/R injury suggesting that generation of the 
anaphylatoxin C5a and initiation of the terminal pathway are important mediates of C induced 
injury (Vakeva et al., 1998, Wada et al., 2001, Zhang and Carroll, 2007). Initial trails 
involving the humanised monoclonal anti-C5 antibody fragment, pexelizumab, which blocks 
the cleavage of C5 to C5a and C5b (Thomas et al., 1996), suggested that blocking systemic 
C5 improved survival rates of a patients with coronary bypass grafting but had no effect on 
survival rates or Ml end points (Granger et al., 2003, Verrier et al., 2004, Shernan et al.,
2004). Larger phase 3 clinical trails found no significant difference in the end-point of 
patients with coronary artery bypass receiving pexelizumab compared with placebo, although 
a reduction in Ml and death was observed 30 days postoperative (Verrier et al., 2004, Smith 
et al., 2006, Testa et al., 2008). However, clinical trials found that pexelizumab had no 
significant effect on infarct size or clinical outcome in patients with Ml (Mahaffey et al., 2003, 
Armstrong and Granger, 2007, Armstrong et al., 2007). It has been suggested that the 
difference between these findings is that pexelizumab given prior to surgery may reduce the 
generalised inflammation process, as observed by reduction in IL-6 and CRP following 
pexelizumab (Theroux et al., 2005). Whereas following Ml local inflammation and injury has 
become irreversible and C activation is already established, therefore invalidating the 
beneficial effects of administration of pexelizumab (Testa et al., 2008). Furthermore, Testa 
and co-workers suggest that following Ml penetration of pexelizumab into the affected tissue 
may be limited due to the microvascular obstruction (Testa et al., 2008). A study by 
Amsterdam and co-workers involving pre-treatment with monoclonal anti-C5a antibody prior 
to l/R injury of the descending coronary artery found that the antibody inhibited the neutrophil 
cytotoxic activity towards C5a but had no effect on MAC formation and neutrophil 
accumulation and therefore did not reduce infarct size in pigs (Amsterdam et al., 1995). 
Studies involving C5aR antagonists, such as PMX-53, have shown promising results by 
reducing l/R injury in rat intestine (Arumugam et al., 2002), kidney (Arumugam et al., 2003), 
liver (Arumugam et al., 2004b), limb (Woodruff et al., 2004) and mouse intestine (Fleming et 
al., 2003) following a period of ischemia (reviewed (Monk et al., 2007)).
1.4.6 Therapeutic strategies to lower serum lipid levels
As shown in table 1.5, atherosclerosis is a highly complex disease where both 
environmental and genetic factors play an important role in its susceptibility and progression. 
However, one of the primary risk factors associated with the disease is serum cholesterol 
levels.
Cholesterol is an important component of all biological membranes and is a precursor
of bile acid and steroid hormones. Cholesterol can be absorbed from the Gl tract or it can be
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synthesised by the liver but it circulates through the blood stream bound to lipoproteins (table 
1.6). Several epidemiological studies have shown that elevated levels of circulating LDL- 
cholesterol is a major risk factor for coronary heart disease and has direct relationship with 
onset of the disease, whereas circulating HDL-cholesterol is inversely proportional (Stamler 
et al., 1986, LRC-CPPT, 1984). The main strategy employed to reduce serum LDL- 
cholesterol is statin therapy, which has been shown to reduce both coronary heart disease 
incidence and mortality by 30 % (NCEP, 2002). Section 1.5 will discuss in more detail how 
statins lower serum LDL-cholesterol levels.
Another risk factor for atherosclerosis is elevated serum triglycerides, which is 
commonly associated with other non-lipid and lipid risk factors (NCEP, 2002). Similar to 
cholesterol, triglycerides can be absorbed from the Gl tract or they can be synthesised by the 
liver and are circulated in the blood bound to lipoproteins VLDL and chylomicrons (table 1.6). 
Fibrates are commonly given to reduce plasma triglyceride concentration by 30-50% (Barter 
and Rye, 2006). Fibrates can also increase levels of circulating HDL-cholesterol and 
occasionally they have been shown to reduce LDL-cholesterol levels (Barter and Rye, 2006). 
They exert their effects by activating PPARa receptor which is a major transcription factor for 
the regulation of intracellular and extracellular fatty acid metabolism. PPARa can stimulate 
lipoprotein lipase which increases the hydrolysis of triglycerides in VLDL or chylomicrons, 
liberating fatty acids that can be stored as fat or metabolised. PPARa can also stimulate the 
[3-oxidation and degradation of fatty acids (Paumelle and Staels, 2008).
Other lipid lowering therapeutic strategies include bile acid sequestrates, which when 
taken by mouth sequester bile acids in the intestine and therefore decrease absorption of 
cholesterol in the Gl tract and nicotinic acid, which can reduce hepatic synthesis of 
triglycerides (NCEP, 2002).
Table 1.6 Major classes of lipoproteins which cholesterol circulate blood stream.
Class Apo lipoprotein
Low density lipoprotein (LDL)
Accounts for 60-70% total serum cholesterol
Apo B
High density lipoprotein (HDL)
Accounts for 20-30% total serum cholesterol
Apo A-1 and - II
Very low density lipoprotein (VLDL) (triglyceride 
rich)
Accounts for 10-15% total serum cholesterol
Apo B-100, Apo C-l, -II and -III and 
Apo E
Chylomicrons (triglyceride rich) Apo B-48, Apo C-l, -II and -III and 
Apo E
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1.5 Statins
Statins are the most common drugs given to reduce circulating LDL-cholesterol levels as 
they have a good safety record and few drug-drug interactions (NCEP, 2002). Statins can 
lower serum cholesterol levels by two separate mechanisms. Firstly they inhibit HMG-CoA 
reductase, the rate-limiting step in cholesterol biosynthesis, and secondly they promote 
clearance of plasma LDL-cholesterol via LDL-receptor mediated endocytosis (NCEP, 2002).
1.5.1 Mevalonate pathway
The mevalonate pathway yields an important precursor, mevalonate, which is essential for 
generation of isoprenoid intermediates (figure 1.8). As well as being a precursor for 
cholesterol biosynthesis, these isoprenoid intermediates are also incorporated into other end 
products such as dolichol, required for glycoprotein synthesis, isopentyl adenine, present in 
some transfer RNAs, haem A and ubiquinone, which partake in electron transport, 
isoprenylated proteins, such as small GTPase mainly involved in intracellular signalling 
pathways; and steroid hormones (Goldstein and Brown, 1990). Thus correct regulation of 
the mevalonate pathway is crucial so that all cells can precisely synthesise enough 
mevalonate without the accumulation of potentially toxic metabolites such as cholesterol.
Regulation of the mevalonate pathway is complicated by the fact that cholesterol 
present in plasma, LDL-cholesterol, can enter the cell by LDL receptor (LDLR) mediated 
endocytosis (figure 1.8). It is therefore essential that each cell can carefully balance these 
external and internal sources of sterols well maintaining synthesis of enough mevalonate. 
Regulation can be achieved by negative sterol feedback loops which can down regulate 
HMG-CoA synthase and HMG-CoA reductase, as well as LDLR expression (figure 1.8) 
(Goldstein and Brown, 1990).
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Figure 1.8 Schematic diagram of the mevalonate pathway. The main end product of the 
mevalonate pathway, cholesterol, can be obtained from two sources: (1) the endogenous pathway by 
synthesis from acetyl CoA; and (2) the exogenous pathway by endocytosis of circulating LDL- 
cholesterol via LDLR. End products which incorporate products from the pathway (blue). Regulation 
of mevalonate is achieved by down regulation of LDLR, HMG-CoA reductase or HMG-CoA synthase 
via cholesterol mediated negative feedback loops (red). Adapted from (Goldstein and Brown, 1990).
1.5.1 Competitive inhibition of HMG-CoA reductase by statins
By inhibiting HMG-CoA reductase, statins are inhibiting the rate limiting step in cholesterol 
biosynthesis. The first statin to be identified, mevastatin, was isolated from Penicillium 
Citrinium. Although it was shown to be a potent inhibitor of HMG-CoA reductase, Kj of 1.4 
nM, it was also found to have unacceptable hepatocellular toxicity which led to its 
discontinuation (Endo et al., 1976). Characterisation of another secondary fungi metabolite, 
isolated from Aspergilla terreus, led to the identification of lovastatin, which was found to be a 
more potent inhibitor of HMG-CoA reductase, Kj 0.6 nM, and reduced cholesterol synthesis in
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human studies without the hepatocellular toxicity (Alberts, 1988, Alberts et al., 1980). Since 
then many other statins have emerged, both naturally occurring and chemically synthesised, 
and are now commercially available with ranging Kj values 0.1 to 2.3 nM.
All statins have a HMG-CoA like moiety which may be present in an inactive form. 
These pro-drugs need to undergo enzymatic hydrolysis in vivo to their active hydroxy-acid 
counterparts (Corsini et al., 1995). When active, statins are competitive inhibitors for HMG- 
CoA reductase and by occupying the HMG binding pocket and part of the binding surface for 
CoA they inhibit access of the HMG-CoA substrate to the enzyme (Istvan and Deisenhofer,
2001). The inhibitory concentration, Kj, of the statins in the nanomolar range is believed to 
be achieved by strong favourable van der Waals interactions between the bulky hydrophobic 
ring structures of the statins and the complementary surface of the HMG-CoA reductase 
(Istvan and Deisenhofer, 2001). Each of the different type of statins has slightly different 
interactions with the HMG-CoA reductase which may explain the ranging Kj values. It has 
also been suggested that the differences in the different statin potencies may be a result of 
different lipophilicity, with lipophilic statins (such as simvastatin and fluvastatin) being more 
likely to enter vascular cells by passive diffusion than hydrophobic statins (such as 
pravastatin and rosuvastatin) which primarily target the liver (Zhou and Liao, 2010). Further 
still, each statin differs slightly in their pharmacokinetics; for instance simvastatin has a 
bioavailability of 5%, Tmax of 1.3-2.4hrs and J y2 of 2-3 hrs, whereas, atorvastatin has a 
bioavailability of 12%, T max of 2-3hrs and T 1/2 of 15-30 hrs (reviewed in (Bellosta et al., 2004).
As well as statins, other inhibitors of cholesterol biosynthesis include zaragozic acids. 
Zaragozic acids, also known as squalestatins, were discovered by two independent groups 
of scientists as potent squalene synthesis inhibitors (Dawson et al., 1992, Baxter et al., 1992, 
Bergstrom et al., 1993). These fungal metabolites are believed to inhibit squalene synthase 
by effectively mimicking the binding of the pS-PP intermediate of sterol synthesis to the 
enzyme (Bergstrom et al., 1995). Despite being potent inhibitors of squalene synthase, their 
poor bioavailability after oral administration has meant that these metabolites are not used 
therapeutically to lower cholesterol but instead are often used experimentally (Amin et al., 
1997).
1.5.3 Increased clearance of serum cholesterol by statins
Another mechanism by which statins lower circulating LDL-cholesterol levels is that they can 
increase expression of LDLRs and therefore increase receptor mediated endocytosis of 
cholesterol mainly by the liver. This is achieved by the negative feedback loop shown in 
figure 1.8, where a decrease in intracellular cholesterol levels leads to the proteolytic 
activation of the transcription factor sterol response element binding protein-2 (SREBP-2) 
and subsequently to an up regulation of the LDLR gene (Brown and Goldstein, 1980).
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1.5.4 Pleiotropic effects of statins
Evidence from several large clinical trials, including CARE, LIPID and HPS, suggested that 
the cardiovascular benefits of statin therapy did not correlate fully with the magnitude of 
cholesterol lowering (Sacks et al., 1996, HPS, 2002, LIPID, 1998). Furthermore, statins were 
also found to reduce the risk of other disease processes, such as transplant-associated 
artheropathy, that are not associated with elevated lipid levels (Kobashigawa et al., 1995, 
Wenke et al., 1997). It is now well accepted that as well as reducing serum cholesterol 
levels, statins can have pleiotropic effects which are independent of cholesterol lowering 
(Jain and Ridker, 2005). These pleiotropic effects have been the main focus of statin 
research over the recent decades and are believed to improve coronary heart disease 
morbidity and mortality by several mechanisms including; improving endothelial function, 
inhibiting inflammation, reducing oxidative stress, improving plaque stability, and inhibiting 
pro-thrombotic outcome (table 1.7). It is believed that the majority of these pleiotropic effects 
are mediated by inhibition of isoprenoid intermediates, farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP) which serve as lipid attachments for the post- 
translational modification, isoprenylation, of a variety of proteins (Zhou and Liao, 2010). 
However, statins have also been shown to inhibit leukocyte function antigen-1, a member of 
the p2 integrin family which is involved in lymphocyte recirculation and leukocyte 
extravasation to sites of inflammation (Weitz-Schmidt et al., 2001). Statins were shown to 
bind to a novel allosteric site within the LFA-1, which was completely independent of 
inhibition of the mevalonate pathway (Weitz-Schmidt et al., 2001).
As discussed in section 1.4.4 the C system has been implicated in atherosclerosis at 
all stages from initiation to destabilisation of the plaque, yet relatively few studies have 
investigated the effects of statins on C. Mason and co-workers found that incubation of 
human umbilical cord and aortic EC with atorvastatin and simvastatin, significantly increased 
DAF expression, which suggests that one of the anti-inflammatory properties of statins is to 
protect the endothelium from C activation by increasing expression of C regulators on EC 
surface (Mason et al., 2002). Another study has since shown that DAF expression on 
monocytes and lymphocytes is significantly lower in patients with hyperlipidemia (Liu et al.,
2005). The expression of CD59 has also been shown to be increased on monocytes, 
lymphocytes and granulocytes in patients receiving atorvastatin therapy (Liu et al., 2005). It 
has also been proposed that one of the anti-inflammatory properties for the treatment of 
rheumatoid arthritis with statin therapy is to increase CD59 expression in vascular 
endothelium under hypoxic conditions (Kinderlerer et al., 2006).
Statins have previously been shown to have no significant effect on in vitro C 
activation by Lappegard and co-workers (2004). In this study they incubated normal human
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serum with atorvastatin and pravastatin in the absence or presence of aggregated human 
IgG (for CP activation) or cobra venom factor (for AP activation) and then measured the 
amount of complement activation products were generated (Lappegard et al., 2004). 
Although this study showed that statins did not directly alter C activation in vitro it did not 
investigate what indirect effects statins may have in vivo (Lappegard et al., 2004).
As previously described in section 1.4.4, one of the main pro-atherogenic roles of the 
C system is formation of the C5b-9 complex. A study by Viedt and co-workers found that 
incubation of VSMC with statins significantly reduced the pro-inflammatory effects of the 
C5b-9 complex (Viedt et al., 2003). They showed that incubation of VSMC with cerivastatin 
reduced C5b-9 activation of ERK and transcription factors AP-1 and NFkB, which in turn 
inhibited IL-6 secretion and cell proliferation (Viedt et al., 2003).
Table 1.7 Pleiotropic mechanisms of statins
Pleiotropic effect Proposed mechanisms
Improved endothelium 
function
•  Increased bioavailability of NO via up regulation of eNOS 
expression (Tsao et al., 1994, Laufs et al., 1998, Laufs and 
Liao, 1998).
Reduced inflammatory 
and immunological 
response
•  Reduced transmigration of leukocytes by down regulation of 
adhesion molecules (ICAM-1, P-, E- and L-selectin) on both 
EC and leukocytes (Niwa et al., 1996).
•  Reduced secretion of chemokines IL-8 and MCP-1 and 
expression CCR2 receptor which reduces leukocyte 
migration (Kothe et al., 2000, Romano et al., 2000, Veillard et 
al., 2006).
•  Reduced expression of inflammatory cytokines IL1b, IL-6 
and TNFa (Pahan et al., 1997).
•  Reduced co-stimulatory molecules, IFNy induced MCH II 
and CD40 activation and thereby regulating Th1/Th2 
commitment (Sadeghi et al., 2001, Townsend et al., 2004, 
Jasinska et al., 2007, Youssef et al., 2002).
Reduced oxidative stress •  Increased expression antioxidant genes and therefore 
protects against oxidative injury (Makabe et al., 2010).
•  Reduced reactive oxygen species generation (Rikitake et 
al., 2001).
Improved plaque stability •  Reduced MMP expression and secretion (Aikawa et al., 
2001, Fukumoto et al., 2001, Sundararaj et al., 2008, 
Fujimoto et al., 2008).
Reduce pro-thrombotic 
outcome
• Increased expression of tissue-type plasminogen activator 
expression (Essig et al., 1998).
•  Decreased expression of plasminogen activator inhibitor-1 
expression (Essig et al., 1998).
To date no published data has investigated what effect, if any, statins may have on 
the anaphylatoxins and their biological receptors. Due to their potent pro-inflammatory 
nature, reducing the biological functions of the anaphylatoxins by decreasing expression
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and/or reducing functioning of their receptors could have valuable implications in many 
inflammatory disease states, especially as the strategies to reduce l/R with anti-C5 and other 
inhibitors are not very successful so far.
1.6 Hypothesis and aims
The potent pro-inflammatory anaphylatoxin C5a exerts its biological actions via the C5aR, a 
GPCR. Cholesterol, a major risk factor in cardiovascular disease, is a crucial component of 
biological membranes. Furthermore cholesterol has previously been shown to regulate 
expression and function of several GPCRs. Statin therapy is the most widely used 
therapeutic strategy to lower serum cholesterol levels. Evidence suggests that statins also 
exert beneficial anti-inflammatory effects, thus further improving cardiovascular disease 
outcome. The principal aim of this thesis was to determine if the C5aR expression and 
function can be modulated by cholesterol. It is hypothesised that statins can exert anti­
inflammatory effects by down regulation of expression and/or function of the receptor for the 
potent pro-inflammatory anaphylatoxin C5a, C5aR.
The aims of this study are:
•  Investigate how C5aR expression is regulated.
•  Determine if statins effect C5aR expression, either basal levels or induced expression
•  Determine the subcellular plasma membrane localisation of the C5aR
•  Investigate whether statins affect the functioning of the C5aR
• Establish a model system in which the above can be measured
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Chapter 2
General Methods
2.1 Chemicals and reagents
2.1.1 General chemicals and reagents
Human recombinant tumour necrosis factor-a (TNFa) was from PeproTech (TNFSF2). 
N6,2’-0-Dibutyryladensine 3’,5’-cyclic monophosphate sodium salt (Bt2cAMP), 
Lipopolysacharide (LPS) Escherichia coli (E . coli) 0111.B4, Phorbol 12-myristate 13-acetate 
(PMA) and propidium iodide (PI) were from Sigma. O-phenylene-diamine (OPD) ELISA 
developing system (S2045) was from Dako (Cambridgeshire, UK). Bovine serum albumin 
(BSA) was from Fluka (05473). Ultrapure agarose was from Invitrogen. 96-well ELISA 
microtitre plates were from ICN Pharmaceuticals (7717305) (Basingstoke, UK). BSA (2 
mg/ml) standards (23209) were purchased from Pierce (Leicestershire, UK). Human 
recombinant C5a was from Calbiochem (Nottingham, UK). Fura-2-AM was purchased from 
Anaspec, Cambridge Bioscience, Cambridge, UK. All other standard laboratory chemicals 
and reagents were obtained from Sigma (Poole, UK).
2.1.2 Mammalian cell culture reagents
All cell culture RPMI media, penicillin/streptomycin/glutamine, sodium pyruvate, foetal calf 
serum (FCS) and tissue culture flasks were obtained from Invitrogen (Paisley, UK) unless 
otherwise stated. Ficoll-Paque™ (17-1440-02) was from GE Healthcare (Buckinghamshire, 
UK).
2.1.3 Commercial antibodies
Monoclonal mouse anti-C5aR (S5/1), anti-GAPDH (SC-47724) and polyclonal rabbit anti- 
C5aR (H-100) were from SantaCruz. Primary antibodies anti-a tubulin (DM1 A) was from 
Calbiochem, and anti-intracellular glycophorin C domain (BRGL100) and anti-CD59 (Bric229) 
were from International Blood Group Reference Laboratory (IBGRL, Bristol, UK).
The following secondary antibodies were used: peroxidase-conjugated rabbit anti­
mouse IgG (RAM-HRPO) and goat anti-rabbit IgG (RAM-HRPO) from Stratech (Suffolk, UK). 
FITC-conjugated goat anti-mouse IgG (GAM-FITC) was from Dako. Goat anti-mouse IgG 
conjugate with Alexa-647 was from Invitrogen.
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2.1.4 Protein biochemistry reagents
All blue precision plus protein standards were from BioRad (161-0373). 30% acrylamide 
(37.5:1) was from Severn Biotech Ltd (20-2100-10). Supersignal chemiluminescence 
substrate (ECL) was from Pierce (34080). Hybond nitrocellulose (RPN3032D) was 
purchased from GE Healthcare Lifesciences.
2.1.5 Molecular biology reagents
Taq polymerase, Q reagent and deoxynucleoside triphosphates (dNTPs) were from Qiagen. 
1 Kbp DNA ladder molecular weight markers (10787-018) were from GIBCO and 100 bp
markers were from Roche (1721933). Primers were ordered from MWG-Biotech AG.
2.2 Buffers
2.2.1 General buffers
•  Phosphate buffered saline (PBS): 145 mM NaCI, 3 mM Na2H P 04 and 2.5 mM Na2H P 04 in 
dH20 , pH 7.4
• FACS buffer: 1 % BSA, 0.01 % NaN3 in PBS, pH 7.4
• Krebs/Hepes buffer: 1.2 M NaCI, 2.5 M Hepes, 0.48 M KCI, 0.12 M KH2P 0 4, 0.12 M
M gS04.7H20 , 0.13 M CaCI2.2H20 , pH 7.4
•  Balanced Saline Solution (BSS): 137 mM NaCI, 2.7 mM KCI, 81 mM Na2H P 04, 1.5 mM 
KH2P 0 4, pH 7.3
2.2.2 Protein biochemistry buffers
•  Stacking acrylamide gel buffer: 0.5 M Tris-HCI, 0.4 % (w/v) SDS, pH 6.8.
• Separating acrylamide gel buffer: 1.5 M Tris-HCI, 0.4 % (w/v) SDS, pH 8.8.
•  Running buffer: 190 mM glycine, 24.8 mM Tris, 0.5 %(w/v)
•  Protein sample buffer (non-reducing): 0.1 M Tris, 10 % (w/v) glycerol, 2 % (w/v) SDS, 0.05
% (w/v) bromophenol blue, pH 6.8.
•  Transfer buffer: 26 mM Tris, 192 mM glycine, 20 % (v/v) methanol
• Blocking buffer (for western blotting): 5 % (w/v) fat-free milk (marvel) in PBS/Tween20 (0.1 
%).
2.2.3 Molecular biology buffers
•  TAE (50 x): 2 M Tris, 2 M acetic acid, 50 mM EDTA, pH 8.5.
•  DNA/RNA sample buffer: 50 mM EDTA pH 8.0, 50 % (v/v) glycerol, 0.25 % (w/v)
bromophenol blue.
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2.3 Methods
2.3.1 General cell culture
U937 were obtained from European Collection of Cell Cultures (U937Ec) and from Dr Peter 
Monk Sheffield University, UK (U937PM). U937 cells previously transfected with human 
C5aR (U 9 3 7 C5aR) (Kew et al., 1997) were obtained from Dr Eric Prossnitz State University 
of New  York at Stony Brook, USA.
All cell cultures were maintained at 37°C in humidified C 0 2 (5%) buffered incubators 
(Hera cell 150, Heraeus). All U937 cell lines were maintained in complete RPMI 1640 
(Invitrogen, 31870-025) media containing 10 % FCS, 100 U/ml penicillin, 100 pg/ml 
streptomycin, 290 jug/ml L-glutamine and 1 mM sodium pyruvate. Depending on cell type, 
cells were routinely split every 2-3 days as follows: U937Ec cells were split approximately 1 in 
10, U937pm cells were split approximately 1 in 4 and U 9 3 7 C5aR were split approximately 1 in 
8.
2.3.2 Isolation of peripheral blood mononuclear cells
Non-clinical buffy coats were obtained from Welsh Blood Service (Cardiff, UK). 
Approximately 40 ml of buffy coat was mixed with approximately 150 ml of RPMI. 12 ml of 
buffy coat was then gently overlaid on 8 ml of RT Ficoll-Paque™ (17-1440-02). The samples 
were centrifuged for 20 min at 750 g and stopped without breaking. The serum was 
discarded and the peripheral blood mononuclear cells (PBMC) interface was collected. Two 
samples were pooled into a new universal tube and resuspended in a total volume of 20 ml 
RMPI. Samples were centrifuged for 12 min at 370 g with break. The supernatant (s/n) was 
discarded; cell pellets were gently resuspended in small volume of RPMI and then two 
samples were pooled and resuspended in a total volume of 20 ml RPMI. The samples were 
centrifuged again for 10 min at 120 g. The s/n was discarded; cell pellets were gently 
resuspended in small volume of RPMI and then two samples were pooled and resuspended 
in a total volume of 20 ml RPMI. The samples were centrifuged for 8 min at 90 g. The s/n 
was discarded and the cell pellets were resuspended in a total volume of 9 ml of 10 % 
DMSO, 20 % FCS and 70 % RPMI. 1 ml aliquots (1 x 108 cells) were added to cryovials 
(Nunc), which were then placed in a Cryol freezing container filled with isopropanol. 
Following 24 hr in the -80 °C freezer (New Brunswick Scientific), the vials were transferred to 
liquid N2 storage containers (Taylor-Wharton). Cells were revived from liquid N2 as described 
below in section 2.3.4. For flow cytometry experiments cells were resuspended at 1 x 106 
cell/ml and for ELISA cells were resuspended at 1.5 x 104 cell/ml in RPMI supplemented with
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15 % FCS, 100 U/ml penicillin, 100 pg/ml streptomycin, 290 pg/ml L-glutamine and 1 mM 
sodium pyruvate.
2.3.3 Isolation of human neutrophils
20 ml of whole blood was collected form healthy volunteers into 200 pi heparin (1000 U/ml, 
CP Pharmaceuticals UK). The heparinised blood was then mixed with 5 ml 6 % dextran T70 
(Pharmacia, 17-0280-07) in BSS and incubated at RT for 40 min without agitation. The 
upper plasma phase was removed using pasture pipette and centrifuged at 750 g for 1 
minute. Supernatant was removed and cell pellet was gently resuspended. The remaining 
erythrocytes were lysed with 5 ml of sterile H20  for 30 s and neutralised with 20 ml BSS. 
The cells were centrifuged again for 1 minute at 750 g. The s/n was discarded and the cell 
pellet was gently resuspended in 5 ml Krebs/Hepes. The cell suspension was layered over 
5ml Ficoll-Paque™ and centrifuged for 25 min at 400g. The upper layers were discarded 
and cell pellet containing the neutrophils was washed and resuspended in either 
Krebs/Hepes, PBS or RPMI depending on what experiment they were later used for.
2.3.4 Cryopreservation of cells
Cells growing in log phase were washed twice in sterile 0.9% NaCI. The cells pellets were 
then resuspended in 1ml filtered sterilised freezing medium (10% (v/v) DMSO, 90% (v/v) 
FCS) and were then added to cryovials (Nunc). The cryovials were then placed in a Cryol 
freezing container filled with isopropanol, which provides a constant cooling rate of 1 °C per 
minute when placed in the -80 °C freezer (New Brunswick Scientific). After 24 hrs in the vials 
were transferred to liquid N2 storage containers (Taylor-Wharton) for long term storage.
Cells were revived from liquid N2 storage by placing the cryovials in a 37 °C water 
bath until completely thawed. The cells were washed twice in pre-warmed cell culture 
medium to remove the DMSO, and cultured as normal.
2.3.5 Stimulation of cells in culture
Incubation of cells with reagents was carried out by seeding the cells at a low density 
(typically 1-2.5 x 105 cell/ml) in fresh culture medium containing the required reagents, and 
culturing at 37 °C with 5 % C 0 2 for the required amount of time. When adding a volume of 
reagent, such as simvastatin, to cells in culture, controls were carried out to ensure uniform 
incubation volumes by adding the same volume of control buffer or vehicle reagent to all 
other wells/ flasks.
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2.3.6 Flow cytometry
Cells were harvested from culture and washed twice in PBS by centrifugation (1200 rpm for 3 
min). The cell number was calculated by resuspended the cell pellet in 3-5 ml of PBS, then 
10 (xl cell solution was removed and added to a Bright-line cell counting chamber (Sigma) 
and counted. The cells were centrifuged again for 3 min at 1200 rpm and resuspended at 
5x10® cell/ml in FACS buffer. 50 pi of cells was incubated with 50 pi of the primary antibody 
(1-10 pg/ml) in a round bottomed 96-well microtitre plate. Following incubation for 30 min on 
ice, the cells were washed twice with 200 pi FACS buffer/well. The cells were incubated for 
a further 30 min on ice with 50 pi of the fluorescently labelled secondary antibody (typically 
diluted 1 in 100 with FACS buffer). The cells were washed twice with FACS buffer (200 
pl/well) and resuspended in 200 pi 1% paraformaldehyde (diluted in FACS buffer from 4 % 
stock). Background fluorescence was determined using cells stained with secondary 
antibody alone, or incubated with an isotype control primary antibody. Cell fluorescence was 
analysed using a FACSCalibur flow cytometer (BecktonDickinson) within 5 days of fixing. 
Dead cells were excluded from analysis by their characteristic forward and side scatter. Data 
was analysed using FlowJo Software. For individual experiments, data is expressed as 
mean fluorescence intensity (MFI), +/- SEM. For repeat analysis data is expressed as either 
percentage or relative change compared with the mean control values unless otherwise 
stated.
2.3.7 SDS-polyacrylamide gel electrophoresis
Acrylamide gels were prepared for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
from stock solutions according to the method of Laemmli (Laemmli, 1970) (see table 2.3.1). 
The percentage of gel used to separate proteins was dependent on the size of the protein. 
Gels (1.5 mm thickness for western blotting or 0.75 mm for zymography) were cast using the 
Hoefer Mighty Small Casters according to manufacturer’s instructions. Immediately after 
pouring the separating gel, the gel was overlaid with 1 ml ethanol to remove any bubbles. 
Once the gel had polymerised, the ethanol was poured off and the stacking gel poured, using 
10 or 15 well combs to create the wells. Once the stacking gel had polymerised the gel was 
assembled into the Hoefer Mighty Small Gel Electrophoresis apparatus and the running 
buffer was added to both the upper and lower chambers. When the tank was full the comb 
was removed and 15 pl-30 \x\ of sample, mixed 1:1 with sample buffer was added to each 
well using a Hamilton Microliter syringe (Hamilton, Switzerland). Electrophoresis was carried 
out at a constant current of 40 mAmp per gel, with continual cooling from passing cold water 
through the electrophoresis unit, until the pre-stained markers (Bio-Rad) had reached the 
desired resolution.
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Table 2.3.1 SDS-PAGE components
Gel component/ 
15 ml
Separating gel 
(12.5%)
Separating gel 
(7.5%)
Stacking gel 
(4%)
Stacking buffer - - 1.2 ml
Separating buffer 3.75 ml 3.75 ml -
30% acrylamide 6.05 ml 5.025 ml 0.675 ml
dH20 150 pi 6.06 ml 3.025 ml
10% w/v ammonium 
persulphate
150 pi 150 pi 50 pi
TEMED 15 pi 15 pi 5 pi
2.3.7.1 Detection of proteins by western blotting
i) Transfer of proteins to nitrocellulose membrane
Following the separation of the sample by SDS-PAGE (as described above), the proteins 
were then transferred onto nitrocellulose membrane (Hybond, GE Health Care) for western 
blotting. Gels were first equilibrated for 10 min in transfer buffer. Then a ‘sandwich’ was 
created of; 1 thin sponge, 2 pieces of filter paper, nitrocellulose membrane, acrylamide gel, 2 
pieces of filter paper and 2 thin sponges, all of which had been pre-soaked in transfer buffer. 
Once the sandwich had been assembled it was placed into the Hoefer Transfer Unit 
apparatus, according to the manufacturers instructions, with the membrane placed between 
the gel and the positive electrode. The proteins were transferred onto the nitrocellulose 
membrane by electrophoresis in transfer buffer for 1 hr at 100 V  with constant cooling by 
water passing across the base of the apparatus.
ii) Immuno-labelling of protein on nitrocellulose membrane
To prevent non-specific binding of the antibody, the membrane was blocked either over night 
(o/n) at 4 °C or 1 hr at RT in 25 ml blocking buffer (5 % fat-free milk in PBS/Tween 0.1 %) 
with constant rolling using Denley Spiramix 10 (Jencons). To enhance the signal for the 
C5aR both the primary and secondary antibodies were diluted with SignalBoost 
Immunoreaction kit (Calbiochem) according to manufacturers instructions mixed 1:1 with 
blocking buffer. The nitrocellulose membrane was then incubated with primary antibody 
(diluted 1 in 200) at RT for 1 hr. The membrane was washed with 3 x 25 ml PBS/Tween (0.1 
%) for 15 min and incubated for another 1 hr at RT with appropriate HRPO-conjugated 
secondary antibody (diluted 1 in 2000). Membranes were washed 3 x 15 min with 
PBS/Tween (0.1 %), followed by 2 x 15 min with PBS.
iii) Detection of immuno-labelled proteins
Detection of the immuno-labelled proteins was carried using enhanced chemiluminescence 
(ECL) system (Pierce, 34080). The ECL system generates light via the oxidation of luminol
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in the presence of H20 2 by the horse-radish peroxidase conjugated to the secondary 
antibody. A stable peroxidase solution was mixed with an equal volume of luminol containing 
buffer, 1 ml of this solution was evenly laid over the nitrocellulose membrane and was 
incubated for approximately 1 minute. Excess solution was removed as the membrane was 
placed between two transparent plastic sheets. This was placed in a photographic cassette 
and exposed to X-ray film for various time periods, ranging from 5s -  o/n, depending on the 
intensity of the chemiluminescence signal.
2.3.8 Ca2+ signalling
Intracellular Ca2+ release was measured using the technique previously described (Davies et 
al., 1991). Cells were harvested, washed and resuspended at 1 x 107 cell/ml in RPMI. The 
cells were incubated in the absence or presence of 1 pM Fura-2-AM for 30 min at RT. The 
cells were washed twice with PBS and then resuspended at 1 x107 cell/ml in Krebs/Hepes. 
Ca2+ measurements were performed in a flat bottom 96 well plate using FLUOstar OPTIMA 
plate reader (BMG Labtech, UK) pre-warmed at 37°C. 100 pi of cells were mixed with 100 pi 
Krebs/Hepes buffer. Following an equilibration period of approximately 5 min, fluorescence 
intensity measurements (2 mm orbital scanning) were taken at emission wavelength 510 nm 
every 5 s following stimulation with excitation wavelength 340 nm, for Ca2+ saturated form, 
and 380 nm, for Ca2+ free chelator. The ratiometric measuring between Ca2+ bound and 
unbound forms of the dye significantly reduces the effects of uneven loading, leakage of dye 
and photobleaching. Measurements were paused while the cells were being stimulated with 
5 nM C5a. Following the addition of C5a (10 pi, final concentration 5 nM) the fluorescent 
intensity measurements were continued immediately. Once the Ca2+ levels appeared to 
return to basal levels with cells were lysed with 10 pi Triton-X100, final concentration 0.5 %, 
to obtained maximum Ca2+ binding to the dye ( R max)- Once the fluorescence intensity had 
plateaued, Ca2+ ions were chelated by the addition of 40 pi EGTA, final concentration 0.36 M, 
to give Rmin. Both the Rmax and the Rmin are crucial for the calibration and estimation of the 
intracellular Ca2+ release.
To estimate intracellular calcium release following stimulation of the cells with C5a, 
the dissociation constant (Kd) needs to be calculated by using equation 1. Once the Kd had 
been determined this allowed the estimation of the intracellular Ca2+ at every 5 s 
measurement using equation 2. Both equations are from (Al-Mohanna and Hallett, 1988).
Equation 1 Kd = Resting [Ca2+] (Rmay-R)
( R “Rmin)
Resting [Ca2+] = 100 nM
R = Base line fluorescence intensity ratio FA,i /FA,2 in which (340 nm)
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and X2 (380 nm) are the fluorescence detection wavelength.
Rmax= Maximum fluorescence intensity ratio FX^FX2 following lysis with 
Tx100
Rmin = Fluorescence intensity ratio FXJFX2 following chelating ions with 
EGTA
Equation 2 [Ca ] — Kd (Runknown ~ Rmm)
(Rmax” Runknown)
Kd = Dissociation constant 
Runknown = Base line fluorescence intensity ratio FXJFX2 in which X1 (340 nm) 
and X2 (380 nm) are the fluorescence detection wavelength.
Rmax= Maximum fluorescence intensity ratio FX^FX2 following lysis with 
Tx100
Rmin = Fluorescence intensity ratio FX1/FX2 following chelating ions with 
EGTA
2.3.9 Propidium iodide exclusion assay
To discriminate between live and dead cells, cells were stained with propidium iodide (PI). PI 
is a dye that intercalates with DNA and RNA, however is excluded from viable cells due to 
their non-porous membrane. Once the cells loose their membrane integrity, due to cell 
death, PI enters the cell and binds to DNA or RNA, thus increasing their fluorescence 
intensity.
Once the cells had been harvested they were washed twice with PBS. The cells 
were counted and resuspended at 5 x 106 cell/ml in FACS buffer. 50 pi of cells was then 
mixed with 50 pi FACS buffer containing 5 pg/ml PI, in a 96 well microtitre plate, and 
incubated on ice for 30 min. The cells were washed twice with 200 pi of FACS buffer and 
immediately analysed by flow cytometry. Percentage cell death was calculated by gating the 
PI positive cells and calculating their percentage from the whole population counted.
2.3.10 Bradford assay
Bradford assay was performed to quantify cellular lysate protein concentrations. A BSA 
standard curve (25-2.5 pg/ml) was made by diluting 1 mg/ml BSA standard (Pierce) with the 
same sample buffer as cellular lysate, a 0 pg/ml which consisted of sample buffer alone was 
also included in the standard curve. The samples to be analysed were diluted (typically 1/20 
to begin with and then performing doubling dilutions) in the sample buffer to achieve a 
sample concentration that lied within the standard curve. In triplicate, 100 pi of the samples 
and BSA standard curve was added to a flat bottom 96-well microtitre plate and 100 pi of RT 
coomassie protein reagent (BioRad; 1856209). The plate was then incubated at RT for 10 
min with gentle shaking. The optical density was measured at 595 nm and sample 
concentrations were calculated from the standard curve, taking into account dilution factors.
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2.3.11 Analysis of DNA by agarose gel electrophoresis
The molecular weight, quality and quantity of DNA fragments was analysed by agarose gel 
electrophoresis. To make the agarose gel, 0.8-2% (w/v) ultra-pure agarose (Invitrogen) was 
added to TAE (1x) and heated for 1 minute in a microwave until completely dissolved. The 
clear solution was allowed to cool to 50 °C after which ethidium bromide was added (0.2 
pg/ml final concentration), the solution was mixed, poured into a gel tray and allowed to set 
at RT. Once the gel was set, it was placed into an electrophoresis tank containing TAE (1x) 
according to the manufacturers instructions (Mini Sub Cell GT, BioRad). DNA samples (5-10 
pi) were mixed with an equal volume of DNA sample buffer and carefully loaded into the 
wells of the agarose gel. Either 10 Kbp or 1 Kbp DNA molecular size markers were also 
loaded onto the agarose gel in order to estimate the size of the DNA fragment analysed. 
Electrophoresis was carried out at a constant voltage (100V) until the dye front had migrated 
approximately 2/3 through the gel. The gel was visualised on a UV transilluminator lamp and 
photographed using gel documentation system (BioRad) and Quantity One software 
(BioRad) for image acquisition.
2.3.12 Statistics
Data was expressed as mean ± standard error of the mean as determined by n samples (n = 
3 unless otherwise stated) for each condition and analysed using GraphPad Prism software. 
Statistical analysis was carried out by One-way ANOVA, followed by either Tukey’s 
multicomparison test which compares all pairs of data or Dunnett’s test which compares all 
sets of data with a set control, or Two-way ANOVA followed by Bonferroni post test using 
confidence intervals of 95 %. Differences were considered significant at values of p<0.05.
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Chapter 3
Regulation of basal levels of C5aR expression
3.1 Introduction
It was first decided to investigate how basal C5aR expression is regulated in the mammalian 
monocytic U937 cell line. To achieve this both the transcriptional control mechanisms, as 
well as, mRNA stability of the C5aR transcripts, will be investigated using EGFP reporter 
constructs.
3.1.1 Methods of regulating gene expression
There are several steps utilised in eukaryotes to control expression of a gene from 
transcription to the production of an active protein, figure 3.1.1. Transcription, the first 
regulation step, allows DNA dependent synthesis of nascent RNA. The nascent RNA is then 
processed by the addition of the 5’cap, splicing out of introns and 3’cleavage and 
polyadenylation (Proudfoot et al., 2002). Before the mRNA can be translated into protein, it 
is first transported into the cytoplasm via the nuclear pore complex. This nuclear-cytoplasm 
compartmentalisation of both mRNA and proteins required for regulating gene expression is 
an important regulation mechanism (Reed and Hurt, 2002). Once in the cytoplasm, the 
mRNA transcripts are either translated into protein, via the ribosome, or targeted for 
degradation. Following protein synthesis the activity of the protein can further be regulated 
by post-translational modifications, such as phosphorylation, glycosylation and 
isoprenylation. Although figure 3.1.1 depicts the stages involved in gene regulation as 
individual steps, it is known that the protein factors responsible for each step (from 
transcription to translation) are functionally and sometimes physically connected (Orphanides 
and Reinberg, 2002). There are no general rules as to the exact mechanism in which a gene 
may be regulated, as different genes are regulated at different stages. Here the regulation of 
gene transcription and mRNA stability will be discussed in more detail and their role in 
regulating the expression of the C5aR will be examined.
57
Nucleus Cytosol
mRNA
degradation
control
RNA
transport
control
Translation
control
Transcriptional control RNA processing 
control
Inactive
protein
Protein
activity
DNA mRNA
Protein
mRNA
Inactive mRNA
Primary
RNA
transcript
control
Figure 3.1.1 Schematic diagram illustrating the different control mechanisms for 
regulating eukaryote gene expression.
3.1.2 Transcription control
Transcription requires both general transcription factors, which initiate transcription, and RNA 
polymerase II, which catalyzes DNA-dependent synthesis of the nascent RNA. Unlike 
ubiquitously expressed genes, transcription of specific genes whose proteins define a certain 
cell lineage or stage in cell cycle or development require promoter specific transcription 
factors whose activity is tightly controlled (Woychik and Hampsey, 2002).
Transcriptional control can be achieved by regulating the binding of transcription 
factors to their regulatory elements, as well as, regulating the activity of these factors 
themselves. Binding of transcription factors to their regulatory elements is greatly influenced 
by the chromatin structure. Heterochromatin is highly condensed and is composed of 
untranscribed regions of the genome, whereas euchromatin is more accessible to 
transcription factors and is composed of transcribed genes (figure 3.1.2) (Richards and Elgin, 
2002, Narlikar et al., 2002). The activation of signalling cascades generally ends with the 
activation of transcription factors. The activity of these factors is regulated by several 
methods including compartmentalisation and post-translational modifications (Orphanides 
and Reinberg, 2002). Once activated, these transcription factors bind to their sequence 
specific DNA elements and with the cooperation of chromatin modifying complexes and other 
co-regulators, they lead to local chromatin re-modelling which allows access of RNA- 
polymerase II and the general transcription machinery to the promoter (McKenna and 
O'Malley, 2002, Narlikar et al., 2002, Orphanides and Reinberg, 2002).
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Figure 3.1.2 Schematic diagram illustrating how gene transcription can be regulated.
AT = activators of transcription complex which contains chromatin modifying enzymes and co­
regulators; TF = transcription factors which binds to regulatory cis-acting elements; GTFs = general 
transcription factor machinery.
3.1.2.1 Transcriptional regulation o f the C5aR gene
The importance of the C5aR has been documented in a variety of pathological conditions 
(see section 1.2.7), despite this very little is known about the regulation of expression. As 
previously described in section 1.2.5 several studies have investigated the transcriptional 
regulation of cell specific, basal levels and induced expression of the C5aR in both human 
(Gerard et al., 1993) and murine cell lines (Hunt et al., 2005, Martin et al., 2007).
Gerard et al. investigated the transcriptional control of the human C5aR using CAT 
(chloramphenicol acetyltransferase) reporter construct. The reporter construct contained ~- 
350bp of the C5aR promoter region, exon 1 and ~450bp of intron 1 (see figure 1.6, Chapter
1) (Gerard et al., 1993). By transiently transfecting the reporter construct into rat basophilic 
lymphoma (RBL) and the neuroblastoma SK-N-SH cell lines, they found that this construct 
contained a cell type specific suppressor activity within -346bp and -225bp from the start 
codon, which prevents the neuroblastoma SK-N-SH cell line from expressing endogenous 
C5aR (Gerard et al., 1993). They identified a CCAAT site at position -280bp and speculated 
this may be responsible for the strong suppressor activity in this region. Deletion 5’ from - 
82bp to -49bp resulted in the reporter activity dropping to baseline levels, suggesting that 
strong promoter activity is present within this region which they speculate could be a putative 
TATAA motif (Gerard et al., 1993).
As well as investigating how cell specific transcriptional regulation of the C5aR gene 
is achieved, Gerard and co-workers also investigated regulation of PMA induced C5aR
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expression. They found that treatment of the RBL cells, which had been transiently 
transfected with the reporter construct, when incubated with PMA, doubled the CAT reporter 
activity. Whereas treatment of the neuroblastoma SK-N-SH cell line with PMA had no effect 
on the CAT reporter activity. They speculated that an AP-1 site could be responsible for the 
increased transcriptional activity in the RBL cells, whereas this activity is suppressed in the 
SK-N-SH cell line (Gerard et al., 1993).
Another group has focused on transcriptional regulation of the mouse C5aR (Hunt et 
al., 2005, Martin et al., 2007). By using 5’ deletions of the mouse C5aR luciferase reporter 
construct (from -2240bp to +38bp), Hunt and co-workers found that the mouse C5aR 
promoter region (-2278bp to -232bp) contained a cell type specific suppressor element which 
prevents the B16 melanoma cell line from expressing C5aR mRNA detected by RT-PCR, 
whereas, this luciferase reporter promoter construct was active in both the mouse 
macrophage (RAW 264.7) and endothelial (bEnd.3 and mHEVc) cell lines (Hunt et al., 2005). 
Furthermore, they found that the majority of the region cloned (-2278bp to -232bp) was 
dispensable for expression in the RAW 264.7, b.End3 and mHEVc cell lines. Hunt and 
colleagues also found that deletion of fragments between -232bp to -132bp and -132bp to - 
90bp, resulted in approximately 40% and 80% reduction in promoter activity respectively, in 
the RAW 264.7, b.End3 and mHEVc cell lines. They identified the transcriptional regulatory 
site most critical for the promoter activity within the -132bp to -90bp is a putative CCAAT site, 
which specifically binds nuclear factor-Y (NF-Y), but not c-Fos or Ets1/2, as determined by 
supershift assay (Hunt et al., 2005). Interestingly the CCAAT site was shown to be 
completely conserved between the human and the mouse sequence, however, its role in 
regulating human C5aR transcription was not investigated (see appendix 9.3 for human and 
mouse C5aR promoter aligned) (Hunt et al., 2005). This study also investigated the role of 
other putative sites, including NFkB (-241 bp), Octamer (-366bp), AP-4 (-273bp), GATA (- 
298bp) and CP-2 (-155bp), by site directed mutagenesis these results are summarised in 
table 3.1.1.
As well as investigating regulation of basal C5aR expression in mouse cell lines, Hunt 
and co-workers also showed that 10ng/ml LPS increased C5aR expression three fold in the 
RAW 264.7 cell line. To further investigate whether any of the putative sites mutated by site 
directed mutagenesis, they incubated the RAW 264.7 cells, which had been transiently 
transfected with the mutant reporter constructs, with 10ng/ml LPS for 18 hrs and then 
monitored CAT activity. They found that LPS increased luciferase activity in NFkB, Oct1, 
AP-4 and GATA mutants, but not CCAAT and CP-2 mutants, suggesting that the putative 
CCAAT and CP-2 sites are important for LPS induced expression of the mouse C5aR in the 
RAW 264.7 cell lines (Hunt et al., 2005).
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Table 3.1.1 Summary of site directed mutagenesis results of putative transcription factor site in 
mouse C5aR promoter region published by (Hunt et al., 2005).
Site of 
mutation
RAW 264.7 b.End3 mHEVc LPS stimulated 
in RAW 264.7
CCAAT (-96bp) Reduced 
reporter activity
Reduced 
reporter activity
Reduced 
reporter activity
Abolished LPS 
induced activity
CP-2 (-155bp) Reduced 
reporter activity
No effect Reduced 
reporter activity
Abolished LPS 
induced activity
NFkB (-241 bp) No effect No effect No effect LPS increased 
CAT activity
AP-4 (-273bp) No effect No effect Reduced 
reporter activity
LPS increased 
CAT activity
GATA (-298bp) No effect Increased 
reporter activity
No effect LPS increased 
CAT activity
Oct1 (366bp) No effect No effect No effect LPS increased 
CAT activity
The same group has further investigated differences in C5aR transcriptional 
regulation mechanisms between mouse microglia and astrocytes (Martin et al., 2007). They 
found that similar to the RAW 264.7 cell line, expression of the C5aR in mouse microglial 
(BV-2) and astrocyte (Ast2.1) cell line has a strong dependency on a CCAAT motif which 
was shown to bind NF-Y, but not c-Fos or ETS1/2, by supershift assay (Martin et al., 2007). 
Whereas they suggest that primary astrocytes are less reliant on the CCAAT motif as only 
weak activity was observed in the shift assay compared with the astrocyte cell line. 
Furthermore, they found that transfection of the mouse C5aR promoter reporter constructs 
into both the astrocyte cell line and the primary astrocytes revealed slightly different 
dependencies on different regions of the promoter, with deletion from -332bp to -232bp in the 
cell line resulting in a reduction of luciferase activity compared with an increase in activity 
observed in the primary astrocytes (Martin et al., 2007). These findings led them to conclude 
that regulation of the C5aR promoter in primary astrocytes is very different from the 
previously described mechanism for macrophages or endothelial cells (Martin, 2007, Hunt et 
al., 2005, Martin et al., 2007).
Several studies have investigated the role of SNPs within the C5 and the C5aR gene, 
and their association with pro-inflammatory disease states such as asthma (Hasegawa et al., 
2004, Barnes et al., 2004, Marceau et al., 1999). A study by Hasegawa and colleagues 
found 5 SNPs within the C5 gene and they identified a combination of these SNPs within 
C5a which were protective against childhood and adult asthma (Hasegawa et al., 2004). 
However, only Barnes and co-workers have investigated the role of SNPs within the 
promoter region of the human C5aR gene (Barnes et al., 2004). This group found a novel
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T/C SNP at position -245bp with the -245C allele having a significantly higher frequency in 
the Afro-Caribbean population compared with the German and Tangier Island population, 
however it had no association with asthma or atopy. By creating luciferase reporter 
constructs of 2711 bp region, starting at -1450bp from transcription start site and part of the 
intro 1, they found that the T to C base substitution, potentially eliminates an AP-4 
transcription factor motif, however this had no effect on its promoter activity when transiently 
transfected into the U937 cell line (Barnes et al., 2004).
3.1.3 mRNA stability
Regulating mRNA stability allows a cell to rapidly respond to changes in internal or external 
stimuli. It is an important regulatory step for mRNAs whose proteins regulate cell growth and 
differentiation, such as proto-oncogenes or encodes pro-inflammatory proteins, such as 
cytokines (Barreau et al., 2005). The stability can be affected by cis-acting elements present 
within different regions of the mRNA (figure 3.1.3).
Decapping followed 
by 5 ’-3 ’ degradation
Nonsense mediated 
decay
Deadenylation followed 
by 3 ’-5 ’ degradation
t t t
5’CAP Coding sequence polyA tail
5’UTR 3’UTR
I
Cis-acting elements 
present in this region 
can stabilise or 
destabilise mRNA
AREs can target mRNA  
for degradation or inhibit 
translation
Figure 3.1.3 Schematic diagram of cis-acting elements present within the mRNA which  
effect its stability.
Both the 5 ’cap and polyA tail protects the mRNA from degradation (Brennan and 
Steitz, 2001). Removal of the cap exposes the 5’ end to degradation by the 5’- 
exoribonuclease, Xrn1 (Liu and Kiledjian, 2006). Likewise, the polyA tail also protects the 
mRNA from 3’-5’ endo/exonucleases and it is this polyA shortening which is often the rate 
limiting step in mRNA turn over (Brennan and Steitz, 2001). Sequences present in the 
5’UTR or the coding sequence can also affect mRNA. For example, the 5’UTR of IL-2 
mRNA contains a cis-acting element which is stabilised by c-Jun N-terminal kinase pathway
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(Chen et al., 1998a). MessengerRNA stability can also be affected by the quality of the 
mRNA. For instance, mRNAs which end prematurely because they have a frameshift or 
nonsense mutation will be targeted for nonsense-mediated decay as a quality control 
mechanism (Maquat and Gong, 2009). The 3’UTR region may contain AU-rich elements 
(AREs), which are the most common c/s-acting elements that are likely to affect mRNA 
stability (Chen and Shyu, 1995).
AREs, which are rich in adenosine and uridine, can be classed into three different 
groups depending on their number and distribution (see table 3.1.2 for examples). ARE- 
binding proteins (ARE-BPs), which bind to the AREs, and can either destabilise or stabilise 
the mRNA. The way in which ARE-BP can destabilise the mRNA is by deadenylation and 
decapping of the mRNA (Barreau et al., 2005). As well as targeting mRNA for degradation, 
ARE can also reduce protein synthesis by interfering with the translation of the mRNA 
(Barreau et al., 2005).
Table 3.1.2 Classification of ARE and examples associated ARE-BPs. Taken from Barreau 
et al 2005.
mRNA Class Motif Example of mRNA
I Multiple dispersed AUUUA motifs, 
U-rich
c-myc, c-fos, IFNy, p21, Cyclin A, 
Cyclin B1
II (A /U ) (A U U U )n A  (A /U ) TNFa, GM-CSF, IFNa, Cox-2, IL-2, 
IL-3, IFNp, VEGF, DAF, C5aR
III No AUUUA, U-rich region c-Jun, GLUT1, p53, hsp70, NF-M, 
GAP-43
3.1.3.1 CSaRmRNA stability
To date it is not known whether the ARE within the C5aR 3’UTR affects mRNA stability. The
ARE-mRNA database (ARED), which analysed the distribution of AREs in human mRNA
sequences using computational analysis, has shown that the C5aR mRNA contained an
ARE which belonged to the class I cluster IV category (section 3.3, figure 3.3.2) (Bakheet et
al., 2003) http://brp.kfshrc.edu.sa/ARED). Although this sequence has been identified as a
putative ARE it has not been investigated if this ARE has any effect on the C5aR mRNA
stability. Further examination of the C5aR 3’UTR sequence also identified a second ARE
like motif (see figure 3.3.2). Although it has not been investigated whether either of these
AREs play a role in the stabilisation or destabilisation of the C5aR mRNA; several other
GPCR, including p2-adrenergic receptor and thyrotropin releasing hormone receptor,
mRNAs have been shown to be regulated by such elements (Collins et al 1991). Additionally
it has been shown that the MCP-1 receptor, CCR2, and the IL-8 receptor, CXCR2, both
contain sequences within their 3’UTR which causes rapid destabilisation of their mRNA
following stimulation by LPS (Sica et al., 1997, Saccani et al., 2000, Lloyd et al., 1995,
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Sprenger et al., 1994). A study by Xu and co-workers found that stimulation of THP-1 cells 
with LPS led to the degradation of mRNA via a two step mechanism; firstly deadenylation 
followed by the rapid destabilisation of the mRNA (Xu et al., 1997). However this study did 
not investigate the exact nature of the sequences responsible for this activity (Xu et al., 
1997).
3.1.4 Methods for studying gene regulation
Several experimental techniques can be used to identify cis-acting elements involved in the 
regulation of expression of a particular gene, as well as identifying the transcription factors 
which interact with these elements. Discussed below in detail are the experimental 
techniques which will be used in this study to investigate regulation of C5aR expression.
3.1.4.1 Identifying cis-acting elements involved in expression of a particular gene using 
reporter gene assays
In order to identify potential cis-acting elements involved in regulation of gene transcription or 
mRNA stability using reporter gene assay, genomic clones for the particular region of interest 
need to be cloned into a reporter vector. By cloning the promoter region of interest upstream 
of the reporter gene, the extent to which the gene is transcribed is dependent on the 
regulatory elements present within that promoter (figure 3.1.4). Likewise, by placing the 
3’UTR down stream of the reporter gene, which is under the transcriptional control of a 
strong promoter, the stability of the reporter mRNA is influenced by regulatory elements 
present within the 3’UTR.
There are several reporter proteins commonly used to investigate gene expression. 
Table 3.1.3 list common reporter proteins used and their advantages and disadvantages. In 
this study it was decided to use pEGFP-1 reporter vector, which encodes a variant of wild- 
type GFP which has been optimised for brighter fluorescence and higher expression in 
mammalian cells (Cormack et al., 1996). The half life of EGPF is 24 hr, therefore making this 
vector particularly useful for studying an increase in expression but less suitable for studying 
decreased in expression. By using this vector, once the cells had been transfected with the 
reporter constructs, fluorescence can easily be detected by flow cytometry (Gray et al., 
2010). The pEGFP-1 vector is a promoter less vector with a multiple cloning site upstream of 
the EGFP gene, which allows the promoter region of interest to be easily inserted (see 
section 3.3 for vector map figure). The SV40 3’UTR and polyadenylation sequence is 
positioned downstream to the EGFP gene in order to direct the proper processing of the 
3’end of the EGFP mRNA. In the case of investigating regulation of transcription of C5aR, 
the ~2Kbp promoter region upstream from the transcription start site will be cloned upstream 
of the EGFP gene using the multiple cloning site. However to investigate the regulation of
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C5aR mRNA, the C5aR 3’UTR will be cloned downstream of the EGFP gene replacing the 
SV40 3’UTR and polyadenylation signal. For this construct to be transcribed, an EGFP 
reporter plasmid with the ubiquitous elongation factor 1a (EF1a) promoter placed upstream 
of the EGFP gene will be used (Gray et al., 2010).
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Figure 3.1.4 Schematic of reporter gene assays.
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Table 3.1.3 Advantages and disadvantages of different reporter assay. Taken from 
(Ausubel et al., 2000).
Reporter gene Assay Strengths Weaknesses
Chloramphenicol 
Acetyltransferas 
e (CAT)
In vitro assays only.
Assays use either
chromatography,
differential
extraction,
fluorescence or
immunoassay
•  Stable protein
• Minimal endogenous 
activity in mammalian cells
•  Assays are time 
consuming and 
laborious
•  Most assays use 
expensive 
radioactive 
substrate
• Relatively low 
sensitivity
Firefly Luciferase Both in vitro and in 
vivo assays 
available using bio­
luminescence
•  Non-isotopic
•  Good sensitivity
•  Minimal endogenous 
activity in mammalian cells
•  Relatively cheap
• Short half life of 
protein
• Require 
luminometer or 
scintillation counter
(3-Galactosidase Both in vitro and in 
vivo assays 
available using 
colorimetric, 
fluorescence, 
chemiluminescence 
and histochemical 
staining
•  Non-isotopic
•  Various assay formats 
available
• Chemiluminescent assay 
very sensitive
• Many cell types 
have high
endogenous activity
•  Require 
fluorometer or 
luminometer
Green
fluorescent
protein
Both in vivo and in 
vivo assays using 
fluorescence 
microscopy or 
FACS analysis
• Reporter gene expression 
and protein localisation in 
live cells
•  Assay does not require 
any additional substrates or 
co-factors
• Quick and easy detection
• Fluorescent signal highly 
resistant to photo bleaching
• No apparent toxic effects 
of GFP expression in 
bacteria or eukaryotes
• Signal intensity 
may be too weak for 
some applications
• At high 
concentrations 
fluorescence signal 
may plateau.
To identify regions of interest, the DNA that is cloned into the reporter construct can 
be manipulated either by creating serial deletions or by incorporating defined mutations 
within a specific sequence. In this study serial deletions will be created from the 2Kbp 
promoter region of the C5aR and once transfected into U937 cells changes in EGFP will be 
detected by flow cytometry. Performing serial deletions of the promoter would identify 
regions with either strong promoter or repressor activity. From this, with the aid of 
computational analysis, the role of individual regulatory elements can further be investigated 
by site directed mutagenesis. To identify what role if any the ARE have on mRNA stability
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the sites will be mutated by site directed mutagenesis and changes in EGFP will be 
monitored by flow cytometry.
In order to monitor EGFP expression in vivo the reporter constructs need to be 
transfected into a eukaryotic cell. There a two types of transfections: transient or stable. 
Transient transfection does not involve the integration of the constructs into the genome and 
therefore the DNA introduced is divided during each cell division and expression is eventually 
lost. However, stable transfection involves the integration of the construct into the genome 
and is therefore inherited to daughter cells. Although electroporation is commonly used to 
produce a stable transfection, which incurs a lot of cell death during initial procedure, it 
allows the sufficient culturing of cells following the procedure to allow the cells to recover. 
Producing stable transfected cells has several advantages over transient transfections, such 
as you can produce clonal populations and it allows the culturing of transfected cells with 
different stimuli for several days. For these reasons it was decided to produce stably 
transfected cells with the reporter constructs. The cell line which will be used for these 
studies is the human monocytic U937. This cell line was derived from a patient with 
histiocytic lymphoma and characterised in 1976 by Sundstrom and Nilsson (Sundstrom and 
Nilsson, 1976). Since then this cell line has been well characterised for its monocytic like 
phenotype and its ability to be differentiated to a more macrophage phenotype and up- 
regulation of the C5aR by stimulation with agents such as PMA and Bt2cAMP (Sheth et al., 
1988, Chenoweth et al., 1984, Rubin et al., 1991a).
3.1.4.2 Identifying transcription factors that interacting with cis-acting elements using 
electrophoretic mobility shift assays
Electrophoretic mobility shift assay or gel retardation assay was first described by Garner 
and Revzin in 1981 as a rapid technique that involves separation of free DNA from DNA- 
protein complexes based on differences in their electrophoretic mobilities in polyacrylamide 
gels (Garner and Revzin, 1981). Incubation of the labelled DNA probe, typically radio- 
isotype-labelled or biotinylated, with cellular extract containing the protein, which recognises 
probe, will create DNA-protein complex that can be separated from unbound probe. The 
addition of unlabelled competitors to the reaction mixture, in excess, can determine the 
specificity of the DNA-protein interaction. Additionally, antibodies against the protein in the 
DNA-protein complex can create a supershift pattern, observed by gel electrophoresis, which 
can be used to confirm the identity of the protein in the complex. Combining these 
approaches can identify proteins which bind to the DNA sequence of interest and the 
specificity of the bond between the DNA probe and the protein.
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3.7.5 Aims and hypothesis
The aim of this chapter is to generate promoter and 3’UTR reporter constructs of the C5aR 
and to investigate how basal levels of expression of human C5aR is regulated in the U937 
cell line. Both regulation of gene transcription and mRNA stability will be investigated. It is 
hypothesised that regulation of human C5aR expression may be similar to that of the mouse 
due to sequence homology which has already been shown by (Hunt et al., 2005).
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3.2 Materials and methods
3.2.1 Chemicals and reagents
3.2.1.1 Molecular biology and cell culture
All general reagents were purchased from Sigma. Phusion High-Fidelity DNA polymerase 
(F-530) was purchased from Finnzymes. QIAampDNA blood kit (51104), QIAquick PCR 
Purification Kit (28104), and plasmid purification kits were from Qiagen. Taq polymerase, 
dNTPs, Q reagent, 25mM MgCI2 pGEM-T easy vector kit, X-Gal and dATP were all from 
Promega. Restriction enzymes (Age I, Dpn I, EcoR I, Kpn I, Pst l,Nco I, Xba /, Not I and Afl
II), T4 ligase and 100bp ladder were from NEB Biolabs. 1Kbp DNA ladder and UltraPure 
Agarose were from Invitrogen. Primers were ordered from MWG-Biotech. pEGFP-1 vector 
was obtained from Clontech. Pfu Turbo DNA Polymerase (600250) was from Stratagene. 
Electroporation cuvettes were from WebScientific. Big Dye 3.1 Terminator cycle sequencing 
mix was from PE Biosystems. Cyclosporin A and G418 were from Calbiochem. G418 was 
dissolved in sterile water to a stock concentration of 50 mg/ml, and was subsequently diluted 
in RPMI to a working concentration of 500 pg/ml. All other reagents were as described in 
Chapter 2.
Whole cell extract buffer: 10 mM Hepes pH 7.9, 0.4 mM NaCI, 0.5 mM DTT, 0.5 mM PMSF, 
5 % glycerol (v/v), 1 fig/m I pepstatin A, 10 fig/m I aprotinin, 10 jig/ml leupeptin, 10 fig/m I type
l-S soybean trypsin inhibitor.
Cvtosolic extract buffer: 10 mM Hepes pH 7.9, 1.5 mM MgCI2, 10 mM KCI, 0.5 mM DTT, 0.5 
mM PMSF, 1 pg/ml pepstatin A, 10 pg/ml aprotinin, 10 pg/ml leupeptin, 10 pg/ml type l-S 
soybean trypsin inhibitor.
Nuclear extract buffer: 20 mM Hepes pH 7.9, 420 mM NaCI, 1.5 mM MgCI2, 0.2 mM EDTA, 
25 % glycerol (v/v), 0.5 mM DTT, 0.5 mM PMSF, 1 pg/ml pepstatin A, 10 pg/ml aprotinin, 10 
pg/ml leupeptin, 10 pg/ml type l-S soybean trypsin inhibitor.
Nuclear extract storage buffer: 10 mM Hepes pH 7.9, 20 mM KCI, 0.1 mM EDTA, 0.5 mM 
PMSF, 1 pg/ml pepstatin A, 10 pg/ml aprotinin, 10 jug/ml leupeptin, 10 jig/ml type l-S 
soybean trypsin inhibitor.
5 x Binding buffer: 50 mM Tris pH 8.0, 750 mM KCI, 2.5 mM EDTA, 0.5 % Triton-X100 (v/v), 
40 % glycerol (v/v) and 1 mM DTT.
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3.2.1.2 Bacteria and bacterial cell culture
i) Reagents
Bacterial cell strain NM522 was a kind gift from Dr L De’Cruz (Cardiff University). XL1-Blue 
cells were a kind gift from Dr A Roftbach. Ampicillin and Kanamycin (Invitrogen) were 
dissolved in dH20  to a stock solution of 100 mg/ml and 30 mg/ml respectively, filter sterilised 
and stored at -20°C. X-Gal (20 mg/ml, U120A, Promega) was stored at -20°C.
Resuspension buffer: 50 mM Tris pH 8.0, 10 mM EDTA and 100 pg/ml RNase A. Stored at 4 
°C.
Lvsis buffer: 200 mM NaOH, 1 % SDS.
Neutralisation buffer: 3 M Potassium acetate, pH adjusted to 5.5 with glacial acetic acid.
ii) Media
LB Medium: 10 g/L bactotryptone, 5 g/L yeast extract and 5 g/L NaCI.
LB-aaar plates were prepared by autoclaving LB medium containing 1.5% agar. Appropriate 
antibiotics, either ampicillin 100 pg/ml or kanamycin 30 |iig/ml, were added once cooled to 
<50°C.
SOC medium: 20 g/L bactotryptone, 5 g/L yeast extract, 0.5 g/L NaCI, 0.18 g/L KCI, 0.95 g/L 
MgCI2
NZY* Broth: 10 g/L NZ amine (casein hydrolysate), 5 g/L yeast extract, 5 g/L NaCI, adjust pH 
to 7.5 and autoclave. Add 12 mM MgCI2, 12 mM M gS04 and 0.4 % (w/v) glucose filter 
sterilised.
2-TY medium: 16 g/L bactotryptone, 10 g/L yeast extract and 5 g/L NaCI.
ii) Preparation o f chemically competent bacteria
Chemically competent NM522 and XL1-Blue cells were generated using the following 
protocol. A single isolated colony growing on LB-agar plates was used to inoculate 10 ml of
2-TY media, which was then cultured overnight at 37 °C. The overnight culture (1ml) was 
used to inoculate 200 ml of 2-TY media and was incubated at 37 °C with vigorous shaking. 
The optical density at Aeoo of the culture was measured every 30 min until approximately 0.6 
A was achieved (app. 2 Vt. hrs). The bacteria were chilled on ice for 30 min and centrifuged 
at 5,000g for 10 min at 4 °C. The cell pellets were resuspended in 10 ml of chilled 0.1M  
MgCI2 (sterile) and incubated on ice for 30 min. The bacteria were centrifuged at 5,000g for 
10 min at 4 °C. The pellets were resuspended in 10 ml of chilled 0.1 M CaCI2 (sterile) and 
incubated for a further 30 min on ice. The bacteria were centrifuged at 5,000g for 2 min at 4 
°C and the pellets were resuspended in 8 ml of chilled 0.1 M CaCI2 with 20% glycerol
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(sterile). Aliquots of 80 pi were snap frozen in liquid nitrogen and stored at -80 °C for up to 1 
year.
3.2.2 Cloning the human C5aR 5’promoter and 3’UTR into the pEGFP 
vector
3.2.2.1 Isolating gDNA from U937 cell line
Genomic DNA was isolated from two human monocytic cell lines U937, obtained from 
European Collection of Animal Cell Cultures U937 ( U 9 3 7 Ec a c c )  and from Dr Peter Monk, 
Sheffield University (U937pM), using QIAampDNA blood kit following manufacturer’s 
instructions (see below).
5 x 10eU937 cells (growing in log phase) were harvested by centrifuging at 1,200 rpm 
for 3 min and resuspended in 200ul PBS. The cells were lysed by adding 20 pi of QIAGEN 
protease and 200 pi buffer AL and were then incubating for 10 min at 56 °C. The sample 
was briefly centrifuged to gather sample to the bottom of the tube. 200 pi ethanol was added 
to the lysate, mixed by pulse vortexing and the tube was then briefly centrifuged. The 
mixture was applied to the QIAamp Spin Column without wetting the rim and centrifuged at 
7,000 rpm for 1 min. The column was placed into a clean 2 ml collection tube. 500 pi buffer 
AW2 was applied to the spin column which was then centrifuged for 3 min at 13,000 rpm. To 
eliminate possible AW2 buffer carry over the spin column was placed in clean 2 ml collection 
tube and centrifuged for 1 minute at 13,000 rpm. The spin column was placed in a clean 1.5 
ml microcentrifuge tube and DNA was eluted in 200 pi buffer AE after incubation for 1 minute 
at RT followed by centrifuging for 1 minute at 7,000 rpm. The DNA was stored at -20 °C in 
10 pi aliquots.
3.2.2.2 PCR amplification of the C5aR promoter and 3VTR
3.2.2.2.1 PCR of the C5aR 5’ promoter
The sequence for the C5aR promoter was obtained from NCBI CoreNucleotide database, 
GeneBank sequence accession number AC_099491. The reverse primer for the C5aR 
promoter was designed just 5’ of transcription start site and the forward primers were 
designed up to 2037bp upstream of the transcription start site (see table 3.2.1). All primers 
were designed with restriction enzyme site overhangs in order to facilitate subcloning from 
the intermediate pGEM-T vector into the pEGFP vector.
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Table 3.2.1 List of primers used for PCR of the C5aR 5’ promoter
Fragment
size
Sequence (5’ to 3’) Restriction
enzyme
overhang
Annealing
temperature
2037bp Forward -  5’GCGAAT TCCCTTCGCTCA AT TACCGCC 3’ 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC 3’
EcoRI 
Kpn 1
71 °C
1524bp Forward -  5’GCGAATTCAGGGATTCCACTGATTCTAC 3’ 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC3’
EcoRI 
Kpn 1
67 °C
1005bp Forward -  5’GCGAATTCAGCTTCCCAAGTAGCTGGG 3’ 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC 3'
EcoRI 
Kpn 1
67 °C
504bp Forward -  5’GCGAATTCGGCGAAACCCCGTCTTTAC 3' 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC 3’
EcoRI 
Kpn 1
71 °C
200bp Forward -  5 GCGAATTCCTGGGAGGTGGTTAGAGTCC 3’ 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC 3’
EcoRI 
Kpn 1
71 °C
101 bp Forward -  5’GCGAATTCGACGGTCATTTCCTCCCTGCATC 3' 
Reverse -  5’CGGTACCGTTCTGGTCTCCTGGGCTCCC 3’
EcoRI 
Kpn 1
71 °C
For the PCR reaction, the following reagents were prepared as shown in the table below.
PCR reaction
5 x High fidelity GC buffer 10 pi
5 x Q reagent 10 pi
dNTPs (10 mM) 0.5 pi
gDNA 0.5 pi
Forward primer (10 pM) 0.5 pi
Reverse primer (10 pM) 0.5 pi
High fidelity Phusion polymerase 0.25 pi
dH2Q 32.75 pi
The PCR reaction mixes were overlaid with 20ul mineral oil to prevent loss of sample and 
were then placed in a PCR sprint thermal cycler (Hybaid). The PCR cycle was as detailed
below.
Thermal cycling conditions
Step Temperature Time Cycle
Initial denaturation 98 °C 30 s 1
Denaturation 98 °C 10s
Annealing Typically 71 °C 30 s 35
Extension 72 °C 1 min
Final elongation 72 °C 10 min 1
3.2 2.2.2 PCR of the C5aR 3’UTR
The sequence for the C5aR 3’UTR was obtained from NCBI CoreNucleotide database, 
GeneBank sequence accession number NM__001736. The forward primer for the C5aR 
3’UTR was designed just 3 ’ of the stop codon and the reverse primer was designed 
overlapping the polyadenylation site (see table 3.2.2). Both primers were designed with 
restriction enzyme site overhangs in order to facilitate from the intermediate pGEM-T vector 
into the pEGFP vector.
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Table 3.2.2 Primers used for PCR of the C5aR 3’UTR
Fragment
size
Sequence (5’ to 3’) Restriction
enzyme
overhang
Annealing
temperature
1233bp Forward -  5’CGCGGCCGCGACAGCCTCATGGGCCACTG 3’ 
Reverse -  5’GCGCCTTAAGCAATATTCA I I 11I ATTTTCCTC 3’
Notl
Aflll
50 °C
Due to differences in the Tm between the forward and reverse primers for the 3’UTR, which 
could not be avoided, the 3’UTR was amplified using GoTaq Flexi polymerase. For the PCR
reaction, the following reagents were prepared as shown in the table below.
PCR reaction
5 x Colourless GoTaq Flexi buffer 10 pi
5 x Q reagent 10 pi
dNTPs (10 mM) 1 pi
gDNA 1 pi
Forward primer (10 pM) 1 pi
Reverse primer (10 pM) 1 pi
MgCI2 (25 mM) 3 pi
GoTaq Polymerase 0.25 pi
dH2Q 22.75 pi
The PCR reaction mixes were overlaid with 20ul mineral oil to prevent loss of sample and 
were then placed in a PCR sprint thermal cycler (Hybaid). The PCR cycle was as detailed
below.
Thermal cycling cond tlons
Step Temperature Time Cycle
Initial denaturation 94 °C 3 min 1
Denaturation 94 °C 30 s
Annealing 50 °C 30 s 35
Extension 72 °C 1 min
Final elongation 72 °C 10 min 1
3.2.2.3 Purification of PCR products using QIAquick PCR purification
To remove unwanted enzymes, primers, salts and dNTPs, which may affect downstream 
applications, the PCR product was purified using QIAquick PCR purification kit following 
manufacturer’s instructions.
5 volumes of buffer PB was added to 1 volume of PCR product. This solution was 
applied to a QIAquick spin column and collection tube and centrifuged for 1 min at 13,000 
rpm. Flow through was discarded and the column was washed with 750 pi of buffer PE and 
centrifuged for an additional minute. The flow through was discarded and the column was 
centrifuged for another minute to remove residue ethanol, which can interfere with down
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stream applications if not removed completely. The QIAquick column was placed in a clean
1.5 ml collection tube, and the DNA was eluted in 30 pi dH20  by centrifugation for 1 minute.
3.2.2.4 Cloning the C5aR 5’promoter and 3’UTR into the intermediate pGEM-T vector
In order for the C5aR 5’promoter and 3’UTR to be cloned into the pEGFP vector in the 
correct orientation they were first cloned into the intermediate cloning vector pGEM-T 
(Promega). As PCR incorporated different restriction enzyme sites both 5’ and 3’ of the 
PCR product (see tables 3.2.1 and 3.2.2) this allows the DNA to be digested out of the 
pGEM-T vector using the specific enzymes and then to be ligated into the pEGFP vector, 
which has also been digested with the same enzymes, in the correct orientation.
3.2.2.4.1 Product extension with GoTaq polymerase
As Phusion polymerase produces blunt-end DNA products, to ligate the C5aR 5’promoter 
fragments into the intermediate pGEM-T vector additional 3’ adenosine residues, which are 
produced by Go Taq polymerase, were required. 4ul of purified PCR product was mixed with 
1 pi GoTaq Polymerase (5 u/pl), 2 pi colourless GoTaq Flexi buffer (5 X), 1 pi dATP (2 mM) 
and 0.6 pi MgCI2 (25 mM). This solution was incubated at 72 °C for 30 min, followed by PCR 
purification using QIAquick purification kit as described in section 3.2.2.3.
3.2.2.4.2 Ligation of C5aR promoter and 3’UTR into pGEM-T
The addition of the 3’ adenosine residues to the PCR fragments provides compatible 
overhangs for the pGEM-T  vector which greatly improves the efficiency of ligation of the PCR 
products into the plasmid vector. Ligation of the C5aR 5’ promoter and 3’UTR into the 
pGEM-T Easy Vector was carried out using Promega kit (A1360) according to manufacture’s 
instructions. The molar ratio of insert: vector was 2:1, for optimum vector insert interactions. 
The reagents detailed below were all added on ice and then incubated overnight at 4 °C for 
maximum number of transformants.
Ligation reaction
pGEM-T Easy Vector (50 ng/pl) 1 pi
Insert DNA 2 pi
2X T4 DNA ligase buffer 5 pi
T4 ligase (3 u/pl) 1 pi
h 2o 1 pi
3.2.2.4.3 Transformation and culture of competent bacteria
Bacterial transformation with recombinant DNA enables replication of the plasmid and thus 
produces large quantities of DNA. The chemically competent bacterial host strain NM522 
were transformed with the ligation reaction mixtures using heat shock method, as described 
below. Heat shock of chemically competent bacteria that have been prepared with calcium
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chloride allows DNA which is bound to the calcium on the surface of the bacterium to be 
taken up by the competent cell.
After an 80 pi aliquot of competent NM522 had thawed on ice, 3 pi of the ligation mix 
was gently added and the mixture was then incubated on ice for 30 min. The bacteria 
received a heat shock at 42 °C for 1 min exactly and were incubated on ice for another 15 
min. 500 pi of RT SOC media was added to the bacteria which were then incubated at 37 °C 
at 225 rpm for 1 hr to allow the bacteria to recover. Aliquots of cells (50 pi and 200 pi) were 
streaked onto solid support LB-agar plates which contained 100 pg/ml ampicillin and a dry 
surface coating of 25 pi X-Gal/plate (50 mg/ml). The plates were incubated overnight at 37 
°C to allow colonies to grow. As the pGEM-T vector contains an ampicillin resistant gene, 
only E. coli which contains the plasmid will grow on LB ampicillin medium or plates.
3.2.2.4.4 Analysis of recombinant plasmids
Successfully transformed NM522 bacteria with the pGEM-T vector will confer resistance to 
ampicillin, which allows selective screening. However it is still necessary to screen cells to 
determine whether they contain plasmid only or plasmid plus insert DNA.
i) Blue/white screening of transformed colonies
Successful cloning of an insert into the pGEM-T vector results in disruption of the lacZ gene 
which encodes the (3-galactosidase enzyme. As a result colonies which contain the DNA 
insert will appear white, whereas those that do not contain the insert will appear blue.
Using a sterile pipette tip a selection of white colonies and a few blue colonies, to 
serve as negative control, were streaked onto a new LB-agar plate contain ampicillin (100 
pg/ml) and 25 pi X-gal (50mg/ml) using a grid system. The plates were then incubated 
overnight at 37 °C to allow the colonies grow approximately 2 mm in diameter.
ii) Size screening of DNA insertion in plasmid
In addition to blue/white screening (see above), the size of the plasmid present in the 
colonies was also analysed as this allows the rapid confirmation of positive colonies as 
sometimes blue/white screening can produce a false positive (Maniatis et al., 2001). 
Approximately 2 mm of cells from the selected colonies on the LB-agar plate were placed in 
a microfuge tube containing 25 pi EDTA (10 mM, pH 8.0) using a sterile pipette tip. 25 pi of 
fresh lysis buffer (0.2 M NaOH, 0.5 % SDS and 20 % sucrose) was added to each tube, 
which were then vortexed briefly. Samples were incubated at 70 °C for 5 min after which
12.5 pi of KCI (0.25 M) and 0.25 % w/v bromophenol blue was added. The samples were 
incubated on ice for 5 min and then centrifuged at 13,000rpm for 5 min at 4 °C. The s/n (30 
pi) was analysed on a 0.7 % agarose gel (without ethidium bromide), run at 100 V  until the
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dye had migrated approximately two thirds down the gel, after which the gel was soaked in 
an ethidium bromide tank (0.5 pg/ml in dH20 )  for 45 min. DNA bands were then visualised 
under UV light.
iii) PCR screening of DNA insertion into plasmid
Colonies that had screened positively by size analysis (see above) were also screened by 
PCR to check for the presence of insert DNA. Approximately 2 mm of cells from the selected 
colonies on the LB-agar plate were placed in a microfuge tube containing 20 pi sterile H20 . 
The samples were then incubated at 99 °C for 10 min followed by incubating on ice for a 
further 10 min. The samples were centrifuged for 10 min at 13,000 rpm at 4 °C. 2 pi of the 
s/n was used as the template in a PCR reaction containing forward and reverse primers for 
either the C5aR promoter region or 3’UTR (see section 3.2.2.2 for details) depending on 
what insert DNA had been used. Following PCR thermal cycle, as described below, the PCR 
products were analysed by 1 % agarose gel electrophoresis.
PCR screening reaction
dH20 7.35 pi
5 X Flexi buffer 3 pi
MgCI2 (25 mM) 1 pi
dNTPs (10 mM) 0.4 pi
Go Taq polymerase 0.25 pi
Forward and Reverse primers (10 pM) 0.8 pi
Thermal cycling conditions
Step Temperature Time Cycle
Initial denaturation 95 °C 5 min 1
Denaturation 94 °C 30 s
Annealing 60 °C 1 min 5
Extension 72 °C 2 min
Denaturation 94 °C 10s
Annealing 60 °C 30 s 25
Extension 72 °C 1 min
Final elongation 72 °C 10 min 1
37 °C 10 min
iv) Isolation o f plasmid DNA
Bacteria transformed with plasmid containing insert DNA, was transferred under aseptic
conditions from LB-agar plate culture into LB medium (5 ml) containing 100 pg/ml ampicillin.
The culture was incubated overnight at 37 °C while constantly shaken at 225 rpm.
Plasmid DNA was isolated and purified according to Qiagen QIAprep Spin Miniprep
kit (27104) protocol. The bacteria were harvested from the 5 ml culture by centrifugation for
5 min at 2,000 rpm. The s/n was then discarded and the pellet was resuspended in 250 pi
resuspension buffer P1. The bacteria were lysed with 250 pi lysis buffer P2 and mixed by
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inverting the tube. The lysis buffer was then neutralised with 350 pi of neutralisation buffer 
N3 which was mixed immediately and thoroughly by inverting the tube. The sample was 
centrifuged for 10 min at 13,000 rpm and the s/n applied to a QIAprep spin column. The 
column was centrifuged further for 60 s at 13,000 rpm and the flow-through was discarded. 
The column was washed with 500 pi buffer PB by centrifugation for 60 s at 13,000 rpm to 
remove trace nuclease activity. The flow-through was discarded and the column was 
washed again by adding 750 pi buffer PE and centrifuging for 60 s at 13,000 rpm. The flow­
through was discarded and the column was centrifuged for another 60 s at 13,000 rpm to 
remove any residual ethanol. The column was placed into a clean 1.5 ml microfuge tube and 
the DNA was eluted by adding 30 pi sterile H20  and incubation at RT for 60 s followed by 
centrifugation for 60 s at 13,000 rpm. The concentration and the purity of the DNA were 
determined by spectrophotometric analysis.
v) DNA sequencing
Positively screened plasmids that were subsequently purified, underwent sequence analysis 
using Big Dye 3.1 (PE Biosystems, ABI Prism, 4303152) as in the ABI protocol. The 
following reagents were added to PCR tubes and overlaid with 20 pi mineral oil.
Big Dye DNA sequencing reaction
Purified plasmid DNA 0.5ug
Primer (pGEM-T forward or reverse) (10 pM) 0.32 pi
5 X reaction buffer 2 pi
Big Dye 3.1 2 pi
Sterile H20 Add to total volume 10 pi
Big Dye thermal cycling conditions
Step Temperature Time Cycles
Initial denaturation 95 °C 1 min 1
Denaturation 95 °C 10s 25
Annealing 50 °C 5 s
Extension 60 °C 4 min
Following heat cycling, as described above, 10 pi of sterile H20  was mixed with the 
PCR tube contents which were pipetted onto a microfilm sheet. The mineral oil residue was 
retained as the solution moved down the film. The remaining oil free solution was then 
placed into a clean 0.2 ml microfuge tube and the DNA was precipitated by adding 80 pi of 
70 % isopropanol. The mixture was incubated at RT in the dark for 1 hr. The DNA 
precipitate was then pelleted by centrifuging at 13,000 rpm for 30 min at 4 °C. The s/n was 
carefully removed and the pellet was washed with 250 pi 70 % isopropanol and centrifuged 
for another 15 min at 13,000 rpm. The s/n was again discarded and the DNA pellet was
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dried by vacuum centrifugation for 20 min then underwent sequence analysis by CBS 
Facilities, Cardiff University.
3.2.2.S Subcloning the C5aR 5’promoter and 3’UTR into the pEGFP-1 vector
Following successful cloning of the C5aR 5’promoter fragments and 3’UTR into the 
intermediate pGEM-T vector these inserts were then subcloned into the pEGFP-1 vector 
(generated in house (Gray et al., 2010)). As PCR incorporated restriction enzyme sites both 
5’ and 3’ of the PCR products these sites allow the insert to be digested from the pGEM-T 
vector and into the pEGFP-1 vector in the correct orientation.
3.2.2.5.1 Restriction enzyme digest o f the 5’promoter/pGEM-T and pEGFP-1 vector
PCR of the C5aR 5’promoter fragments introduced an EcoR I and a Kpn I restriction enzyme 
site 5’ and 3’ of the PCR fragments respectively, see table 3.2.1. As the pEGFP vector also 
contained an EcoR I and Kpn I site within the multiple cloning site both the 
5’promoter/pGEM-T vectors and the pEGFP vector can be digested with these restriction 
enzymes and then ligated together. The resulting product, 5’promoter +pEGFP, will allow the 
C5aR promoter to drive transcription of the EGFP gene as it is positioned immediately 
upstream of the gene (see figures 3.3.10 for schematic diagram of constructs generated).
The following reagents were combined; 5 pi BSA (10X), 5 pi buffer 1 (10X, NEB), 1 pi 
EcoR I (10,000 U/ml), 1 pi Kpn I (10,000 U/ml), 1 pg 5’promoter/pGEM-T (first reaction 
mixture) or 1 pg pEGFP (second reaction mixture) and sterile H20  to a total volume of 50 pi, 
reagents were then incubated for 1 h at 37 °C. A sample of both restriction enzyme digests 
were removed and analysed on a 0.8 % agarose gel.
3.2.2.5.2 Generation o f the 355bp 5 ’promoter fragment
An additional 355bp 5’promoter fragment was also created at this stage as the C5aR 
5’promoter region contains a Pst I site at -355bp downstream of the transcription start site 
which with the Kpn I site incorporated during PCR will facilitate cloning into the pEGFP-1 
vector (figure 3.3.10).
The following reagents were combined; 5 pi BSA (10X), 5 pi buffer 1 (10X, NEB), 1 pi 
Pst I (20,000 U/ml), 1 pi Kpn I (10,000 U/ml), 1 pg 2kbp 5’promoter/pGEM-T (first reaction 
mixture) or 1 pg pEGFP (second reaction mixture) and sterile H20  to a total volume of 50 pi, 
reagents were then incubated for 1 hr at 37 °C. A sample of both restriction enzyme digests 
were removed and analysed on a 0.8 % agarose gel.
3.2.2.5.3 Restriction enzyme digest o f the 3 ’UTR/pGEMT and EF1a + pEGFP-1 vector
In order to identify what effect the C5aR 3’UTR has on mRNA stability the 3’UTR needs to be 
cloned into the pEGFP-1 vector which also contains a promoter upstream of the EGFP gene.
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The powerful elongator factor 1a promoter (EF1a) was previously cloned into the multiple 
cloning site of the pEGFP-1 vector by Dr Lisa Gray (Dept. Pharmacology, Cardiff University) 
which will drive transcription of the EGFP gene (Gray et al., 2010). The C5aR 3’UTR was 
then cloned into the EF1a+pEGFP vector using Not I and an Afl II restriction enzyme sites 
which were incorporated during PCR. The C5aR 3’UTR will then replace the SV40 
polyadenylation site and therefore direct the proper processing of the EGFP mRNA.
The following reagents were combined; 5 pi BSA (10X), 5 pi buffer 2 (10X, NEB), 1 pi 
Not I (10,000 U/ml), 1 pi Afl II (20,000 U/ml), 1 pg 3’UTR/pGEM-T (first reaction mixture) or 1 
pg EF1a+pEGFP (second reaction mixture) and sterile H20  to a total volume of 50 pi, 
reagents were then incubated for 1 hr at 37 °C. A sample of both restriction enzyme digests 
were removed and analysed on a 0.8 % agarose gel.
3.2.2.5.4 Preparation of 5’promoter/pGEM-T, 3’UTR/pGEM-T, pEGFP and EF1a+pEGFP DNA for 
ligation
After successful restriction enzyme digest, the products were precipitated as follows; 10 pi of 
5’promoter/pGEM-T or 3’UTR/pGEM-T (first reaction solution) and 2 pi of pEGFP or EF1a + 
pEGFP (second reaction solution) respectively were mixed with 8 pi sterile H20  and 80 pi 
isopropanol (70%), then incubated at RT for 1 hr. The DNA was pelleted by centrifuging at
13,000 rpm for 20 min at 4 °C and washed with 250 pi 70 % ethanol, followed by another 
centrifugation at 13,000 rpm for 10 min at 4 °C. The s/n was removed and the pellet was 
dried on a heating block 37 °C for approximately 1 h to remove remain ethanol.
3.2.2.5.5 Ligation o f 5’promoter fragments into pEGFP or 3’UTR into EF1a+pEGFP vector
The dried DNA was dissolved in 8 pi sterile H20 , 1 pi T4 ligase buffer (NEB) and 1 pi T4 
ligase (1 U/pl, NEB) and was incubated o/n at 16 °C.
3.2.2.5.6 Analysis o f 5’promoter fragments +pEGFP and EF1 a+pEGFP+3’UTR constructs
1 pi of the ligation product was used to transform NM522 chemically competent cells by heat 
shock, as described in section 3.2.2.4.3. This was followed by; plasmid screening by size 
and PCR, plasmid purification and finally sequencing of the positive colonies (all methods are 
as described previously). On this occasion sequencing was carried out using a selective 
forward and reverse primer for pEGFP promoter or 3’UTR region (table 3.2.3).
Table 3.2.3 Primers for pEGFP vector
pEGFP vector 
primers
Sequence
MCS Forward - 5 ’-TAG TTA TTA CTA GCG CTA CCG G-3’ 
Reverse - 5 ’-GTG AAC AGC TCC TCG CCC TT-3’
3’UTR Forward - 5 ’-GCC TGT GCT TCT GCT AGG AT-3’ 
Reverse - 5 ’-GCC GAT TTC GGC CTA TTG GT-3’
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Colonies containing correctly sequenced 5’promoter fragments +pEGFP or EF1a 
+pEGFP + 3’UTR were grown up in 5 ml LB medium at 37 °C o/n then frozen (-80 °C) in 15 
% glycerol (in LB medium).
3.2.3 Site directed mutagenesis of potential c/s-acting elements and All 
rich elements
Following the successful cloning of the C5aR promoter fragments into the EGFP reporter 
vector, the sequence for the 2 Kbp promoter region was entered into Genomatrix 
Matlnspector Software. Matlnspector will predict transcription factor binding sites which 
could potentially control transcription initiation (Cartharius et al., 2005). A total of 292 
potential transcription factor binding sites were identified by Matlnspector (appendix 9.4), 
however only three sites were mutated using site directed mutagenesis, NFkB (-238bp to - 
232bp), CCAAT/NF-Y (-123bp to -119bp) and NFAT (-93bp to -87bp) within the 355bp 
5’promoter +pEGFP reporter construct. The ARE database Search Engine identified one AU 
rich element within the C5aR 3’UTR, 5’-ATGTATTTATTTA-3’, which belongs to the class I 
cluster 5 group (Bakheet et al., 2001, Bakheet et al., 2003). A second potential AU rich 
element was also identified by the sequence, 5’-TAATTTAAA-3’. Both AREs were mutated 
by site directed mutagenesis as detailed below.
3.2.3.1 Oligonucleotide-directed mutagenesis
Site directed mutagenesis is a valuable molecular biology technique commonly used in 
studying gene expression elements. Oligonucleotide-directed mutagenesis is a PCR based 
method which involves mutant primers annealing to the denatured DNA template and then 
being extended using a high fidelity DNA polymerase. The parental methylated and 
hemimethylated DNA is then digested using Dpn I endonuclease, leaving the mutant 
daughter DNA template which is then transformed into competent cells XL-blue cells.
The following reagents were combined; 2 pi reaction buffer (x10), 20 ng dsDNA 
template (355bp 5’promoter + pEGFP or EF1a + pEGFP + 3’UTR), 125 ng mutant forward 
primer, 125 ng mutant reverse primer, 0.4 pi dNTPs (10 mM), 4 pi Q reagent (x5), 0.4 jul Pfu 
Turbo and sterile H20  to a final volume of 20 pi. The mutant primers, each complementary to 
opposite strands of the vector, were designed in a manner so that they incorporated a new 
restriction enzyme site at the site of the mutation which will allow easy screening for positive 
mutants (table below 3.2.4). For schematic diagram of mutants see section 3.3 figures 3.3.15 
and 3.3.34).
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Table 3.2.4 Primers used for site directed mutagenesis
Primers Sequences Restriction 
enzyme site 
inserted
NFkB
mutant
Forward primer 5’- GGGCCGAGCCTGCACAGGACCATGGTCGGTTTTCCGA-3’ 
Reverse primer 5’- TCGGAAAACCGACCATGGTCCTGTGCAGGCTCGGCCC-3’
Ncol
CCAAT
mutant
Forward primer 5 ’-
CAGTGCCCAGTGTGCAGACTCTAGAGAGCCCCAGAGAGAAAG-3’ 
Reverse primer 5 ’-
CTTT CT CTCTGGGGCTCT CTAG AGT CT GC ACACTGGGC ACT G-3’
X b a l
NFAT
mutant
Forward primer 5’-
CCCCAGAGAGAAAGACGGTCCTTAAGGCCCTGCATCTTCCCTTGGGG-3’ 
Reverse primer 5’-
CCCCAAGGGAAGATGCAGGGCCTTAAGGACCGTCTTTCTCTCTGGGG-3’
Afl 1
UJO' 
£
b
*3 
V 
E Forward primer 5’- CTTAAAAAAAATGTACCGGTTTTATGGCAAGTTG-3’ Reverse primer 5’- CAACTTGCCATAAAACCGGTACA rTTTTTTTAAG-3’
Age 1
2m ARE  
mutant
Forward primer 5’-
TAAGCT CTT GTAAGT GAGTT GGTACCAAAAGAAAATTAGGCT GAG-3’ 
Reverse primer 5’-
CT C AGCCTAATTTTCTTTTTGGTACCAACT CACTTACAAGAGCTT-3’
Kpn!
Extension of the oligonucleotide primers was performed using PCR sprint thermal 
cycler which produced a mutant plasmid containing staggered nicks. Each reaction mixture
was subjected to temperature cycling as detailed below.
Thermal cycling conditions for NFkB, CCAAT and NFAT mutant
Step Temperature Time Cycles
Initial denaturation 95 °C 30s 1
Denaturation 95 °C 30 s 18
Annealing 55 °C 1 min
Extension 68 °C 6 min
Hold 4 °C Hold 1
Thermal cycling conditions for 3’UTR mutants
Step Temperature Time Cycles
Initial denaturation 95 °C 1 min 1
Denaturation 95 °C 30 s 18
Annealing 45 °C 1 min
Extension 68 °C 6 min
Hold 4 °C Hold 1
Following thermal cycling 1 pi of Dpn I (10 U/pl) was added to the PCR mixture which 
was incubated at 37 °C for 2 hr. Dpn I endonuclease is specific for methylated and 
hemimethylated DNA, this means that the parental DNA template, isolated from a dam 
methylated E. Coli strain NM522, which does not contain the desired mutation will be 
digested and only mutant daughter template will remain. The nicked daughter DNA 
incorporating the desired mutation was transformed into XL1-blue competent cells, which are 
able to repair the nicked DNA, using the heat shock method as described in section
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3.2.2.4.3. Following transformation, 50 pi and 200 pi aliquots of the cells were streaked onto 
LB-agar plates which contained 30 pg/ml kanamycin and incubated o/n at 37 °C.
3.2.3.2 Screening mutant plasmids
Successful transformation of XL1-blue bacteria with the pEGFP vector will confer resistance 
to kanamycin, which allows selective screening. However, it is still necessary to screen cells 
to determine whether they contain the correct mutation. As the mutant primers incorporated 
new restriction enzyme sites, the colonies were first screened by restriction enzyme digest 
and then positive colonies were sent for DNA sequencing analysis.
i) Purifying plasmid DNA
Plasmid DNA was purified from bacterial cells using an alkaline lysis method based on a 
method developed by Birnboim and Doly (Birnboim and Doly, 1979). A sample of the 
colonies was selected using a sterile pipette tip and grown o/n in 3 ml of LB-media containing 
30 pg/ml kanamycin. 2 ml of the bacteria culture was centrifuged for 5 min at 2,000 rpm and 
the pellet was resuspended in 100 pi of resuspension buffer. The remaining 1 ml of the 
bacterial culture was frozen with 15 % glycerol and kept at -80 °C for stock. 200 pi of lysis 
buffer was added to the resuspended bacterial cells and mix by inversion. The cells were 
lysed for 5 min at RT before adding 150 pi of neutralisation buffer and mixing by inversion. 
The samples were centrifuged for 5 min at 13,000 rpm 4 °C. The s/n was recovered and the 
DNA was purified by performing phenol:chloroform:isoamyl alcohol extraction. An equal 
volume of phenol:chloroform:isoamyl alcohol was added to the s/n, vortex for 10 s and 
centrifuged for 1 min at 13,000 rpm. The upper aqueous phase was recovered and placed in 
a clean 1.5 ml tube. 2.5 times volume of 95 % ethanol was added to the DNA solution which 
was incubated for 1 h at -20 °C to precipitate DNA. The DNA was pelleted by centrifuging at
13,000 rpm for 5 min at 4 °C. The s/n was discarded and the DNA pellet washed with 200 pi 
75 % ethanol and centrifuged at 13,000 rpm for 5 min at 4 °C. The s/n was removed and 
residue ethanol was allowed to evaporate by air drying pellet o/n. The DNA pellet was 
dissolved in 50 pi 10 mM Tris pH 8.0.
ii) Screening by restriction enzyme digest
As site directed mutagenesis introduced new restriction enzyme sites, mutant colonies could 
be identified by performing restriction enzyme digests as described below.
1 pi of purified DNA was mixed with 100 U of the appropriate restriction enzyme and 
1 X buffer, see table below. 1 X BSA was also added to some of the reaction mixes and the 
reaction volume was made up to 10 pi using sterile H20 . The mixtures were incubated at 37 
°C for 2 hr and were analysed on a 1 % agarose gel containing ethidium bromide.
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Restriction enzyme Buffer BSA
N col NEBuffer 3 -
X b a l NEBuffer 4 +
Afl II NEBuffer 4 +
Age 1 NEBuffer 1 -
Kpn 1 NEBuffer 4 +
iii) Isolation o f plasmid DNA and DNA sequencing
Plasmid DNA of positive colonies identified by restriction enzyme digest was subsequently 
purified using Qiagen QIAprep Spin Miniprep kit and sequenced using Big Dye 3.1, see 
section 3.2.2.4.4, to confirm the correct mutation had been introduced.
3.2.4 Stable transfection of constructs into the U937 cell line
In order to study the effects of different promoter or 3’UTR reporter constructs on EGFP 
expression the EGFP reporter constructs were stably transfected into the U937 cell lines by 
electroporation.
U937 cells growing in log phase were washed three times in cold RPM I and then 
resuspended at 3 x107 cells/ml. 450 pi of cells were added to 10 pg DNA in a 0.4 cm 
electroporation cuvette which was incubated on ice for 10 min. The cells were 
electroporated with a Gene Pulser (BioRad) using 0.975 mF and 0.270 V  which have been 
previously optimised in house for optimum transfection yield (Powell et al., 1997). Following 
electroporation the cells were placed on ice for 10 min and were then placed in 5 ml of cold 
RPMI for 15 min at RT. The cells were placed in additional 30 ml RPMI supplemented with 
10 % FCS, antibiotics and 1.25% DMSO and placed at 37 °C with 5 % C 0 2 o/n. The 
following day the cells were collected by centrifugation for 3 min and 1,200 rpm and 
resuspended in 20 ml of RPMI selection media containing 500 pg/ml G418, 10 % FCS and 
antibiotics. Medium was refreshed 2-3 times per week. Approximately 2-3 weeks after 
transfection EGFP fluorescence was assessed by flow cytometry.
3.2.5 Flow cytometry
Once cells were growing in log phase EGFP fluorescence was monitored by flow cytometry 
as previously described in section 2.3.6.
To monitor changes in C5aR expression, the cells were stained with monoclonal anti- 
C5aR (S5/1) primary and GAM-FITC secondary antibody for C5aR staining in the presence 
of EGFP, as previously described in section 2.3.6.
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3.2.6 Electrophoretic mobility shift assay
3.2.6.1 Generation of cellular exact
i) Whole cell extract
Cells growing in log phase were harvested by centrifugation at 1,200 rpm for 3 min and 
washed with ice cold PBS. The cell suspension in PBS was transferred to an eppendorf and 
centrifuged for a further 5 min at 10,000 rpm at 4 °C. The s/n was discarded and the cell 
pellet was freeze thawed in liquid N2 3 times. The pellet was resuspended in 5 times pellet 
volume of whole cell extract buffer and pipetted up and down several times. The debris was 
pelleted by centrifugation for 5 min at 10,000rpm, 4°C and the s/n, containing the whole cell 
extract, was frozen in liquid nitrogen and stored at -80°C. Prior to use protein concentration 
was determined by performing a Bradford assay, as described in section 2.3.10
ii) Cytosolic and nuclear extract
Cells growing in log phase were harvested by centrifugation at 1,200 rpm for 3 min and 
washed with ice cold PBS. The cells were counted and resuspended at 5 x106 cell/ml in cold 
cytosolic extract buffer. The cells were pelleted by centrifugation for 1 minute at 13,000 rpm, 
4°C. The pellet was resuspended in 50 j j . I /5  x106 cells cold cytosolic extract buffer which 
contained 0.1 % NP-40. The suspension was incubated on ice for 5 min, followed by 
centrifugation for 5 min at 13,000 rpm, 4°C. The s/n, which contained the cytosolic extract 
was frozen in liquid nitrogen and placed in -80°C for long term storage. The nuclear pellet 
was resuspended in 15 jul/5 x106 cells cold nuclear extract buffer and incubated on ice for a 
further 15 min. Following centrifugation for 5 min at 13,000rpm, 4°C, the s/n was transferred 
to a new tube and a further 75 pl/5 x106 cells cold nuclear extract buffer was added to the 
nuclear extract and was then frozen in liquid nitrogen and stored at -80°C. Prior to use, 
protein concentration was determined by performing a Bradford assay, as described in 
section 2.3.10.
3.2.6.2 Incubation ofDNA probe with cellular extract
Prior to incubation of the DNA probe with the cellular extract, the single stranded DNA 
probes were mixed with an equal quantity of complementary sequence probe and heat 
inactivated for 5 min at 95°C using PCR machine. The probes were cooled on the bench to 
allow the complementary sequences to anneal thus forming a double stranded DNA probe. 
Once cooled the dsDNA probes were kept on ice prior to use.
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Table 3.2.5 EMSA probes sequences
Probe Sequence
CCAAT 
labelled with 
biotin
Forward 5’-CCCAGTGTGCAGACCAATGAGAGCCCCAGA-3’ biotin 
Reverse 3’-GGGTCACACGTCTGGTTACTCTCGGGGTCT-5’
CCAAT self Forward 5’-CCCAGTGTGCAGACCAATGAGAGCCCCAGA-3’ 
Reverse 3’-GGGT CACACGT CT GGTTACT CT CGGGGT CT-5’
CCAAT/NF-Y
consensus
Forward 5’-AAGAGATTAACCAATCACGTACGGTCT-3’ 
Reverse 3’-TT CT CTAATT GGTTAGT GCAT GCCAGA-5’
CCAAT
mutant
Forward S’-CCCAGTGTGCAGACTCTAGAGAGCCCCAGA-S’ 
Reverse 3’-GGGT CACACGT CT GAGAT CT CT CGGGGT CT-5’
NFAT labelled 
with biotin
Forward 5-AGAGAAAGACGGTCATTTCCTCCCTGCATCTTCC-3’ biotin 
Reverse 3’-TCTCTTTCTGCCAGTAAAGGAGGGACGTGAAGG-5’
NFAT self Forward 5’-AGAGAAAGACGGT CATTT CCT CCCT GCAT CTT CC-3’ 
Reverse 3’-T CT CTTT CTGCCAGTAAAGGAGGGACGT GAAGG-5’
NFAT
consensus
Forward 5’-CGCCCAAAGAGGAAAATTTGTTTCATA-3’ 
Reverse S’-GCGGGTTTCTCCTTTTAAACAAAGTAT-S’
NFAT mutant Forward 5’-
CCCCAGAGAGAAAGACGGT CCTTAAGGCCCT GCAT CTT CCCTT GGGG 
Reverse 3’-
GGGGT CT CT CTTT CT GCCAGGAATT CCGGGACGTAGAAGGGAACCCC
The following were mixed in exact order as described; 8 jug cellular extract, 5 x 
binding buffer, sterile H20  (to make total volume 20 jj.1), 1 pg polydkdC, 40 pmoles competitor 
and 40 fmoles biotin-labelled probe. The reaction mixture was incubated at RT for 20 min.
3.2.6.3 Non-denaturing polyacrylamide gel electrophoresis
Following incubation, 20 pi of the reaction mixture was loaded onto a 6 % non-denaturing 
polyacrylamide gel electrophoresis (see table below), which had been pre-run for 20 min at 
100 V. The gel was run for approximately 2 hrs at 100 V, 4 °C in 1 x TBE, until the control 
lane which contained bromophenol blue within the binding buffer had reached approximately 
2/3 down the gel.
6 % non-denaturing polyacrylamide gel
40 % Acrylamide (29:1) 2.25 ml
5 x TBE 1.5 ml
Sterile H20 11.085 ml
10% APS 150 pi
TEMED 15 pi
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3.2.6.4 Denaturing polyacrylamide gel electrophoresis
To obtain approximate information regarding the molecular weight of the protein bound to the 
DNA probe a denaturing SDS-polyacrylamide gel electrophoresis was performed. Following 
incubation, the reaction mixture was placed in a 96-well microtitre plate and cross-linked 
twice using the autocross-linking settings on the Stratalinker ®  UV Cross Linker, which emits 
1200 microjoules of UV. The reaction mixture was then mixed with an equal volume of 
protein sample buffer, as described in Chapter 2, which contained 0.5 mM DTT. 20 jul of the 
reaction mixture was loaded onto a 12.5 % separating gel with 6 % stacking gel and run as 
previously described in 2.3.7. Once the samples had been separated the protein-DNA 
complexes were transferred to nitrocellulose membrane as described in section 2.3.7 and 
was then visualised using protocol described in section 3.3.6.6.
3.2.6.5 Transfer Biodyne® Nylon membrane
Protein-DNA binding complexes, which were separated on a non-denaturing polyacrylamide 
gel, were transferred onto a positively charged Biodyn® Nylon membrane. To do this, the 
gel was overlaid with the nylon membrane which had been pre-soaked in 1x TBE and 
sandwiched between 2 pieces of soaked filter paper (Whatman #5) and 1-2 thin sponges, on 
either side. The gel-membrane ‘sandwich’ was loaded into a transfer apparatus unit (Hoefer) 
according to the manufacturer’s instructions, with the membrane placed between the gel and 
the positive electrode. The proteins were transferred onto the nylon membrane by 
electrophoresis in 1x TBE for 1 hr at 100 V  (constantly cooled with water passing across the 
base apparatus).
3.2.6.6 Detection of biotinylated labelled DNA probe by chemiluminescence
Prior to detecting biotinylated DNA probe using chemiluminescence, the DNA-protein 
complexes were cross-linked onto the nylon or nitrocellulose (for denaturing PAGE) 
membrane using Stratalinker ®  UV Cross Linker, by placing the membrane facing upwards 
towards the lamps and using the autocross-linking function which emits 1200 microjoules of 
UV.
Once the DNA-protein complexes had been cross-linked to the membrane, the blots
were developed using Pierce Chemiluminescent Nucleic Acid Detection Kit (89880, Pierce)
following manufacturer’s instructions. Briefly, the blocking and 4x wash buffer were warmed
in a 37 °C water bath until precipitate had dissolved. The membrane was blocked with 15 ml
of blocking buffer for 15 min with gentle agitation. 66.7 pi of stabilised streptavidin-
horseradish peroxidase conjugate was added to 20 ml of blocking buffer and the blocking
buffer was decanted from the membrane and replaced with the conjugated/blocking solution.
1x Wash solution was prepared by adding 25 ml of 4x wash buffer with 75 ml ultrapure water.
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Following incubation of the membrane for a further 15 min, the membrane was transferred to 
a new container and washed 5 times with 20 ml wash solution. The membrane was 
transferred to another new container and incubated for 5 min with 30 ml of substrate 
equilibration buffer, with gentle agitation. The substrate working solution was prepared by 
mixing 3 ml of luminol enhancer solution to 3 ml stable peroxide solution. The membrane 
was removed from the substrate equilibration buffer and excess buffer was blotting the 
membrane carefully onto paper towel. The substrate working solution was poured onto the 
membrane which was incubated for a further 5 min without shaking. The membrane was 
removed from the working solution and was then placed between two clear plastic sheets 
avoiding bubbles. The membrane was exposed by placing it in a film cassette and exposing 
X-ray film for approximately 5 min.
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3.3 Results
To determine how C5aR expression is regulated in the mammalian U937 cell line, the C5aR 
5’promoter region and 3’UTR were cloned into the pEGFP-1 reporter vector. By placing the 
C5aR 5’promoter region upstream to the EGFP gene the rate at which EGFP is transcribed, 
once stably transfected into the U937 cell line, is dependent on the cis-acting elements within 
the promoter region and also the presence of trans-acting factors within this cell line. 
Likewise, by placing the C5aR 3’UTR downstream of the EGFP gene the stability of the 
EGFP mRNA can be regulated by the presence of AU-rich elements within the 3’UTR.
3.3.1. Cloning the C5aR 5’promoter fragments and 3’UTR into the pEGFP 
vector
To clone the C5aR 5’promoter region and 3’UTR, gDNA was extracted from the U937Ec and 
U937pm cell lines. Specific primers for the C5aR 5’promoter region and 3’UTR were designed 
for PCR as shown in figures 3.3.1 and 3.3.2 respectively. PCR of the C5aR 2Kbp promoter 
region was performed using high fidelity polymerase and separate reactions were performed 
using gDNA isolated from either U937Ec or U937PM as the template DNA (figure 3.3.3). 
5’Promoter deletions were then created by PCR using the 2Kbp PCR fragment generated 
from U937ec gDNA as the template DNA (figure 3.3.4). Restriction enzyme digestion was 
used to create the 355 bp promoter construct. PCR of the C5aR 3’UTR was performed using 
GoTaq Flexi polymerase due to differences between the Tm of the primers which could not 
be prevented (figure 3.3.5). Following PCR the DNA was purified and, where appropriate, 
the DNA underwent extension with GoTaq polymerase to add additional 3’ A residues prior to 
cloning into pGEM-T. The DNA was ligated into the pGEM-T vector and transformed into 
chemically competent NM522 using heat shock. Successfully transformed NM522s were 
screened for the correct insert using both size screening and PCR screening methods. 
Figure 3.3.6 shows an example of a size screen of colonies that were selected as potential 
positives. Lane 3 shows a potential positive colony as it has run slower through the gel 
compared with the samples in lanes 2, 4 and 5. Positive colonies were confirmed by DNA 
sequence analysis.
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Figure 3.3.1 Human C5aR promoter region gDNA sequence (accession number 
AC_099491). Forward primers as indicated in blue were used to create a series of 5’promoter 
deletions when paired with the reverse primer indicated in 0 | .  Potential transcription factor binding 
sites which were later mutated using site directed mutagenesis are illustrated in
-2035 -2025 -2015 -2005 -1995
2Kbp forward primer
1 C C C TTC G C TC  A TA TTA C C G C  C AGATCAGGGG CGGAATTACA
GGGAAGCGAG TATAATG G CG GACTAGACAG T C TA G TC C C C G C C TTA A TG T
-1985 -1975 -1965 -1955 -1945
51 TTC T C A TA A G AGCGTGAACC CAGGCCGGGC GCAGTGGCTC AAG CCTG TAA
A A G A G TA TTC TC G CACTTG G GTCCGGCCCG CGTCACCGAG TTC G G A C A TT
-1935 -1925 -1915 -1905 -1895
101 TC C C A G C A TT TTGGGAGGCT GAGGCGGGTG GATCACGAGG TCAGGAGTTC
AG G G TCG TAA AACC C TC C G A CTCCG CCCAC CTA G TG C TC C AG TCCTCAAG
-1885 -1875 -1865 -1855 -1845
151 GAGATCAGCC TGGCCAAGAT GGTGAAACCA C G TC TC TA C T A A AAA TACAA
CTC TA G TC G G A C C G G T TC T A C C A C TTTG G T GCAGAGATGA T T T T T A T G T T
-1835 -1825 -1815 -1805 -1795
201 AA A TTA G C C G GGTGCAGTGG TAGGCACCTG TAGTCCCAGC TACTCGGGAG
T TTA A TC G G C CCACGTCACC ATCCGTGGAC ATCAGGGTCG ATGAGCCCTC
-1785 -1775 -1765 -1755 -1745
251 GCTGAGGCAG G AGAATCGCT TGAACCTGGG AGGCGGAGGT TGCAGTGTGC
CG ACTCCG TC C TC TTA G C G A ACTTG G ACCC TC CG CCTCC A ACGTCACACG
-1735 -1725 -1715 -1705 -1695
301 CGAGATCGTG C C A CTG CACT CTAGCCTGGG TGAGAGAGTG A G A CTCCATC
G CTCTAG CAC GGTGACGTGA GATCGGACCC A C TC TC TC A C TCTGAGGTAG
-1685 -1675 -1665 -1655 -1645
351 TC A A A A A A A A AAAAA AAAAA AAAAAGAGCA TGA ACCCTG T TGTGAACAGC
A G T T T T T T T T T ip ip rp fpi ip rpi ip ipi ipi T T T T T C T C G T ACTTG G G ACA A C A C TTG TC G
-1635 -1625 -1615 -1605 -1595
401 GCATGTGAGG G A TC TG G G TT GCAAGCTCCT TATG A G A A TC TA A TG C C TG A
C G TA C A C TC C C TAG ACCCAA CGTTCGAGGA A TA C TC T TA G A TTA C G G A C T
-1585 -1575 -1565 -1555 -1545
451 T G A TC T G TC A C T G TA T C C C A TCACCCCCAG ATAG G ACCAT C TC G TTA C A G
A C TAG ACAG T GACATAGGGT AGTGGGGGTC T A TC C T G G TA GAGCAATGTC
-1535 -1525 -1515 -1505 -1495
1.5Kbp forward primer
501 GAAAACAAGC TC A G G G A TTC C A C TG A TTC T H r ^ T T A T G T T G A A T TG T A TA
C T T T T G T T C G A G TC C C TA A G GTGACTAAGA TG TA A TA C A A C T TA A C A TA T
89
551
601
651
701
751
801
851
901
951
1001
1051
1101
1151
-1485 -1475 -1465 -1455 -1445
ATTATTTCAT TAT AT ATT AC AATGTAACAA TAATAGATGG AGATGGTTGT
TAATAAAGTA ATATATAATG TTACATTGTT ATTATCTACC TCTACCAACA
-1435 -1425 -1415 -1405 -1395
GGCTTGTGTA GTTGGGGGAC AGGGTAGCTC CATTTTCTAT TGCCAACTTT
CCGAACACAT CAACCCCCTG TCCCATCGAG GTAAAAGATA ACGGTTGAAA
-1385 -1375 -1365 -1355 -1345
ATAACCCTAG AAGGATGATT TTTTTCTTTT CTTTTCTTTT TCTTTTCTTT
TATTGGGATC TTCCTACTAA AAAAAGAAAA GAAAAGAAAA AGAAAAGAAA
-1335 -1325 -1315 -1305 -1295
T T T TT T T *1* T T TGAGATTGAG TCTTGGTGTT GTCAGCCTGG GCTGGAGTGC
AAAAAAAAAA ACTCTAACTC AGAACCACAA CAGTCGGACC CGACCTCACG
-1285 -1275 -1265 -1255 -1245
AATGGTGCAA TCTCTGCTCA CTGCAACCTC CGCCTCCTGG GTTCCAGCAA
TTACCACGTT AGAGACGAGT GACGTTGGAG GCGGAGGACC CAAGGTCGTT
-1235 -1225 -1215 -1205 -1195
TTCTCCTGCC TCAGCCTTCT GAGTAGCTGA GATTACAGGC ACCCACCACC
AAGAGGACGG AGTCGGAAGA CTCATCGACT CTAATGTCCG TGGGTGGTGG
-1185 -1175 -1165 -1155 -1145
ACGCCTGGCT AATTTTTGTA TTTTTAGTAG AGATGGGGTT TCACCATATT
TGCGGACCGA TTAAAAACAT AAAAATCATC TCTACCCCAA AGTGGTATAA
-1135 -1125 -1115 -1105 -1095
GGCCAGGCTG GTGACGATGG T T T T T T *1* T T T TTGAGACAGA GTCTTGCTTT
CCGGTCCGAC CACTGCTACC AAAAAAAAAA AACTCTGTCT CAGAACGAAA
-1085 -1075 -1065 -1055 -1045
GTTGCCCAGG CTGGAGTGCA GTGGCGCAAT CTTGGCTCAC TGCAACCTCT
CAACGGGTCC GACCTCACGT CACCGCGTTA GAACCGAGTG ACGTTGGAGA
-1035 -1025 -1015 -1005 -995
lKbp forward primer
GCCTCCCAGG TTTAAGCAAT TCTCCTGCCT CAGCTTCCCA AGTAGCTGGG
CGGAGGGTCC AAATTCGTTA AGAGGACGGA GTCGAAGGGT TCATCGACCC
-985 -975 -965 -955 -945
ATTACAGGCA CCTGCCACCA CACCTGGGTA ATTTTTGTAT TTTTAGTAGA
TAATGTCCGT GGACGGTGGT GTGGACCCAT TAAAAACATA AAAATCATCT
-935 -925 -915 -905 -895
GACAGGGTTT CACCATGTTG GCCAGACTCG TCTTGAACTC CTGACCTCAA
CTGTCCCAAA GTGGTACAAC CGGTCTGAGC AGAACTTGAG GACTGGAGTT
-885 -875 -865 -855 -845
GTGATTCATT TGCCTCAGCC TCCCAAAGTG CTGGGATTAT AGGTGTGAGC
CACTAAGTAA ACGGAGTCGG AGGGTTTCAC GACCCTAATA TCCACACTCG
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-835 -825 -815 -805 -795
1201 CATTGCACCT GGCCCTAGAA GGAAGATTTA ACAGTAAAAT ATACTTAAAT
GTAACGTGGA CCGGGATCTT CCTTCTAAAT TGTCATTTTA TATGAATTTA
-785 -775 -765 -755 -745
1251 GCTGGGCTAC CTCCGCAGAC TAGCTCAGCC TCTTTGGGTC TCAAATCAGC
CGACCCGATG GAGGCGTCTG ATCGAGTCGG AGAAACCCAG AGTTTAGTCG
-735 -725 -715 -705 -695
1301 CTGGCCGGGA GGCTGAGTGG AGGTTACAGT CTCTGCTTTC TTGAATCCCA
GACCGGCCCT CCGACTCACC TCCAATGTCA GAGACGAAAG AACTTAGGGT
-685 -675 -665 -655 -645
1351 AGGGAGGGGT TTAAGCCAAC TGCATTCCTG AGCTTTTGCC CAGAAGGCTG
TCCCTCCCCA AATTCGGTTG ACGTAAGGAC TCGAAAACGG GTCTTCCGAC
-635 -625 -615 -605 -595
1401 GCGTCTTAGG AGGAAAGAGA TAGATGGCTC CAGGCCGGGC GCAGTGGCTC
CGCAGAATCC TCCTTTCTCT ATCTACCGAG GTCCGGCCCG CGTCACCGAG
-585 -575 -565 -555 -545
1451 ACACTTGTAA TTCTAGCACT TTGGGAGGTT GAGGTGGGTG ATTGCCTGAG
TGTGAACATT AAGATCGTGA AACCCTCCAA CTCCACCCAC TAACGGACTC
-535 -525 -515 -505 -495
500bp forward primer
1501 CTCAGGAGTT TGAGTCCAGC CTGGCCAACA TfcGCGAAACC C C G TC TTTA C
GAGTCCTCAA ACTCAGGTCG GACCGGTTGT ACCGCTTTGG GGCAGAAATG
-485 -475 -465 -455 -445
1551 TAAAAATACA AAAAATTAGC CGGGGGTGGT GACACACACG TGTAATCCCA
a t t t t t a t g t TTTTTAATCG GCCCCCACCA CTGTGTGTGC ACATTAGGGT
-435 -425 -415 -405 -395
1601 GCTACTCGGG AGGCTGAGGC AGGAGAAGTG CTTGAACCCA GGAGGCAGAG
CGATGAGCCC TCCGACTCCG TCCTCTTCAC GAACTTGGGT CCTCCGTCTC
-385 -375 -365 -355 -345
PstI used for 355bp fragment
1651 GTTACAGAGA GCCGAGATTG CACCACTCCA CTG$||CCTG GGCGACACAG
CAATGTCTCT CGGCTCTAAC GTGGTGAGGT GACGTCGGAC CCGCTGTGTC
-335 -325 -315 -305 -295
1701 CAAGACTCTA TCAAAAAAAA AAAAAAAAAA ATGAGAGAGA AGAGATGGCC
GTTCTGAGAT AGTTTTTTTT T T *1* T T T T T T *1* TACTCTCTCT TCTCTACCGG
-285 -275 -265 -255 -245
NFkB site
1751 CCAAATAGGG AAACCAAGGC CAGGAGAGGG GCCGAGCCTG
GGTTTATCCC TTTGGTTCCG GTCCTCTCCC CGGCTCGGAC GTGTCCTCGA
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-235 -225 -215 -205 -195
200bp forward primer
1801 I H c g g t t t  t c c g a g c g c c  g g c c c c c c t t  c t c t g H H H H H H
AGGAGCCAAA AGGCTCGCGG CCGGGGGGAA GAGACGGACC CTCCTCCACC 
-185 -175 -165 -155 -145
3.851 ■ ■ ■ ■ c  CTGGGTGTGT GCCCCGCAGA GGGAGCTCTG GCCTCAGTGC
AATCTCAGGG GACCCACACA CGGGGCGTCT CCCTCGAGAC CGGAGTCACG 
-135 -125 -115 -105 -95
CCAAT binding factors (NFY) lOObp forward primer
ccagtgtg^ ^ ^ ^ B H ^ H cccagag agaaa| H H H H B H H I
GGTCACACGT CTGGTTACTC TCGGGGTCTC
Nuclear factor of activate T-cells 
-85 -75 -65 -55 -45
1951 ■ M tt c c c t t g g g g c  t t t a a a a a c c  a c a g c c c t t g  g g c a g g a g g g
|g a c g t a g a a  g g g a a c c c c g  a a a t t t t t g g  t g t c g g g a a c  c c g t c c t c c c
-35 -25 -15 -5
Start codon
2001 ACCTTCGATC CTCGGGGAGC CCAGGAGACC AGAACATGGT GAGTCTCGAA
TGGAAGCTAG G A G C H ^ ^ I ^ ^ ^ H ^ H ^ ^ H TACCA CTCAGAGCTT
Reverse primer
92
a Lire 3.3.2 Human C5aR 3’UTR cDNA sequence. Primers used for PCR are highlighted in for the forward primer and ■  for the reverse primer. The two AU rich elements (ARE) are highlighted in and the polyadenylation signal is underlined.
Forward primer
1 g c ^ c a g c c t  c a t g g g c c a c  tc^tggcccga tgtccccttc CTTCCCGGCC
51 ATTCTCCCTC TTGTTTTCAC TTCACTTTTC GTGGGATGGT GTTACCTTAG
101 CTAACTAACT CTCCTCCATG TTGCCTGTCT TTCCCAGACT TGTCCCTCCT
151 TTTCCAGCGG GACTCTTCTC ATCCTTCCTC ATTTGCAAGG TGAACACTTC
201 CTTCTAGGGA GCACCCTCCC ACCCCCCACC CCCCCCACAC ACACCATCTT
251 TCCATCCCAG GCTTTTGAAA AACAAACAGA AACCCGTGTA TCTGGGATAT
301 TTCCATATGG CAATAGGTGT GAACAGGGAA CTCAGAATAC AGACAAGTAG
1st ARE
351 AAAGATTCTC GCTTAAAAAA a ^ ^ ^ ^ ^ H t g g c a AGTTGGAAAA
401 TATGTAACTG GAATCTCAAA AGTTCTTTGG GACAAAACAG AAGTCCATGG
2 nd ARE
451 AGTTATCTAA GCTCTTGTAA g t g I ^ ^ ^ ^ H I a a a a a g a AAATTAGGCT
501 GAGAGCAGTG GCTCACGCCT GTAATCCCAG AACTTTGGGA GGCTAAGGTG
551 GGTGGATCAC CTGAGGTCAA GAGTTCCAGA CCAGGCTGGC CAGCATGGTG
601 AAACCCCGTC TGTACTAAAA ATACAAAAAA TTAACTGGGC ATGGTAGTGG
651 GTGCCTGTAA TCCCAGCTAC TTGGGAGGCT GAGGTGGGAG AATTGCTCGA
701 ACTTGGAGGT GGAGGTTGTG GTGAGCCATG ATCGCACCAC TGCACTCTAG
751 CCTGGGTGAC CGAGGGAGGC TCTGTCTCAA AAGCAAAGCA AAAACAAAAA
801 CAAAAACACC TAAAAAACCT GCAGTTTTGT TTGTACTTTG TTTTTAAATT
851 ATGCTTTCTA TTTTGAGATC ATTGCAAACT CAACACAATT GTAAGTAATG
901 ATACAGAGGG ATCTTGTGTA CCCTTCACCC AGCCTCCCCC AATGGCAACA
951 TCTTGCAAAA CTACAATGTA GTCTCATAAC CAGGATATTG ACATTGATAC
1001 AGTGAAGATA CAGGACATTC T CATC ACC AC AGGGATCCCC AGGATGCCCA
1051 CTTCCCTCCA CCCCCACACC CCAGCCGTGT CCCTAACCCC TGGCAACCAG
1101 GAATCCACTC TCCATTTCTA TAATGTTGTC ATTTCAAGAA TGTTATTCAA
1151 TGGAATCATA TAGTATGTAA CCTGTTTTGA GCTTAAAAAA AAAGTATACA
Reverse primer
1201 TGACTTTAAT |A G G A A / \ A A T G A ^ ^ H |
Polyadenylation signal
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Figure 3.3.3 PCR of the C5aR 2Kbp 5’promoter region. Genomic DNA isolated from 
U937Ec (A) or U937PM (B) was used as a template for PCR amplification of the C5aR 2Kbp 5’promoter 
region. To determine the approximate molecular weight the PCR product were analysed by agarose 
(1 %) gel electrophoresis. (A) Lane 1 molecular weight markers and lane 2 PCR using C5aR 2Kbp 
5’promoter specific primers. (B) Lane 1 molecular weight markers and lane 2 PCR using C5aR 2Kbp 
specific primers.
B
506/517
396 bp 
344 bp 
298 bp
220 bp
100 bp
1636 bp 
1015 bp
506/517 
bp
Figure 3.3.4 PCR of the 5’promoter deletion fragments. The 5’promoter deletions were 
generated by PCR using the 2 Kbp 5’promoter fragment from U937EC as the template. To determine 
the approximate molecular weights, PCR products were analysed by agarose (1 %) gel 
electrophoresis. (A) lane 1, molecular weight markers; lane 2, PCR using 1.5 Kbp 5’ promoter specific 
primers; lane 3, PCR using 1 Kbp 5’promoter specific primers; lane 4, PCR using 500 bp 5’promoter 
specific primers. (B) Lane 1, molecular weight markers; lane 2, 200 bp 5’promoter specific primers; 
lane 3, 100 bp 5’promoter specific primers.
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Figure 3.3.5 PCR of the C5aR 3’UTR. U937EC gDNA was used as a template for PCR 
amplification of the C5aR 3’UTR region. To determine the approximate molecular weight the PCR 
product were analysed by agarose (1 %) gel electrophoresis; lane 1, molecular weight markers; lane 
2, PCR using C5aR 3’UTR specific primers.
1 2 3 4 5
Figure 3.3.6 Size screening for potentially positive colonies. Plasmid DNA was isolated 
from potential 2Kbp 5’promoter/pGEM-T colonies using the alkaline lysis method as described in 
section 3.2.2.4.4. To identify potential positive colonies, plasmid DNA was separated by agarose (0.7 
%) gel electrophoresis; lane 1, molecular weight markers; lanes 2, 4 and 5, show colonies with just the 
pGEM-T vector; lane 3, successful 2Kbp 5’promoter/pGEM-T colony.
In order to obtain EGFP reporter constructs that could then be transfected into the 
U937 cell lines, the C5aR 5’promoter fragments or 3’UTR were subcloned into the pEGFP-1 
or EF1a+pEGFP-1 vectors respectively using restriction enzymes sites which were 
incorporated during PCR (see tables 3.2.1 and 3.2.2 for full details). Figure 3.3.7 shows both 
the pGEM-T and pEGFP-1 vector systems used for cloning and important restriction enzyme 
sites. Figure 3.3.8 shows in lane 2 the 2Kbp 5’promoter has been successfully excised from 
2kbp 5’promoter/pGEM-T, in lane 3 successfully digested pEGFP-1 vector. NM522 
bacteria were transformed with the 5’promoter+pEGFP or EF1a+pEGFP+3’UTR constructs. 
Colonies resistant to kanamycin were screened by size and PCR. Figure 3.3.9 shows an 
example of a PCR screen of colonies which were being screened for the 2 Kbp 5’promoter 
fragment; lane 2 shows a positive colony as a band was seen at approximately 2 Kbp; lane 1 
shows a negative colony which contains a smaller insert. Positive colonies were confirmed 
by sequence analysis, which were then aligned with published sequences.
Detailed in appendix 9.1 are the full sequences for the 5’promoter fragments 
generated using gDNA from U937Ec. Appendix 9.2 shows the consensus 2 Kbp promoter 
sequence from U937Ec and U937PM aligned with the human sequence already published by 
Gerard and colleagues and GeneBank AC_099491, as well as, the chimpanzee promoter 
sequence.
Seven base pair differences were found between the U937EC and U937PM 5’promoter
sequences (table 3.3.1). Three of these differences (-1663bp, -1662 and -1661 bp) are
additional adenosine residues present in the U937PM and chimpanzee sequence but not the
U937ec. This region of the promoter contains 25 adenosine residues repeated, which could
potentially result in errors during cloning procedures. However, as they are also present
within the chimpanzee sequence this suggests they could be insertions/deletions. The
U937ec sequence has a C insertion at position -730bp and a G to A substitution at position -
464bp, which are unique to this cell line suggesting that this could be due to errors during
cloning or sequencing (table 3.3.1). However both these differences resulted in an
insertation or deletion of a new putative c/s-acting element compared with the U937PM cells
as predicted by Matlnspector (table 3.3.2). The C insertion at position -730bp resulted in a
new putative site, E2F-myc activator/cell cycle regulator, being present in the U937EC cells
promoter but absent in the U937PM promoter. Furthermore, the matrix similarity, which is the
similarity with the consensus neighbouring residues (not key residues), altered slightly in the
putative neuron-restrictive silencer factor between the U937Ec and U937PM promoter (table
3.3.2). The -464 G/A substitution resulted in the putative zinc binding proteins factor sites
being absent in the U937EC promoter compared with the U937PM (table 3.3.2). Several other
substitutions (A/G -464bp, A/G -396bp and T/C -253bp) have been previously been identified
as SNPs with their unique SNP identification number listed in table 3.3.2. Both the -396bp
96
(A/G) and -253bp (T/C) substitution resulted in a reduced core similarity in two putative sites, 
activator protein 2 and MAF and AP1 related factors, between the two promoters (table
3.3.2). However these differences indentified by Matlnspector do not necessarily equate to 
changes in promoter activity as these sites are only predicted sites. Shown in appendix 9.5 
are the sequence alignments for the C5aR 3’UTR region. There are 8bp differences 
between the U937Ec and U937PM 3’UTR, 7 of these differences are unique to either one of 
these sequences. Shown in figure 3.3.10 is a schematic diagram of the C5aR 5’ promoter 
and 3’UTR EGFP reporter constructs generated.
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Figure 3.3.7 Plasmid maps.
reference points.
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Figure 3.3.8 Analysis of plasmid restriction enzyme sites prior to sub-cloning.
Restriction enzyme digest (EcoRI and Kpnl) of 2 Kbp 5’promoter/pGEM-T and pEGFP-1 analysed by 
agarose (0.8%) gel electrophoresis. Lane 1, molecular weight markers; lane 2, restriction enzyme 
digest of 2 Kbp 5’promoter/pGEM-T; lane 3, restriction enzyme digest of pEGFP-1.
1 2 3
<___ 2036
«  1636
«----- 1015
Figure 3.3.9 PCR screen for potential 2Kbp 5’promoter + pEGFP colonies. PCR was
performed using approximately 2mm2 sample of bacteria colonies which had been transformed with 2 
Kbp 5’promoter+pEGFP reporter construct. The bacteria were incubated at 99 °C for 10 mins followed 
by incubating on ice for a further 10 mins. Following centrifugation 2 pi of s/n, which contained the 
plasmid DNA, was used as the template DNA and PCR was performed using pEGFP-1 specific 
primers (see table 3.2.3). Lane 1, negative colony which produced a number of smaller DNA 
fragments; lane 2, positive colony for the 2 Kbp 5’promoter+pEGFP reporter construct; lane 3, 
molecular weight markers.
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Position U937pm U937ec Genebank
Chimpanzee
sequence
Published by 
(Gerard et 
al., 1993)
SNPs
previously
identified
-1663 bp A - - A
-1662 bp A - - A
-1661 bp A - - A
-730 bp - C - -
-464 bp G A G G rs60925053
-396 bp A G A G rs59259352
-253 bp T C C C T rs10404456
Table 3.3.1 Base pair differences between the U937Ec and U937PM 2 Kbp promoter 
sequences. For full alignment see appendix 9.2. Position number is based on the U937EC 
sequence numbering. Previously published SNPs were identified using blastn suite-SNP 
(http://blast.ncbi.nlm.nih.qov/Blast.cqi?PROGRAM=blastn&BLAST SPEC=SNP&BLAST PROGRAM 
S=meqaBlast&PAGE TYPE=BlastSearch&SHOW DEFAULTS=on).
Position
Strand CoreSimilarities
Matrix
SimilaritiesFrom to
Neuron-restrictive silencer 
factor -738 -718 - 0.782 0.707
-738 -718 - 0.782 0.721
E2F-myc activator/cell 
cycle regulator -737 -721
+ 0.809 0.859
Absent in U937PM
Zinc binding protein factors -474 -452 1.000 0.925
Absent in u937ec
Zinc binding protein factors -471 -449 - 1.000 0.943
Absent in u937ec
Activator protein 2 -469 -455 + 0.881 0.925
-469 -455 + 0.830 0.912
MAF and AP1 related 
factors -258 -238
+ 0.875 0.948
-258 -238 + 0.750 0.905
Table 3.3.2 Putative sites which differ between the U937Ec (in green) and U937PM (in 
blue). Core similarity is the similarity between the core residues of the consensus sequences for the 
putative sites. Matrix similarities are the similarities between the surrounding residues which are less 
critical for transcription factor binding.
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Figure 3.3.10 Schematic diagram of C5aR 5’promoter and 3’UTR EGFP reporter 
constructs. The C5aR 5’promoter region was cloned upstream of the EGFP gene, where as the 
3’UTR was placed down stream. (A) C5aR 2 Kbp 5’promoter fragment; (B) C5aR 1.5 Kbp 5’promoter 
fragment; (C) C5aR 1 Kbp 5’promoter fragment; (D) C5aR 500 bp 5’promoter fragment; (E) C5aR 355 
bp 5’promoter fragment; (F) C5aR 200 bp 5’promoter fragment; (G) C5aR 100 bp 5’promoter 
fragment; (H) promoter-less pEGFP vector, negative control; (I) EF1a promoter + pEGFP + SV40; (J) 
EF1a promoter + pEGFP + C5aR 3’UTR.
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3.3.2 The majority of the 2Kbp 5’promoter is dispensable for expression
By placing the C5aR 2Kbp 5’promoter region upstream of the EGFP cDNA, the rate at which 
EGFP is transcribed is dependent on the cis-acting elements present within this promoter. 
EGFP was chosen as it allows changes in transcription activity and therefore EGFP 
expression to be easily detected by flow cytometry. Transfection of the 2Kbp 5’promoter 
EGFP reporter constructs into the mammalian U937 cell lines will allow us to investigate how 
the expression of the C5aR is regulated in this cell line. Subsequent deletion analysis can 
then identify regions within the promoter that contain strong promoter or suppressor activity 
which together with Genomatix Matlnspector Software can be used to predict potential 
transcription factor binding sites.
The 5’promoter+pEGFP reporter constructs were stably transfected into the U937 cell 
line using electroporation. Following electroporation the cells were placed in complete RPMI 
media with 1.25% DMSO for 24 h and then in 500 |ig/ml G418 selection media for 2-3 
weeks. DMSO has previously shown to improve transfection efficiency in HL-60, TR146, 
Cos-7 and L132 cell lines, and was applied to these experiments as it reduced the time 
needed for the U937 cells to recover following electroporation from 4 weeks to 2-3 weeks, 
data not shown (Melkonyan et al., 1996). Once the cells had recovered and were growing in 
log phase, EGFP fluorescence was analysed by flow cytometry. Figure 3.3.11 shows a 
typical histogram plot of U937 cells transfected with an EGFP reporter construct. The 
histogram plot shows two different fluorescent cell populations, an EGFP negative and an 
EGFP positive population. The EGFP negative population was always present, even after 2- 
3 weeks in G418 selection media which killed the non-transfected U937 control cells. These 
results suggest that the EGFP negative population expresses the neomycin-resistance 
cassette but not the EGFP gene. Stable cell lines are generated when the exogenous DNA 
aligns with the chromosomal DNA of the cell and a homologous recombination event occurs 
which results in the exogenous DNA being inserted into the chromosomal DNA. It is 
therefore possible that during the homologous recombination only the neomycin resistance 
gene is inserted into the chromosomal DNA of these cells and hence their G418 resistance 
but EGFP negative nature. Alternatively the recombination may have occurred within the 
EGFP coding region and therefore disrupting the EGFP gene. When analysing the effects of 
different reporter constructs on EGFP fluorescence only the EGFP positive cells was 
measured from multiple transfection typically n=4.
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Figure 3.3.11 Histogram plot of U937Ec which have been transfected with the 2 Kbp 
5’promoter + pEGFP reporter construct. Following transfection of U937EC cell line with the 2 
Kbp 5’promoter+pEGFP reporter construct, the cells were run on the flow cytometer and EGFP 
fluorescence was measured using FL1. The histogram plot shows two different fluorescent cell 
populations.
The 2Kbp 5’promoter constructs generated using either gDNA from U937Ec 
(2Kbp(EC)+pEGFP) or U937PM (2Kbp(PM)+pEGFP) were transfected into both cell lines and 
changes in EGFP fluorescence was monitored by flow cytometry. Figure 3.3.12 shows that 
there was no significant difference in promoter activity between the two reporter constructs, 
which suggests that there is no detectable difference in the transcriptional activity between 
the two 2Kbp promoter regions cloned. Figure 3.3.12 also shows that there was no 
significant difference between the cell lines used, which suggests that both cells contain the 
necessary transcription factors to drive transcription.
When the 5’promoter deletion fragments were transfected into the U937Ec cell line, it 
was shown that the majority of the -2 Kbp 5 ’promoter is dispensable for basal expression 
(figure 3.3.13). Deletions from -1.5Kbp to -1Kbp and -1Kbp to -500bp both resulted in a 
slight, although not statistically significant, increase in EGFP fluorescence, which suggest 
that some suppressor elements might be deleted. Figure 3.3.13 shows that a significant 
decrease in EGFP expression was observed between the -1Kbp and -500bp and the -100bp 
fragment. Although deletion from -200bp to -100bp resuited in a decrease in promoter 
activity this was not statistically significant. The figure also shows that the -100bp fragment 
still contained double the promoter activity compared with the pEGFP control vector, which 
suggest that this fragment still contains some promoter activity.
Transfection of the U937PM cell line with 5 ’promoter deletion reporter constructs
produced similar pattern as the U937EC cell line transfected with the same constructs (figure
3.3.14). As shown in figure 3.3.14 there was a statistically significant increase in EGFP
fluorescence between the -2Kbp fragment and the -500bp, -355bp and 200bp fragments
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suggesting there may be some suppressor activity between -2Kbp and -500bp. The -100bp 
fragment displayed significantly less EGFP fluorescence compared with the -500bp and the - 
355bp fragments suggesting that some promoter activity was deleted between these regions 
(figure 3.3.14). However, deletion between the -200bp and the -100bp fragment failed to 
produce a statistical significance despite a reduction in EGFP fluorescence being observed 
(figure 3.3.14).
□  U937ec 
EM|U937pM
Construct
Figure 3.3.12 Comparison of EGFP fluorescence in both U937 cell lines transfected 
with the 2kbp 5’promoter+pEGFP reporter constructs generated from both gDNA 
templates. U937Ec and U937PM cells were transfected with either 2Kbp (EC) or 2Kbp (PM) + pEGFP 
reporter construct. Once the cells were growing in log phase EGFP fluorescence was monitored by 
flow cytometry. Two-way ANOVA performed on the promoter EGFP report constructs showed no 
significant difference between the cell line used or the 2Kbp promoter EGFP construct transfected.
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Figure 3.3.13 Transfection of U937Ec with C5aR 5’promoter deletion EGFP reporter 
constructs. U937EC cells were transfected with series 5’promoter deletion EGFP reporter constructs 
and once growing in log phase EGFP fluorescence was monitored by flow cytometry. One-way 
ANOVA followed by Tukey’s multiple comparison test showed significant difference from pEGFP 
**p<0.01 and p<0.001 or from -100bp fragment ♦♦p<0.01.
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Figure 3.3.14 Transfection of U937PM with C5aR 5’promoter deletion EGFP reporter 
constructs. U937PM cells were transfected with series 5’promoter deletion EGFP reporter constructs 
and once growing in log phase EGFP fluorescence was monitored by flow cytometry. One-way 
ANOVA followed by Tukey’s multiple comparison test showed significant difference; to -2 Kbp 
fragment ^<0.05, ♦♦p<0.01; to -100bp fragment *p<0.05, ••<p<0.01; to pEGFP *p<0.05, **p<0.01,
***p<0.0001
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3.3.3 Putative CCAAT/NF-Y and NFAT binding sites are important 
promoter elements for transcription control of EGFP in the - 
355bp+pEGFP reporter construct
As well as using the promoter deletions to identify regions of promoter or suppressor activity, 
the -2Kbp promoter sequence from both cell lines were entered into Genomatrix 
Matlnspector Software, which can be used to predict potential transcription factor binding 
sites, in each case a total of 292 putative sites were identified (appendix 9.4).
To determine which cis-acting elements are important for transcription, potential 
transcription factor binding sites were mutated using site directed mutagenesis. Site directed 
mutagenesis allows us to introduce specific mutations within the core sequence of potential 
cis-acting elements which will then prevent the necessary transcription factor from 
recognising the site. If the transcription factor binding site is important for transcription, then 
mutating the core sequence should prevent transcription.
Three potential c/s-acting elements, NFkB (-238bp to -232bp), CCAAT/NF-Y (-123bp 
to -119bp) and NFAT (-93bp to -87bp) were mutated within the -355bp 5’promoter+pEGFP 
reporter construct (figure 3.3.15). The putative NFkB site was mutated as this transcription 
factor regulates expression of genes whose proteins encode pro-inflammatory molecules or 
involved in the immune response (Hoffmann et al., 2006). Although this site was mutated by 
Hunt and co-workers and was shown to have no effect on C5aR expression in the mouse, 
the human and the mouse sequence in this region show less homology (appendix 9.3) (Hunt 
et al., 2005). Furthermore, statins have been shown to interfere with NFkB activation and 
therefore regulate the expression of other genes including MCP-1 and IL-6 (see Chapter 5 
for full details) (Veillard et al., 2006, Ortego et al., 1999, Massy et al., 2000, Guijarro et al., 
1996). It was decided to mutate the CCAAT site as this site has been previously been 
shown to be an important site in regulation of the mouse C5aR expression and there is great 
homology between the mouse and human sequence within this region of the promoter 
(appendix 9.3)(Hunt et al., 2005, Martin, 2007). The decision to mutate the putative NFAT 
site was based on induced expression of the C5aR. Previously NFAT has been shown to 
regulate induced expression of several cytokines, cell surface GPCRs, including CCR2, 
FcyRs and thrombin receptor (see table 3.4.2 for full details), however its role in C5aR 
expression has not been investigated.
Site directed mutagenesis of each putative element was designed to incorporate a 
new restriction enzyme site, which would allow easy screening of potential mutants prior to 
sequencing. Figures 3.3.16, 3.3.17 and 3.3.18 each show the restriction enzyme digest and 
the sequencing results confirming the mutated NFkB, CCAAT/NF-Y and NFAT sites 
respectively. Following transfection of these mutant-constructs into the U937Ec cell line
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changes in EGFP fluorescence were monitored by flow cytometry. Figure 3.3.19 shows that 
mutating either putative CCAAT/NF-Y or NFAT in the -355bp promoter fragment resulted in 
the EGFP fluorescence being barely above the background pEGFP fluorescence, suggesting 
that both sites play a key role in transcription of the C5aR gene. Figure 3.3.19 also shows 
that some promoter activity was also attributed to the putative NFkB site, as site directed 
mutagenesis of this site significant reduced EGFP fluorescence compared to the wt -355bp 
fragment.
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Figure 3.3.15 Schematic diagram illustrating the location of each of the putative site 
mutated by site directed mutagenesis. (A) Wild type -355bp + pEGFP generated from U937EC; 
(B) NFkB site; (C) CCAAT/NF-Y site; (D) NFAT site. Sequences in black are the wild type sequences, 
whereas in blue is the sequence following site directed mutagenesis.
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Figure 3.3.16 Screening for 355bp NFkB mutant. Potential colonies were first screened by 
restriction enzyme digest (A). Lane 1 shows a positive 355bp 5’promoter NFkB mutant colony as the 
plasmid DNA has been cut four times by Nco I into fragments 1809bp, 1719bp, 703bp and 265bp. 
Lane 3 shows the wild type 355bp 5’promoter+pEGFP construct which has been cut three times with 
Nco I; lane 2 shows undigested DNA. (B) To confirm the correct mutation had been introduced the 
355bp NFkB mutant DNA was sequenced. Sequence alignment shows wild type sequence bottom 
and mutated sequence top.
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Figure 3.3.17 Screening for 355bp 5’promoter CCAAT/NF-Y mutant. Potential colonies 
were first screened by restriction enzyme digest (A). Lane 1 shows a positive 355bp 5’promoter NFAT 
mutant colony as the plasmid DNA has been cut once by Xba I into a 4496bp fragment; lane 2 the wild 
type 355bp 5’promoter+pEGFP construct which did not get cleaved by Xba I. (B) To confirm that the 
correct mutation had been introduced the 355bp NFkB mutant DNA was sequenced. Sequence 
alignment shows wild type sequence bottom and mutated sequence top.
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Figure 3.3.18 Screening for 355bp 5’promoter NFAT mutant. Potential colonies were first 
screened by restriction enzyme digest (A). Shown in lane 1 is the wild type 355bp 5’promoter+pEGFP 
construct which has been cut once with Afl II; lane 3 shows a positive 355bp 5’promoter NFAT mutant 
colony as the plasmid DNA has been cut twice by Afl II into a 3414bp and 1082bp fragments. (B) To 
confirm the correct mutation had been introduced the 355bp NFkB mutant DNA was sequenced. 
Sequence alignment shows wild type sequence bottom and mutated sequence top.
***
* * *
Figure 3.3.19 Site directed mutagenesis of putative CCAAT/NF-Y or NFAT cis-acting 
elements abolished transcription control in -355bp+pEGFP reporter construct. Mutant - 
355bp promoter construct were transfected into the U937EC cell line and once cells were growing in 
log phase EGFP fluorescence was monitored by flow cytometry. One-way ANOVA followed by 
Tukey’s multiple comparison test show significant difference, as marked by asterisk, with the WT - 
355bp construct, * p<0.05, ***p<0.001, and with the NFkB , ■■■p<0.001, n = 4.
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Figure 3.3.20 EMSA of CCAAT/NF-Y probe mixed with different cell extracts from 
U 9 3 7 Ec cell line. Whole cell, cytosolic or nuclear extract were mixed with the biotinylated 
CCAAT/NF-Y probe in the absence or presence of competitor (see table 3.2.5 for probe sequences). 
Samples were run on a 6% non-denaturing PAGE. Yellow and blue arrows indicate bands present in 
both whole cell and cytosolic lysate. Red arrow indicates band appearing in both whole cell and 
nuclear lysate. Green arrow indicates band appearing in cytosolic lysate only.
NF-Y Consensus 
Human C5aR CCAAT 
Human CCAAT mutant 
Mouse CCAAT mutant
l lAGAGATTAACCAATCjgCGTACGGTCT 
CCAGTGTGC AGACT A A ! GAGAGCCCC AG, 
;CCAGTGTGACGAC I ( I AGAGAGCCCCAi 
:CCAGTGTGCAGACCO(\GAGAGCCCCA(
Figure 3.3.21 CCAAT/NF-Y probes aligned. Mouse CCAAT mutant was the same sequence as 
the mutant probe used by (Hunt et al., 2005).
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Figure 3.3.22 EMSA of NFAT probe mixed with different cell extracts from U937EC cell 
line. Whole cell, cytosolic or nuclear extract were mixed with the biotinylated CCAAT-NFY probe in 
the absence or presence of competitor (see table 3.2.5 for probe sequences). Samples were run on a 
6% non-denaturing PAGE.
NFAT mutant 
C5aR NFAT 
NFAT consensus
C C C C AG AG AGA AAG AC G G TlC T IA A G  
AGAG AAAGACGGT C ATT TCC
iT iC T T T C A A A  M
■  C TAA GCCCTGCAl 
fc lflcCTGCAT
V A T tlC C K T T H G G C
CATCTTCCCTTGGGG 
CCTG CTTCC
l t i B g g c g
Figure 3.3.23 NFAT probes aligned.
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Comparison of CCAAT/NF-Y EMSA using either U937EC or U937PM whole cell extract 
found that both extracts produced three similar bands (figure 3.3.24 A, indicated by yellow, 
red and blue arrows). In both cases the two lower bands were competed out by all of the 
competitors (red and blue arrows), whereas, the higher band was competed out by the self 
and the CCAAT/NF-Y mutant but not the NF-Y consensus (yellow arrow)(figure 3.3.24 A). 
The NFAT EMSA produced similar results to that of the CCAAT/NF-Y EMSA in the sense 
that three bands were produced (figure 3.3.24 B, indicated by yellow, red and blue arrows). 
However, in the NFAT EMSA the lower band (blue arrow) was not competed out by all the 
probes, instead it was only competed out by the NFAT mutant. The higher band (yellow 
arrow) was again competed out by the NFAT self and the NFAT mutant competitors but not 
by the NFAT consensus and the middle band (red arrow) was competed out by all the 
competitors (figure 3.3.24 B).
As in both the CCAAT/NF-Y and the NFAT EMSA there is a higher band (yellow 
arrow), which is competed out by self competitors and the mutants but not by either the NF-Y 
consensus or the NFAT consensus it was decided to run both CCAAT/NF-Y and NFAT 
EMSAs alongside each other. As shown in figure 3.3.25 when both the CCAAT/NF-Y and 
the NFAT biotinylated probe were mixed with whole cell extract from U937EC there appears 
to be a similar higher band (yellow arrow) being produced by both probes bound to protein. 
The CCAAT/NF-Y biotinylated probe in this experiment was competed out by all the probes, 
however this was unique to this one experiment, whereas the NFAT biotinylated probes was 
competed out by the self, NFAT and the CCAAT mutant but not the NFAT consensus (figure 
3.3.25). This same experiment was performed alongside a denaturing EMSA were the 
samples had been cross-linked prior to running samples on a 12.5% SDS-PAGE. The 
denaturing EMSA showed the same results with the competitors as the normal EMSA as well 
as being able to give more information on the size of the proteins bound to the probe (figure 
3.3.26, as indicated by red arrows). As shown in figure 3.3.26 the denaturing EMSA for both 
the CCAAT/NF-Y and the NFAT biotinylated probes produced two bands which were 
approximately 80 kDa and 110 kDa (indicated by red arrows). These observed Mw bands 
are consistent with Mr for NFAT, range from 83 to 136 kDa (Lyakh et al., 1997). However 
due to the high background of the blot these bands are quite difficult to see. These results 
taken together suggest that the protein which binds to both these probes is likely to be the 
same protein and is unlikely to be either NF-Y or NFAT as it has a tendency not to be 
competed out by either of these consensus sequences.
As shown in figure 3.3.27 both the putative CCAAT/NF-Y and NFAT sites are in very 
close proximity and in the case of the mutant probes they overlap sequences. For this 
reason new shorter probes, which had no overlapping sequences between the CCAAT/NF-Y 
or the NFAT probes, were designed and the EMSAs were repeated (figure 3.3.28). Figure
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3.3.29 shows that repeating both the CCAAT/NF-Y and the NFAT EMSA with the short 
probes drastically reduced the amount the number of proteins binding to the probe. A 
consistent band was seen in multiple experiments using the NFAT biotinylated probe 
however this was competed out by all the competitors, suggesting either non-specific binding 
or a very weak interaction between the DNA probe and the protein. The shorter CCAAT 
biotinylated probe also exhibited protein binding however this was less consistent than the 
NFAT results but was still competed out by all the competitors (figure 3.3.29).
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Figure 3.3.24 EMSA of CCAAT/NF-Y or NFAT probe with lysate from either U937PM or 
U937ec. Whole cell lysate from either U937Ec or U937PM was incubated with (A) CCAAT/NF-Y probe 
or (B) NFAT probe. Samples were run on a 6% non-denaturing PAGE.
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Figure 3.3.25 EMSA of CCAAT/NF-Y or NFAT probe run on the same gel. Nuclear extract 
from U937ec was incubated with either CCAAT/NF-Y or NFAT biotinylated probe in the absence or 
presence of different competitors. Samples were run on a 6% non-denaturing PAGE.
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Figure 3.3.26 Denaturing EMSA. Nuclear extract from U937Ec was incubated with either 
CCAAT/NF-Y or NFAT biotinylated probe in the absence or presence of different competitors. 
Samples were run on a 12.5% SDS-PAGE. Arrows indicate bands produced from proteins binding to 
the biotinylated probes, unfortunately the background is very high and has interfered with the 
scanning.
NF-Y Consensus 
CCAAT mutant 
C5aR CCAAT 
NFAT mutant 
C5aR NFAT 
NFAT consensus
AAGAGATTAACCAATCACGTACGGTCT 
CCCAGTGTGACt 
CCCAGTGTGCA'
GACI \  G AG AGCCCCAGA
GAC \ \  ! GAC-AGCCCCAGA
CCCCAGAGAGAAAGACGGTCCTTAA
a g  yCGGTC \ r r  re
l r |c r r r c A A A B
CTGCATCTTCCCTTGGGG
CTGCATCTTCC
Figure 3.3.27 Probe sequence alignments. Underlined sequences show key residues for 
transcription factor binding. Highlighted sequences show sequence homology.
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C5aR CCAAT/NF-Y CAGACCAATGAGAGC
CCAAT mutant CAGACTC TAGAGAGC
CCAAT/NF-Y consensus IT A ^ ^ ta H H c lc G T A
C5aR NFAT 
NFAT mutant 
NFAT consensus
Figure 3.3.28 Shorter EMSA probes aligned
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Figure 3.3.29 EMSA with shorter CCAAT and NFAT probes. Nuclear extract from U937EC 
was incubated with either CCAAT/NF-Y or NFAT biotinylated probe in the absence or presence of 
different competitors. Samples were run on a 6% non-denaturing PAGE.
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As the EMSAs were unable to determine the exact trans-acting factors binding to the 
regions of interest it was decided to incubate the cells with cyclosporin A. Cyclosporin A 
inhibits calcineurin activity, which normally dephosphorylates NFAT, so that it can be 
transported to the nucleus. Thus if NFAT plays an important role in regulating C5aR 
expression, incubation with cyclosporin A should reduce C5aR expression.
As shown in figure 3.3.30 incubation of U937EC with 10 pg/ml cyclosporin A 
significantly reduced C5aR expression compared with the control, however this decrease 
was less than what was anticipated as previously mutating the NFAT site abolished the 
promoter activity (figure 3.3.19). At this concentration, however, there was a reduced cell 
number following incubation for 2 days (data not shown), suggesting that this concentration 
may have anti-proliferative effects.
When the -355bp+pEGFP reporter constructs were incubated with 10 pg/ml 
cyclosporin A, both the wild type construct and the NFkB mutant showed a decrease in 
EGFP fluorescence compared with the control, although this was not statistically significant. 
The EGFP fluorescence remained unchanged in both the NFAT and CCAAT mutants 
following incubation with cyclosporin A (figure 3.3.31).
19^
Control
0.1 ptg/ml cyclosporin A 
1 pg/ml cyclosporin A 
10 pg/ml cyclosporin A
No primary Ab Isotype Anti-C5aR
Figure 3.3.30 Effects of cyclosporin A on C5aR expression. Following incubation of U937EC 
for 2 days with increasing concentration of cyclosporin A, C5aR expression was detected by flow 
cytometry using anti-C5aR (S5/1) followed by goat anti-mouse-FITC. IgGi isotype control (anti- 
glycophorin) was used to measure non-specific binding via the Fc receptors. One-way ANOVA 
followed by Tukey’s post test shows significant difference to the control, ** p < 0.01.
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Control
10 i^g/ml Cyclosporin A
Figure 3.3.31 Effects of cyclosporin A on EGFP fluorescence in 355bp + pEGFP 
reporter construct. Following incubation of -355bp constructs with 10 jug/ml cyclosporin A for 2 
days EGFP fluorescence was monitored by flow cytometry. Two-way ANOVA followed by Bonferroni 
post test showed that the construct used to transfect into the U937EC cell line significantly effected 
EGFP fluorescence (p < 0.0001), however, incubation with cyclosporin had no significant effect on 
EGFP fluorescence
3.3.5 Site directed mutagenesis of 3’UTR AU rich elements and 
transfection of 3’UTR EGFP reporter constructs into the U937 cell line
To determine if the C5aR expression is regulated at the mRNA level, the 3’UTR was cloned 
down stream of the EGFP gene in the EF1a + pEGFP vector. The two AU-rich elements, 
one of which has been identified by ARED database, were mutated using site directed 
mutagenesis (figures 3.3.32 and 3.3.33). Again site directed mutagenesis introduced new 
restriction enzyme sites, which allowed rapid screening for mutants (table 3.2.4). Shown in 
figure 3.3.34 is a schematic diagram of the C5aR 3’UTR EGFP constructs which were 
transfected into the U937Ec cell line. Once growing in log phase changes in EGFP 
fluorescence were detected by flow cytometry (figure 3.3.35). As shown in figure 3.3.35 the 
C5aR W T 3’UTR had lower EGFP fluorescence as compared to the SV40 3’UTR, which is 
what would be predicted as the SV40 3 ’UTR is very stable. Mutating either the 1st or the 2nd 
ARE appeared to have no significant effect on EGFP fluorescence compared to the WT, 
however, it was not investigated whether mutating both sites at the same time had an effect 
on mRNA stability (figure 3.3.35).
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Mutant sequence---------- ►TGTACCGGTTTTA
1111 11111 WT sequence---------- MVSTATTTATTTTA
Figure 3.3.32 Sequencing results for 3’UTR 1st ARE mutant. Site directed mutagenesis 
introduced a new Age I site which was used to screen mutants. Shown here is the sequencing results 
aligned with the WT sequence.
Lane 1 Lane 2
Figure 3.3.33 Restriction enzyme digest screening for 3’UTR 2nd ARE mutant. Site 
directed mutagenesis introduced a Kpn I site which was used to confirm the 3’UTR 2nd ARE had been 
mutated.
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EF1a promoter C5aR 3’UTR
EcoRI Kpnl
pEGFP
Notl Aflll
C5aR 3’UTR (1) ARE mutantEF1a promoter
pEGFP
KpnlEcoRI Aflll
A T T T A T T T T
A C C G G T T T T
C5aR 3’UTR (2) ARE mutantEF1a promoter
pEGFP
KpnlEcoRI AflllNotl
T A A T T T A A A
T G G T A C C A
Figure 3.3.34 Schematic diagram of C5aR 3’UTR EGFP reporter constructs. The C5aR 
3’UTR was cloned down stream of the EGFP gene in the EF1a+pEGFP vector using specific 
restriction enzyme sites as indicated in the figures. (A) wild type C5aR 3’UTR; (B) C5aR 1st ARE 
mutant; (C) C5aR 2nd ARE mutant. Blue indicates sequences mutated by site directed mutagenesis.
2000-,
Figure 3.3.35 Effects of 3’UTR ARE mutations on EGFP fluorescence. Following 
transfection of U937Ec cell line with the EGFP reporter constructs changes in EGFP fluorescence was 
monitored by flow cytometry. One-way ANOVA performed comparing the C5aR 3’UTR WT, 3’UTR(1) 
ARE mutant and 3’UTR(2) ARE mutant showed no significant difference.
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3.4 Discussion
The aim of this Chapter was to investigate how basal levels of the human C5aR expression 
is regulated in the monocytic U937 cell line.
The 2Kbp promoter region upstream from transcription start site of the C5aR gene 
was cloned into the pEGFP-1 vector using gDNA isolated from two U937 cell lines: U937Ec 
(obtained from the ECACC) and the U937PM (obtained from Dr Peter Monk, Sheffield 
University). As previously described in section 3.3.1, sequencing of both promoters revealed 
seven base pair differences between the 2 Kbp promoter generated from U937Ec and 
U937pm (table 3.3.1 and appendix 9.2). Although these differences could be due to errors 
during PCR or sequencing, they could also be due to single nucleotide polymorphisms 
(SNPs). As five out of the seven differences align with either the chimpanzee or Genebank 
sequence (table 3.3.1), this would suggest that these differences could be SNPs, however, 
further experiments are needed to confirm this. A study by Barnes and co-workers has 
previously identified a novel T/C polymorphism within the promoter region of the C5aR 
(Barnes et al., 2004). This published SNP corresponds with the -253bp T/C base pair 
substitution observed between the U937EC and U937PM sequences (table 3.3.1). Although 
Barnes and colleagues had previously shown that this polymorphism was not associated with 
any changes in promoter activity, when transfected into the U937 cell line using luciferase 
reporter assay (Barnes et al., 2004), it was decided to transfect each cell line with the 
reporter construct generated from the gDNA of the other cell line.
As shown in figure 3.3.12 there were no significant differences in EGFP expression 
between the -2Kbp(EC) and -2Kbp(PM) reporter constructs irrespective of which cell line 
they were transfected into. This suggests that the differences between the two promoter 
sequences (table 3.3.1) and putative cis-acting sites (table 3.3.2) had no significant effect on 
the promoter activity. Furthermore, it suggests that both cell lines contained the necessary 
trans-acting factors to drive transcription from each promoters. To determine whether the 
differences between the sequences were actual SNPs further genotyping would need to be 
performed on whole populations and ideally each bp difference would then be investigated 
individually for differences in promoter activity.
Serial 5’deletion analysis of -2Kbp (EC) reporter construct revealed that the majority
of the promoter was dispensable when transfected into both U937EC (figure 3.3.13). A
significant reduction in EGFP fluorescence was observed in the -100bp reporter construct,
although some promoter activity still remained within this region. Hunt and colleagues have
previously shown similar results with the mouse C5aR promoter region. They attributed this
reduction in promoter activity to a CCAAT motif present within the deleted region (Hunt et al.,
2005) (as illustrated in figure 3.4.1). This study also suggested that the human C5aR may
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also be regulated in a similar manner due to high sequence homology within this region of 
both the mouse and human promoter. Transfection of the U937PM cell line with the serial 
5’promoter deletions produced a similar pattern as the U937Ec cell line (figure 3.3.14). 
However they appeared to be more sensitive with deletion from -2Kbp to -500bp suggesting 
the presence of suppressor elements within this region and deletion from -500bp to -200bp 
suggesting promoter activity within this region (figure 3.3.14). It is important to note here that 
as the cells were stably transfected with the EGFP reporter constructs integration of the 
constructs into a position in the genome close to strong promoter or suppressor activity may 
have an effect on the rate at which the EGFP gene is transcribed. However, the position at 
which the reporter constructs are integrated into the genome is more favourable at loosely 
pack euchromatin rather than heterochromatin. As each transfection was repeated 4 times 
this would be a sufficient number of repeats to highlight whether integration near a strong 
promoter or suppressor activity may interfere with the transcription of the EGFP gene. 
Further still, the EGFP fluorescence was measured in mixed cell populations therefore the 
natural spread/range was recorded for each reporter construct transfected.
To test whether the putative CCAAT motif (-123bp to -119bp) within the human C5aR 
promoter was responsible for transcriptional activity of the human C5aR gene this site, along 
with putative NFkB (-238bp to -232bp) and NFAT (-93bp to -87bp) sites, were mutated by 
site directed mutagenesis. As shown in figure 3.3.19 site directed mutagenesis of the 
putative CCAAT resulted in a significant reduction in EGFP fluorescence compared with the 
wt -355bp promoter region. This correlates with results previously observed in mouse C5aR 
promoter region when transfected into mouse macrophage, RAW 264.7, and endothelial, 
b.End3 and mHEVc, cell lines (Hunt et al., 2005). The CCAAT motif is one of the most 
common promoter elements in eukaryotic promoters (Maity and de Crombrugghe, 1998). 
The motif can be found in either the forward or reverse orientation and is preferentially 
located -80/-100 bp to start site (Mantovani, 1998). As shown in table 3.4.1, several binding 
proteins have been found to recognise the CCAAT motif. Matlnspector analysis of the 
human C5aR promoter sequence predicted that the CCAAT motif present at position -123bp 
to -119bp would likely bind NF-Y binding protein, which would correlate with the study by 
Hunt and co-workers who showed, using EMSA and super shift EMSA, that NF-Y, but not c- 
Fos or ETS1/2, bound to the homologous CCAAT motif present in the mouse C5aR 
promoter (Hunt et al., 2005).
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Table 3.4.1 CCAAT binding proteins. Taken from (Mantovani, 1998).
Binding protein Recognising sequence
CCAAT/enhance binding protein 
(c/EBP)
Palindromic repeats occasionally containing CCAAT 
pentanucleotide in the intervening sequences
CCAAT transcription factor 
(CTF/NF1)
Recognises TGG(N)6GCCAA sequence, with a T after 
CCAA occasionally but not strictly required
CCAAT displacement protein 
(CDP)
Recognises repeated CCAAT motifs
NF-Y (also called CCAAT binding 
factor CBF)
Recognises only exact CCAAT motifs
Although it was anticipated that mutating the CCAAT motif would reduce 
transcriptional activity based on previous published findings on the mouse C5aR promoter, 
the decision to mutate the NFAT site was one based on induced expression of the C5aR. 
NFAT (nuclear factor of activated T-cells) is a family of transcription factors that regulate 
inducible expression of many cytokine and cell surface receptors critical for the immune 
response (Lee and Park, 2006). Shown in table 3.4.2 is a list of stimuli which have been 
shown to elicit NFAT activation, and target proteins whose expression changes as a result of 
this activation. Of particular interest was that PMA can stimulate CCL23 expression in the 
U937 cell line via activation of NFAT (Shin et al., 2007). As PMA has been well documented 
in the literature to increase C5aR expression in the U937 cell line, this led to the putative 
NFAT site within the C5aR promoter region being investigated (Rubin et al., 1991a, Burg et 
al., 1996). Site directed mutagenesis of the putative NFAT site revealed a significant 
reduction in transcriptional activity in mutant promoter compared with the wild type -355bp 
fragment (figure 3.3.19). As described above this site was mutated on the presumption it 
may be involved in regulation of induced expression of the C5aR, which makes this finding 
more interesting.
Table 3.4.2 Stimuli that elicits NFAT activation. Adapted from (Rao et al., 1997).
Receptor/Function Stimulus/Drug Cell type tested Reference
Immunoreceptors/
chemokines
T cell receptor
CD40
FcyR
CCR2
CCL23
Ag/MHC 
CD40L plus IL-4 
Ag/IgG, <xCD16 
lonomycin 
PMA
T cells 
B cells 
NK cells, 
macrophages 
Neuron cell line F11 
U937 cell line
(Rao, 1994)
(Choi et al., 1994) 
(Aramburu et al., 1995) 
(Jung and Miller, 2008) 
(Shin etal., 2007)
G protein coupled 
receptors
H1 histamine receptor 
Thrombin receptor
Histamine
Thrombin
Endothelial cells 
(Human umbilical 
vein)
(Rao et al., 1997) 
(Rao et al., 1997)
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Inactive NFAT normally resides in the cytoplasm in a heavily phosphorylated form 
(Lee and Park, 2006). As illustrated in figure 3.4.1, the stimulation of cell surface receptors 
that are linked to phospholipase C signalling pathway results in an increase in intracellular 
Ca2+, which activates calmodulin. Activated calmodulin in turn activates calcineurin, which 
dephosphorylates NFAT allowing its translocation into the nucleus. As the site directed 
mutagenesis results showed a decrease in transcriptional activity following mutation of the 
putative NFAT site, this would suggest that in the ‘resting’ U937 cells NFAT is present in its 
active form within the nucleus. Although the transfection process itself could result in the 
stimulation and activation of the cells, here stable transfectants were generated in order to 
allow the cells time to recover from the shock of electroporation. Alternatively, this result 
may be observed if site directed mutagenesis introduced a new suppressor element or even 
if another promoter element was also disrupted by the mutagenesis. Although both these 
scenarios were checked by Matlnspector prior to mutagenesis and no obvious new motif was 
introduced or deleted, this software can only predict known binding sites.
Calmodulin
PLCy DAG 
 ► +
IP3
PIP.
Ca2+/Calmodulin
Calcineurin - PCalcineurin
NFAT
NFAT
Figure 3.4.1 Schematic diagram illustrating NFAT activation
As shown in figure 3.3.19, mutation of the putative NFkB site at -238bp to -232bp 
also resulted in significant reduction in EGFP fluorescence compared to the W T fragment, 
albeit less than the CCAAT and NFAT mutants. NFkB is another family of transcription 
factors which is associated with the transcriptional regulation of genes whose proteins are 
involved in inflammation and the immune response (Hoffmann et al., 2006). NFkB 
transcription factors are dimers bound by inhibitory IkB proteins, which controls the DNA
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binding activity and nuclear localisation of NFkB (Hoffmann et al., 2006). Upon stimulation 
by stimuli such as cytokines, reactive oxygen species, bacterial wall products, viral infection 
or DNA damage, IkB dissociates from NFkB, allowing its translocation into the nucleus where 
it can then regulate the transcription of target genes (Brasier, 2006). Although the results 
presented here suggest that the putative NFkB site in the human C5aR promoter contains a 
small amount of transcriptional activity, it has previously been shown that the homologous 
NFkB site within the mouse promoter contains little promoter activity when transfected into 
mouse macrophage, RAW 264.7, and endothelial, b.End3 and mHEVc, cell lines (Hunt et al., 
2005).
Taken together the results from the site directed mutagenesis combined with 
5’deletion analysis suggests that deletion of the putative CCAAT site at position -123bp to - 
119bp may explain why a reduction in EGFP fluorescence was observed at the -100bp 
deletion fragment and that the remaining promoter activity within the -100bp fragment may 
be attributed to the putative NFAT site (-93bp to -87bp), as illustrated in figure 3.4.2. 
However it is important to note that the -100bp fragment contains the core promoter TATA 
box which may be contributing towards the remaining transcriptional activity.
NFAT
-93bp to -97bp
100 bp
CCAAT NFAT
-123bpto -119bp -93bp to -S7bp
300bp 200bp 100bp
CCAANFkB
-23Sbp to-232bp -123bp to-119bp -93bp to -87bp
Percentage EGFP
Figure 3.4.2 Schematic diagram illustrating how the putative NFkB, CCAAT and NFAT 
affect EGFP fluorescence during 5’promoter deletion analysis.
In an effort to determine which trans-acting factors may be binding to the putative 
CCAAT and NFAT sites, EMSAs were performed using several competitors including the 
CCAAT/NF-Y and NFAT consensus sequences. Unfortunately in both cases there appeared 
several proteins that recognised and bound to both CCAAT and NFAT labelled probes, which 
made interpreting the results more difficult (figures 3.3.20 and 3.3.22 respectively). 
However, it appeared that some of the proteins binding to the different probes were similar 
(figure 3.3.25 and 3.3.26). Although this could mean that the same non-specific protein has
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bound to both probes, this did not appear to be the case as some specific displacement by 
the self and mutant competitors but not the NFAT consensus was observed. Alternatively 
this may be explained by the close proximity of the two sites, with only 9bp separating the 
two full sites as identified by Matlnspector. Possibly there is some cooperation between the 
two sites and the transcription factors which bind to them (figure 3.3.1). For instance, NFAT1 
which bind to the NFAT sequence can cooperate with adjacent, no more than a single bp 
separation, AP-1 dimers in murine IL-2 promoter (Rao et al., 1997). This cooperation results 
in the NFAT1:AP-1:DNA complex being significantly more stable, and higher affinity than the 
NFAT1 alone (Rao et al., 1997). Similar several studies have also document NFAT 
cooperating with the CCAAT binding protein C/EBP (Yang and Chow, 2003, Oh et al.). 
However no published data has reported any cooperation with NF-Y which was the CCAAT 
binding protein that was previously shown to interact with the mouse C5aR promoter (Hunt et 
al., 2005).
Although the addition of antibodies to the EMSA incubation mixture can be used to 
identify the proteins which bind to the labelled probes, it was decided to incubate the cells 
with cyclosporin A, an inhibitor of NFAT activation. It was anticipated that cyclosporin A 
should reduced C5aR expression if NFAT plays a key regulatory role in regulting expression 
of the receptor in vivo. However, C5aR expression was only significantly decreased at the 
higher concentration of cyclosporin A (10 pg/ml), and this decrease was not as significant as 
was expected based on the mutagenesis results of the NFAT site which abolished the 
promoter activity (figure 3.3.30). This result suggests that although it appears that the 
putative NFAT site is important for the transcriptional activity in the -355bp reporter fragment, 
in vivo the C5aR expression is not regulated by NFAT. To confirm NFATs involvement in the 
transcriptional activity of -355bp reporter fragment, this reporter construct along with the 
mutant reporter constructs were also incubated with cyclosporin A. Cyclosporin A had no 
effect on EGFP fluorescence in these reporter constructs, which provides further evidence 
that result observed by mutating the putative NFAT site is due to either the disruption of 
another important promoter element or the introduction of a new suppressor element. To 
confirm which is the likely scenario, this site should be mutated again using different 
residues.
As well as looking at transcriptional regulation of the C5aR, this chapter has also
investigated whether its mRNA can be affected by AU-rich elements present within the
3’UTR. As shown in figure 3.3.35, site directed mutagenesis of either the 1st ARE or the 2nd
ARE had no effect on EGFP fluorescence. Therefore, unlike other ARE belonging in class I
(see table 3.1.2 for details), the AREs in the C5aR 3’UTR do not contribute towards mRNA
stability. However this study only mutated the sites individually, it was not investigated
whether mutating these sites together would have any effect. Although these sites are
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approximately 100 bp apart, they may still be within close spatial proximity during folding of 
the mRNA and therefore allowing cooperation between the two AREs and their binding 
proteins.
3.4.1 Summary
This chapter has found that the majority of the -2Kbp promoter region was dispensable for 
expression, although some transcriptional activity was deleted between -200bp to -100bp in 
the U 9 3 7 Ec cell line. Site directed mutagenesis of a putative CCAAT motif at position -123bp 
to -119bp resulted in a significant decrease in promoter activity compared to the WT -355bp 
fragment, suggesting that this site may be important for the transcriptional activity lost 
between -200bp to -100bp. Site directed mutagenesis of a putative NFAT site at position - 
93bp to -87bp, also suggested that this site may be responsible for some transcriptional 
activity. However, further analysis indicate that another promoter element may have been 
disrupted or a suppressor element introduce during mutagenesis as cyclosporin A, an 
inhibitor of NFAT, was unable to significantly reduced transcriptional activity. Site directed 
mutagenesis of the putative NFkB site at position -238bp to -232bp also found that this site 
contains some promoter activity, although not as significant as the CCAAT or NFAT motifs. 
This chapter has also shown that mutating either of the ARE within the C5aR mRNA had no 
effect on mRNA stability.
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Chapter 4
Characterisation of induced C5aR expression and function 
in the U937 cell line
4.1 Introduction
The U937 cell line is frequently used to study the expression and function of the C5aR, but 
because C5aR is low on these cells, it is usually differentiated with a range of stimuli in order 
to induce a more macrophage like phenotype and increase expression of the C5aR. The aim 
of this chapter is to characterise and investigate which stimuli are the best inducers of C5aR 
expression in the U937 cell line in order to set up a model system to investigate effects of 
lipid lowering drugs on the expression and function of the C5aR.
4.1.1 Stimuli that regulate C5aR expression
Early studies involving differentiation in the U937 cell line mainly focused on artificial stimuli 
such as Bt2cAMP, 1,25-dihydroxy vitamin D3, trans retinoic acid and PMA (Chenoweth et al., 
1984, Rubin et al., 1986, Gavison et al., 1988, Nilsson et al., 1980). Although all these 
stimuli have been shown to differentiate the U937 cell line, they generate dissimilar 
maturation patterns such as PMA increases adherence whereas Bt2cAMP causes cells to 
remain in suspension. Table 1.2 (Chapter 1) summarises which stimuli has been shown to 
regulate C5aR expression and the methods which have been used to detect changes in 
expression.
Bt2cAMP, which is a membrane permeable cAMP analogue, was first shown to 
increase functional C5aR expression in the U937 cell by Chenoweth and co-workers in 1984. 
Although its main cellular target is believed to be protein kinase A, raised intracellular cAMP 
levels can also activate cyclic nucleotide-gated ion channels, as well as exchange proteins 
directly activated by cAMP (Epacs) (Sands and Palmer, 2008). Surprisingly other inducers of 
cAMP, such as prostaglandin E2, dimaprit and isoproterenol, have been unable to increase 
C5aR expression. It has been suggested by Shayo and co-workers that the histamine H2 
receptor agonist (dimaprit), which increases intracellular cAMP levels transiently, was unable 
to induce C5aR expression because of rapid desensitisation of the H2 receptor, whereas 
forskolin could induce differentiation and up-regulation of C5aR via a sustained elevated 
cAMP level within the cells (Shayo et al., 1997, Brodsky et al., 1998). Although 
prostaglandin E2 and isoproterenol, a (3-adrenoreceptor agonist, are unable to induce C5aR 
expression on their own, when combined with 1,25-dihydroxy vitamin D3 they have been
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shown to induced C5aR expression proportional to cAMP induction (Rubin et al., 1986). In 
these experiments, the induction of C5aR expression was not solely explained by PKA 
activation and it was suggested that protein kinase C (PKC) may also be activated (Rubin et 
al., 1991b). Further evidence that activation of PKC can contribute towards differentiation of 
the U937 cell line came from studies that have shown that PMA (PKC activator) is able to 
increase C5aR expression alone and it can be augmented with 1,25-dihydroxy vitamin D3 or 
Bt2cAMP (Burg et al., 1996, Rubin et al., 1991b).
Other more physiological stimuli that have been reported to regulate C5aR 
expression are also shown in Chapter 1 table 1.2. Of particular interest to this project are the 
cytokines that have been implicated in atherosclerosis. Section 1.3.1 has previously 
described chemokine MCP-1 as important chemoattractant of monocytes into the intima 
during early stages of atherosclerosis (Libby, 2002). Although no published data has shown 
whether these stimuli are able to regulate C5aR expression, other pro-inflammatory and pro- 
atherogenic cytokines (TNFa, IL-1, IL-6 and IFNy) are able to increase the receptor 
expression, see table 1.2. Shown in figure 4.1 are the principal signalling pathways used by 
these pro-inflammatory cytokines. The exact mechanisms by which these pro-inflammatory 
cytokines regulate C5aR expression is not known. However, as C5a has previously been 
shown to increase expression of TNFa, IL-1 and IL-6 cytokines, and these cytokines 
increase expression of the C5aR (Okusawa et al., 1987, Okusawa et al., 1988, Goodman et 
al., 1982, Scholz et al., 1990), it is likely that the mechanism is complex with 2-directional 
interaction.
IFNyIL-1
NFkB
JNK
NFkB
| Gene Transcription
Figure 4.1 Schematic diagram illustrating the principal signalling pathways activated 
by the pro-inflammatory cytokines IL-1, TNFa and IFNy. Adapted from (Tedgui and Mallat, 
2006).
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4.1.2 Methods for detecting changes in C5aR expression
As shown in table 1.2, several techniques have been employed to investigate changes in 
C5aR expression. Some investigators choose to monitor changes in mRNA, using 
techniques such as northern blotting, RT-PCR and Q-PCR, as an indication for changes in 
protein expression. Although the latter techniques are quite sensitive, changes in mRNA 
does not always equate to changes in protein expression. It is therefore important to also 
monitor changes in protein expression when these techniques are used.
Earlier studies used ligand binding studies using 125l-C5a to monitor changes in the 
C5aR expression, however due to their radio-active nature this technique has become less 
popular. Furthermore results from ligand binding studies are complicated now by the 
discovery of the second C5a receptor C5L2, which also binds C5a with a similar affinity as 
the C5aR (Cain and Monk, 2002).
The wide spread availability of flow-cytometers has made flow cytometry a popular 
method for monitoring changes in surface receptor expression. Flow cytometry is 
advantageous over other techniques because it allows the user to monitor expression of 
several surface antigens at the same time on the same cells. To check whether changes in 
C5aR expression is reflected by changes in sensitivities towards C5a several studies also 
perform functional assays such as chemotaxis towards C5a using chemotactic chambers 
and C5a induced Ca2+ release as an indication for changes in functional C5aR expression.
In order to characterise induced C5aR expression in this chapter, techniques 
including western blotting and flow cytometry will be used to measure changes in receptor 
expression and C5a induced Ca2+ release will be monitored to determine whether changes in 
expression equate to changes in biological function of the receptor.
4.1.2.1 Flow cytometry
Flow cytometry allows the rapid and sensitive measurement of multiple parameters at any 
one time on a given cell. Using fluorescently labelled antibodies against the particular 
antigen of interest, flow cytometry provides the user with information regarding the 
fluorescence intensity of each cell which is proportional to the amount of fluorescent antibody 
bound to the antigen and therefore the expression levels of that particular antigen. It 
achieves this by passing a stream of single cells through the laser beam and capturing light 
emitted from each cell as depicted in figure 4.2. The use of different fluorophores attached to 
different antibodies allows multiple antigens to be analysed at the same time on one cell. 
Flow cytometry also provides information regarding the cell shape and granularity, which 
together allows the distinction between different cell populations. Due to this rapid and multi-
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parametric nature of flow cytometry, this technique will be used to monitor changes in C5aR 
expression levels.
Fluidics
Optics
Laser
Detectors
Figure 4.2 Schematic diagram of flow cytometry.
4.1.2.2 Western blotting
Western blotting will also be used to monitor changes in C5aR expression as it can detect 
changes in both extracellular and intracellular protein. The technique involves separating 
proteins from cell samples according to their molecular weight using SDS-PAGE. The 
separated proteins are then transferred from the SDS-PAGE onto a membrane, typically 
nitrocellulose or PVDF. Once on the membrane the proteins can be probed using antibodies 
against the specific antigen of interest. Antibody binding can be visualised using horse 
radish peroxidase conjugated secondary antibody, followed by either chemiluminescence or 
colourimetric analysis.
4.1.2.3 C5a induced intracellular Ca2+ release
Following activation of the C5aR one of the first responses observed within the cell is a rise 
in intracellular Ca2+ concentration which arises due to activation of PLCp signalling pathway 
(figure 1.3) (Maurya and Subramaniam, 2007b, Maurya and Subramaniam, 2007a, Jiang et 
al., 1996, Camps et al., 1992). C5a induced Ca2+ release can therefore be used to monitor 
changes in functional C5aR expression. Intracellular Ca2+ acts as a diffusible secondary 
messenger which can bind and activate Ca2+ binding proteins. Although the exact Ca2+
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binding proteins activated through stimulation of C5aR are not well characterised, typically 
these proteins regulate cellular processes such as enzyme activation, motility, morphology, 
cell cycle progression and gene regulation.
As the U937 cell line is a cell suspension cell line, intracellular Ca2+ measurements 
will be recorded using the FLUOstar Optima plate reader. This method allows the average 
Ca2+ measurement of the total cell population as opposed to using techniques such as 
confocal microscopy which allow Ca2+ measurements of individual cells. The Ca2+ 
fluorescent indicator Fura-2-AM will be used to measure intracellular Ca2+ as its 
acetoxymethyl (AM) group allows it to diffuse into the cell, however once in the cell it is then 
cleaved by intracellular esterases causes it to become trapped within the cell. This form of 
dye is less invasive than dextran or salt forms which need to be microinjected or 
electroporated into the cells due to their cell impermeable nature. Another advantage of 
using the Fura-2-AM dye is that upon ion binding the dye exhibits a spectral shift in its 
excitation wavelength which allows ratiometric measurements of Ca2+ concentrations that are 
essentially independent of uneven dye loading, cell thickness, photobleaching and dye 
leakage (Grynkiewicz et al., 1985).
4.1.3 Hypothesis and aims
The hypothesis of this chapter is that stimulation of the U937 cell line with different stimuli, as 
listed in table 1.2, should cause up-regulation of C5aR expression and differentiation of the 
cells to a more macrophage like phenotype. The aim is to find the best inducer of C5aR 
expression in the U937 cell line and study their effects on functions of the C5aR.
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4.2 Materials and methods
4.2.1 Chemicals and reagents
As previously described in section 2.1 all general reagents were purchased from Sigma. 
Lipopolysaccharide LPS was from Sigma (E.coli 0111:B4). Human recombinant tumour 
necrosis factor-alpha (TNFa) (TNFSF2), IL-6 (200-06-B) and interferon gamma (IFNy) 
(H00003458) were from were from Tebu-bio.
4.2.2 Cell culture
Human monocytic cell lines U937PM and U937Ec were routinely cultured in complete RPMI as 
already described in section 2.3.1. The cells were seeded at 1 x105 cell/ml (U937Ec) or 2.5 x 
105 cell/ml (U937pm) and stimulated for 48 hrs, unless otherwise stated, with various 
concentrations of PMA, Bt2cAMP, IFNy, TNFa, LPS or IL-6.
4.2.3 Flow cytometry
C5aR expression was analysed by flow cytometry as previously described in section 2.3.6. 
C5aR was detected using specific monoclonal anti-C5aR (S5/1, from SantaCruz) which 
according to the data sheet is an lgG1 isotype and therefore lgG1 isotype matched control 
anti-glycophorin (BGRL100, from IBGRL) was used to detect non-specific binding via the Fc 
receptors. However later investigation found that the monoclonal anti-C5aR S5/1 clone is an 
lgG2a isotype and therefore later experiments were incubated with aggregated IgG (56834, 
from Sigma) prior to staining for flow cytometry, where stated, to block non-specific binding 
via the Fc receptors as oppose to using an isotype matched control (Oppermann et al., 
1993). Aggregated IgG was generated by heating IgG (1 mg/ml in PBS) at 63 °C until 
solution became cloudy, approximately 20 min. To monitor changes in Fc receptors 
expression flow cytometry was also performed using monoclonal anti-CD16 (3G8; lgG1; from 
ATCC) and CD32 (IV.3; lgG2b; from ATCC). The secondary antibody used for all 
experiments was a goat anti-mouse FITC conjugate, as previously described in section 2.3.6. 
Cells were stained in the absence of aggregated human IgG unless otherwise stated.
4.2.4 Western blotting
Western blotting was performed as previously described in section 2.3.7 using polyclonal 
anti-C5aR (H-100).
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4.2.5 Ca2+ signalling
Intracellular Ca2+ was measured using Fura-2-AM as previously described in section 2.3.8.
4.2.6 Propidium iodide staining
Cell viability was assessed using propidium iodide exclusion as previously described in 
section 2.3.9.
135
4.3 Results
The U937 cell line is frequently used to study the C5aR expression and function. The cell 
line is differentiated using stimuli such as Bt2cAMP, PMA and IFNy, in order to obtain a more 
macrophage like phenotype and induce up regulation of the C5aR (see table 1.2). To 
investigate which stimulus is the best inducer of C5aR expression and function in our U937 
cell lines, the cells were incubated with a variety of different stimuli and changes in C5aR 
expression and function were then analysed.
4.3.1 Comparison of two U937 cell lines in their responsiveness to PMA, 
Bt2cAMP, IFNy, IL-6, LPS and TNFa
Initial studies using the U937 cell line obtained from the ECACC (U937Ec) found that 
Bt2cAMP, which has been well documented in the literature as a strong inducer of C5aR 
expression in the U937 cell line, failed to alter receptor expression in these cells (figure 
4.3.1). Subsequently, a U937 cell line was obtained from Dr Peter Monk (Sheffield 
University; U937PM). In this Chapter the two different cell lines were incubated with different 
stimuli for 48 hrs and changes in C5aR expression and function were compared.
Although both U937Ec and U937PM had similar resting levels of C5aR expression, 
which was quite low, each cell line differed in their responses to the different stimuli. Figure
4.3.1 shows that incubating the U937EC cell line with PMA, IFNy and IL-6 increased C5aR 
expression when detected by flow cytometry using the monoclonal antibody S5/1, however, 
only IFNy and IL-6 induced effects were statistically significant. Although other stimuli, 
including Bt2cAMP, TN Fa and LPS, have been previously reported to increase C5aR 
expression in the U937 cell line (see table 1.2 for details), here they had no effect on its 
expression in the U937EC cell line (figure 4.3.1). The U937PM cells, however, responded with 
an increased C5aR expression when treated with Bt2cAMP, PMA and IFNy, while TNFa, LPS 
and IL-6 had no significant effects on its expression (figure 4.3.2). The results showed that 
these cells not only differ in which stimuli they respond to, they also differ in the magnitude of 
their responses. Figure 4.3.3 compares the relative change in C5aR expression in the 
U937ec with the U937PM. Following treatment with the different stimuli, the most obvious 
difference is observed when comparing the effects of Bt2cAMP treatment. In U937Pm this 
stimuli resulted in average ~ 5 fold increase in C5aR expression compared with the control, 
however, in U937ECf Bt2cAMP had no effect on C5aR expression (figure 4.3.3). Although 
both cell lines responded to PMA, the U937PM cell line exhibited an average ~ 5 fold increase 
in C5aR expression compared with the -  2 fold increase shown in the U937EC cell line. 
Incubation with IFNy resulted in the strongest responses with a ~ 13 and ~ 12 fold increase in
136
fluorescence in the U937EC and U937PM cell line respectively. U937Ec increased C5aR 
expression, ~ 3 fold, following incubation with IL-6, whereas in the U937PM cell line the 
receptor expression remained unchanged (figure 4.3.3).
As well as differing in their C5aR expression following treatment with different stimuli, 
these cell lines also differ in their sensitivity to the cytotoxic effects of the stimuli. Using 
propidium iodide staining as a indicator of cell death, the U937EC was shown to be more 
sensitive to the cytotoxic effects of IFNy compared with U937PM and that U937PM was more 
sensitive to PMA compared with U937EC (figure 4.3.4) The morphology of each cell line also 
differed slightly following incubation with either PMA or Bt2cAMP (figure 4.3.5). PMA 
incubation caused both cell lines to become more adherent. The U937PM cells were 
completely adherent with only dead/dying cells present in the culture supernatant, whereas, 
U937ec cells had viable cells present in both the supernatant and adherent to the culture 
flask (figure 4.3.5). As PMA treatment resulted in cells becoming adherent, cells were 
harvested by cell scrapping which may contribute to the higher cell death seen in figure 
4.3.4. Incubation of U937PM cells with Bt2cAMP changed their cell morphology from a 
spherical like shape to an irregular shape with lots of protrusions. The U937EC cells however 
displayed little change in cell morphology following incubation with Bt2cAMP (figure 4.3.5). 
The two cell lines also exhibited different morphologies when unstimulated with the U937EC 
being more spherical compared with the U937PM cells, furthermore the U937EC cells grew 
quicker in routine culture compared with the U937PM cells.
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Figure 4.3.1 Effects of different stimuli on C5aR expression in the U937Ec cell line.
U937Ec were incubated for 48 hr with various concentrations of PMA (A), IL-6 (B), Bt2cAMP (C), IFNy 
(D), TNFa (E) and LPS (F). C5aR expression was detected by flow cytometry as described in section 
4.2.3. (G) Relative C5aR change was calculated as described in Chapter 2 section 2.3.6. One-way 
ANOVA followed by Dunnett’s multiple comparison test was performed, **p<0.01 cf. control.
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Figure 4.3.2 Effects of different stimuli on C5aR expression in the U937PM cell line.
U937PM were incubated for 48 hr with various concentrations of PMA (A), IL-6 (B), Bt2cAMP (C), IFNy 
(D), TNFa (E) and LPS (F). C5aR expression was detected by flow cytometry as described in section 
4.2.3. (G) Relative C5aR change was calculated as described in Chapter 2 section 2.3.6. One-way 
ANOVA followed by Dunnett’s multiple comparison test was performed, **p<0.01 cf. control.
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Figure 4 .3 .3  Comparison of relative changes in C5aR expression in the U 9 3 7 Ec and 
U937pm cell lines following incubation with different stimuli. Following incubation of the 
different cell lines with the different stimuli for 48 hr, changes in C5aR expression was detected by 
flow cytometry. Two-way ANOVA followed by Bonferroni post test showed significant differences 
between the cell lines as indicated by the asterisk; *** p<0.001.
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Figure 4.3.4 Effects of different stimuli on cell viability in the two different U937 sub 
cell lines. Following incubation of the different cell lines with the different stimuli for 48 hr, cell 
viability was assessed using propidium iodide (PI). The results are expressed as average percentage 
of PI positive cells as determined by flow cytometry. Two-way ANOVA followed by Bonferroni post 
test showed significant difference between the cell lines as indicated by the asterisk; ***p<0.01.
140
U 9 3 7 e c  U 9 3 7 p m
Figure 4.3.5 Effects of different treatments on cell morphology. U937EC or U937PM were 
incubated for 48 hrs in the absence or presence of 10 nM PMA or 0.5 mM Bt2cAMP. Cell images were 
taken at X 40 magnification.
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4.3.2 Comparison of changes in C5aR expression by western blotting
To confirm the results as observed by flow cytometry, both U937EC and U937PM cell lines 
were incubated with either PMA, Bt2cAMP, IFNy or IL-6 for 2 days and C5aR expression was 
detected by western blotting.
Shown in figure 4.3.6A is a representative western blot from the U937Ec cells 
incubated with the different stimuli. The C5aR expression could not be detected in the 
control samples which was consistent with results from flow cytometry which had already 
shown that the basal levels of expression in these cells is quite low (figure 4.3.1). As flow 
cytometry had already shown that incubation with IFNy and IL-6 increased C5aR expression 
in the U937EC cell line (figure 4.3.3) it was anticipated that following incubation with these 
stimuli we would be able to detect a specific molecular band at approximately 42 kDa 
corresponding to increased C5aR expression. However, western blotting of U937EC cells 
which had been incubated with IFNy or IL-6 as well as PMA and Bt2cAMP failed to detect 
C5aR expression (figure 4.3.6A). One explanation for this outcome could be that FACS only 
measures surface protein expression whereas western blotting measures total protein and if 
for instance IFNy or IL-6 do not actually change total protein expression rather they act by 
redistributing proteins to the cell surface this would appear to increase levels by FACS but 
not by western blotting. The western blot of the U937EC cells treated with PMA and Bt2cAMP 
displayed a high molecular weight band which appeared to remain in the stacking gel (figure 
4.3.6). This band could be aggregated C5aR, however, as this film was exposed o/n this 
may explain why the same bands were not observed in the U937PM blot which was only 
exposed for 5 min (figure 4.3.6A and B). During the optimisation of western blotting it was 
observed that heat treating and both heat treatment plus a reducing reagent increased the 
amount of C5aR which aggregated in the stacking gel. Therefore it was decided not to heat 
treat or reduce the samples prior to western blotting to reduce the amount of aggregated 
C5aR.
Similar to the U937EC C5aR expression in the U937PM cells could not be detected in 
the control cells by western blotting which correspond to both cell lines having similar low 
levels of C5aR (figure 4.3.6B). Although IFNy was previously shown to be the biggest 
inducer of C5aR expression in the U937PM cell line western blotting of the same samples 
failed to display any bands corresponding to the C5aR (figure 4.3.3 and 4.3.6B). Incubation 
with both PMA and Bt2cAMP produced strong bands at the approximate molecular weight of 
the C5aR although flow cytometry had shown these stimuli were less able to induce C5aR 
expression compared with IFNy (figures 4.3.6B and 4.3.3). Figure 4.3.6B also shows that the 
U937pm cells incubated with Bt2cAMP produced a more intense C5aR band compared to
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incubation with PMA (figures 4.3.6B). Western blot of U937PM cells which had been 
incubated with IL-6 also suggested that in these cells IL-6 had no effect on C5aR expression 
which correlates with flow cytometry results (figure 4.3.6B and 4.3.3).
Together these results suggest that although figure 4.3.3 shows IFNy being the 
strongest inducer of C5aR expression in both U937EC and U937PM cell lines by flow 
cytometry, only Bt2cAMP and PMA are able to increase C5aR expression in the U937PM cell 
line as detected by western blotting (figure 4.3.6).
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Figure 4.3.6 Western blot analysis of C5aR expression in U937EC (A) and U937PM (B) 
cells treated with different stimuli for 48 hr. U937EC (A) and U937PM (B) were incubated for 2 
days in the absence or presence of 10 nM PMA, 0.5 mM Bt2cAMP, 5 ng/ml IFNy or 2 ng/ml IL-6. 1 X 
10 cells were then loaded onto a 12.5% SDS-PAGE. C5aR expression was detected using polyclonal 
anti-C5aR (H-100, SantaCruz). Results presented are representative from multiple analysis. Panel (A) 
is an o/n exposure whereas panel (B) is 5 min exposure.
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4.3.3 Effects of induction of C5aR on C5a induced Ca2+ release
The aim of this section was to investigate whether an increase in C5aR expression 
corresponded to an increased responsiveness to C5a. C5a induced Ca2+ release was 
measured using the ratiometric calcium indicator Fura-2AM.
Both the U 9 3 7 Ec  and U937PM control cells showed a similar increase in Ca2+ release 
following the addition of C5a, which correlates with their similar basal levels of C5aR 
expression (figure 4.3.7A and B). Pre-incubation with PMA failed to increase the 
responsiveness to C5a induced Ca2+ release in the U937EC cells, which corresponded to the 
observation that PMA did not induce significant changes in C5aR expression (figure 4.3.7A). 
Furthermore, incubation with either IFNy or IL-6 also failed to increase the C5a induced Ca2+ 
response in these cells, despite their apparent higher C5aR cell surface expression (figure 
4.3.7A). These results correlated with the results shown by western blot but not flow 
cytometry (sections 4.3.2 and 4.3.1 respectively). Treatment with Bt2cAMP, however, 
showed a significant increase in Ca2+ release in response to either 5 nM or 50 nM C5a when 
compared to the control in the U937Ec (figure 4.3.7A).
U937pm treated with Bt2cAMP showed a strong and significant increase in Ca2+ 
release when stimulated with either 0.5 nM, 5 nM or 50 nM C5a, which correlates with results 
observed by flow cytometry and western blotting which showed an increased C5aR cell 
surface and protein expression induced by this agent (figure 4.3.7B). PMA treatment of 
U937pm also caused an increase in C5a induced Ca2+ release compared with the control, 
however, this increase was only statistically significant at 50nM C5a (figure 4.3.7B). This 
increased responsiveness to C5a after PMA incubation also correlates with the increased 
C5aR expression as detected by both FACS and western blotting. As with the U937EC cell 
line, incubation of U937PM cells with IFNy failed to increase the cells responsiveness to C5a 
(figure 4.3.7B). This result correlates with the results from western blotting which showed 
that IFNy had no effect on C5aR expression in the U937PM cell line but not flow cytometry 
(sections 4.3.2 and 4.3.1 respectively). Incubation of U937PM with IL-6 had no effect on the 
C5a induced Ca2+ release compared with the control which corresponds with both the flow 
cytometry and western blotting results that show that IL-6 had no effect on C5aR expression 
(figure 4.3.7B and 4.3.3).
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Figure 4.3.7 Effects of treatment on C5a induced Ca2+ release in the U937EC (A) or 
U937PM (B) cell lines. U937EC (A) or U937PM (B) cells were incubated for 48 hrs with either control, 
10 nM PMA, 0.5 mM Bt2cAMP, 5 ng/ml IFNy or 2 ng/ml IL-6. Following incubation the cells were 
loaded with 10 pM Fura-2-AM. Average maximum Ca2+ release following the addition of C5a was 
calculated as described in section 2.3.8. Two-way ANOVA followed by Bonferroni post test showed 
significant difference compared with the control as marked by the asterisk, ** p < 0.001.
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4.3.4 Apparent increase in cell surface C5aR expression induced by IFNy 
and IL6, but not Bt2cAMP and PMAy is caused by aspecific binding of the 
anti-C5aR antibody
Due to the nature of using monocytic cells it is crucial that the necessary controls are 
performed in order to identify non-specific binding via the Fc receptors. Typically using non­
related isotype matched control is sufficient to detect any non-specific binding of antibodies 
via the Fc region, however, it is sometimes necessary to include human immunoglobulins in 
the buffer to block Fc receptors.
As results observed by C5a-induced calcium release and western blotting did not 
correlate with results observed by flow-cytometry, it was decided to repeat flow cytometry in 
the absence or presence of human aggregated IgG to block non-specific binding via Fc 
receptors. Although both cell types appeared to express some basal C5aR levels when 
stained in the absence of aggregated IgG, incubation with aggregated IgG prior to staining 
for flow cytometry resulted in the C5aR expression levels for the control cells to be barely 
above the background isotype control fluorescence (figure 4.3.8). The U937Ec, when stained 
in the absence of aggregated human IgG, both IFNy and IL-6 appeared to cause significant 
upregulation of C5aR, whereas incubation with PMA and Bt2cAMP had no effect. However, 
when the same cells were also stained in the presence of aggregated IgG the results showed 
that none of these stimuli, PMA, Bt2cAMP, IFNy or IL-6, actually upregulated cell surface 
C5aR expression (figure 4.3.8). Similarly, when U937PM were incubated with IFNy the cells 
stained in the absence of aggregated IgG showed a significant increase in cell surface C5aR 
expression which was not observed when the cells were stained in the presence of 
aggregated IgG (figure 4.3.8). Although treatment of U937PM with PMA and Bt2cAMP 
showed a significant increase in C5aR expression when stained in both the absence and 
presence of aggregated IgG (figure 4.3.8). These results taken together with results from the 
western blotting (section 4.3.1.2) and the functional studies (section 4.3.1.3) suggest that the 
increase in C5aR expression observed by IFNy or IL-6 is due to an increase in non-specific 
binding of the antibody and not actually C5aR expression. However if this was the case it 
would be anticipated that the isotype control should also bind non-specifically and results 
shown in figure 4.3.8 show that binding of the isotype control did not alter when cells were 
incubated in the absence or presence of aggregated IgG. The isotype control used was anti- 
glycophorin (intracellular domain) lgG1 isotype. This antibody was chosen for the control as 
the data sheet for the monoclonal anti-C5aR S5/1 from SantaCruz stated that this antibody 
was an lgG1 isotype. Further investigation into the background of the anti-C5aR S5/1 
antibody revealed that this antibody is in fact an lgG2a/k isotype which may explain why the
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lgG1 isotype did not detect any non-specific binding via the Fey receptors (FcyR) 
(Oppermann etal., 1993).
Members of the FcyR family bind to the Fc portion of IgG class of antibodies. There 
are several isoforms of the FcyR, FcyR I (CD64), FcyR II (CD32), FcyR Ilia (CD16A) and 
FcyR lllb (CD16B), which all differ in their antibody affinities (Indik et al., 1995). Flow 
cytometry was performed using antibodies against CD32 and CD16 to determine if these 
receptors were up regulated by any of treatments in the U937PM and U937EC cell lines. Both 
cell lines expressed high levels of CD32 but no CD16 (figure 4.3.9). Furthermore CD16 
expression in U937Ec and U937PM remained unchanged after incubation with PMA, Bt2cAMP, 
IFNy or IL-6, whereas, CD32 expression was significantly increased by Bt2cAMP in both cell 
lines (figure 4.3.9). PMA, IFNy and IL-6 had no effect on CD32 expression in U937PM cell line 
but slightly decreased CD32 expression in the U937EC cell line (figure 4.3.9). Although IFNy 
or IL-6 were not shown here to up regulate CD16 or CD32 they may increase expression of 
CD64.
Together these results suggest that only Bt2cAMP and PMA are able to induce C5aR 
expression in the U937PM cell line.
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Figure 4.3.8 Effects of addition of aggregated human IgG on C5aR expression 
following treatment of different stimuli detected by FACS. Following treatment of U937EC (A 
and B) and U937PM (C and D) with different stimuli for 48 hrs, the cells were harvested and incubated 
in the absence (A and C) or presence (B and D) of aggregated human IgG (100ug/ml). Cells were 
stained for C5aR expression using anti-C5aR (S5/1) as described in section 4.2.3 and an lgG1 isotype 
control (anti-glycophorin C, intracellular epitope (BGRL100)) was also used to detect non-specific 
binding of the primary antibody. One-way ANOVA followed by Dunnett’s test showed significant 
difference in C5aR expression compared with the control as marked by the asterisk, **p<0.01,
***p<0.001.
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Figure 4.3.9 Effects of different treatment on FcyR III (CD16) and FcyR II expression 
(CD32). U937Ec (A) and U937PM (B) were incubated for 48 hrs in the absence or presence of either 
10 nM PMA, 0.5 mM Bt2cAMP, 5 ng/ml IFNy or 2 ng/ml IL-6. Cells were harvested and incubated with 
100 fig/ml human aggregated IgG prior to staining for FACS analysis. CD16 expression was detected 
using anti-CD16 (3G8) and CD32 expression was detected using anti-CD32 (IV.3), as described 
section 4.2.3. One-way ANOVA followed by Dunnett’s test shows significant difference from the 
control as marked by the asterisk, *p<0.05, **p<0.01.
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4.3.5 Effects of Bt2cAMP and PMA on C5aR promoter reporter expression
To investigate further whether the C5aR promoter contained any cis-acting elements which 
responded to either Bt2cAMP or PMA, cloned from either U937EC (-2Kbp(EC)+pEGFP) or 
U937pm (-2Kbp(PM)+pEGFP) (see Chapter 3 for full details), both cell lines were transfected 
with the two reporter construct and changes in EGFP fluorescence were monitored by flow 
cytometry.
4.3.5.1 U937ec cell line transfected with C5aR promoter reporter constructs
When the U 9 3 7 ec cells transfected with the -2Kbp(EC)+pEGFP reporter construct were 
incubated with PMA, EGFP expression was shown to increase slightly although this was not 
statistically significant (figure 4.3.10). This result is in agreement with the finding that PMA 
had no significant effect on C5aR expression in the U937EC cell line (section 4.3.4). Similarly 
when the -2Kbp(PM)+pEGFP reporter construct was transfected into the U937EC cell line, 
incubation of these cells with PMA had no effect on EGFP fluorescence (figure 4.3.10).
Bt2cAMP incubation of U937EC transfected with either -2Kbp(EC)+pEGFP or - 
2Kbp(PM)+pEGFP resulted in a decrease in EGFP fluorescence compared with the controls 
however, in the promoter-less pEGFP control vector fluorescence was also decreased, which 
suggest that this is a general effect on background fluorescence (figure 4.3.10).
Incubation of the U937EC cells, expressing the C5aR 3’UTR EGFP reporter construct, 
with PMA and Bt2cAMP had no effect on EGFP fluorescence (figure 4.3.11). This result 
suggests that the ARE within the 3 ’UTR are not regulated by either of these stimuli which 
correlates with the finding that neither PMA nor Bt2cAMP alter C5aR expression in the 
U937ec cell line.
4.3.5.2 U937PU cell line transfected with C5aR promoter reporter constructs
When the U937PM cell line transfected with -2Kbp(EC)+pEGFP and -2Kbp(PM)+pEGFP were 
incubated with PMA, EGFP fluorescence increased slightly compared with the control, 
although this was not classed as statistically significant (figure 4.3.12a). This result does not 
correlate with changes in C5aR expression which increased following incubation of the 
U937pm cell line with PMA (section 4.3.4).
Incubation of the U937PM cell line which had been transfected with the - 
2Kbp(EC)+pEGFP reporter construct with Bt2cAMP showed a statistically significant increase 
in EGFP expression compared with the pEGFP control vector and -2Kbp(PM)+pEGFP 
transfected cells (figure 4.3.12b). However, incubation of the -2Kbp(PM)+pEGFP transfected 
cells with Bt2cAMP showed no significant difference compared with the pEGFP control cells 
which is inconsistent with changes in C5aR expression which increased following incubation 
with Bt2cAMP (figure 4.3.12b).
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Figure 4.3.10 Effects of Bt2cAMP and PMA incubation on EGFP expression in U937EC 
cell line transfected with the -2Kbp 5’promoter+pEGFP reporter constructs. U937EC cell 
line was transfected with either -2Kbp(EC)+pEGFP (red), -2Kbp(PM)+pEGFP (blue) or promoter-less 
pEGFP vector (orange). Once growing in log phase the cells were incubated for 2 days in the 
absence or presence of 10 nM PMA (A) or 0.5 mM Bt2cAMP (B). Changes in EGFP fluorescence 
were then monitored by flow cytometry as described in section 4.2.3, dotted line represents the control 
value. One-way ANOVA followed by Tukey’s multi comparison showed no significant difference 
between the different constructs when cells were treated with either PMA (A) or Bt2cAMP (B).
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Figure 4.3.11 Incubation with PMA (A) or Bt2cAMP (B) has no effect on the 3’UTR of 
C5aR. U937Ec cell line which had been transfected with C5aR 3’UTR reporter constructs or SV40 
control were incubated for 48 hr with either (A) 10 nM PMA or (B) 0.5 mM Bt2cAMP. Changes in 
EGFP fluorescence were then monitored by flow cytometry as described in section 4.2.3, dotted line 
represents the control value. One-way ANOVA showed no significant difference between the different 
reporter constructs.
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Figure 4.3.12 Effects of Bt2cAMP and PMA incubation on EGFP expression in U937PM 
cell line transfected with the -2Kbp 5’promoter+pEGFP reporter constructs. U937PM cell 
line was transfected with either -2Kbp(EC)+pEGFP (red), -2Kbp(PM)+pEGFP (blue) or promoter-less 
pEGFP vector (orange). Once growing in log phase the cells were incubated for 2 days in the 
absence or presence of 10 nM PMA (A) or 0.5 mM Bt2cAMP (B). Changes in EGFP fluorescence 
were then monitored by flow cytometry as described in section 4.2.3, dotted line represents the control 
value. One-way ANOVA followed by Tukey’s multi comparison showed no significant difference 
between the different reporter constructs when the cells were treated with PMA (A), however a 
significant difference was observed when the cells were incubated with Bt2cAMP, * p< 0.05, ** p< 0.01 
(B).
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4.4 Discussion
The aim of this chapter was to characterise and investigate which stimuli are the best 
inducers of C5aR expression in the U937 cell line in order to set up a model system to 
investigate the effects of statins on C5aR function and expression.
Results from this chapter have identified two U937 cell lines, U937Ec and U937PM, 
which differ in their responses to stimuli that have previously been documented in the 
literature to increase expression of the C5aR. These differences were most obvious when 
both cell lines were incubated with Bt2cAMP and PMA for 48 hr and C5aR expression was 
detected by flow cytometry and western blotting (figures 4.3.3 and 4.3.4). Both these stimuli 
were able to increase C5aR expression in the U937PM cell line but had no significant effect 
on the receptor expression in the U937Ec cell line. The cell lines also differed in their 
sensitivities to the cytotoxic effects following incubation with either Bt2cAMP or PMA. As 
shown in figure 4.3.4, the U937PM cell line showed three times more cell death following 
incubation with PMA compared with the U937EC cell line, however, incubation with Bt2cAMP 
produce very little cell death in both cell lines compared with the controls. The results 
observed by U937PM cell line correlate with previous published findings that have shown that 
5 nM PMA is more cytotoxic than 1 mM Bt2cAMP in the U937 cells when incubated for 2 
days (Hetland, 1997). Incubation with Bt2cAMP and PMA also induced different 
morphological changes in the cells, which also differed slightly between the two different cell 
lines. Incubation of both cell lines with PMA resulted in the cells becoming adherent with a 
macrophage morphology (figure 4.3.5). Although the U937EC cells still contained some cells 
in suspension, the U937PM were solely adherent with only dead looking cells in suspension 
(figure 4.3.5). Whereas, incubation with Bt2cAMP caused both cell lines to remain in 
suspension however the U937PM became more macrophage like with lots of membrane 
protrusions (figure 4.3.5). The morphology of the U937PM cell line following stimulation with 
either PMA or Bt2cAMP appears more similar to previous described morphological changes 
described in the literature such as becoming adherent following incubation with PMA and 
having a more ruffled membrane following stimulation with Bt2cAMP (Sheth et al., 1988, 
Rubin et al., 1991a).
To coincide with increased C5aR expression following stimulation of the U937PM cell
line with Bt2cAMP and PMA, these cells release more intracellular Ca2+ following stimulation
with C5a (figure 4.3.7B). However, the cells which were incubated with PMA required 50 nM
C5a to show significant difference from the control, whereas cells which were incubated with
Bt2cAMP required 0.5 nM C5a to show significant difference from the control. These findings
correspond with Bt2cAMP being a stronger inducer of the C5aR compared with PMA in the
U937pm cell line. Interestingly the U937EC cells which were incubated with Bt2cAMP also
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showed a significant increase in C5a induced Ca2+ release, at 5 nM and 50 nM C5a, 
although this stimulus did not increase C5aR expression in this cell line (figure 4.3.7A). This 
suggests that Bt2cAMP may be able to increase signalling capacity of the C5aR on the cell 
surface. The mechanism by which this is achieved is not clear as signalling via the C5aR 
increases intracellular Ca2+ release following the stimulation of phospholipase C p2, whereas 
Bt2cAMP is a cAMP analogue which activates PKA and exchange proteins directly activated 
by cAMP (Epacs) (Sands and Palmer, 2008).
Although both the U937EC and U937PM should technically be the same cell line, it is 
well known that when cells are over cultured or cultured in different laboratories this can lead 
to a selective pressure and genetic drift, to an extent in which the cells exhibit reduced or 
altered key functions, and no longer represent a reliable model of their original source 
material (Hughes et al., 2007). The U937 cell line was derived from a patient with histiocytic 
lymphoma and was characterised in 1976 by Sundstrom and Nilsson, since then this cell line 
has been widely used by many laboratories (Sundstrom and Nilsson, 1976). This is not the 
first time that different U937 cell lines have been identified. A study by Kaszubowska and 
colleagues found two U937 sublines which differed in their responses to TNFa, although this 
study did not look at changes in C5aR expression. Kaszubowska and co-workers found that 
the two sublines originated from a common origin, however cytogenetic studies revealed 
complex translocations and gene re-arrangements may be responsible for the different 
phenotypes observed between the two sub cell lines (Kaszubowska et al., 2001). Also in our 
laboratories two U937 sub-lines, one CD59 positive and the other CD59 negative have also 
been reported (van den Berg et al., 1994). Similarly to the U937Ec cells, neither of these 
cells expressed the C5aR or responded to PMA with an increase in C5aR. Rubin and co­
workers had previously found that Bt2cAMP differentiation occurs only in a subset ~60-80 % 
of U937 cells (Rubin et al., 1986). It is therefore possible that over time in culture either the 
U937ec cell line has lost the subset of cells which respond to Bt2cAMP and U937PM has lost 
the subset of cells which do not respond to Bt2cAMP due to selective pressure. As initial 
experiments carried out using the U937Ec cell line found these cells do not respond to PMA 
and Bt2cAMP in the way in which the literature has reported, this resulted in the U937PM cell 
line being obtained by Dr Peter Monk from Sheffield University.
Incubation of both U937PM and U937EC cell lines with IFNy and U937Ec with IL-6 
caused a significant apparent increase in C5aR cell surface expression when detected by 
flow cytometry (figure 4.3.3). However, these results were contradicted by the results from 
western blotting and C5a induced Ca2+ release, which suggested that neither IFNy nor IL-6 
altered C5aR expression when compared with the control (figures 4.3.6 and 4.3.7). As 
described in section 4.3.4, incubation of both U937PM and U937Ec cells with aggregated
154
human IgG prior to staining for flow cytometry abolished the IFNy and IL-6 induced C5aR 
expression in these cells, which suggested that the antibodies may be binding non- 
specifically via the Fc receptors (figure 4.3.8). This finding was unexpected as lgG1 isotype 
control did not detect any non-specific binding throughout the flow cytometry experiments. 
However, further investigation into the primary anti-C5aR (S5/1) from Santa Cruz found that 
although this monoclonal antibody was sold as an lgG1 isotype it is in fact an lgG2a isotype 
(Oppermann et al., 1993). This discovery had huge implications for our flow cytometry 
experiments as it meant that the isotype control was no longer relevant. As the U937 cell 
line is a monocytic cell line, they express cell surface FcyR which binds the Fc portion of IgG 
coated surfaces aiding their phagocytosis. Each of the class of FcyR have different affinities 
for the different isotypes of IgG class antibodies which makes using the correctly match 
isotype essential to detect non-specific binding of antibodies via the FcyR. To investigate 
whether increased expression of FcyRIII (CD16) or FcyRII (CD32) may be responsible for the 
apparent increase in C5aR expression following incubation with IFNy or IL-6, flow cytometry 
was performed using anti-CD16 or anti-CD32 antibodies. Although staining for FcyRIII 
(CD16) and FcyRII (CD32) showed that neither of these receptors increased following 
treatment with IFNy or IL-6, these stimuli may still up-regulate expression of the FcyRI 
(CD64) which was not investigated. Indeed, IFNy (100U/ml) has previously been shown to 
up-regulate CD64 expression (three fold) in the U937 cell line which could explain the 
increased non-specific binding of the antibodies via their Fc portion (Karehed et al., 2007). 
Furthermore CD64 has 3 times more affinity for lgG2a isotype compared with lgG1 isotypes 
(van de Winkel et al., 1991). In contrast differentiation of the U937 cell line with Bt2cAMP has 
been previously characterised to decrease CD64 expression in these cells, whilst increasing 
CD11b and CD14 (Sheth et al., 1988, Gavison et al., 1988, Brodsky et al., 1998).
Although results presented here suggest that the apparent increase in C5aR by IFNy 
and IL-6 was due to non-specific binding of the antibody, these findings contradict several 
studies which have reported these stimuli to increase C5aR expression in the U937 cell line 
(Burg et al., 1996, Burg et al., 1995, Gasque et al., 1998). In order for Burg and co-workers 
to achieve an increase in C5aR expression in the U937 cell line following treatment with 
IFNy, they carried out their experiments on a sub clonal population, which had considerable 
gene rearrangement (Burg et al., 1995). Furthermore, Burg and co-workers used 125l-C5a 
ligand binding studies to monitor changes in C5aR expression following incubation with 
IFNy (Burg et al., 1996, Burg et al., 1995). However, these experiments are now 
compromised by the discovery of a second C5a receptor, C5L2, which binds to C5a with 
similar affinities as C5aR (Cain and Monk, 2002). Although Gasque and colleagues used 
both flow cytometry and RT-PCR to monitor changes in C5aR in the U937 cell line following
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incubation with IFNy, their flow cytometry experiments used mouse anti-C5aR (P12/1) from 
Santa Cruz which is also an lgG2a isotype and they do not mention incubating the cells with 
aggregated IgG prior staining to eliminate non-specific binding via the FcyRs nor do they use 
an isotype control (Gasque et al., 1998). Furthermore their results from RT-PCR only 
produced a small change in mRNA levels following incubation with IFNy while incubation with 
PMA saw a big increase by comparison in C5aR mRNA despite this stimulus being a weaker 
inducer for C5aR expression. Together these results suggest that his interpretation of the 
ability of IFNy to increase C5aR expression is wrong (Gasque et al., 1998). As already 
discussed above, there is likely to be some heterogeneity between the U937 cell lines 
between different laboratories, due to selective pressure and over culturing of the cells. 
Taken together these results highlight the problem of using over cultured and over passaged 
cell lines.
To investigate whether differences between the cell lines is attributed to differences in 
their regulatory sequences or regulatory proteins within the cells, each -2Kbp EGFP reporter 
construct generated from each cell line was transfected into both U937 cell lines and were 
then incubated with the different stimuli. From these experiments it was shown that neither 
the -2Kbp(EC)+pEGFP or -2Kbp(PM)+pEGFP reporter constructs when transfected into 
either cell lines responded to PMA (figure 4.3.10A and figure 4.3 .12A). Previously Gerard 
and colleagues found that a CAT reporter construct which contained the -355bp promoter 
region of the C5aR, and some of the intron, contained a regulatory element which was 
responsive to PMA when transfected into the RBL cells (Gerard et al., 1993). The difference 
between our results could be explained by several factors; firstly the C5aR promoter reporter 
construct studied by Gerard et al consisted of -355bp of the promoter region and ~500bp 
intronic sequence, therefore the element which was responsive to PMA might be present 
within the intron which was not cloned in this study; secondly there are 11 bp differences 
between the sequences in the -355bp region published by Gerard and co-workers compared 
with the sequences used in this study (see appendix 9.2), although our results are most 
similar to other published results; and thirdly they transfect the rat basophilic leukaemia 
(RBL) cell line with their reporter constructs which may contain different transcription factors 
to the U937 cell line.
When the 2Kbp(EC)+pEGFP reporter construct was transfected into the U937PM cells 
a significant increase in EGFP fluorescence was observed when the cells were incubated 
with Bt2cAMP compared with the other constructs (figure 4.3.12 b). However, this was not 
observed when the U937Ec cells were transfected with this construct. This result suggests 
that the -2Kbp promoter region of the C5aR gene isolated from U 9 3 7 e c  cells contains a cis- 
acting element which is responsive to Bt2cAMP, however, only when it is transfected into the
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U937pm cells does the activity become apparent (figure 4.3.1 OB and 4 .3 .12B). The extent of 
EGFP increase (~1.75 fold) is far less than the actual increase in C5aR expression (~6 fold). 
This could suggest that stronger regulatory activity is outside the region cloned. Interestingly 
however the -2Kbp promoter isolated from U937PM cell line showed no promoter activity 
towards PMA or Bt2cAMP when transfected into the U937PM cell line, which was unexpected 
as this cell line responded to both PMA and Bt2cAMP by increasing C5aR expression (figure 
4.3.12). One explanation for these results could be that, as previously described in chapter 
3, there are several bp differences between the U937Ec and U937PM promoter region cloned, 
including a SNP at position -245bp (T/C) which has previously been identified by (Barnes et 
al., 2004). If for instance U937PM is heterozygous at a given SNP position, and the position 
of the SNP is critical for responsiveness to Bt2cAMP, then the non-responder SNP may have 
been cloned in these studies. As the U937Ec cell line was unresponsive to Bt2cAMP, neither 
reporter construct containing the C or T SNP would respond, due to a lack of the necessary 
regulatory proteins. This theory could be tested by performing site directed mutagenesis on 
the promoter cloned from the U937PM cells to match the sequence obtained from the U937EC 
cell line and then transfecting it back into the U937PM cells. Future studies could further 
investigate whether the bp differences between the two cell lines are true SNPs and whether 
the U937pm cell line is heterozygous at any of these positions.
As previously described Bt2cAMP is a cAMP analogue that has been suggested to 
regulate C5aR expression via activation of PKA. Following activation of PKA several 
transcription factors can be activated including cAMP regulatory element binding protein 
(CREB), cAMP response element modulator (CREM) and ATF-1 (Sands and Palmer, 2008). 
More recently raising intracellular cAMP levels has been shown to also activate cyclic 
nucleotide-gated ion channels, as well as exchange proteins directly activated by cAMP 
(Epacs) (Sands and Palmer, 2008). Epacs can also activate small GTPase binding proteins 
which can also regulate activity of several transcription factors, such as NFAT in cardiac 
myocytes (Morel et al., 2005). Taken together these results suggest that the U937PM cell line 
may contain one or more of these target transcription factors that are not present in the 
U937ec cell line. The results from this chapter suggest that there may be a regulatory protein 
or transcription factor, which is responsive to Bt2cAMP, present in the U937PM but not U937EC 
cell line.
Although PMA and Bt2cAMP can increase C5aR expression in the U937PM cell line,
the promoter region cloned is only 2Kbp up-stream of the transcription start site of the C5aR
gene and therefore the regulatory elements responsive to these stimuli could be out side the
region cloned or even within the intron or 3’UTR. When the 3’UTR EGFP reporter
constructs, generated from the U937Ec cell line, were transfected into the U937EC cell line,
incubation with PMA or Bt2cAMP had no effect on EGFP fluorescence compared with the
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SV40 control vector (figure 4.3.11). However, it was not investigated whether the 3’UTR 
isolated from the U937PM cell line could be regulated by either PMA or Bt2cAMP.
4.4.1 Summary
This chapter has identified two U937 cell lines which differ in their responses to Bt2cAMP and 
PMA. The differences between their C5aR expression patterns following stimulation by 
these stimuli appear to be due to both differences in the sequences of the -2Kbp promoter 
region cloned and the due to differences in expression of the regulatory proteins responsive 
to these stimuli. This chapter has also highlighted the need to use proper controls for non­
specific binding when using cell lines which express Fc receptors. The results from this 
chapter have found that incubation of the U937PM cell line with Bt2cAMP, results in the 
highest function and expression the C5aR, which provides a good model system to 
investigate the effects of lipid lowering drugs on the function and expression of the C5aR.
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Chapter 5
The effects of statins on C5aR expression 
5.1 Introduction
Inhibition of HMG-CoA reductase by statins prevents biosynthesis of isoprenoid 
intermediates and cholesterol (figure 5.1.1). Isoprenoid intermediates are vital for the post- 
translational modification, isoprenylation, of small GTP binding proteins. These proteins are 
typically components in intracellular signalling cascades which can regulate the activity of 
several transcription factors. As cholesterol can also regulate the transcriptional activity of 
genes containing sterol-regulatory-elements present within their promoter regions, statins 
have the potential to regulate the transcriptional activity of several genes (figure 5.1.1). 
Furthermore statins can also affect gene expression by regulating mRNA stability, as well as 
altering membrane cholesterol content and therefore altering cell surface expression. The 
regulation of genes that encode pro-inflammatory, immunomodulating and pro-thrombotic 
proteins by statins has attracted a lot of interest over the last decades, and the regulation of 
expression of these genes has been attributed to some of the pleiotropic effects of statins.
Evidence suggests that C activation occurs within atherosclerotic plaques and that 
the C system contributes towards the development and maturation of these plaques; see 
section 1.3.2 for full details. As the C5aR has previously been shown to be present in 
atherosclerotic plaques (Oksjoki et al., 2007), this chapter aims to investigate whether statins 
regulate the expression of the receptor in vitro.
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Statins — I
I  Cholesterol
i  Mevalonate
|  Isoprenoids
HMG-CoA Isoprenylated
J Kinase cascade
|  Activation of transcription factors
|  Gene expression
Figure 5.1.1 Mechanisms by which statins can regulate gene transcription. Adapted 
from (Massy and Guijarro, 2001).
5.1.1 Regulation of gene expression by statins independent of 
cholesterol lowering
Isoprenylated small GTP binding proteins are crucial components for several intracellular 
signalling pathways including extracellular signal-regulated kinase (ERK) and p38-MAPK, c- 
Jun N-terminal kinase (JNK) and phosphatidylinositol-3-kinase (PI3K) (Paumelle and Staels
2005). Inhibition of these signalling pathways by reducing isoprenylation is an important 
mechanism by which statins can regulate the expression of target genes and elicits a broad 
range of pleiotropic effects, table 5.1.1. The main transcription factors affected by statins are 
NFkB and PPARs but evidence has shown STAT-family members are similarly regulated. 
As well as regulating gene transcription, statins have also been shown to regulate mRNA 
stability via Rho family members. The mechanisms which statins affects these trans-acting 
factors will be discussed below in more detail.
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Table 5.1 Effects of statins on gene regulation of target genes.
Pleiotropic effect Target genes and mechanism for regulation
Improves
endothelial function
•  Increase eNOS expression by increasing mRNA stability via 
Rho/ROCK signalling pathway (Laufs et al., 1998, Laufs and Liao, 
1998).
•  Lower adhesion molecules expression, such as ICAM-1 by reducing 
STAT-1a expression (Chung et al., 2002).
•  Increase DAF expression by via activation of protein kinase C and 
inhibition of RhoA signalling (Mason et al., 2002).
Decreases 
inflammation and 
cell infiltration
•  Reduce LDL and oxidised LDL induced IL-6 expression by inhibition 
of NFkB activation (Massy et al., 2000, Guijarro et al., 1996).
•  Reduce MCP-1 expression by inhibition of RhoA signalling and 
therefore reduced NFkB activation (Veillard et al., 2006, Ortego et al., 
1999).
•  Reduce chemokine receptors CCR2 and CCR5 expression on 
monocytes by depletion of isoprenoid GGPP and cellular cholesterol 
which together leads to increased PPARy activation (Han et al., 2005, 
Chen et al., 2005, Yin et al., 2007).
•  Reduce IL-1p expression by increasing PPARa expression (Inoue et 
al., 2000).
Reduce T-cell
activation:
immunomodulation
•  Reduce IFNy induced MHC II expression therefore reducing T cell 
activation (Sadeghi et al., 2001, Kwak et al., 2000).
•  Reduce expression of co-stimulatory molecules such as IFNy 
induced CD40 expression by reducing STAT-1a expression 
(Townsend et al., 2004, Lee et al., 2007).
•  Regulate Th1/Th2 balance by suppressing Th1 pro-inflammatory 
cytokines by inhibiting NFkB and promoting Th2 development 
(Jasinska et al., 2007).
•  Regulate Th1/Th2 lineage commitment by decreasing STAT-4 
phosphorylation and increasing STAT-6 phosphorylation (Youssef et 
al., 2002).
Enhances stability 
of atherosclerotic 
plaques
•  Reduce expression of MMPs such as MMP-2 and -9 via Rho/ROCK 
signalling pathways (Li et al., 2008, Turner et al., 2005).
Decreased
thrombosis
•  Inhibition of tissue factor expression by decreased NFkB activation 
(Colli et al., 1997).
5.1.2.1 Inhibition of NFkB by statins
NFkB exists as either a homodimer or heterodimer made up from the different members of 
the NFkB family. It is present in an inactive form in the cytoplasm bound by an inhibitory 
subunit IkB. Upon stimulation IkB is released and degraded allowing NFkB to translocate to 
the nucleus (figure 5.1.2). Once inside the nucleus, NFkB promotes the transcriptional 
activity of target genes which contain a NFkB promoter element. These genes are typically 
involved in the expression of pro-inflammatory molecules such as cytokines and adhesion 
molecules. The signal is eventually terminated by the new synthesis of IkB (Hoffmann et al.,
2006).
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NFkB is a crucial transcription factor in atherogenesis initiation and progression by 
regulating expression of adhesion molecules and pro-inflammatory cytokines (Thurberg and 
Collins, 1998). Although NFkB can be regulated by numerous MAPK signalling pathways, 
several studies have suggested that the reduced NFkB activation caused by statins is 
mediated by inhibition of the Rho/Rho Kinase (ROCK) signalling pathway however the exact 
mechanism still needs to be confirmed (Colli et al., 1997, Turner et al., 2005, Veillard et al., 
2006, Guijarro et al., 1996).
Figure 5.1.2 Schematic diagram of NFkB signalling pathway.
5.1.2.2 Activation of PPARs by statins
Peroxisome proliferator-activated receptors (PPAR) are transcription factors which become 
activated upon stimulation with their ligands (fatty acid derivatives and eicosanoids) 
(Paumelle and Staels, 2008). There are three different isotypes identified so far (PPARa, 
PPARy and PPAR 5/p). Statins have been shown to activate both PPARa and PPARy in 
endothelial cells, hepatocytes and macrophages (Yano et al., 2007, Inoue et al., 2000, 
Paumelle et al., 2006). Several mechanisms of how statins increase PPARa and PPARy 
activation have been suggested (figure 5.1.3). One mechanism is that inhibition of RhoA by 
statins leads to a reduction in PKC phosphorylation of PPARa which would normally repress 
PPARa activity (Martin et al., 2001, Paumelle et al., 2006, Paumelle and Staels, 2008). 
Another study has also suggested that inhibition of RhoA/Cdc42 by statins leads to activation 
of p38 MAPK, which in turn increases and activates COX-2 expression (Yano et al., 2007). 
This statin induced COX-2 expression leads to an increase in the PPARa and PPARy ligand 
15-deoxy-delta (12,14)-prostaglandin J(2) (15d-PGJ(2). However, results from an earlier 
study found that incubation with statins reduced COX-2 expression, therefore this 
mechanism is still not clear (Inoue et al., 2000). It has also been suggested that statins may
I
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regulate gene transcription of PPARa however the exact mechanism has yet to be 
established (Landrier et al., 2004, Paumelle and Staels, 2008). PPARa and PPARy are also 
regulated by other drugs including fibrates, activators of PPARa, and their structural 
analogue anti-diabetic agents thiazolidinediones, which activate PPARy (Jasinska et al., 
2007).
Isoprenylated proteins 
RhoA, Cdc42,Rac
PKC MAPK
COX-2
t PPARa " 15d-PGJ(2)
V
PPARy
|  Triglycerides f HDL
Figure 5.1.3 Potential mechanisms which statins activate PPARa and PPARy. Adapted 
from (Jasinska et al., 2007).
5.1.2.3 Regulation of other transcription factors by statins
Statins have also been shown to inhibit IFNy induced MHC II expression on endothelial cells, 
macrophages and microglia; however the exact mechanism in which they modulate this is 
controversial (Katznelson, 1999, Kwak et al., 2000, Sadeghi et al., 2001). Kwak and 
colleagues showed that IFNy induced MHC II expression on endothelial cells and 
macrophages was inhibited via the down regulation of CIITA-PVI transcription factor, which 
normally mediates MHC II expression (Kwak et al., 2000, Kwak et al., 2001). However other 
studies have shown that CIITA-PVI mRNA levels remain unchanged following treatment with 
simvastatin (Kuipers and van den Elsen, 2007).
Statins have been shown to regulate members of the STAT-family. STAT activation 
is achieved by signalling of IFNy via its receptor which leads to the activation of Janus 
kinases (JAK) 1 and 2 that can in turn activate STATs (Kuipers and van den Elsen, 2007). 
Decreased phosphorylation of STAT-4 and increased phosphorylation of STAT-6 by
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atorvastatin in vivo is believed to reduce Th1 and promote Th2 lineage commitment (Youssef 
et al., 2002). Inhibition of STAT-1 by lovastatin has also been suggested to suppress IFNy 
induced CD40 expression in microglia (Townsend et al., 2004, Lee et al., 2007).
5.1.2.4 Regulation of mRNA stability by statins
As previously described in section 3.1.3 regulating mRNA stability is another mechanism 
which gene expression can be effected. Previously statins have been shown to alter 
expression of eNOS by regulating mRNA stability. Laufs and colleagues found that ox-LDL 
was able to reduce mRNA expression of eNOS in human endothelial cells and that this 
reduction was prevented by incubation with simvastatin, lovastatin and mevastatin (Laufs et 
al., 1998). They identified that the inhibition of geranylgeranylation of Rho by statins 
improved the half life of the mRNA transcripts suggesting that Rho is a negative regulator for 
eNOS mRNA (Laufs and Liao, 1998). Although they did not investigate how Rho affects 
eNOS mRNA stability they suggested that as Rho is important for re-organisation of the 
actin-cytoskeleton Rho may effect the eNOS mRNA translation and stability via effects on 
cytoskeleton localisation of the mRNA (Laufs and Liao, 1998).
5.1.2 Regulation of gene expression by cholesterol
As cholesterol is a crucial component for maintaining membrane integrity, mammals have 
developed several feedback regulation mechanisms to sustain cholesterol homeostasis 
within the cell (see section 1.5) (Goldstein and Brown, 1990). Many genes that are involved 
in cholesterol metabolism are regulated by sterol-regulatory-element-binding protein 
(SREBP), which allows the cell to sense cholesterol levels and regulate the transcription of 
target genes accordingly. At high cholesterol levels, SREBP is trapped within the 
endoplasmic reticulum where it is bound to SREBP cleavage activator protein (SCAP) in its 
inactive form (Muller-Wieland et al., 1997, Maxfield and Tabas, 2005). Inactivation of 
SREBP leads to a reduction of cholesterol biosynthesis by reduction in gene transcription of 
HMG-CoA synthase and HMG-CoA reductase, as well as reducing uptake of LDL-cholesterol 
via down regulation of the LDL receptor gene. When cholesterol levels are low the SREBP- 
SCAP complex exits the endoplasmic reticulum and undergoes proteolytic cleavage to 
release SREBP. SREBP is translocated into the nucleus where it regulates the transcription 
of many genes such as HMG-CoA reductase, HMG-CoA synthase and LDL receptor gene 
(Muller-Wieland et al., 1997). Plasma LDL-cholesterol has also been shown to increase 
expression of the MCP-1 receptor, CCR2, in the THP-1 cell line; furthermore its expression 
was dramatically increased on monocytes from hypercholesterolemic patients (Han et al., 
1998). Later investigations found that in a mouse hypercholesterolemia model the CCR2
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gene in circulating monocytes is under the transcriptional control of SREBP and PPARy 
within the promoter region (Chen et al., 2005).
As cholesterol is an integral part of cellular membranes it can also affect expression 
of genes which encode cell surface molecules by influencing membrane fluidity and therefore 
the proper processing and targeting to plasma membrane. For instance simvastatin has 
been suggested to reduce surface expression of MHC-II molecules by disrupting the 
cholesterol-containing microdomains which are important for the transport and concentration 
of MHC-II at the cell surface (Kuipers et al., 2005).
5.1.3 Regulation of C5aR expression by statins
C5aR expression has been shown to be altered in numerous inflammatory disease states 
(see section 1.2.8 for full details) including atherosclerotic plaques where C5aR expression 
was detected on macrophages, T-cells, mast cell, EC and SMC (Oksjoki et al., 2007). Few 
studies have investigated the mechanisms of regulation of C5aR expression and to date no 
published data has investigated whether statins may alter its expression (see 1.2.3 for full 
details). One potential mechanism by which statins could regulate C5aR expression would 
be to regulate gene transcription as is the case for chemokine receptors CCR2 and CCR5 
(Han et al., 2005, Chen et al., 2005, Yin et al., 2007). This could be achieved by regulation 
of NFkB, PPARs or STATs transcription factors by statins. Chapter 3 has previously 
identified a NFkB site at position -238bp to -232bp within the -2Kbp promoter region of the 
C5aR, which offers a potential mechanism that statins may alter receptor expression.
Statins could also regulate C5aR expression by affecting its mRNA stability as is the 
case for eNOS (see section 5.1.2.4 for details) (Laufs et al., 1998). Messenger RNA stability 
can be affected by ARE with the 3’UTR (see section 3.1.3). Although it was shown in 
Chapter 3 that the C5aR gene contained two ARE within the 3’UTR and they had no effect 
on basal mRNA stability, these elements may still offer a mechanism by which statins may 
regulate C5aR expression. Recently DAF mRNA has been shown to be destabilised by an 
ARE present within the 3 ’UTR region (Gray et al., 2010). Although statins have been shown 
to increase DAF expression it has not been investigated whether they can increase mRNA 
stability via the ARE present within the 3’UTR (Mason et al., 2002, Gray et al., 2010).
As well as regulating gene transcription and mRNA stability, statins may also regulate 
surface C5aR expression by altering membrane cholesterol and thus affecting receptor 
internalisation and intracellular trafficking. As discussed in Chapter 1 section 1.3, GPCRs 
whose internalisation is regulated by membrane cholesterol content are localised in lipid raft 
regions of the plasma membrane or move in or out of such regions following stimulation with 
their ligand. Although initially there were conflicting results as to whether C5aR
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internalisation was mediated by clathrin dependent or independent mechanism, it is now 
believed that following stimulation of the C5aR with C5a the receptor clusters into clathrin 
coated pits where it is then internalised in a (3-arrestin, dynamin, and clathrin-dependent 
pathway (Gilbert et al., 2001, Licht et al., 2003, Braun et al., 2003, Suvorova et al., 2005, 
Huttenrauch et al., 2005). As lipid raft dependent endocytosis is characterised by clathrin- 
independence, this would suggest that the C5aR is unlikely to be internalised in a lipid raft 
dependent manner; however, it has not been investigated whether C5aR internalisation is 
dependent on cholesterol (Lajoie and Nabi, 2010). Membrane localisation of the C5aR will 
be investigated in Chapter 6.
5.1.4 Hypothesis and aims
As statins have been shown to down regulate expression of numerous other pro- 
inflammatory molecules, such as chemokine receptors CCR2 and CCR5 (see table 5.1 for 
details), this chapter hypothesises that statins may also down regulate expression of the 
C5aR and thereby exerting an anti-inflammatory effect. The aim of this chapter is to 
investigate whether statins regulate resting or induced C5aR expression in vitro using U937 
cell lines and PBMCs.
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5.2 Materials and methods
5.2.1 Chemicals and reagents
All general reagents were purchased from Sigma. Alamar blue was purchased from AbD 
Serotec. See section 2.1.1 for all other reagents and suppliers.
5.2.2 Cell culture
Both U937pm and U 9 3 7 C5aR cell lines were maintained in complete RPMI media as previously 
described in section 2.3.1. Unless otherwise stated cells were seeded at 2.5 x105 cell/ml and 
incubated for 48 hrs with appropriate stimuli prior to analysis (section 2.3.5). PBMCs isolated 
as previously described in sections 2.3.2, were seeded at 1 x106 cell/ml for 24 hr with the 
appropriate stimuli (section 2.3.5).
5.2.3 Flow cytometry
C5aR expression and CD 14 expression was analysed by flow cytometry using specific 
monoclonal antibodies outlined in chapter 2 and GAM/FITC secondary antibody according to 
the method described in Chapter 2.3.6. EGFP fluorescence in EGFP reporter constructs 
transfected cells was also measured by flow cytometry. Relative change was calculated by 
subtracting the background fluorescence from all values and then dividing the treatment 
fluorescence by the control fluorescence.
5.2.4 Western blotting
Western blotting was performed as previously described in section 2.3.7 using polyclonal 
anti-C5aR (H-100, Santa Cruz) and anti-GAPDH (mAb, Santa Cruz SC47724) or anti-tubulin 
(mAb, Oncogen CP66) for equal loading control.
5.2.5 Alamar blue cell proliferation assay
Cells growing in log phase were washed in fresh complete RPMI media and counted. Cells 
were resuspended at 2x105 cell/ml in complete RPMI. 50 pi of cells was added to 100 pi 
complete RPMI media containing stimulus. Following 40 hr incubation, 50 pi Alamar blue, 
diluted 1:1 with complete medium was added. For a 100% reduced control, Alamar blue 
diluted 1:1 with complete RPMI was autoclaved for 15 min and mixed with 150 pi complete 
RPMI. Fluorescence was monitored every 1 hr using FLUOstar Optima plate reader (BMG 
Labtech), excitation wavelength 560 nm and emission wavelength 590 nm. Percentage
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Alamar blue reduction was then calculated using equation 1. Rate constant was calculated 
by one phase exponential association equation using GraphPad Prism 4.
Equation 1 Percentage reduction = Fluorescence intensity of sample x 100
Fluorescence intensity of 100% reduced Alamar blue
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5.3 Results
The aim of this chapter was to investigate if statins can regulate basal levels or induced 
C5aR expression in the U937 cell line and human monocytes. Changes in C5aR expression 
were monitored by flow cytometry and western blotting.
5.3.1 Simvastatin had no effect on basal C5aR expression levels in 
U937pM cells
As the U937pm cell line behaved most like the U937 cell line as reported in the literature it 
was decided to continue with this cell line rather than the U937Ec cell line (see Chapter 4 for 
full details). The effects of simvastatin were first investigated on basal C5aR expression 
levels.
Incubation of undifferentiated U937PM with increasing concentration of simvastatin 
initially showed a slight reduction in basal C5aR expression (figure 5.3.1.A). However, 
incubation of these cells with aggregated human IgG prior to staining for flow cytometry 
showed that treatment with simvastatin had no effect on basal C5aR expression (figure 
5.3.1.B). Furthermore this experiment also showed that there is no detectable basal C5aR 
expression in these cells.
When the U937PM cell line transfected with -2Kbp(PM)+pEGFP promoter reporter 
construct was incubated with simvastatin no change in EGFP fluorescence was detected by 
flow cytometry (figure 5.3.2). This suggest that either there are no c/s-acting elements in the 
promoter region cloned which are responsive to simvastatin or there could be a repressor 
present which over rides any enhancer activity. Simvastatin incubation was also shown to 
have no effect on the C5aR 3’UTR mRNA stability as incubation of the C5aR 3’UTR EGFP 
reporter constructs with simvastatin had no effect on EGFP fluorescence (figure 5.3.3). 
Similarly simvastatin had no effect on EGFP fluorescence in the 3’UTR mutant constructs 
3’UTR(1)ARE and 3’UTR(2)ARE (figure 5.3.3).
A B
■ ■  Control ™  Control
■  0.1 |iM Simvastatin ?s ™  0.1 pM Simvastatin
1 pM Simvastatin 1 Simvastatin
No primary Ab Anti-C5aR No primary Ab
Figure 5.3.1 Simvastatin has no effect on basal levels of C5aR expression in U937PM 
cell line. U937PM cells were incubated with simvastatin for 48 hr. Cells were harvested and 
incubated in the absence (A) or presence (B) of human aggregated IgG prior to staining for flow 
cytometry, section 5.2.3 for details. One-way ANOVA showed no statistical difference with the control.
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Figure 5.3.2 1uM simvastatin has no effect on EGFP expression in U937PM transfected 
with the 2Kbp (PM) + pEGFP reporter construct. U937PM transfected with the 2Kbp (PM) + 
pEGFP or pEGFP control vector were incubated with 1 pM simvastatin for 2 days. Following 
incubation changes EGFP fluorescence was monitored by flow cytometry, described section 5.2.3. (A) 
Result from representative experiment and (B) relative EGFP change comparing control with 1 pM 
simvastatin. Student t-test showed no statistical significance between the two groups.
Figure 5.3.3 0.1 pM (A) and 1 pM (B) simvastatin have no effect on mRNA stability.
U937ec transfected with the 3’UTR EGFP reporter constructs (see section 3.3.3 for more details) were 
incubated with 0.1 pM simvastatin (A) or 1 pM simvastatin (B) for 2 days. Following incubation 
changes in EGFP fluorescence was monitored by flow cytometry, described in section 5.2.3. One-way 
ANOVA showed no statistical significance.
5.3.2 Simvastatin reduces Bt2cAMP induced C5aR expression in U937PM 
cells
As simvastatin had no effect on basal levels of C5aR expression in the U937PM cell line, the 
effects of simvastatin on induced expression were investigated. C5aR expression was 
previously shown to increase in the U937PM cell line by stimulation with PMA or Bt2cAMP 
(section 4.3). As PMA was the weaker inducer of C5aR expression and it was shown to be 
cytotoxic to these cells (figure 4.3.4) it was decided to investigate the effects of simvastatin 
on Bt2cAMP induced C5aR expression only.
Results from both flow cytometry, for cell surface expression, and western blots, total 
C5aR expression, showed that incubation with 1 pM simvastatin significantly reduced
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Bt2cAMP induced C5aR expression, whereas 0.1 pM simvastatin had no effect (figures 5.3.4 
and 5.3.5).
To investigate if incubation for a longer duration with the lower concentration of 
simvastatin would have any effect on C5aR expression, U937PM were incubated with 0.1 juM 
simvastatin for 9 days, replacing the media every 2 days. After 7 days with 0.1 pM 
simvastatin the cells were incubated for a further 2 days with either 0.1 pM simvastatin or 
0.5mM Bt2cAMP plus 0.1 pM simvastatin, alongside cells incubated with Bt2cAMP alone for 2 
days. Results from these experiments showed that incubating U937PM cells with 0.1 pM 
simvastatin for 9 days increased C5aR expression slightly although this was not statistically 
significant and that treating these cells with Bt2cAMP for the final 2 days with the simvastatin 
had no effect on its ability to up regulate C5aR expression (figure 5.3.6).
No primary Ab Antl-CSaR
Control
BtjCAMP ,
BtjCAMP + 0.1nM Simvastatin = 4  
Bt,cAMP + 1 Simvastatin 1
BtjCAMP 0.5mM  
Simvastatin
+
0.1
Figure 5.3.4 Incubation with 1 pM simvastatin reduces Bt2cAMP induced C5aR 
expression detected by flow cytometry. U937PM cells were incubated with Bt2cAMP and 
simvastatin for 48 hr. Cells were incubated with aggregated IgG prior to staining for flow cytometry, 
section 5.2.3 for details. Results expressed as mean fluorescence intensity from one representative 
experiment (A) and relative change from three separate experiments (B). One-way ANOVA followed 
by Dunnett’s multiple comparison test was performed. Data marked with an asterisks represents 
significant difference from Bt2cAMP treated cells, **p <0.01.
0 .5  m M  Bt2c A M P  
Sim vastatin  pM 0.1 1
75 kDa
50 kDa75 kDa
50 kDa 37 kDa
37 kDa
25  kDa
0.1 1
Figure 5.3.5 Incubation with 1 pM simvastatin reduces Bt2cAMP induced C5aR 
expression in the U937PM cell line as detected by western blot. Following incubation of 
U937pm with Bt2cAMP and simvastatin, expression of C5aR (A) and tubulin (B) were detected by 
western blotting as described in section 5.2.4. Results shown are from one experiment but are 
representative of multiple analysis (n=3).
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Figure 5.3.6 Incubation of U937PM with 0.1 pM simvastatin for 9 days has no effect on 
C5aR expression. Following incubation for 7 days with 0.1 pM simvastatin U937PM cells were 
treated for a further 2 days with either 0.1 pM simvastatin or 0.1 pM simvastatin plus 0.5 mM Bt2cAMP. 
C5aR expression was compared by FACS analysis with untreated control cells and cells incubated 
with 0.5mM Bt2cAMP for 2 days. Cells were incubated with aggregated IgG prior staining for flow 
cytometry. C5aR expression was detected by flow cytometry as described in section 5.2.3. Results 
expressed as mean fluorescence intensity from one representative experiment (A) and relative C5aR 
change compared with untreated control U937PM (B). Paired student T-Test compared control against 
0.1 pM simvastatin and 0.5 mM Bt2cAMP against 0.1 pM simvastatin plus 0.5 mM Bt2cAMP showed 
no significant difference.
5.3.3 Incubation of U937PM with Bt2cAMP and 1uM simvastatin 
significantly reduced cell proliferation
To investigate whether simvastatin reduced cell proliferation following treatment of U937PM 
with simvastatin for 40 hrs, the rate of Alamar blue reduction was monitored. Figure 5.3.7 
shows that incubation with both 0.5 mM Bt2cAMP and 1 pM simvastatin significantly reduced 
cell proliferation rates, however alone these agents had no significant effect on proliferation.
Control
0.1 pM Simvastatin 
T 1 pM Simvastatin
BtjCAMP
—  B^cAMP ♦ 0.1 pM Simvastatin 
m B^cAMP ♦ 1 pM Simvastatin
Time (hr) Time (hr)
Rate constant (K) 
% reduction/hr
Control 0.4519 (+/- 0.06330)
0.1 ^M Simvastatin 0.4736 (+/- 0.04763)
1 jiM Simvastatin 0.3051 (+ /- 0 .03242)
Rate constant (K) 
% reduction/hr
0.5 mM Bt2cAMP 0.3796 (+/- 0.05639)
0.5 mM Bt2cAMP+ 0.1 nM Simvastatin 0.3384 (+/- 0.04165)
0.5 mM Bt2cAMP+ 1 nM Simvastatin 0.1649 (+ /-0 .02621)
Figure 5.3.7 Incubation of U937PM with 0.5 mM Bt2cAMP plus 1 pM simvastatin 
significantly decreases cell proliferation. Following 40 hr incubation of U937PM with 
simvastatin, in the absence or presence of 0.5 mM Bt2cAMP, Alamar blue was added to a final 
concentration 12 % and reduction in Alamar blue was then recorded every 1 hr for 7.5 hr. Rate 
constant was calculated using one phase exponential association equation and one-way ANOVA 
followed by Dunnett’s multiple comparison test. Data marked with an asterisk is significantly different 
from Bt2cAMP alone, *p <0.05.
173
5.3.4 Addition of mevalonate or GGPP prevented the effects of 
simvastatin
To further investigate how 1 pM simvastatin reduces Bt2cAMP induced C5aR expression, 
U937pm were incubated with Bt2cAMP plus 1 pM simvastatin and either 10 pM mevalonate or 
10 pM GGPP. If simvastatin is having a direct effect on Bt2cAMP induced C5aR expression 
by inhibition of cholesterol and/or isoprenoid synthesis, via HMG-CoA reductase, adding 
back mevalonate should reverse the effects of simvastatin (see Chapter 1, figure 1.8). 
Whereas adding back GGPP will reverse the effects of the simvastatin only if they are due to 
inhibition of isoprenoid synthesis (figure 1.8). Surprisingly, results from both flow cytometry 
and western blots showed that adding back GGPP but not mevalonate restored the ability of 
Bt2cAMP to increase C5aR expression in the presence of 1 pM simvastatin (figures 5.3.8 and
5.3.9).
w 1.0
No primary Ab Antl-C5aR 0.5 mM Bt2cAMP + + +
^ B t 2cAMP 1 m Simvastatin + +
B f B t 2cAM P + Simvastatin
□ ~ ]B t2cAM P + Simvastatin + Meva 10 ^M Mevalonate -
I B  Bt2 cA M P + Simvastatin + GGPP 1 0 ^ M G G P P
Figure 5.3.8 Adding back 10 pM GGPP, but not 10 pM mevalonate, restores Bt2cAMP 
induced C5aR expression in the presence of 1 pM simvastatin as detected by flow 
cytometry. U937PM cells were incubated for 48 hrs with 0.5 mM Bt2cAMP plus 1 pM simvastatin and 
either 10 pM mevalonate or 10 pM GGPP. Cells were incubated with human aggregated IgG and 
stained for C5aR expression as described in section 5.2.3. Results expressed as mean fluorescence 
intensity from one representative experiment (A) and relative C5aR change compared with Bt2cAMP 
(B). One-way ANOVA followed by Dunnett’s multiple comparison test shows significant difference 
from Bt2cAMP + 1 pM simvastatin, * p < 0.05.
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Figure 5.3.9 Adding back 10 pM GGPP, but not 10 pM mevalonate, restores Bt2cAMP 
induced C5aR expression in the presence of 1 pM simvastatin as detected by western 
blot. U937pm cells were incubated for 48 hrs with 0.5 mM Bt2cAMP plus 1 pM simvastatin and either 
10 pM mevalonate or 10 pM GGPP. C5aR (A) and GAPDH (B) expression were detected by western 
blotting as described in section 5.2.4. Results shown are from one experiment but are representative 
of multiple analyses.
As previously described in section 4.3, incubation of U937PM with Bt2cAMP causes 
the cells to develop an irregular cell shape morphology. Incubation of these cells with 
Bt2cAMP and 1 pM simvastatin resulted in them obtaining a spherical cell morphology (figure
5.3.10). The addition of 10 pM GGPP, but not mevalonate, prevented the effects of 
simvastatin on the cell morphology and maintained the irregular shaped morphology of the 
Bt2cAMP stimulated U937PM cell line (figure 5.3.10).
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Figure 5.3.10 Adding back 10 pM GGPP, but not 10 pM mevalonate, restores Bt2cAMP 
induced cell morphology. Images taken following 2 day incubation with (A) 0.5 mM Bt2cAMP, (B) 
0.5 mM Bt2cAMP plus 1 pM simvastatin, (C) 0.5 mM Bt2cAMP, 1 pM simvastatin and 10 pM GGPP 
and (D) 0.5 mM Bt2cAMP, 1 pM simvastatin and 10 pM mevalonate.
As 10 pM GGPP but not 10 pM mevalonate appeared to prevent the effects of 1 pM 
simvastatin it was decided to repeat these experiments but using a higher concentration of 
mevalonate. Figures 5.3.11 and 5.3.12 show that the addition of 50 pM mevalonate was 
able to prevent the inhibitory effects of 1 pM simvastatin on Bt2cAMP induced C5aR 
expression and retaining the U937PM cell morphology (figure 5.3.11 and 5.3.12).
To further investigate if adding back either 50 pM mevalonate or 10 pM GGPP 
prevented the anti-proliferative effect of 0.5 mM Bt2cAMP plus 1 pM simvastatin an Alamar 
blue assay was performed. Figure 5.3.13 shows that adding back mevalonate or GGPP 
restored the proliferation rate of the U937PM cells when incubated with 0.5 mM Bt2cAMP plus 
1 pM simvastatin (figure 5.3.13). To investigate whether mevalonate or GGPP themselves 
had any affect on Bt2cAMP induced C5aR expression, U937PM cells were incubated with 
Bt2cAMP and either GGPP or mevalonate. Flow cytometry results from incubations with 
Bt2cAMP plus mevalonate or GGPP showed that neither mevalonate nor GGPP had an 
effect on Bt2cAMP induced C5aR expression (figure 5.3.14).
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Figure 5.3.11 Adding back higher concentration of mevalonate restores the C5aR 
expression. (A) U937PM cells were incubated for 48 hrs with 0.5 mM Bt2cAMP plus 1 pM 
simvastatin and either 50 pM or 100 pM mevalonate. Results expressed as mean fluorescence 
intensity from one representative experiment. (B) Relative C5aR change compared to 0.5mM 
Bt2cAMP. One-way ANOVA followed by Dunnett’s multiple comparison test shows significant 
difference from Bt2cAMP plus simvastatin, *p<0.05.
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Figure 5.3.12 Adding back 50 pM mevalonate restores cell morphology. Images taken 
following 2 day incubation with (A) 0.5 mM Bt2cAMP, (B) 0.5 mM Bt2cAMP plus 1 pM simvastatin, (C) 
0.5 mM Bt2cAMP, 1 pM simvastatin and 10 pM GGPP and (D) 0.5 mM Bt2cAMP, 1 pM simvastatin and 
50 pM mevalonate, x40 magnification.
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0.5 mM Bt2cAMP + 1 jtM Simvastatin 0.3094 (+/- 0.02862)
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Figure 5.3.13 Mevalonate or GGPP prevents the inhibitory effects of Bt2cAMP plus 
simvastatin on cell proliferation. Following 40 hr incubation of U937PM with 0.5 mM Bt2cAMP, 1 
jiM simvastatin and 10 pM GGPP or 50 pM mevalonate Alamar blue was added to a final 
concentration 12 %. Reduction in Alamar blue was then recorded every 1 hr for a further 7.5 hr using 
fluorescence. Rate constant was calculated using one phase exponential association equation and 
one-way ANOVA followed by Dunnett’s multiple comparison test was performed. Data marked with an 
asterisk shows significant difference compared to the Bt2cAMP + 1 pM simvastatin, * = p <0.05.
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Figure 5.3.14 In the absence of simvastatin 50 mevalonate or 10 jiM GGPP have no 
effect on Bt2cAMP induced C5aR expression U937PM cells were incubated for 48 hrs with 0.5 
mM Bt2cAMP plus 10 pM GGPP or 50 pM mevalonate. Cells were incubated with human aggregated 
IgG and stained for C5aR expression as described section 5.2.3. Results expressed as mean 
fluorescence intensity from one representative experiment (A) and relative C5aR change compared 
with Bt2cAMP alone (B). One-way ANOVA shows no significant difference between the treatments.
5.3.5 Simvastatin did not inhibit Bt2cAMP induced C5aR expression via 
c/s-actin elements present within the -2Kbp promoter fragment
To investigate whether simvastatin was able to reduce the Bt2cAMP induced C5aR 
expression at the gene transcription level the -2Kbp(PM)+pEGFP C5aR reporter construct 
(see Chapter 3 for full details) was transfected into the U937PM cell line. Once growing in log 
phase clonal cell populations were incubated for 2 days in the absence or presence of 
Bt2cAMP, simvastatin, mevalonate or GGPP. Changes in EGFP expression were then 
monitored by flow cytometry.
Shown in figure 5.3.15 are the effects of the different treatments on EGFP 
fluorescence relative to the control. This figure shows that incubation with Bt2cAMP 
decreased EGFP fluorescence compared with control which was unexpected as Bt2cAMP 
increases C5aR expression on the cell surface (see section 4.3.5 for more details). This 
figure also showed that incubation with Bt2cAMP and 1 simvastatin increased EGFP 
fluorescence slightly which was prevented by the addition of either mevalonate or GGPP 
(figure 5.3.15). However as the promoter-less pEGFP control vector also shows a similar 
pattern this suggests that the effect is not specifically due to regulation via cis-acting 
elements present within the -2Kbp(PM) promoter region cloned.
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Figure 5.3.15 0.5mM Bt2cAMP plus 1 pM simvastatin does not down regulate C5aR 
expression via any cis-actin elements present within the 2 Kbp promoter fragment.
U937PM which have been transfected with the 2Kbp (PM) + pEGFP or pEGFP control vector were 
incubated with 0.5 mM Bt2cAMP, 1 pM simvastatin, 10 pM GGPP or 50 pM mevalonate for 2 days. 
Following incubation changes EGFP fluorescence will be monitored by flow cytometry. Two-way 
ANOVA showed that the treatment had significant effect on EGFP fluorescence (p=<0.0001), 
however, transfection with the -2Kbp(PM)+pEGFP reporter construct showed no significant difference 
from the pEGFP control vector (p=0.0658). Bonferroni post-test showed no significant difference 
between the -2Kbp(PM)+pEGFP and pEGFP vector.
5.3.6 Zaragozic acid had no effects on Bt2cAMP induced C5aR 
expression in U937PM cell line
To further investigate the effects of inhibition of the cholesterol synthesis pathway on 
Bt2cAMP induced C5aR expression, U937PM cells were incubated with Bt2cAMP plus the 
squalene synthase inhibitor zaragozic acid, either 0.1 pM or 1 pM (see figure 1.8). As 
squalene synthase converts two FFPP molecules into squalene, an important precursor of 
cholesterol, its inhibition will result in reduction of cholesterol synthesis independently of the 
HMG-CoA reductase inhibitors.
Incubation with Bt2cAMP plus zaragozic acid had no effect on Bt2cAMP induced 
C5aR expression nor cell proliferation, which further suggests that the effects seen by 
simvastatin are due to inhibition of isoprenoid synthesis rather than inhibition of cholesterol 
synthesis (figure 5.3.16 and 5.3.17).
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Figure 5.3.16 Zaragozic acid has no effect on Bt2cAMP induced C5aR expression.
U937pm cells were incubated for 48 hrs with 0.5mM Bt2cAMP and 0.1 pM or 1 pM zaragozic acid (ZA). 
Cells were incubated with human aggregated IgG and stained for C5aR expression as described in 
section 5.2.3. Results expressed as mean fluorescence intensity from one representative experiment 
(A) and relative change compared with Bt2cAMP alone (B). One-way ANOVA showed no statistical 
significance between the treatments.
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0.5 mM Bt2cAMP 0.2149 (+/-0.06906)
0.5 mM Bt2cAMP + 0.1 pM Zaragozic acid 0.2461 (+/- 0.07438)
0.5 mM Bt2cAMP + 1 jaM Zaragozic acid 0.3309 (+/- 0.08372)
Figure 5.3.17 Zaragozic acid has no effect on cell proliferation. Following 40 hr incubation 
of U937pm with 0.5 mM Bt2cAMP and 0.1 pM or 1 pM ZA, Alamar blue was added to a final 
concentration 12 %. Reduction in Alamar blue was then recorded every 2 hrs for a further 7.5 hr
using fluorescence. Percentage reduction was calculated using 100 % reduced Alamar blue, 
achieved by autoclaving for 15 min. Rate constant was calculated using one phase exponential 
association equation and One-way ANOVA showed no significant difference between the treatments.
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5.3.7 Increasing concentration of simvastatin reduced C5aR expression 
in the U937CsaR cell line
The U937C5aR cell line has previously been transfected with the human C5aR so that it 
expresses high levels of functioning receptor without the need to differentiate the cells (Kew 
et al., 1997). Although the C5aR expression on these cells is mainly exogenous expressed 
C5aR and not under the transcriptional control of the C5aR promoter it was still important to 
monitor the effects of simvastatin on the receptor expression in these cells as statins could 
still effect C5aR expression by altering membrane cholesterol content and therefore the 
surface expression (as described in section 5.1.2) and/or statins may regulate the activity of 
the promoter which drives transcription of the exogenous C5aR expression (although this is 
not known). It was anticipated that this cell line would be useful to monitor effects of 
membrane cholesterol composition and statins on C5aR function and expression.
Results from flow cytometry showed that following 2 day incubation with simvastatin 
the U937C5aR cell line reduces its C5aR expression in a concentration dependent manner 
(figure 5.3.18).
To determine if incubation with simvastatin reduced cell proliferation rates an Alamar 
blue assay was performed. Results in figure 5.3.19 show that although these cells treated 
with 1 pM simvastatin do have a slightly lower cell proliferation rate this reduction was not 
statistically significant (figure 5.3.19). Adding back either 50 pM mevalonate or 10 pM GGPP 
partially restored the change in C5aR expression induced by 1 pM simvastatin (figure
5.3.20).
Incubation of the U937C5aR cells with increasing concentration of zaragozic acid, a 
squalene synthesis inhibitor, had no effect on C5aR expression levels, which suggest that 
inhibition of cholesterol biosynthesis has no effect on C5aR expression in these cells (figure
5.3.21).
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Figure 5.3.18 Incubation with simvastatin reduces C5aR expression in the U 9 3 7 C5aR cell 
line. U 9 3 7 C5aR cells were incubated with increasing concentration of simvastatin for 48 hr. Cells were 
harvested and incubated with human aggregated IgG prior to staining for flow cytometry. C5aR 
expression was detected by flow cytometry as described in section 5.3.2. (A) Results from one 
representative experiment expressed as mean fluorescence intensity and (B) relative C5aR change 
comapred with the control. One-way ANOVA followed by Dunnett’s post-test shows significant 
difference to the control; ** p<0.01.
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Figure 5.3.19 Incubation of U 9 3 7 C5aR with simvastatin has no significant effect on cell 
proliferation. Following 40 hr incubation of U937C5aR with increasing concentration of simvastatin, 
Alamar blue was added to a final concentration 12 %. Reduction in Alamar blue was then recorded 
every 1 hr for 7.5 hrs using fluorescence. Percentage reduction was calculated using 100 % reduced 
Alamar blue, achieved by autoclaving for 15 min. Rate constant was calculated using one phase 
exponential association equation and One-way ANOVA showed no statistical difference between the 
treatments.
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Figure 5.3.20 Adding back mevalonate or GGPP partially restores C5aR expression in 
U 9 3 7 C 5aR  cell line incubated with 1 pM simvastatin. U937C5aR were incubated for 48 hrs in the
absence or presence of simvastatin plus 50 pM mevalonate or 10 pM GGPP. Cells were harvested 
and incubated with human aggregated IgG prior to staining for flow cytometry. C5aR expression was 
detected by flow cytometry as described in section 5.2.3. (A) Results from one representative
experiment. (B) Relative C5aR change compared with control cells. One-way ANOVA followed by 
Dunnett’s post-test shows significant difference to the 1 pM simvastatin treated cells; *** p < 0.01.
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Figure 5.3.21 Effects of zaragozic acid incubation on C5aR expression in U 9 3 7 C 5aR cell 
line. U 9 3 7 C5aR cells were incubated in the absence or presence of increasing concentration of 
zaragozic acid for 48 hrs. Cells were harvested and incubated with human aggregated IgG prior to 
staining for flow cytometry. C5aR expression was detected by flow cytometry as described in section 
5.2.3. (A) Results from one representative experiment. (B) Relative C5aR change compared with the 
control. One-way ANOVA showed no significant difference between the treatments.
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5.3.8 Incubation with fenofibrate but not simvastatin or lovastatin 
lowered C5aR expression in CD14 positive monocytes
As previously described in section 1.5.1, several naturally occurring and chemically 
synthesised statins are commercially available which have ranging inhibitory concentrations 
(Ki) for HMG CoA reductase. To further investigate whether different statins or other lipid 
lowering drugs had any effect on C5aR expression, human PBMCs were incubated with 
simvastatin, lovastatin or fenofibrate, a PPARa agonist (see section 1.3.6), for 24 hrs and 
changes in receptor expression were monitored by flow cytometry. By using the monocytic 
cell marker CD14 during FACS analysis allowed the C5aR expression to be monitored 
specifically on the CD14 positive monocytes.
Results shown in figure 5.3.22 show that incubation of human PBMC with simvastatin 
had no effect on C5aR or CD14 expression in CD14 positive monocytes (figure 5.3.22). 
Similarly, incubation of the PBMCs with lovastatin had no significant effect on C5aR or CD14 
expression in CD14 positive cells (figure 5.3.23). Fenofibrate, however, significantly down 
regulated C5aR expression and it also lowered CD14 expression but this was not classed as 
statistically significant, p=0.0748 (figure 5.3.24).
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Figure 5.3.22 Simvastatin has no effect on C5aR or CD14 expression in CD14 positive 
monocytes. Human PBMCs isolated from buffy coat were incubated with increasing concentration 
of simvastatin for 24 hrs. Cells were harvested and stained for the monocyte cell surface marker 
CD14 or C5aR by flow cytometry as described in section 5.2.3. (A) Mean fluorescent intensity from 
CD14 positive population in one representative experiment. (B) Relative C5aR change compared with 
the control. (C) Relative CD14 change compared with the control, n=4. One-way ANOVA showed no 
statistical difference in C5aR or CD14 expression following incubation with simvastatin.
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5.3.23 Lovastatin has no effect on C5aR or CD14 expression in CD14 positive 
monocytes. Human PBMCs isolated from buffy coat were incubated with increasing concentration 
of lovastatin for 24 hrs. Cells were harvested and stained for the monocyte cell surface marker CD14 
or C5aR by flow cytometry as described in section 5.2.3. (A) Mean fluorescent intensity from CD14 
positive population in one representative experiment. (B) Relative C5aR change compared with the 
control. (C) Relative CD14 change compared with the control, n=4. One-way ANOVA showed no 
statistical difference in C5aR or CD14 expression following incubation with lovastatin.
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5.3.24 Fenofibrate significantly lowers C5aR expression in CD14 positive monocytes.
Human PBMCs isolated from buffy coats were incubated with fenofibrate for 24 hrs. Cells were 
harvested and stained for the monocyte cell surface marker CD14 or C5aR by flow cytometry as 
described in section 5.2.3. (A) Mean fluorescent intensity from CD14 positive population in one 
representative experiment. (B) Relative C5aR change compared with the control. (C) Relative CD14 
change compared with the control, n=4. Results marked with an asterisk represent significant 
difference from the control using paired Student T-test, ** p<0.01, n=4.
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5.4 Discussion
The aim of this chapter was to investigate whether C5aR expression could be regulated by 
statins in the U937 cell line and in primary human monocytes isolated from buffy coats.
The effects of simvastatin on basal C5aR expression was investigated in the U937PM 
cell line. It was initially thought that simvastatin may down regulate basal levels of C5aR; 
however when C5aR staining was repeated in the presence of aggregated human IgG to 
prevent non-specific binding via the Fc receptors this effect disappeared, which suggests that 
simvastatin may have an effect on Fc receptor expression (figure 5.3.1). However a previous 
study by Hillyard and co-workers showed that fluvastatin had no effect on FcyRI or FcyRII 
expression in the U937 cell line (Hillyard et al., 2004). The incubation of the U937PM cell line 
with aggregated human IgG led to very little/no basal C5aR expression being detected in 
these cells which makes it difficult to determine whether statins have any effect on basal 
C5aR expression using this cell line (see Chapter 4 for more details). Incubation of the 
U937pm, which had been transfected with the -2 Kbp(PM)+pEGFP reporter construct or 
pEGFP vector control, with simvastatin suggested that there was no c/'s-acting element within 
the promoter region cloned that was regulated by simvastatin (figure 5.3.2). Similarly 
incubation of the C5aR 3’UTR EGFP reporter constructs with simvastatin had no effect on 
EGFP fluorescence, suggesting that simvastatin does not affect mRNA stability of the C5aR 
(figure 5.3.3).
To investigate the effects of simvastatin on induced C5aR expression, the U937PM 
cell line was differentiated with Bt2cAMP in the absence or presence of simvastatin. As 
previously described in Chapter 4 it was originally proposed to differentiate the cells with a 
more physiologically relevant stimulus such as IFNy, which has emerged as a significant 
factor in atherogenesis (McLaren and Ramji, 2009), however the C5aR expression in the 
U937pm cell line was unresponsive to such stimuli, see Chapter 4 for full details. Incubation 
of the U937pm with 1 pM simvastatin significantly reduced the Bt2cAMP induced C5aR 
expression as observed by flow cytometry and western blotting (figures 5.3.4 and 5.3.5 
respectively).
Although alone incubation with simvastatin or Bt2cAMP had no effect on the rate of 
cell proliferation, when combined they significantly reduced the proliferation rate of the 
U937pm cells (figure 5.3.7). However the concentrations of statins used in this study are far 
greater, at least ten times, than the maximum pharmacological concentration of simvastatin 
(30-70 nM (Krishna et al., 2009)). Although 1-10 pM simvastatin is commonly used for most 
in vitro experiments published (reviewed by (Bjorkhem-Bergman et al., 2011), results 
obtained at these concentrations are therefore unlikely to have any therapeutic implications
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due to in vivo toxicity. However these results yield information about the role of 
isoprenylation in the mechanism of C5aR expression.
Statins have previously been shown to inhibit cell growth by inhibiting isoprenylation 
of the growth-regulating p21ras proteins (Brown and Goldstein, 1980, Kaneko et al., 1978, 
Quesney-Huneeus et al., 1979). The effects of the 1 pM simvastatin and 0.5 mM Bt2cAMP 
on cell proliferation rates were prevented by the addition of either mevalonate or GGPP, 
which also suggests that inhibition of isoprenylation rather than cholesterol biosynthesis were 
responsible for the effects on cell proliferation (figure 5.3.13). Interestingly the addition of 
mevalonate or GGPP were also able to prevent the inhibitory effects of 1 pM simvastatin on 
Bt2cAMP induced C5aR expression, which also suggests that inhibition of isoprenylation was 
also responsible for this effect (figure 5.3.11). Incubation with Bt2cAMP in the presence of 
zaragozic acid had no effect on C5aR expression or cell proliferation rates, therefore further 
suggesting that the effects of simvastatin are solely due to inhibition of isoprenylation (figures 
5.3.16 and 5.3.17). Together these results could suggest that inhibition of Bt2cAMP induced 
C5aR expression by simvastatin could be caused by the cells entering a quiescent state by 
inhibition of isoprenylation of cell growth regulating proteins, such as p21ras, rather than 
specifically preventing the regulation of the C5aR gene by Bt2cAMP. However, its has 
recently been shown in our lab that DAF expression increased in the U937PM cells following 
incubation with 0.5mM Bt2cAMP and 1pM simvastatin which suggests that the findings 
presented in this thesis is due to specific regulation of the C5aR gene.
To circumvent the problems associated with using a higher concentration of 
simvastatin on cell proliferation, a lower concentration of simvastatin (0.1 pM) was also used 
for a longer duration however this had no effect on Bt2cAMP induced C5aR expression 
(figure 5.3.6).
Incubation of U937PM cells transfected with -2Kbp(PM)+pEGFP reporter constructs 
with both Bt2cAMP and simvastatin showed a slight increase in EGFP fluorescence 
compared with Bt2cAMP alone, however this was also observed in the pEGFP promoter-less 
vector (figure 5.3.15). Although this result suggest that there is no cis-acting element within 
the -2Kbp promoter region cloned which is specifically regulated by Bt2cAMP and 
simvastatin, these reagents could still regulate C5aR expression via regulatory elements 
outside the promoter region cloned. As previous results had shown that the mRNA stability 
was not to be regulated by incubation with simvastatin or Bt2cAMP individually and as the 
3’UTR EGFP reporter constructs were generated using 3’UTR isolated from U937Ec it was 
not investigated whether dual incubation of these stimuli altered EGFP fluorescence (figure 
4.3.12 and 5.3.3).
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As described in Chapter 4 Bt2cAMP is believed to differentiate the U937 cell line to a 
more macrophage like phenotype. As well as increasing C5aR expression, incubation with 
Bt2cAMP has been documented to cause a reduction in cell size, inhibition in DNA synthesis, 
irregular morphology and often ruffled cell membranes (Sheth et al., 1988). The presence of 
1 fxM simvastatin during the incubation with 0.5 mM Bt2cAMP prevented the irregular 
appearance of the U937PM cells caused by Bt2cAMP treatment alone and instead caused 
cells to obtain a more spherical cell morphology (figure 5.3.12). Thus it appeared that the 
presence of 1 jxM simvastatin prevented the 0.5 mM Bt2cAMP induced differentiation of the 
U937pm cell line. This effect of simvastatin was reversed by the addition of either 50 jxM 
mevalonate or 10 jxM GGPP, which suggested that inhibition of isoprenylation or 
isoprenylation and cholesterol biosynthesis were responsible for these effects (figure 5.3.12). 
The cAMP analog, Bt2cAMP, has previously been suggested to cause differentiation in the 
U937 cell line via activation of PKA (Shayo et al., 1997, Brodsky et al., 1998). The results 
presented here would therefore suggest that simvastatin effects Bt2cAMP activation of PKA 
or its down stream targets. However more recently cAMP has also been found to activate 
two other targets, cAMP regulated ion channels and guanine nucleotide exchange factors 
activated by cAMP (known as Epac) (Bos, 2006). Activation of Epac can regulate small GTP 
binding proteins such as Rap which requires geranylgeranyl prenylation for correct 
functioning (Bos, 2006, Altschuler et al., 1995, Vasudevan et al., 1999). As Bt2cAMP is not 
specific for either PKA or Epac activation, this therefore suggests that statins could 
potentially prevent the Bt2cAMP induced C5aR expression via several mechanisms as 
outlined in figure 5.4.1. To confirm which mechanisms are involved, future experiments 
could involve the use of selective Epac activators such as 8-pCPT-2’OMe-cAMP (also known 
as 007), alternatively the same experiments could be repeated using FPP rather than GGPP 
as Rap is a gernylgeranylated protein.
191
Bt2cAMP
Statins
Statins
t Transcription factors and 
target proteins
Statins
U937 differentiation
• Increased C5aR expression
• More macrophage morphology
• Reduced cell proliferation
Figure 5.4.1 Potential mechanisms which simvastatin may inhibit Bt2cAMP induced 
C5aR expression. Bt2cAMP can activate guanine nucleotide exchange factor (Epac), which can in 
turn regulate small GTP binding proteins such as Rap and/or it can activate protein kinase A (PKA).
The incubation of the U 93 7 C5aR cell line with simvastatin found that in these cells the 
C5aR expression decreased in a concentration dependent manner (figure 5.3.18). As these 
cells had previously been transfected with the human C5aR, the majority of the receptor 
being expressed was due to exogenous expression (Kew et al., 1997). This makes it difficult 
to determine whether the decreased C5aR expression observed is due to specific regulation 
of simvastatin on a regulatory element with the promoter region or 3 ’UTR of the C5aR gene 
in these cells or whether the vector used to clone the C5aR into these cells is regulated by 
the statin. Unfortunately we were unable to identify which plasmid was used during the 
cloning process by Kew et al. (1997) and therefore unable to speculate whether its promoter 
or 3’UTR may be affected by incubation with statins. Alternatively C5aR surface expression 
may be reduced via a cholesterol dependent mechanism such as disrupting in the 
intracellular trafficking of the receptor; however as the results suggest the mechanism by 
which simvastatin down regulates receptor expression is via inhibition of isoprenoid synthesis 
rather than cholesterol biosynthesis, as both mevalonate and GGPP were able to prevent the 
effects of simvastatin, whereas zaragozic acid had no effect (figures 5.3.20 and 5.3.21), this 
makes this scenario unlikely.
Interestingly, in these cells 50 pM mevalonate and 10 pM GGPP did not completely 
prevent the effects of simvastatin on C5aR expression, whereas in the U937PM cell line these 
concentrations were able to completely prevent the effects. The concentration of mevalonate 
and GGPP used in other in vitro experiments involving statins is commonly 10 times the
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concentration of statin, however this concentration may depend on how metabolically active 
the cells being studies are. For example the U 9 3 7 C5aR cells grow significantly quicker in 
routine culture compared with the U937PM cell line and therefore may need higher 
concentration of mevalonate or GGPP to prevent the effects of the statin. It would therefore 
be interesting to see if adding back a higher concentration of mevalonate or GGPP would 
completely prevent the effects of simvastatin on the C5aR expression in the U 9 3 7 C5aR cells. 
Interestingly the rate of cell proliferation was unaltered by incubation with 1 pM simvastatin in 
the U 9 3 7 C5aR cells unlike the U937PM cells which showed a slight reduction metabolic rate 
(figures 5.3.19 and 5.3.7).
As cell lines have their limitations, PBMCs were also incubated with simvastatin and 
other lipid lowering drugs and their effects on C5aR expression were monitored by flow 
cytometry. Results showed that incubation with simvastatin or lovastatin for 24 hrs had no 
effect on basal C5aR expression in CD14 positive cells (figures 5.3.22 and 5.3.23). These 
results were particularly disappointing as one of our hypothesis was that statins may exert 
anti-inflammatory effects via down regulation of the C5aR, as they have been previously 
shown to do for the chemokine receptors CCR2 and CCR5. However it was shown that 
incubation with fenofibrate reduced C5aR and CD14 expression in human primary monocyte 
(figure 5.3.25). This result is particularly interesting as fenofibrates can lower plasma 
triglycerides by increasing hepatic fatty acid uptake, reducing hepatic triglyceride 
biosynthesis and increasing clearance of VLDL. As previously described in sections 1.3.6 
and 5.1.2.2, the mechanism in which fenofibrates achieve this is via activation of a family of 
nuclear hormone receptors called PPARs, who can in turn regulate the transcriptional activity 
of genes whose proteins encode enzymes in fatty acid metabolism such as fatty acid 
synthase and acetyl-CoA caroxylase (Staels et al., 1998). Although statins have also been 
demonstrated to activate PPARa and PPARy which results in reduced IL-1f3 and TNFa 
expression (Inoue et al., 2000, Zhou and Liao, 2010), this result suggests that the C5aR 
expression may be regulated by fenofibrate via activation of PPARs through a mechanism 
that was not investigated in the U937PM and U937C5aR cell lines. Although these experiments 
use primary monocytes isolated from buffy coat from healthy individuals donating to the 
Welsh Blood Service they still have limitations as the plasma cholesterol levels are unknown 
in the donors. Ideally future experiments would involve measuring C5aR expression on 
monocytes isolated from patients with hypercholesterolemia and control volunteers, followed 
by lipid lowering drug therapy and then re-measuring C5aR expression once plasma 
cholesterol levels had been lowered.
As it was shown that simvastatin reduced the Bt2cAMP induced C5aR expression in
the U937pm cell line, it would be interesting to see if simvastatin would have any effect on
induced expression in primary monocytes using a more physiologically relevant stimulus,
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such as oxLDL, which is abundant within the atherosclerotic plaques. As previously 
discussed in Chapter 4 several physiological stimuli have been reported to increase C5aR 
expression, such as TNFa, IL-1 IL-6 and IFNy, unfortunately none of these stimuli had any 
effect on C5aR expression in the U937PM cell line, however it was not investigated whether 
they can induce C5aR expression in primary monocytes. It would also be interesting to 
investigate effects of statins or fenofibrate on C5aR expression in animal models which have 
shown altered receptor expression, such as the increased C5aR on infiltrating neutrophils 
following l/R injury (Arumugam et al., 2003, Proctor et al., 2004).
5.4.1 Summary
This chapter has found that incubation with simvastatin prevented the Bt2cAMP differentiation 
and up regulation of the C5aR in the U937PM cell line and this effect was mediated by 
inhibition of isoprenoid biosynthesis. However no effect could be detected on basal levels of 
C5aR expression. Investigations using the -2Kbp promoter reporter construct for the C5aR 
gene found that there was no cis-acting element within this region which was regulated by 
simvastatin. It was also shown that simvastatin and lovastatin had no effect on C5aR 
expression on primary monocytes in vitro, although fenofibrate significantly reduced it.
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Chapter 6
The effects of statins on C5aR function
6.1 Introduction
As previously described in Chapter 1 section 1.3, cholesterol is a crucial component of 
biological membranes. As well as being essential for maintaining membrane fluidity, 
cholesterol also has an important role in the formation of distinct cholesterol enriched 
microdomains, termed lipid rafts (Burger et al., 2000, Maxfield and Tabas, 2005). As GPCRs 
are commonly found localised in these cholesterol enriched lipid rafts or move into such 
regions following stimulation with their ligand (see table 1.4, Chapter 1); their function and 
expression can often be regulated by membrane cholesterol.
Chapter 5 has already investigated whether statins can regulate expression of the 
C5aR in the human monocytic cell line, as well as primary monocytes isolated from human 
peripheral blood. Chapter 5 has shown that incubation with simvastatin inhibited the 
Bt2cAMP induced expression of the C5aR in U937PM cells, and reduced C5aR expression in 
the stably transfected U 9 3 7 C5aR cell line. Further investigation of C5aR expression in primary 
monocytes found that ex-vivo statins did not alter C5aR expression in these cells. This 
chapter will investigate the effects of simvastatin on the biological functioning of the C5aR in 
PBMCs, as well as the monocytic cell lines U937PM and U 9 3 7 C5aR-
6.1.1 Could statins have a cholesterol dependent anti-inflammatory effect 
on the function of the C5aR
As previously described in Chapter 1, section 1.3, membrane cholesterol can regulate 
several GPCRs functions by; altering sub-membrane compartmentalisation into lipid rapid 
rafts; altering the structural properties of GPCRs or their signalling components; and 
regulating internalisation and intracellular trafficking of the receptors and necessary 
components. Summarised below are the mechanisms by which statins could potentially 
regulate C5aR function by regulating membrane cholesterol content.
The sub-compartmentalisation of signalling components into lipid raft or non-lipid raft 
regions of the membrane can act as an important regulatory mechanism for the signalling 
cascade (Lingwood and Simons, 2010). While cholesterol plays an important role in this 
compartmentalisation, relatively few studies have actually investigated what effect statins 
may have on the enrichment of receptors or other signalling components within these regions 
upon stimulation. Recently atorvastatin has been shown to impair the selective recruitment 
of TLR4 and IL-2 receptor p chain into lipid raft regions following stimulation with their
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respective ligands (Chansrichavala et al., 2010, Goebel et al., 2005). It has therefore been 
suggested that one of the anti-inflammatory properties of statins is their ability to alter raft 
enrichment of signalling components following stimulation with their ligands (Goebel et al., 
2005).
To date no data have been published to indicate whether the C5aR is located in a 
lipid raft region and what effect C5a binding has on its membrane localisation. As a large 
number of other GPCR have been shown to be localised into lipid raft regions and their 
location can vary depending on whether they have been stimulated by their ligand (see 
Chapter 1, table 1.4), it is quite possible that the C5aR could also reside in a lipid raft region 
or is recruited in or out of such regions following stimulation with C5a. In this case statins 
could for example exert their anti-inflammatory effect by altering the C5aR membrane 
enrichment, as is the case for TLR4 and IL-2 receptor p chain (Chansrichavala et al., 2010, 
Goebel et al., 2005).
As already discussed in section 1.3.1 polarisation of cell surface receptors and 
associated proteins towards the leading edge is a crucial feature in chemoattractant 
stimulated cells (Manes et al., 2001). For example, interaction of the FPR with its ligand 
causes receptor clustering and redistribution towards the leading edge, followed by 
chemotaxis towards the source. However depletion of membrane cholesterol using methyl- 
p-cyclodextrin (MpCD) prevents this clustering and redistribution of the fMLP receptor 
towards the leading edge (Xue et al., 2004, Bath et al., 1991, Dunzendorfer et al., 1997, 
Wolach et al., 1992). Furthermore a study by Dunzendorfer and co-workers showed that 
treatment of neutrophils and monocytes with the statin pravastatin significantly decreased 
chemotaxis triggered by fMLP (Dunzendorfer et al., 1997). However, to contradict these 
findings another study by Sitrin et al. has suggested that the fMLP receptor is not located in 
lipid rafts neither does it require intact rafts for its signalling capacity (Sitrin et al., 2006).
As previously described (section 1.3.1) evidence suggests that the C5aR is unlikely to 
form clusters at the membrane edge towards C5a. A study by Servant et al. found that the 
C5aR appeared to cluster at the plasma membrane towards the C5a source, however this 
was instead due to an increase in relative abundance of plasma membrane rather than 
preferential accumulation of the receptor at the leading edge (Servant et al., 1999). Despite 
this a study by Nagao and co-workers found that cholesterol loading of mouse macrophages 
J774A.1 cells with cholesterol MpCD led to a significant decrease in transmigration towards 
C5a suggesting that the chemotactic functioning of the receptor is sensitive to membrane 
cholesterol (Nagao et al., 2007). Although this study did not investigate whether cholesterol 
loading had any effect on the clustering/membrane compartmentalisation of the C5aR, 
instead it found that cholesterol loading reduced activation of Rho A, a GTP binding protein 
involved in downstream signalling of the C5aR (Nagao et al., 2007).
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As well as affecting sub-membrane compartmentalisation, membrane cholesterol can 
also affect the structural properties of the GPCRs or their signalling components (previously 
described in Chapter 1, section 1.3.2). GPCRs whos function can be regulated in such a 
manner are located within the lipid raft regions or move in or out of such regions following 
interaction with their ligand (Burger et al., 2000). To date little is known about the membrane 
localisation of the C5aR. This chapter will investigate whether the C5aR is localised in lipid 
raft regions of the plasma membrane or moves in or out of such regions following stimulation 
with C5a. From these findings we will be able to speculate whether the structural properties 
of the receptor will be affected either directly or indirectly by cholesterol.
Regulation of membrane cholesterol can also effect GPCR internalisation and 
intracellular trafficking (described in Chapter 1 section 1.3.4). Several studies have reported 
that C5a-C5aR interaction causes the receptor to cluster into clathrin coated pits where it is 
then internalised in a |3-arrestin, dynamin, and clathrin-dependent pathway (Gilbert et al., 
2001, Licht et al., 2003, Braun et al., 2003, Suvorova et al., 2005, Huttenrauch et al., 2005). 
To date no published studies have directly investigated whether the C5aR is located within 
the lipid raft region of the plasma membrane or whether it moves in or out of such regions 
following interaction with its ligand. Despite this lipid raft dependent endocytosis is 
characterised by clathrin-independence, which would therefore suggest that the C5aR is 
unlikely to be internalised in a lipid raft dependent manner; however it has not been 
investigated whether C5aR internalisation is dependent on cholesterol (Lajoie and Nabi, 
2010).
6.1.2 Could statins have a cholesterol independent anti-inflammatory 
effects on the functioning of the C5aR
Inhibition of the mevalonate pathway by statins does not exclusively inhibit cholesterol 
biosynthesis, but also reduces the synthesis of isoprenoid intermediates (see figure 1.8). 
These isoprenoid intermediates, FPP and GGPP, serve as important lipid attachments in the 
post-translational modification isoprenylation (Zhang and Casey, 1996). Proteins which 
undergo this modification include the y subunit of heterotrimeric G-proteins, heme-a, small 
GTP-binding proteins such as the Rho family members, and nuclear lamins (Liao and Laufs, 
2005). As small GTP-binding proteins serve as important signalling intermediates in a 
variety of signalling cascades, their inhibition by preventing isoprenylation has been identified 
as an important cholesterol independent effect of statins.
6.1.2.1 Isoprenylation of small GTP-binding proteins
GTP-binding proteins are involved in a variety of signalling pathways which regulate cell 
growth, proliferation, shape and motility, membrane trafficking and transcriptional control
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(Van Aelst and D'Souza-Schorey, 1997, Mackay and Hall, 1998, Jasinska et al., 2007). 
They can exist in an active GTP-bound form where they are found associated to the plasma 
membrane or an inactive GDP-bound form present in the cytoplasm. Isoprenylation of the 
GTP-binding proteins allows the translocation of the inactive form to the plasma membrane 
where it can then become active (Liao and Laufs, 2005). Statins can therefore lead to the 
accumulation of inactive GTP-binding proteins within the cytoplasm. Summarised in Table
6.2 is the pleiotropic effects of statins caused by inhibition of isoprenylation of GTP-binding.
Stimulation of the C5aR with C5a results in the activation of Cdc42, Rac and Rho G 
GTP-binding proteins (see section 1.2.6 for full details). It is believed that chemotaxis of 
leukocytes towards C5a is in part mediated by the activation Cdc42, which in turn activates 
the MAP-kinase signalling pathway (Li et al., 2003, Tardif et al., 2003). It has also been 
suggested that activation of Rac may have a role in mediating leukocyte functions such as 
chemotaxis, phagocytosis and respiratory burst upon stimulation of C5a (Welch et al., 
2002a). Condliffe et al. have also shown that Rho G knockout mice have an impaired 
respiratory burst in response to C5a (Condliffe et al., 2006). Furthermore the HL-60 cell line 
has shown an impaired respiratory burst in response to fMLP in the presence of mevastatin 
which was attributed to the inhibition of isoprenylation of small GTP binding proteins (Bokoch 
and Prossnitz, 1992). As the C5aR signalling cascade involves the activation of numerous 
GTP-binding proteins which are important for the biological functioning of the C5aR it is 
possible that inhibition of isoprenylation by statins may have a direct effect on the signalling 
capacity of these intermediate proteins however to date no studies have investigated this.
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Table 6.2 Pleiotropic effects of statins by inhibition of isoprenylation of small GTP-binding 
proteins
GTP-binding protein Pleiotropic effects
Rho A • Improve endothelial function by increasing the stability of eNOS 
mRNA (Laufs et al., 1998, Laufs and Liao, 1998).
•  Reduces vascular smooth muscle cell proliferation by inhibition 
of the Rho/Rho-kinase signalling pathway (Yang et al., 2000, 
Laufs et al., 1999).
•  Reduces monocyte adherence to endothelial cells by reducing 
integrin expression in vitro (Kawakami et al., 2002, Hiraoka et al., 
2004).
•  Reduces cardiac hypertrophy by reducing myocardial expression 
of atrial natriuretic factor, fetal gene, and myosin light chain-2, 
contractile element (Laufs et al., 2002).
•  Improves plaque stability by inhibiting Rho dependent 
expression of MMPs (Turner et al., 2005, Massaro et al., 2010).
Rac 1 •  Reduces cardiac hypertrophy by inhibiting myocardial oxidative 
stress caused by Rac NADPH oxidase activity (Takemoto et al., 
2001, Zhou and Liao, 2010, Nakagami et al., 2003).
•  Reduces cardiac hypertrophy by reducing myocardial expression 
of atrial natriuretic factor, fetal gene, and myosin light chain-2, 
contractile element (Laufs et al., 2002).
Ras • Reduces oxidised LDL induced macrophage proliferation 
(Senokuchi et al., 2005).
6.1.3 Monitoring the biological functions of the C5aR
Stimulation of the C5aR with C5a can elicit a broad range of biological functions depending 
on which cell type is being stimulated (see section 1.2.1 for full details). As this chapter is 
investigating the effects of statins on the functioning of the C5aR in primary monocytes and 
the monocytic U937 cell lines, below will discuss in detail the experimental techniques that 
will be used to monitor the biological functions in these cells. This chapter will also 
investigate the C5a induced Ca2+ release which has already been described in 4.1.2.3.
6.1.3.2 F-actin assembly
C5a is a potent chemoattractant for leukocytes. Following stimulation of the C5aR, GTP- 
binding proteins, Rac 1 and Cdc42, become activated by the exchange of GDP to GTP 
(Welch et al., 2002b, Tardif et al., 2003). The activation of both these GTP-binding proteins 
results in the stimulation of scaffold proteins, SCAR/WAVE and WASP respectively, which 
relay the signal from Rac/Cdc42 to the actin nucleation machinery, Arp2/3 (Affolter and 
Weijer, 2005, Charest and Firtel, 2007, Bi and Zigmond, 1999). The Arp2/3 complex is 
crucial for actin polymerisation, which is responsible for the formation of membrane 
protrusion during cell migration (Insall and Machesky, 2009). The Arp2/3 complex binds to 
existing actin filaments and allows the nucleation and elongation of new actin filaments,
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filamentous actin (F-actin), by the addition of monomeric soluble actin, G-actin (Insall and 
Machesky, 2009).
Chemotaxis can be measured directly using techniques such as the Boyden 
chamber, which is composed of two medium-filled compartments separated by a 
microporous membrane. The cells can then migrate from the upper chamber through the 
membrane to the lower chamber which contains the chemoattractant (Chen, 2005). 
Chemotaxis can also be measured in agar plate assay where the cells are placed in one 
groove in the agarose and the chemoattractant is then placed in another and the cells then 
migrate through the agarose towards the chemoattractant source (Laevsky and Knecht,
2001).
An alternative to measuring chemotaxis directly are studies which measure the 
formation of F-actin as an indication of chemotactic activity. The monocytic cell line U937 
has previously been shown to increase F-actin assembly following stimulation with C5a using 
phalloidin binding, a bicyclic peptide isolated from poisonous mushrooms (Banks et al., 
1988). Phalloidin has been conjugated to numerous Alexa Fluor dyes which allows its rapid 
and sensitive detection by Flow Cytometry.
6.1.3.3 MMP secretion
The excess secretion of matrix metalloproteinases (MMPs) during late stages of 
atherosclerosis can degrade the fibrous cap surrounding the lesion, leading to plaque rupture 
and clinical events such as myocardial infraction or ischaemic stroke (Newby, 2007). 
Stimulation of neutrophils and eosinophils with C5a has previously been shown to induce 
MMP secretion, mainly MMP-1 and MMP-9 (DiScipio et al., 2006, Takafuji et al., 2003). 
More recently C5a has also been shown to induce MMP-1 and MMP-9 in human monocyte 
derived macrophages (Speidl et al., 2011). Secretion of MMPs from these cells is necessary 
for the transmigration of the cells towards the source of C5a (DiScipio et al., 2006). It has 
been shown that the secretion and activation of the proMMP to active MMP is dependent on 
the respiratory burst as inhibition of NADPH oxidase and nitric oxide synthase, by DPI and L- 
NIL respectively, abrogated C5a-mediated chemotaxis through basement membranes 
(DiScipio et al., 2006).
There are numerous ways to investigate MMP secretion, however the simplest and 
most traditional technique is zymography (Heussen and Dowdle, 1980). For MMPs 
belonging to the gelatinase family, MMP-2 and MMP-9, SDS-PAGE is carried out using 
gelatin impregnated gel. Samples are run in the same way as a standard SDS-PAGE under 
Laemlli non heat denaturing and non-reducing conditions, which allows the separation of 
proteins based on their molecular weight. Following electrophoresis the gel is washed to 
remove remaining SDS which allows the proteins to refold. The incubation of the gel
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overnight at 37°C in a calcium containing zymography buffer allows the enzymatic activity of 
the MMPs to digest the gelatin within the gel. Staining of the gel with Coomassie Brilliant 
Blue R then allows the visualisation of the bands. This technique also allows the 
quantification and identification of the proforms as the process of denaturation and 
renaturation following electrophoresis causes the activation of the proforms, however these 
will have a higher molecular weight than the secreted active forms (Heussen and Dowdle, 
1980). Although ELISAs have also been developed to quantify and discriminate between 
different MMPs they are much more expensive than zymography (Zucker et al., 1992).
6.1.3.5 Cytokine secretion
C5a stimulation of leukocytes can cause an increased secretion of a number of pro- 
inflammatory cytokines including IL-1, IL-6, IL-8, TNFa and MCP-1 (Goodman et al., 1982, 
Okusawa et al., 1988, Scholz et al., 1990, Vecchiarelli et al., 1998, Ember et al., 1994, Izumi 
et al., 1997). Of particular interest to this project is the chemotactic cytokines, chemokines 
IL-8 and MCP-1, as both have been implicated in atherosclerosis (see section 1.3.1 for full 
details) (Apostolakis et al., 2009, Weber et al., 2004, Barlic and Murphy, 2007). The most 
common method for measuring cytokine secretion is ELISAs, as they are sensitive and fairly 
easy to perform.
6.1.4 Methods for determining membrane localisation and cholesterol 
dependency
Several techniques are commonly used to investigate the sub-membrane 
compartmentalisation and cholesterol dependency of membrane proteins. Traditionally 
techniques involve indirect methods, such as cold detergent or mechanical extraction of lipid 
rafts or cholesterol depletion by cyclodextrins. These techniques, however, have an 
undesired disruptive nature, which can in turn induce artefacts (Lingwood and Simons, 
2010). Despite this they are still commonly used to suggest lateral heterogeneity of 
membrane proteins and a dependency of cholesterol (Coskun and Simons, 2010). Recent 
advances in microscopy and spectroscopy techniques, such as single particle tracking and 
fluorescence resonance energy transfer, are now offering a more dynamic and physiological 
relevant approach to visualising membrane proteins and lipids (reviewed by (Lingwood and 
Simons, 2010). However as this study will use detergent extraction and cyclodextrins (CD) 
to assess membrane localisation and function of cholesterol on C5aR, only these techniques 
will be discussed in more detail below.
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6.1.4.1 Detergent extraction of lipid rafts
Although it was known in the 1970s that different membrane proteins had different resistance 
towards detergents, it wasn’t until Brown and Rose found that newly synthesised GPI- 
anchored proteins are sorted into these detergent insoluble fractions that the important 
application of these sphingolipid-cholesterol enriched fractions was realised (Yu et al., 1973, 
Brown and Rose, 1992). Following selective solubilisation of cellular membranes with Triton 
X-100 at 4°C, sphingolipid-cholesterol rafts remain insoluble and sucrose gradient 
centrifugation allows the separation of denser detergent soluble fractions from the lighter 
detergent insoluble fractions. Both the temperature and the type of detergent used during 
the extraction can greatly influence the lipid composition of the fractions collected (Brown 
and Rose, 1992). Once fractions are collected they can then be probed for proteins of 
interest by performing a standard SDS-PAGE followed by transfer to nitrocellulose 
membrane and western blotting using antibodies raised against the protein of interest.
6.1.4.2 Cholesterol depletion by cyclodextrins
CD are water soluble cyclic oligosaccharides which can encapsulate various hydrophobic 
molecules via their hydrophobic cavity (Zidovetzki and Levitan, 2007). p-CDs are efficient in 
extracting membrane cholesterol and the degree of cholesterol depletion is dependent on the 
concentration, incubation time, temperature and the type of cells (Irie et al., 1992). Although 
cholesterol is removed faster from lipid raft regions, it is also important to note that they can 
also remove cholesterol from non-lipid raft regions albeit a little more slowly (Zidovetzki and 
Levitan, 2007). It is therefore possible to selectively remove cholesterol from lipid raft 
regions alone under the correct conditions. However, experiments that completely remove 
cholesterol are non-physiological and can only hint towards a functional effect as removing 
cholesterol may have pleiotropic effects (Maxfield and Tabas, 2005). As well as removing 
cholesterol from the membrane p-CDs can also donate cholesterol to the membrane and 
increase cholesterol levels. Experiments involving p-CD, however, need to be approached 
with caution as they have been shown to interact with membrane phospholipids and 
hydrophobic amino acids of membrane proteins (Zidovetzki and Levitan, 2007).
6.1.5 Hypothesis and aims
As previous studies have shown a role of cholesterol on GPCR functioning by either 
influencing the membrane compartmentalisation into lipid rafts, or the structural properties of 
the receptor or its internalisation (see above), our hypothesis is that cell activation after 
interaction of the C5aR with its ligand C5a is dependent on association of the receptor within 
cholesterol rich lipid rafts. Furthermore, it is hypothesised that statins may negatively
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regulate the functioning of the C5aR either by reducing membrane cholesterol levels or by 
inhibiting the isoprenylation of small GTP-binding proteins, which are important in 
downstream signalling cascade.
The aims for this chapter are:
•  To investigate whether statins have cholesterol dependent or independent effects on the 
biological functioning of the C5aR by using techniques as discussed above.
•  To determine whether the C5aR is localised within a lipid raft region of the plasma 
membrane or is recruited in or out of such regions following stimulation with C5a.
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6.2 Materials and methods
6.2.1 Reagents
Alexa Fluor 488 phalloidin (A12379) was purchased from Invitrogen. Commercial IL-8 ELISA 
kit (Biosource International, CHC1303) was from purchased from Invitrogen. MCP-1 ELISA 
kit was purchased from R&D systems. All other chemicals and reagents were as described 
in section 2.1.
6.2.2 Cell culture
Both U937pm and U 9 3 7 C5aR cell lines were maintained in complete RPMI media as previously 
described in section 2.3.1. Unless otherwise stated cells were seeded at 2.5 x105 cell/ml and 
incubated for 48 hrs with appropriate stimuli prior to analysis (section 2.3.5). PBMCs isolated 
as previously described in sections 2.3.2, were seeded at 1 x106 cell/ml for 24 hr with the 
appropriate stimuli (section 2.3.5).
6.2.3 Antibodies
Primary antibodies used were monoclonal anti-CD59 (Bric229, obtained from International 
Blood Group Reference Laboratory IBGRL, Elstree, UK) and polyclonal rabbit anti-C5aR (H- 
100 from SantaCruz) for western blotting of sucrose gradient fractions. Secondary antibodies 
were as described in section 2.1.3.
6.2.4 Ca2+ signalling
Intracellular Ca2+ was measured using Fura-2-AM as previously described in section 2.3.8. 
For samples which were treated with either MpCD or ChMpCD, prior to adding Fura-2-AM 
MpCD (40 mM made up fresh everyday in RPMI) or ChMpCD were added to the cells (1 x 
107 cell/ml) at final concentration of 10 mM. Fura-2-AM was added as normal and the cells 
were incubated for 30 min at RT. After washing, the cells were resuspended at 1 x107 cell/ml 
in Krebs buffer as described in section 2.3.8.
6.2.5 Measuring F-actin assembly
Cells were harvested and resuspended at 1 x 107 cell/ml in PBS unless otherwise stated. 
200 pi of cells were stimulated with 10 pi C5a (final concentration 5 nM) for 5 min at RT. The 
F-actin content was determined by addition of 200 pi of cell lysis buffer and staining solution 
(containing 0.33 pM phallodin-AI488, 70 pg/ml lysophosphatidylcholine (LPC) and 0.5 % 
paraformaldehyde). After 20 minute incubation at RT, the cells were centrifuged for 5 min at
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2,000 rpm. The cells were washed with 500 pi of PBS and centrifuged again. The cells were 
then resuspended in 200 pi FACS buffer and then cell fluorescence was measured 
immediately using flow cytometry.
6.2.6 Gelatin zymography
Prior to gelatin zymography cells were washed and incubated o/n in RPMI media (containing 
100 U/ml penicillin, 100 pg/ml streptomycin, 290 pg/ml L-glutamine and 1 mM sodium 
pyruvate) in the absence of FCS. Cells (2 x 105 cell/ml) were then incubated in the absence 
or presence of C5a (5 nM), for 24 hrs. The s/n was harvested by centrifugation for 3 min at 
1,200 rpm and stored at -20 °C until analysis. The s/n was mixed with an equal volume of 
protein sample buffer and 20 pi of sample was loaded onto a 12.5 % SDS-PAGE containing 
1 mg/ml gelatine (from bovine skin, Sigma). Following electrophoresis (as described in 
section 2.3.7), the gel was washed twice with 0.1 % Triton-X100 for approximately 30 min to 
remove the SDS. The gel was incubated in zymography buffer (containing 50 mM Tris, 10 
mM CaCI2, and 0.05 % Brij35 (v/v) in dH20 , pH8.2) o/n at 37°C.
The gel was washed twice in dH20  to remove detergent and then stained using 
coomassie brilliant blue. Once excess SDS had been removed, the gel was incubated for 
approximately 3 hrs with gentle agitation (Red Rocker, Hoefer) with coomassie staining 
solution (40 % (v/v) methanol, 10 % (v/v) acetic acid, 0.1 % (w/v) coomassie brilliant blue 
(CBB) in dH20 .). The gel was destained (40 % (v/v) methanol, 10 % (v/v) acetic acid in 
dH20 )  until the correct contrast had been achieved. Clear bands on a blue background are 
an indication of gelatinase activity. For presentation purposes, the gels were inverted so 
bands appear dark on a light background. Densitometry of bands was performed using Bio- 
Rad GS-710 scanner and software. Results were normalised by calculating OD/mm2 for 
each treatment, minus or plus C5a, as a percentage compared to the control minus C5a.
6.2.7 IL-8 and MCP-1 ELISA
IL-8 secretion from culture fluid s/n (as described in 6.2.2) was quantified using a commercial 
kit (Invitrogen) according to the manufacturer’s instructions. 96 well ELISA microtitre plates 
were coated o/n at 4 °C with 50 pl/well anti-IL-8 antibody (58.130.09, 1 pg/ml diluted in PBS). 
For MCP-1 quantification, the 96 well ELISA microtitre plates were coated o/n at 4 °C with 50 
pl/well of capture polyclonal anti-MCP-1 (R&D systems; MAB679, 1 pg/ml diluted in PBS). 
Wells were washed four times with 200 pi PBS/Tween20 (0.1 %) and blocked with 200 
pl/well 0.5 % BSA in PBS for 2 hr at 37°C. The wells were washed four times with 
PBS/Tween20 (0.1%) and 50 pl/well of sample and standard was added. For the IL-8 ELISA 
recombinant human IL-8 standards (58.130.10, diluted in 0.5 % BSA in PBS), ranging from
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12.5 to 800 pg/ml was used. For the MCP-1 ELISA, standards ranged from 10 pg/ml to 1 
ng/ml, were diluted in 0.5 % BSA in PBS. The microtitre plate was incubated at RT for 1 hr 
and was washed again with PBS/Tween20. For IL-8 ELISA, 50 pi of biotinylated anti-IL-8 
antibody (58.130.03, 0.4 pg/ml in 0.5 % BSA in PBS) was added and incubated at RT for 1 
hr. For MCP-1 ELISA 50 pi of 50 ng/ml biotinylated anti-MCP-1 antibody was added to each 
well. After washing the plate, 50 pi of streptavidin-HRPO (41.000.03, diluted 1 in 2500 in 0.5 
% BSA in PBS) was added to each well and incubated for 30 min at RT. Wells were again 
washed four times with PBS/Tween20 after which 50 pi of substrate was added (OPD kit 
Dako; 1 tablet plus dH20  with 5 pi H20 2). Reaction was stopped after 2-4 min with 50 pi of 1 
M H2S 0 4 and the absorbance of samples was read at 492 nm.
6.2.8 Sucrose gradient floatation
To determine the subcellular localisation of the C5aR, U 9 3 7 C5aR cells (7  x 106 cell/ml) were 
harvested and mixed with either U 9 3 7 C d 59-g p i  or U 9 3 7 Cd 59-t m  ( 3  x  103 cell/ml). The U 9 3 7 Cd 59- 
g p i cells have been previously transfected with the GPI anchored CD59 which is present 
within lipid raft regions of the plasma membrane (Powell et al., 1997). Conversely the 
U 9 3 7 Cd 59-t m  cells have been previously transfected with the CD59 chimera with the 
transmembrane region of MCP which is localised within non-lipid raft regions of the plasma 
membrane (Van Den Berg et al., 2002). Therefore these cells can allow the plasma 
membrane localisation of the C5aR to be determined by monitoring its co-localisation with 
either U 9 3 7 Cd 59-g p i , a  marker for lipid rafts, or U 9 3 7 Cd 59-t m , a marker for non-lipid raft regions.
Sucrose gradient floatation was performed as previously described (Hiscox et al.,
2002). Either U937PM differentiated with Bt2cAMP or U 9 3 7 C5aR cell were cultured as 
described in section 6.2.2. Once harvested the cells were washed twice in PBS and 
resuspended in ice-cold sucrose gradient cell lysis buffer (20 mM Tris, 2 mM EDTA, 140 mM 
NaCI, pH 8.2) containing 40 % sucrose and 1 % Brij58. The lysate (1 ml) was loaded on the 
bottom of a 5 ml ultra-clear centrifuge tube. The lysis buffer (3.5 ml) containing 30 % sucrose 
and 1 % Brij58 was overlaid followed by 0.8 ml 1 % Brij58 in lysis buffer. Lysates were spun 
in a Beckmann SW55Ti swing-out rotor for 16 hr at 200,000g, 4°C. Fractions (0.5 ml) were 
collected starting from the top of the gradient. Samples were then separated on a 12.5 % 
SDS-PAGE gel under non-reducing conditions, as previously described in section 2.3.7. 
Western blotting of nitrocellulose membrane was performed using anti-CD59 (Bric229) and 
anti-C5aR (H-100), as previously described in section 2.3.7.2.
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6.2.9 Propidium iodide exclusion assay
To monitor changes in cell viability propidium iodide cell exclusion assays were 
performed as previous described in section 2.3.9.
208
6.3 Results
The aims of this chapter were to investigate whether statins had any cholesterol dependent 
or independent effects on functioning of the C5aR and to determine whether C5aR is 
localised within a lipid raft region of the plasma membrane or is recruited in or out of such 
regions following stimulation with C5a. C5aR function was monitored in the U 9 3 7 PM cell line 
differentiated with Bt2cAMP, the U 9 3 7 C5aR cell line, which has been previously transfected 
with the C5aR and therefore do not need stimulating to induce receptor expression, and in 
human PBMCs. The effects of lipid altering stimuli on the biological functions of the C5aR 
were investigated by detecting changes in C5a induced Ca2+ release, F-actin assembly, 
MMP production and cytokine production (IL-8 and MCP-1).
6.3.1. C5a induced Ca2+ release
Binding of C5a to the C5aR causes a rise in intracellular Ca2+ concentration via the activation 
of PLCp2 (Jiang et al 1996). Intracellular Ca2+ concentrations following stimulation with C5a 
can easily be measured using the ratiometric Ca2+ indicator Fura-2-AM. Following incubation 
with simvastatin, cells were loaded with Fura-2-AM and the effects of simvastatin on C5a 
induced Ca2+ release was measured using the FluorStar plate reader.
6.3.1.11ncubation of undifferentiated U937PM with 1 juM simvastatin reduces C5a induced Ca2* 
release
The effects of simvastatin on C5a induced Ca2+ release was first investigated in 
undifferentiated U937PM cells. Although these cells had very little C5aR expression, as 
detected by FACS (Chapter 5, section 5.3.1), the cells still released some Ca2+ following 
stimulation with 5 nM C5a (figure 6.3.1). This concentration of C5a was chosen as it was 
shown in Chapter 4 to induce an intracellular Ca2+ release; furthermore this is the highest 
physiologically achievable C5a concentration (Guo and Ward, 2006). Figure 6.3.1 also 
shows that incubation with 1 |liM simvastatin significantly reduced the C5a induced Ca2+ 
release when compared with the control. However treatment with MpCD, a cholesterol 
chelator, had no effect on C5a induced Ca2+ release which suggests that the effect of 1 pM 
simvastatin is unlikely to be due to its cholesterol lowering ability (figure 6.3.1). Loading the 
cells with cholesterol, using ChMpCD prior to Ca2+ signalling experiments, showed a 
significant decrease in C5a induced Ca2+ release when compared with the control. However, 
as shown in figure 6.3.2, incubation with ChMpCD caused a significant increase in cell death 
which suggests that the decrease in C5a induced Ca2+ could be due to its cytotoxicity rather 
than cholesterol loading (figures 6.3.1 and 6.3.2). Adding back both mevalonate and GGPP
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restored the C5a induced Ca2+ release which was reduced by incubation with 1uM 
simvastatin, however, this was not statistically significant, p = 0.0551 (figure 6.3.3).
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Figure 6.3.1 Incubation with 1 jliM simvastatin reduces C5a induced Ca2+ release in 
the U937pm cell line. Cells were incubated for 2 days in the absence or presence of simvastatin. 
Cells were harvested and loaded with Fura-2-AM. As a control for cholesterol depletion cells were 
incubated with 10 mM MpCD, cholesterol chelator during Fura-2-AM loading or loaded with excess
cholesterol using 10 mM ChMpCD. (A) Average maximum Ca2+ release following stimulation with 5 
nM C5a from 3 separate experiments carried out in duplicate. One-way ANOVA followed by Dunnett’s 
multiple comparison test compared significance to the control *p <0.05, **p <0.01. (B) Ca2+ release 
trace following the addition of 5 nM C5a, as indicated by arrow, from one representative experiment.
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Figure 6.3.2 Cholesterol loading with ChMpCD significantly decreased cell viability in 
U937pm cell line. Cells were incubated either with simvastatin for 2 days or with 10 mM MpCD or 10 
mM ChMpCD for 30 min at RT to staining with 0.5 pg/ml of propidium iodide. Percentage viability was 
then determined by flow cytometry. Shown is average of 3 experiments +/- SEM. One-way ANOVA 
followed by Dunnett’s multiple comparison test compared significance to the control **= p <0.01.
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Figure 6.3.3 Effects of adding back mevalonate and GGPP on C5a induced Ca2+ 
release. U937PM cells were incubated for 2 days in the absence or presence of 1uM simvastatin plus 
50uM mevalonate or 10uM GGPP. Cells were harvested and loaded with Fura-2-AM. (A) Average
maximum Ca2+ release following stimulation with 5 nM C5a from 3 separate experiments. One-way
ANOVA showed no significant difference (p = 0.0551). (B) Ca2+ release trace following the addition of 
5 nM C5a, as indicated by arrow, from one representative experiment.
6.3.1.2 Incubation of Bt2cAMP differentiated U937PM with 1 fjM simvastatin reduces C5a induced 
Ca2* release
As undifferentiated U937PM expressed very little C5aR and the C5a induced Ca2+ release 
was quite small (see Chapter 4 for details), the cells were differentiated with Bt2cAMP to 
induce C5aR expression for 2 days in the absence or presence of simvastatin and the C5a 
induced Ca2+ release was assessed using Fura-2-AM.
As previously shown in section 4.3.1 incubation of U937PM with Bt2cAMP significantly 
increased C5a induced Ca2+ release when compared with the control. Incubation of U937PM 
with 0.5 mM Bt2cAMP and 0.1 pM simvastatin had no effect on C5a induced Ca2+ release 
(figure 6.3.4). However, incubation with 0.5 mM Bt2cAMP and 1 pM simvastatin caused a 
significant decrease in C5a induced Ca2+ release in the U937PM cell line (figure 6.3.4). 
Cholesterol loading with ChMpCD also significantly reduced C5a induced Ca2+ release of 
Bt2cAMP treated U937PM cells, however, this is likely due to its cytotoxicity (figures 6.3.4 and 
6.3.2). Figure 6.3.4 also shows that incubation of Bt2cAMP treated U937PM cells with MpCD 
during Fura-2-AM loading showed a slight decrease in C5a induced Ca2+ release although 
this was not significantly different from the Bt2cAMP alone.
To further investigate the effect of 1 pM simvastatin on C5a induced Ca2+ release in 
Bt2cAMP differentiated U937PM, these experiments were performed in the presence of either 
50 pM mevalonate or 10 pM GGPP. The addition of mevalonate, but not GGPP, prevented 
the reduction of 1 pM simvastatin on the C5a induced Ca2+ release (figure 6.3.5). This would 
suggest that the effects seen here by simvastatin are due to inhibition of cholesterol 
synthesis rather than isoprenoid synthesis, which is opposite to the results seen when 
looking at changes in Bt2cAMP induced C5aR expression. To investigate if mevalonate or 
GGPP had an effect on C5a induced Ca2+ release, U937PM cells were incubated with 
Bt2cAMP and either 50 pM mevalonate or 10 pM GGPP and changes in Ca2+ release were 
measured. Figure 6.3.6 shows that neither mevalonate nor GGPP had an effect on C5a 
induced Ca2+ release when co-incubated with Bt2cAMP.
To confirm that the effects of 1 pM simvastatin were due to its inhibition of cholesterol 
synthesis rather than isoprenoid synthesis, U937Pm cells were incubated with 0.5mM 
Bt2cAMP and increasing concentrations of zaragozic acid, the squalene synthase inhibitor 
(see figure 1.8). Figure 6.3.7 shows that zaragozic acid had no effect on C5a induced Ca2+ 
release in Bt2cAMP differentiated U937PM cells. This suggest that cholesterol synthesis plays 
no role in the C5a induced Ca2+ release, which contradicts the results observed by adding 
back mevalonate and GGPP as described above.
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Figure 6.3.4 Incubation of U937PM with Bt2cAMP plus 1 pM simvastatin significantly 
decreases C5a induced Ca2+ release in U937PM cell line. Cells were incubated for 2 days with 
0.5 mM Bt2cAMP in the absence or presence of simvastatin. Cells were harvested and loaded with 
Fura-2-AM. As a control for cholesterol depletion cells were incubated with MpCD, cholesterol 
chelator, during Fura-2-AM loading or loaded with excess cholesterol using ChMpCD. (A) Average 
maximum Ca2+ release following stimulation with 5 nM C5a from 3 separate experiments. One-way 
ANOVA followed by Dunnett’s multiple comparison test compared significance to the Bt2cAMP only 
treated cells *p <0.05, **p <0.01. (B) Ca2+ release trace following the addition of 5 nM C5a, as 
indicated by arrow, from one representative experiment.
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Figure 6.3.5 Adding back mevalonate but not GGPP restores C5a induced Ca2+ release 
in 0.5mM Bt2cAMP plus 1 pM simvastatin differentiated U937PM cells. Cells were incubated 
for 2 days with 0.5 mM Bt2cAMP plus 1 pM simvastatin in the absence or presence of either 50 pM 
mevalonate or 10 pM GGPP. Cells were harvested and loaded with Fura-2-AM. (A) Average 
maximum Ca2+ release following stimulation with 5 nM C5a from 3 separate experiments. One-way 
ANOVA followed by Dunnett’s multiple comparison test compared significance to the Bt2cAMP plus 
simvastatin treated cells *p <0.05, **p <0.01. (B) Ca2+ release trace following the addition of 5 nM 
C5a, as indicated by arrow, from one representative experiment.
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Figure 6.3.6 Incubation with mevalonate or GGPP in the absence of simvastatin had no 
effect on C5a induced Ca2+ release in 0.5mM Bt2cAMP differentiated U937PM cells. Cells 
were incubated for 2 days with 0.5 mM Bt2cAMP in the absence or presence of either 50 pM 
mevalonate or 10 pM GGPP. Cells were harvested and loaded with Fura-2-AM. (A) Average 
maximum Ca2+ release following stimulation with 5 nM C5a from 3 separate experiments. (B) Ca2+ 
release trace following the addition of 5 nM C5a, as indicated by arrow, from one representative 
experiment.
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Figure 6.3.7 Zaragozic acid has no effect on C5a induced Ca2+ release in 0.5mM 
Bt2cAMP differentiated U937PM cells. Cells were incubated for 2 days with 0.5 mM Bt2cAMP in 
the absence or presence of zaragozic acid. Cells were harvested and loaded with Fura-2-AM. (A)
Average maximum Ca release following stimulation with 5 nM C5a from 3 separate experiments. (B) 
Ca2+ release trace following the addition of 5 nM C5a, as indicated by arrow, from one representative 
experiment.
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6.3.1.3 Simvastatin has no effect on C5a induced Ca2+ release in U937CsaR cell line
To investigate whether simvastatin had any effect on C5a induced Ca2+ release in the 
U937csaR once harvested, these cells were incubated with 1 pM Fura-2-AM and the C5a 
induced Ca2+ release was monitored. Results in figure 6.3.8 show that incubation with 
increasing concentration of simvastatin had no significant effect on the C5a induced Ca2+ 
release in this U 9 3 7 C5aR cell line (figure 6.3.8). At 50 nM C5a there was a significant 
difference between the control cells and cells incubated with the cholesterol chelator, MpCD 
(figure 6.3.8A).
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Figure 6.3.8 Simvastatin has no effect on C5a induced Ca2+ release in the U 9 3 7 C5aR cell 
line. Cells were incubated for 2 days in the absence or presence of simvastatin. Cells were 
harvested and loaded with 1 pM Fura-2-AM. As a control for cholesterol depletion cells were 
incubated with 10 mM MpCD during Fura-2-AM incubation. (A) Maximum Ca2+ following stimulation 
with various concentrations of C5a. Results expressed as mean Ca2+ release from 4 separate 
experiments. One-way ANOVA followed by Dunnett’s multiple comparison test compared significance 
from the control at each separate C5a concentration; *p <0.05. (B) Ca2+ release trace following the 
addition of 50 nM C5a, as indicated by the arrow, from one representative experiment.
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218
6 .3 .2  C 5a  in d u c e s  F -ac tin  a s s e m b ly  in h u m an  n eu tro p h ils  but not in 
U937pM o r U 9 3 7 C5aR c e lls
As previously described, C5a is a potent chemoattractant for leukocytes. Filamentous actin 
(F-actin) plays a central role in cell motility by forming the meshed framework for the 
protruding lamellipodia towards a chemotactic source (Small et al., 1999). Using Phalloidin- 
488, which binds tightly to actin filaments, allows changes in F-actin assembly to be easily 
detected by flow cytometry (see section 6.1.3.2).
Bt2cAMP differentiated U937PM have previously been shown to increase F-actin 
following the addition of C5a, (Banks et al., 1988, Monk and Banks, 1991). In our 
experiments, however, the U937PM cells were unresponsive to C5a while the freshly isolated 
human neutrophils exhibited a dramatic increase in their F-actin staining (figure 6.3.9). 
Similarly when U 9 3 7 C5aR cells were stimulated with C5a no changes were observed in the F- 
actin assembly (figure 6.3.10).
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Figure 6.3.9 Flow cytometry staining of F-actin assembly following addition of C5a in 
presence of PBS. U937PM cells were incubated for 2 days in the absence or presence of 0.5 m M  
Bt2cAMP. Cells were harvested and incubated in the absence or presence of C5a for 5 min. 
Following incubation with C5a the cells were incubated with F-actin staining solution, containing 0.33 
pM phalloidin-AI488 and 70ug/ml LPC for 20 min. Cells were washed and F-actin assembly was 
detected by flow cytometry.
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Figure 6 . 3 . 1 0  F-actin assembly in the U 9 7 3 C5aR cell line. U937c5aR cells and freshly isolated 
human neutrophils were incubated in the absence or presence or 5 nM C5a for 5 min. The cells were 
incubated with F-actin staining solution containing; 0.33 pM Phalloidin-AI488, 70 pg/ml LPC and 1 % 
paraformaldehyde, for 20 min. Cells were washed and F-actin assembly was detected by flow 
cytometry.
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6.3.3 Effects of simvastatin on C5a induced MMP secretion
MMPs are capable of degrading components of the extracellular matrix, such as collagen, 
proteoglycans and elastin. C5a has been shown to cause release of MMP-1 and MMP-9 
from neutrophils and eosinophils (Takafuji et al., 2003). The U937 cell line has been well 
documented in the literature for expressing different MMPs (Sundararaj et al., 2008, Yue et 
al., 2009, Liu and Chang, 2010), yet to our knowledge no one has investigated the effects of 
C5a on MMP secretion in these cells. Here the effect of simvastatin on C5a induced MMP 
secretion was investigated in both the U937PM and U937C5aR cell line using gelatin 
zymography.
6.3.3.1 Simvastatin increased C5a induced MMP-9 secretion in Bt2cAMP differentiated U937PM 
cell line
Gelatin zymography of culture supernatant from U937PM cell line showed that these cells 
mainly secrete MMP-2 and that the addition of C5a did not change the amount being 
secreted (figure 6.3.11). It was also shown that incubation of the U937PM cells with 
increasing concentration of simvastatin had no effect on this MMP-2 secretion (figure 6.3.11).
However, stimulation of the U937PM cells with Bt2cAMP caused the cells also to 
secrete MMP-9 (figure 6.3.12.A). Furthermore, the MMP-9 secretion was increased by the 
addition of C5a, whereas, MMP-2 secretion remained unchanged (figure 6.3.12 B and 6.3.12 
C). Surprisingly, incubation with simvastatin significantly increased the C5a induced MMP-9 
secretion, while it did not affect basal levels of MMPs (figure 6.3.12 B).
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Figure 6.3.11 The U937PM cell line MMP-2 secretion remains unchanged by both the 
addition of C5a and/or incubation with simvastatin. U937PM cells were incubated for 2 days 
with simvastatin in serum free media. Following 24 hr, 5 nM C5a was added. The harvested s/ns 
were run on a 10 % SDS-gelatin polyacrylamide gel and bands were visualised after staining with 
Coomassie Brilliant Blue R. (A) Representative inverted gel image. (B) Percentage change in MMP-2 
secretion from multiple experiments. Two-way ANOVA shows no significant effect of C5a or 
simvastatin.
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Figure 6.3.12 Effects of simvastatin on C5a induced MMP production in Bt2cAMP 
differentiated U937PM cell line. U937PM cells were incubated for 2 days with simvastatin in serum 
free media. Following 24 hr, 5 nM C5a was added. The harvested s/ns were run on a 10 % SDS- 
gelatin polyacrylamide gel and bands were visualised after staining with Coomassie Brilliant Blue R. 
(A) Representative inverted gel image. (B) Percentage MMP-9 changed compared to Bt2cAMP alone. 
Two-way ANOVA followed by Bonferroni post-test shows significant difference as marked by asterisks 
**p< 0.01. (C) MMP-2 secretion. Two-way ANOVA shows no significant effect of C5a or simvastatin on 
MMP-2 secretion.
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6.3.3.2 Simvastatin had no effect on C5a induced MMP production in the U937C5aR cell line
The U 9 3 7 C5aR cell line was shown to secrete mainly MMP-2 and some MMP-9 (figure 6.3.13 
A). MMP-2 and MMP-9 secretion remained unchanged by the addition of C5a (figure 6.3.13 
B and C). Furthermore, incubation with simvastatin had no statistically significant effect on 
either MMP-2 or MMP-9 secretion (figure 6.3.13 B and C).
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Figure 6.3.13 Effects of simvastatin on C5a induced MMP production in the U937C5aR 
cell line. U937C5aR cells were incubated for 2 days with simvastatin in serum free media. Following 
24 hrs, 5 nM C5a was added. The harvested s/ns were run on a 10 % SDS-gelatin polyacrylamide gel 
and bands were visualised after staining with Coomassie Brilliant Blue R. (A) Representative inverted 
gel image; (B) Percentage MMP-9 change compared with the control. Two-way ANOVA showed no 
significant effect of simvastatin or C5a on MMP-9 secretion; (C) Percentage MMP-2 change compared 
with the control. Two-way ANOVA showed no significant effect of simvastatin or C5a on MMP2 
secretion.
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6.3.4 C5a induced cytokine production
Stimulation of leukocytes with C5a causes an increased production of a number of pro- 
inflammatory cytokines (Goodman et al., 1982, Okusawa et al., 1988, Scholz et al., 1990, 
Vecchiarelli et al., 1998, Ember et al., 1994, Izumi et al., 1997). Here the effects of C5a on 
IL-8 and MCP-1 production will be investigated in the undifferentiated and Bt2cAMP 
differentiated U937PM cells and the U 9 3 7 C5aR line, as well as, human PBMCs. Using ELISA 
the effects of simvastatin and other lipid lowering agents on C5a induced IL-8 and MCP-1 will 
be investigated.
6.3.4.1 Simvastatin reduces C5a induced IL-8 production in Bt2cAMP differentiated U937PM via 
inhibition of isoprenoid synthesis
Stimulation of U937PM cells with C5a caused a slight increase in IL-8 production, although 
this was not statistically significant (p= 0.0519) (figure 6.3.14). Incubation of these cells with 
simvastatin had no effect on resting or C5a induced IL-8 production (figure 6.3.14). 
Differentiation of U937PM cells with Bt2cAMP, however, significantly increased both the 
resting and C5a induced IL-8 production (figure 6.3.15). Furthermore, the addition of 
simvastatin reduced the C5a induced IL-8 production (figure 6.3.15).
To determine if the effects of the simvastatin were caused by inhibition of cholesterol 
synthesis and/or isoprenoid synthesis, U937PM cells were incubated with Bt2cAMP plus 
simvastatin and either 50 pM mevalonate or 10 pM GGPP. The addition of both mevalonate 
and GGPP restored the C5a induced IL-8 production, which was significantly reduced by the 
addition of 1 pM simvastatin (figure 6.3.16). This suggests that the effects of the simvastatin 
are due to inhibition of isoprenoid synthesis. To further investigate the role of the cholesterol 
synthesis pathway on C5a induced IL-8 production in Bt2cAMP differentiated U937 cell line, 
these cells were incubated with the squalene synthesis inhibitor zaragozic acid. Figure 
6.3.17 shows that incubation of U937PM cells with both Bt2cAMP and zaragozic acid had no 
effect on the C5a induced production of IL-8. This result combined with results from above 
suggests that the effects seen by the simvastatin on IL-8 production are due to inhibition of 
isoprenoid synthesis alone.
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Figure 6.3.14 Incubation with simvastatin has no effect on C5a induced IL-8 production 
in the U937PM cell line. Cells were incubated for 48hr in the absence or presence of simvastatin. 
After 24hr 5nM C5a was added. Two-way ANOVA showed that neither C5a (p = 0.0519) nor 
simvastatin significantly affected IL-8 production (p = 0.9830).
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Figure 6.3.15 Incubation with simvastatin significantly decreases C5a induced IL-8 
production in Bt2cAMP differentiated U937PM cell line U937PM cells were incubated with 
0.5mM Bt2cAMP in the absence or presence of increasing concentration of simvastatin for 48hr. 
Following 24hr 5nM C5a was added. Two-way ANOVA followed by Bonferroni post-test shows 
difference as marked by an asterisks *p<0.05 and **p<0.01.
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6.3.16 Adding back mevalonate or GGPP restores C5a induced IL-8 production in 
Bt2cAMP plus 1uM simvastatin treated U937PM cell line U937PM cells were incubated with 
0.5mM Bt2cAMP plus 1 pM simvastatin and 50 pM mevalonate or 10 pM GGPP for 48hr. Following 
24hr 5nM C5a was added. Two-way ANOVA followed by Bonferroni post-test shows difference as 
marked by an asterisks *** = p<0.001.
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6.3.17 Zaragozic acid has no effect on IL-8 production in Bt2cAMP stimulated U937PM 
cells. U937pm cells were incubated with 0.5mM Bt2cAMP and zaragozic acid for 48hr. Following 
24hr 5nM C5a was added. Two-way ANOVA followed by Bonferroni post-test shows difference as 
marked by an asterisks *** p<0.001.
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6.3.4.2 MCP-1 secretion is not s ignificantly altered by the addition o f C5a or by incubation with 
sim vastatin in the U937PM cell line
Although the U937PM cells secreted MCP-1, its levels were not significantly altered by the 
addition of C5a (figure 6.3.18). Incubation of these cells with simvastatin showed a slight 
reduction in resting and C5a induced MCP-1 secretion although this was not statistically 
significant (figure 6.3.18). U937PM cells, which had been differentiated with Bt2cAMP, 
resulted in an increase in MCP-1 production following the addition of C5a although this was 
not statistically significant; however, combination of C5a and 0.1 pM simvastatin produced a 
statistically significant increase in MCP-1 secretion (figure 6.3.19).
Figure 6.3.18 Simvastatin has no effect on C5a induced MCP-1 production in the 
U937pm cell line. U937PM cells were incubated with simvastatin for 48hr. Following 24hr, 5nM C5a 
was added. Two-way ANOVA followed by Bonferroni post-test showed no significant difference in 
MCP-1 secretion following addition of C5a or incubation with simvastatin.
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Figure 6.3.19 Effects of simvastatin on C5a induced MCP-1 production in the Bt2cAMP 
differentiated U937PM cell line. U937PM cells were incubated with 0.5mM Bt2cAMP and increasing 
concentration of simvastatin for 48hr. Following 24hr 5nM C5a was added. Two-way ANOVA 
followed by Bonferroni post-test shows difference as marked by an asterisks * = p<0.05.
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6.3.4.3 Incubation o f U937CsaR with sim vastatin has no effect on C5a induced IL-8 or MCP-1 
production
Results from the IL-8 ELISA showed that the U937C5aR cell line secreted IL-8 (figure 6.3.20). 
Following stimulation with C5a, IL-8 secretion increased, although this was only statistically 
significant at 1 pM simvastatin (figure 6.3.20) The U937C5aR cells were also found to secrete 
MCP-1 and in the control cells C5a appeared to increase MCP-1 secretion but this was not 
statistically significant (figure 6.3.21). However, incubation with simvastatin appears to 
reduce this C5a induced MCP-1 secretion, although this was not statistically significant 
(figure 6.3.21).
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Figure 6.3.20 Incubation with simvastatin has no effect on C5a induced IL-8 production
in the U 9 3 7 CsaR cell line. U937C5aR cells were incubated with simvastatin for 48 hr. Following 24 hr 
5 nM C5a was added. Two-way ANOVA followed by Bonferroni post-test shows difference as marked 
by an asterisks * = p<0.05.
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Figure 6.3.21 Incubation with simvastatin reduces C5a induced MCP-1 secretion in the 
U 9 3 7 C 5aR  cell line. U937C5aR cells were incubated with simvastatin for 48 hr. Following 24 hr C5a, 5 
nM, was added. Two-way ANOVA followed by Bonferroni post-test showed no significant difference in 
MCP-1 secretion following addition of C5a or incubation with simvastatin.
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S.3.4.4 Effects of lipid altering stimuli on C5a induced IL-8 and MCP-1 production in human 
PBMCs
To further investigate the effects of lipid lowering agents on C5aR function, human PBMCs 
were incubated with simvastatin, lovastatin or fenofibrate and their effects on C5aR 
expression and the C5a induced IL-8 production was monitored. By using mixed PBMCs 
population this will allow interactions between the different cell types and their different 
cytokine and chemokine secretions which will mimic a more in vivo situation.
Stimulation of the control human PBMCs with C5a had no significant effect on IL-8 
secretion (figure 6.3.22). When the mononuclear cells were incubated with simvastatin there 
was no significant difference in resting IL-8 secretion compared with the controls (figure 
6.3.22 A). Furthermore, incubation with simvastatin had no effect on C5a induced IL-8 
secretion (figure 6.3.22 A). Similarly, incubation with lovastatin or fenofibrate had no 
significant effect on resting or C5a induced IL-8 secretion (figure 6.3.22 B and C).
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Figure 6.3.22 Effects of lipid lowering drugs on C5a induce IL-8 secretion in human 
PBMCs. Human PBMCs isolated from buffy coat were incubated with simvastatin (A), lovastatin (B) 
or fenofibrate (C) for 24 hrs in the absence or presence of 5 nM C5a. IL-8 ELISA was performed 
using harvested s/n. Data displayed as percentage IL-8 change compared with the control. Two-way 
ANOVA showed that C5a significantly increase IL-8 release whereas none of the treatments had any 
effect.
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6.3.5 C5aR appears to be localised within the non-lipid raft region of the 
plasma membrane in both the U937PM and U937C5aR cell line
The membrane localisation of the C5aR was investigated in both the U937PM and the 
U 9 3 7 C5aR cell lines using a discontinuous sucrose gradient floatation in the presence of 1 % 
Brij58. The membrane localisation of GPI anchored CD59 ( U 9 3 7 CD59-g p i)  and 
transmembrane anchored CD59 ( U 9 3 7 Cd 59-t m )  were used as positive and negative controls 
respectively for lipid raft associated (detergent resistant) and non-lipid raft (detergent soluble) 
molecules; these constructs had been previously characterised using this method ((Hiscox et 
al., 2002) and van den Berg unpublished data). As described in section 6.2.8, the C5aR 
expressing cells were mixed with U 9 3 7 Cd 59-t m  or U 9 3 7 Cd 59-g p i cells prior to sucrose gradient 
floatation. Due to the differences between the molecular weight of the C5aR (~42 kDa) and 
CD59 (between 18-20 kDa for GPI anchored and 20-25 kDa for TM), this allowed the same 
samples to be stained for both C5aR and CD59 by cutting the membrane in half at ~30kDa 
prior to incubation with the antibodies.
In order to detect the C5aR in the U937PM cell line using western blotting, these cells 
were differentiated with 0.5 mM Bt2cAMP for 48 hrs prior to sucrose gradient floatation. As 
the C5aR was detected following sucrose gradient floatation solely in the lower fractions 
(fractions 7-9), alongside the detergent soluble transmembrane CD59, this suggests that the 
C5aR is localised in a non-lipid raft region of the plasma membrane (figure 6.3.23). If the 
C5aR was localised in a lipid raft region then it would be localised in the upper detergent 
resistant fractions alongside the GPI-anchored CD59 (fractions 1-3) (figure 6.3.23). Despite 
this however, both the GPI-anchored and the transmembrane CD59 were detected in other 
fractions, although very small amounts, which suggests that some of the CD59 from both cell 
lysates was partially detergent soluble and insoluble respectively.
To determine if the C5aR in the Bt2cAMP differentiated U937PM cell line is clustered 
into the lipid rich microdomains following stimulation with C5a, these cells were incubated 
with 5 nM C5a prior to sucrose gradient floatation. As shown in figure 6.3.24 the C5aR 
remained localised in the detergent soluble fractions (fraction 6-8), alongside the 
transmembrane CD59 (fractions 7 and 8), even after C5a stimulation in the Bt2cAMP 
differentiated U937PM cell line. Furthermore, C5aR expression following stimulation with C5a 
appears less in the U937PM cells differentiated with Bt2cAMP (figure 6.3.24) compared with 
the western blot results in the absence of C5a (figure 6.3.23), suggesting that some C5aR 
may become degraded following stimulation with its ligand. Results from sucrose gradient 
floatation of the U 9 3 7 C5aR cell lysate also show that the C5aR localised in the lower detergent 
soluble fractions (fractions 6-8) both in the absence and presence of 5 nM C5a (figures 
6.3.25 and 6.3.26).
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Figure 6.3.23 The C5aR in the Bt2cAMP differentiated U937PM cell line is localised in the 
detergent soluble fractions of the sucrose gradient floatation. The U937PM cell line was 
differentiated with 0.5mM Bt2cAMP for 48 hr to upregulate C5aR expression. 7 x106 Bt2cAMP 
differentiated U937PM cells were mixed with 3 x106 U937 cells transfected with either the GPI- 
anchored CD59 or transmembrane CD59. The cell mixture was then solubilised in 40 % sucrose, 1 % 
Brij58 prior to gradient centrifugation at 45,000 rpm for 16 hr at 4 °C in order to isolate membrane 
microdomain associated proteins. Fractions (0.5 ml) were collected starting from the top of each 
sample and subjected to SDS-PAGE and western blotting with an anti-C5aR (H-100, Santa Cruz) or 
anti-CD59 (Bric229).
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Figure 6.3.24 Stimulation of Bt2cAMP differentiated U937PM cell line with C5a has no 
effect on the membrane localisation of the C5aR as observed by sucrose gradient 
floatation. The U937PM cell line was differentiated with 0.5mM Bt2cAMP for 48 hr to upregulate 
C5aR expression. 7 x106 Bt2cAMP differentiated U937PM cells were mixed with 3 x106 U937 cells 
transfected with transmembrane CD59. The cell mixture was then incubated with 5 nM C5a for 5 min 
prior to solubilising in 40 % sucrose, 1 % Brij58 prior to gradient centrifugation at 45,000 rpm for 16 hr 
at 4 °C in order to isolate membrane microdomain associated proteins. Fractions (0.5 ml) were 
collected starting from the top of each sample and subjected to SDS-PAGE and western blotting with 
anti-C5aR (H-100, Santa Cruz) or anti-CD59 (Bric229)
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Figure 6.3.25 The C5aR in the U 9 3 7 C 5 a R  cell line is localised in the detergent soluble 
fractions of the sucrose gradient floatation. 7 x106 U937C5aR cells were mixed with 3 x106 
U937 cells transfected with either the GPI-anchored CD59 or transmembrane CD59 . The cell mixture 
was then incubated with 5 nM C5a for 5 min prior to solubilising in 40 % sucrose, 1 % Brij58 prior to 
gradient centrifugation at 45,000 rpm for 16 hr at 4 °C in order to isolate membrane microdomain 
associated proteins. Fractions (0.5 ml) were collected starting from the top of each sample and 
subjected to SDS-PAGE and western blotting with an anti-C5aR (H-100, Santa Cruz) or anti-CD59 
(Bric229)
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Figure 6 .3 .2 6  Stimulation of the U 9 3 7 CsaR cell line with C5a has no effect on the 
membrane localisation of the C5aR as observed by sucrose gradient floatation. 7 x106 
U 9 3 7 C5aR cells were mixed with 3 x106 U937 cells transfected with transmembrane CD59. The cell 
mixture was then incubated with 5 nM C5a for 5 min prior to solubilising in 40 % sucrose, 1 % Brij58 
prior to gradient centrifugation at 45,000 rpm for 16 hr at 4 °C in order to isolate membrane 
microdomain associated proteins. Fractions (0.5 ml) were collected starting from the top of each 
sample and subjected to SDS-PAGE and western blotting with an anti-C5aR (H-100, Santa Cruz) or 
anti-CD59 (Bric229)
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6.4 Discussion
Evidence suggests that the cholesterol dependent and independent effects of statins have 
beneficial anti-inflammatory properties (Arnaud et al., 2005). As complement activation leads 
to the generation of C5a, which acts via the C5aR, this Chapter has investigated whether 
simvastatin can exert anti-inflammatory effects by modulating the function of the C5aR. 
Although the effects of simvastatin on the biological functioning of the C5aR will be 
discussed below, it is important to note that as Chapter 5 has previously shown that 
simvastatin can alter the receptor expression, this makes it difficult to determine whether the 
effects seen in this Chapter are due to lowered C5aR expression or both lowered expression 
and reduced biological function of the receptor.
6.4.1 Effects of simvastatin incubation on biological functioning of the 
C5aR
As previously described in section 6.1 statins can modulate GPCR functions by cholesterol 
dependent and independent mechanisms. The cholesterol dependent mechanisms are 
mediated by altering membrane cholesterol levels which can in turn alter the sub-membrane 
localisation, structural properties and internalisation of GPCRs and their signalling 
components. The cholesterol independent mechanisms are mediated by inhibition of 
isoprenoid biosynthesis, which are important for the post-translational modification 
isoprenylation of small GTP binding proteins. In this Chapter the biological functions of the 
C5aR were monitored in U937PM cells, which were either undifferentiated or differentiated 
with Bt2cAMP to increase C5aR expression, U937C5aR. which had been stably transfected 
with the human C5aR, and PBMCs. Following incubation of these cells with statins, the C5a 
induced Ca2+ release, F-actin assembly, MMP-secretion and cytokine secretion were 
monitored, as previously described in sections 6.1 and 6.2.
6.4.1.1 C5a induced intracellular Ca2* release
Stimulation of the C5aR with C5a leads to activation of PLCp which results in a rise in 
intracellular Ca2+ (Maurya and Subramaniam, 2007a, Jiang et al., 1996, Camps et al., 1992). 
The effects of simvastatin on C5a induced Ca2+ release, in the U937PM and U 9 3 7 C 5 a R  cell 
lines, was monitored using Fura-2-AM, as previously described in section 4.1.2.3.
As described in section 6.3.1.1 the undifferentiated U937PM cell line observed a 
decrease in C5a induced Ca2+ release following incubation with 1 pM simvastatin (figure
6.3.1). Although not statistically significant, this reduction was reversed by adding back 
either mevalonate or GGPP (figure 6.3.3). These results are particularly interesting as 
previously Chapter 5 (section 5.3.1) was unable to detect C5aR expression in these cells by
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flow cytometry, yet here these cells were able to induce intracellular Ca2+ release following 
stimulation with C5a and furthermore this response decreased by incubation with 
simvastatin. Despite being unable to detect C5aR expression by flow cytometry or western 
blotting in these cells, we cannot rule out that simvastatin does not alter receptor expression 
levels. For this reason it is difficult to conclude whether the decrease in C5a induced Ca2+ 
release following incubation with simvastatin is due to functional changes in the receptor or 
its signalling components and/or changes in receptor expression. Figure 6.3.1 also shows 
that the C5a induced Ca2+ release was significantly reduced by cholesterol loading, which 
suggests that the receptor may have sensitivity towards cholesterol levels. This result 
correlates with other published reports that have found other GPCR, such as the fMLP 
receptor, to be sensitive to membrane cholesterol content (Bath et al., 1991, Dunzendorfer et 
al., 1997, Wolach et al., 1992, Xue et al., 2004). For the fMLP receptor it was shown that 
membrane depletion of cholesterol by using M(3CD, reduced the ability of the neutrophils to 
undergo chemotaxis towards fMLP (Xue et al., 2004). However in our experiments only 
cholesterol loading had a significant effect on C5a induced Ca2+ release in the U937PM cell 
line whereas MpCD had no significant effect (figure 6.3.1). Our findings also correlate with a 
study by Nagao and co-workers, which found that cholesterol loading of mouse 
macrophages J774A.1 cells with ChMpCD led to a significant decrease in transmigration 
towards C5a (Nagao et al., 2007). Together these findings suggest that some of the C5aR 
biological functions, C5a induced Ca2+ release reported here and C5a induced migration 
reported by (Nagao et al., 2007), are sensitive to membrane cholesterol and that simvastatin 
exerts an anti-inflammatory effect by reducing the C5a induced Ca2+ in the U937PM cell line. 
It is also important to note that using CD to either deplete or load cell membranes of 
cholesterol have their limitations as their non-physiological actions can often cause non­
specific artefacts (Maxfield and Tabas, 2005, Zidovetzki and Levitan, 2007). This was true 
for these experiments as incubation with ChMpCD significant decrease cell viability (figure
6.3.2).
Incubation of Bt2cAMP differentiated U937PM cells with 1 jaM simvastatin decreased 
C5a induced Ca2+ release (figure 6.3.4). As this effect was prevented by the addition of 
mevalonate but not GGPP, this suggests that the C5a induced Ca2+ release may be sensitive 
to lowered cholesterol levels (figure 6.3.5). However, to contradict this result incubation with 
MpCD, cholesterol chelator, (figure 6.3.4) or zaragozic acid, a squalene synthase inhibitor, 
(figure 6.3.7) had no effect on C5a induced Ca2+ release. One explanation for these results 
is differences in C5aR expression levels. As described in Chapter 5, incubation with 
simvastatin reduced the Bt2cAMP induced C5aR expression, whereas zaragozic acid had no 
effect on receptor expression. Therefore it is difficult to determine whether these differences
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are due to functional changes and/or changes in expression. If changes in expression were 
entirely to blame for the reduced C5a induced Ca2+ release then it would be expected that 
the addition of both mevalonate and GGPP reversed the effects of simvastatin on C5a 
induced Ca2+ release, as they did for Bt2cAMP induced C5aR expression. However, this was 
not observed (figure 6.3.5), and one explanation could be that initial batches of Bt2cAMP 
were more able to induce higher levels of C5a induced Ca2+ compared to later batches. This 
made it difficult to show statistical differences in later experiments as incubation with 1 nM 
simvastatin in initial experiments reduced the C5a induced Ca2+ release by half whereas later 
experiments it was reduced only by a quarter (figure 6.3.5 and 6.4.4 respectively). Another 
possibility could be that the intracellular signalling is more sensitive to inhibition of 
isoprenylation and therefore higher concentrations of mevalonate and GGPP are needed to 
completely reverse the effects of the simvastatin. In these experiments it was chosen to 
stimulate the cells with 5 nM C5a as this was shown in Chapter 4 to induce the maximum 
intracellular Ca2+ release; furthermore this is the highest physiologically achievable C5a 
concentration (Guo and Ward, 2006). However if future experiments could be performed 
using a suboptimal dose of C5a this might make any changes in the C5aR function more 
pronounced.
To circumvent problems associated with changes in expression, experiments were 
repeated using the U 9 3 7 C 5 a R  cell line which had previously been stably transfected with the 
C5aR (Kew et al., 1997). However, these cells were also shown to be sensitive to 
simvastatin as incubation with the statin caused a significant reduction in C5aR expression, 
section 5.3.7. Despite this reduction in expression, simvastatin had no significant effect on 
C5a induced Ca2+ release (figure 6.3.8). This result was particularly interesting as it 
suggests that not all the C5aR on the cell surface is fully functional or that downstream 
signalling components are acting as a limiting factor in the functioning of the signalling 
pathway. This is further supported by the fact that although the U 9 3 7 C 5 aR  cells express 
higher levels of C5aR on their cell surface compared with U937PM differentiated with 
Bt2cAMP (general observations), they produced far less intracellular Ca2+ response following 
stimulation with 5 nM C5a compared with U937PM differentiated with Bt2cAMP (figures 6.3.8 
and 6.3.4 respectively).
6.4.1.2 C5a induced F-actin assembly
The Bt2cAMP differentiated U937 cell line has frequently been shown to increase F-actin 
assembly following stimulation with C5a (Banks et al., 1988, Monk and Banks, 1991, Kew et 
al., 1997). Despite this our experiments failed to detect changes in F-actin assembly in 
either U937PM or U937C5aR cell lines following stimulation with C5a, although human 
neutrophils showed a significant increase in F-actin assembly after stimulation (figure 6.3.9
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and 6.3.10). This result was particularly disappointing as it was hypothesised that statins 
would reduce F-actin assembly by preventing the isoprenylation of small GTP-binding 
proteins, Cdc42 and Rac, which have been implicated in chemotaxis of leukocytes towards 
C5a (Li et al., 2003, Tardif et al., 2003, Welch et al., 2002a). One explanation why we were 
unable to F-actin assembly in these cells might be explained by their cell morphology. Both 
cells exhibited an irregular cell morphology, which could mean that their F-actin assembly 
could already be maximum polymerised (figure 4.3.5). However, as incubation with 
simvastatin resulted in the cells becoming more spherical maybe these cells may have less 
F-actin staining using phalloidin compared with the Bt2cAMP alone (figure 5.3.12). This 
would make an interesting future experiment. As F-actin assembly is not a direct measure 
for chemotaxis, future experiments could involve direct methods for measuring chemotaxis 
such as the Boyden chamber, however, as F-actin assembly is a prerequisite for chemotaxis 
it is quite possible these cells might not respond. It would also been interesting to see if the 
cells were responsive to other chemoattractants such as fMLP to determine whether these 
cells were just unresponsive to C5a or not able to re-arrange their F-actin.
Previously incubation with 1 mM Bt2cAMP, for up to 48 hrs, has been used to 
differentiate the cells and cause an increase in F-actin assembly following stimulation with 
C5a (Banks et al., 1988). Although our initial experiments found 0.25 mM Bt2cAMP had the 
same effect of increasing C5aR expression as 1 mM (figure 4.3.2); we later found that 
different batches of Bt2cAMP were less able to up regulate C5aR expression and therefore 
used higher concentrations of Bt2cAMP. Although the Bt2cAMP concentration used was able 
to increase the C5aR expression, maybe a higher concentration is needed to induce F-actin 
assembly. As Bt2cAMP differentiation of U937 cell line has been previously characterised by 
an increase in CD11b and CD14, a decrease in FcyRI/CD64 expression and increased non­
specific phagocytosis, it may be useful to monitor these changes following Bt2cAMP 
differentiation to confirm whether the concentration and duration of Bt2cAMP incubation used 
is enough (Sheth et al., 1988, Gavison et al., 1988, Brodsky et al., 1998).
6.4.1.3 C5a induced MMP secretion
As C5a had previously been shown to increase MMP secretion in neutrophils and 
eosinophils it was decided to investigate whether C5a could induce MMP secretion in the 
U937 cell line. Furthermore, as one of the pleiotropic effects of statins is to improve plaque 
stability by reducing MMP secretion, it was investigated whether simvastatin incubation 
hadany impact on C5a induced MMP secretion in the U937 cell line.
Results shown in section 6.3.3 found that the U 9 3 7 C 5 a R  cell line secreted both MMP-2 
and MMP-9, however the addition of C5a had no significant effect on the secretion of either 
of these (figure 6.3.13). Furthermore, incubation with simvastatin had no significant effect on
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MMPs secretion in these cells (figure 6.3.13). The U937PM cell line secreted MMP-2 and 
following differentiation with Bt2cAMP, this cell line also secreted MMP-9 (figure 6.3.11 and 
6.3.12). In both cases the MMP-2 secretion was unchanged by the addition of C5a; whereas 
in the Bt2cAMP differentiated U937PM cells there was an increase in MMP-9 secretion 
following the addition of C5a (figure 6.3.12). These results are in line with a recent 
publication from Speidl et al. who found that differentiated monocytes are able to secrete 
MMP-9 and also MMP-1 following stimulation with C5a (Speidl et al., 2011). Although it was 
not investigated exactly how C5a may induce MMP secretion in this study one possible 
mechanism could be that MMP-9 expression is regulated by NFkB and C5a has previously 
been shown to activate NFkB (Hsu et al., 1999, Kastl et al., 2006). Surprisingly, incubation 
of the Bt2cAMP differentiated U937PM cells with simvastatin significantly increased the C5a 
induced MMP-9 secretion. This result contradicts all published findings which show that 
statins prevent MMP secretion and therefore improve plaque stability (Aikawa et al., 2001, 
Fukumoto et al., 2001, Fujimoto et al., 2008, Sundararaj et al., 2008). Furthermore, this 
result does not correlate with changes in the C5aR expression or C5a induced Ca2+ release, 
which were both reduced when the cells were incubated with both Bt2cAMP and simvastatin 
compared with Bt2cAMP alone (figure 5.3.4 and 6.3.4). One possible reason for the opposite 
effects being observed could be that for MMP zymography the cells are incubated in the 
absence of FCS, to remove exogenous MMPs that will interfere with the assay, whereas, all 
other experiments were carried out in the presence of FCS. Possible future experiments 
could investigate whether C5aR expression changes in the absence of serum and the effect 
on statins. Alternatively the C5a induced MMP secretion may somehow involve the second 
C5a receptor C5L2, which was not investigated in these studies due to the lack of a specific 
antibody against the receptor. However to circumvent this problem, future experiments could 
be carried out in the presence of C5aR blocking antibodies or antagonist; in which case if 
these results were solely due to C5aR they will be prevented by such agents; whereas if 
C5L2 had an involvement then incubation with the C5aR blocking peptide or antagonist 
would have no effect on the overall outcome.
6.4.1.4 C5a induced cytokine secretion
C5a has previously been shown to increase pro-inflammatory cytokine secretion in 
leukocytes (section 6.1.3.5). As MCP-1 and IL-8 have been implicated in atherosclerosis, it 
was investigated whether the U937 cell lines expressed these cytokines and whether C5a 
induced their secretion in these cells. Furthermore, it was investigated whether simvastatin 
could exert anti-inflammatory properties by regulating the C5a induced secretion of these 
pro-inflammatory cytokines, IL-8 and MCP-1.
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As described in section 6.3.4.1 the undifferentiated U937PM cells showed an increase 
in IL-8 secretion following stimulation with C5a, however this was not statistically significant 
p=0.0519 (figure 6.3.14). This result does not correlate with the Ca2+ signalling results which 
found that these cells were responsive to C5a by raising intracellular Ca2+ concentrations 
(figure 6.3.1). However, as Chapter 5 has previously shown that these cells express very 
little C5aR on their cell surface (figure 5.3.1), possibly there is not enough C5aR on the cell 
surface to produce an increase in IL-8 secretion following C5a stimulation. Although 
incubation of these cells with simvastatin reduced C5a induced Ca2+ release, figure 6.3.14 
shows that simvastatin had no effect on IL-8 secretion or C5a induced IL-8 secretion.
Upon differentiation of the U937PM with Bt2cAMP the basal IL-8 secretion increased 
dramatically which suggests that this cAMP analogue itself can regulate IL-8 secretion either 
by regulating gene expression of IL-8 directly or by a secondary effect such as regulating the 
expression of other cytokines (figure 6.3.15). This result confirms findings from a study by 
Kavelaars and co-workers demonstrating that Bt2cAMP can increase basal IL-8 and LPS 
induced IL-8 production in the U937 cell line (Kavelaars et al., 1997). This study suggested 
that transcription factors such as NFkB, c-FOS and Jun-B, which are influenced by cAMP, 
may mediate this IL-8 production, although they cannot rule out secondary effects by other 
cytokines or regulatory proteins (Kavelaars et al., 1997). This result also correlates with 
MMP-9 secretion which increased following incubation with Bt2cAMP in the absence of C5a 
(figure 6.3.12).
Additionally our results show that stimulation of Bt2cAMP differentiated U937PM cells 
with C5a significantly increased IL-8 secretion (figure 6.3.15). This result correlates with 
these cells becoming more responsive to C5a by significantly increasing their intracellular 
Ca2+ release following its addition (figure 4.3.7). Furthermore, incubation with simvastatin 
significantly reduced the C5a induced IL-8 secretion (figure 6.3.15), which correlates with 
both a decrease in C5aR expression (figure 5.3.4) and C5a induced Ca2+ release (figure 
6.3.4). Although it was not investigated here the exact signalling pathway through which C5a 
mediates IL-8 secretion in the U937PM cell line, it has been shown by Wang et al. that it is 
dependent on ERK 1/2 and p38 pathway but is independent of JNK 1/2 in human whole 
blood (Wang et al., 2010). Furthermore, a study by Hsu and co-workers found that NFkB 
activation following C5a stimulation in the RAW264.7 cell line was crucial for induced IL-8 
gene expression (Hsu et al., 1999).
As Chapter 5 has previously shown that incubation with simvastatin reduces the
Bt2cAMP induced C5aR expression (figure 5.3.4), it is difficult to determine whether the
reduced C5a induced IL-8 secretion is caused by reduced receptor expression or reduced
function of the C5aR and its signalling components, or both. The addition of mevalonate or
GGPP to the incubation was able to reverse the effects of simvastatin on C5a induced IL-8
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secretion, which suggests isoprenoid biosynthesis is critical for the C5a induced IL-8 
secretion in these cells (figure 6.3.16). However, the addition of these agents also reversed 
the effects of simvastatin on Bt2cAMP induced C5aR expression, therefore we cannot say 
whether these effects are due to changes in expression alone or expression and function 
(figure 5.3.11).
Interestingly incubation with the squalene synthesis inhibitor zaragozic acid had no effect on 
basal Bt2cAMP IL-8 secretion or C5a induced IL-8 secretion (figure 6.3.17). As zaragozic 
acid had no effect on C5aR expression, this suggests that the C5a induced IL-8 secretion in 
Bt2cAMP differentiated U937PM cell was not affected by inhibition of cholesterol biosynthesis. 
However, it is important to note here that all these experiments were carried out in the 
presence of 10 % FCS (except for the gelatine zymography experiments), which means that 
although cholesterol biosynthesis was inhibited, the cells could still take up cholesterol-LDL 
via the LDL receptors. Although LDLR expression has not been characterised in this study, 
the U937 cell line has previously been shown to express mRNA for this receptor (Hammad et 
al., 2009). While some studies that investigate the effects of statins or cholesterol in cell 
culture in the absence of serum, to remove all exogenous cholesterol, serum starvation itself 
can cause non-specific effects independent of cholesterol such as cell cycle growth arrest 
(Lundberg and Weinberg, 1999, Pardee, 1989). Furthermore, to completely remove 
cholesterol by inhibiting cholesterol biosynthesis and preventing uptake from the environment 
by removing exogenous cholesterol is non-physiological and can only hint towards biological 
function (Maxfield and Tabas, 2005). Although FCS could provide an exogenous source of 
cholesterol, previous studies have demonstrated that supplementing RPMI media with 10 % 
FCS contains on average 80 mg/L free cholesterol of which 30 mg/L is LDL-cholesterol (Han 
et al., 2005, Han et al., 1998). When this value is compared with normal cholesterolemic 
LDL-cholesterol values in humans, which is ideally 1000 mg/L, the actual concentration of 
LDL-cholesterol in our experiments is far below physiologically normal concentrations 
(NCEP, 2002). Therefore the benefit of supplement the media with serum, to provide the 
cells with the necessary growth factors, far outweigh the negligible risk of LDL-cholesterol 
interference from the FCS. Further still, patients receiving statin therapy still consume 
cholesterol in their diet. For this reason it seemed more physiological to carry out 
experiments in the presence of 10% FCS for our experiments.
The U937C5aR cells also appeared to increase IL-8 secretion following stimulation with
C5a; however, this was only statistically significant with 1 pM simvastatin due to large error
bars (figure 6.3.20). The data from this experiment is particularly interesting as it shows that
incubation with simvastatin increases the IL-8 secretion, whereas Chapter 5 has previously
shown that statins down regulate C5aR expression in these cells (figure 5.3.18). These
findings, together with the results from the C5a induced intracellular Ca2+ release, further
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suggest that not all the C5aR on the cell surface may be functional; if it were all functional 
then you would expect to see a significant decrease in both C5a induced Ca2+ and IL-8 
release.
In both the undifferentiated U937PM and U 9 3 7 C 5 a R  cell lines, stimulation with C5a 
failed to increase MCP-1 secretion and incubation with simvastatin had no effect on the basal 
or C5a induced MCP-1 secretion (figure 6.3.18 and 6.3.21). However, differentiation of the 
U937pm cells with Bt2cAMP, led to C5a stimulated increase in MCP-1 secretion but this was 
only significant at 0.1 pM simvastatin due to large error bars (figure 6.3.19). Although the 
exact mechanism by which C5a may induce MCP-1 secretion in these Bt2cAMP stimulated 
U937pm cells has not been investigated in this study, one possible mechanism could be the 
increase in intracellular cAMP concentration has led to the activation of protein kinase A that 
can in turn phosphorylate target proteins such as CREB which can then regulate expression 
of target genes that regulate MCP-1 secretion. Alternatively other regulatory proteins such 
as cytokines could be stimulated by C5a which in turn regulate MCP-1 secretion by autocrine 
regulation.
As cell lines have their limitations it was decided to further investigate the effects of 
statins and fenofibrate on the C5a induced IL-8 secretion using human PBMCs. It was 
decided to use PBMCs rather than purified monocytes for these experiments as it would 
represent a more in vivo situation where you would have cytokine secretion and autocrine 
regulation between the different cell types. However, the disadvantage is that you are 
unable to monitor changes in one cell type alone. As described previously in section 6.1.3.5, 
several studies have demonstrated that stimulation of the human PBMCs with C5a increased 
their IL-8 secretion (Ember et al., 1994, Vecchiarelli et al., 1998). However, in our 
experiments C5a failed to significantly increase IL-8 secretion (figure 6.3.22). The results 
shown here may differ from that published in the literature as once the PBMCs were isolated 
from the buffy coat they were then frozen until they were needed. This freeze thaw process 
may have activated the cells; therefore, these experiments could be repeated using fresh 
PBMCs. Not surprisingly, incubation of the PBMCs with simvastatin, lovastatin or fenofibrate 
did not statistically alter either basal or C5a induced IL-8 secretion (figure 6.3.22). While 
these results for simvastatin and lovastatin correlate with no changes in C5aR expression 
being observed in Chapter 5; it was anticipated that fenofibrate may lower C5a induced IL-8 
secretion, as this drug was previously been shown to down regulate expression of the 
receptor in CD 14 monocytes (Chapter 5). The differences between these experiments may 
be explained by the fact that the ELISAs were performed using PBMCs whereas changes in 
C5aR expression were only monitored in CD14 positive monocytes. Therefore it would be 
interesting to monitor the effects of fenofibrate incubation on IL-8 secretion in CD14 positive 
monocytes.
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6.4.2 Sub-membrane localisation of the C5aR
As previously described in section 6.1, cholesterol enriched micro domains, or lipid rafts, play 
an important role in the sub-membrane compartmentalisation of GPCR and their signalling 
components. As membrane cholesterol has been found to be crucial for clustering and 
redistribution of the FPR into lipid rafts following stimulation with fMLP (Xue et al., 2004, Bath 
et al., 1991, Dunzendorfer et al., 1997, Wolach et al., 1992), this study aimed to investigate 
the sub-membrane localisation of the C5aR, which is structurally homologous to the fMLP 
receptor.
Using detergent extraction and sucrose gradient floatation the results presented in 
section 6.3.6 suggest that in Bt2cAMP differentiated U937PM cells the C5aR is localised in a 
non-lipid raft region of the plasma membrane (figure 6.3.23). Furthermore, stimulation of the 
receptor with C5a had no effect on the membrane distribution (figure 6.3.24). Similarly the 
C5aR was also found to be localised in the non-lipid raft region of the plasma membrane in 
the U937C5aR cells, and its membrane localisation was un-affected by the addition of C5a 
(figure 6.3.25 and 6.3.26). These findings could suggest that membrane cholesterol is 
unlikely to have a direct effect of the functioning on the C5aR. However, this study has only 
investigated the location of the receptor itself and has not investigated the location of other 
signalling components in the membrane. It is also important to note that detergent extraction 
has it limitations due to its disruptive nature, which can in turn induce artefacts (Lingwood 
and Simons, 2010). This is evident when different detergents are used during the extraction 
process, which can lead to different fraction composition being produced following sucrose 
floatation (Brown and Rose, 1992). Brij58 used in these studies, has a mild detergent action 
and was the only detergent that allowed the discrimination between GPI-anchored raft 
associated CD59 and non-raft associated molecules such as a transmembrane anchored 
form of CD59 under conditions used in this study (van den Berg et al., 1995, Hiscox et al., 
2002) and unpublished data).
Although this is the first study to investigate whether the C5aR is present within a lipid 
raft region or is redistributed in or out of such regions following C5a stimulation, other 
research groups have found that the C5aR clusters following stimulation and is then 
internalised via p-arrestin, dynamin and clathrin-dependent pathway (Licht et al., 2003, 
Braun et al., 2003, Suvorova et al., 2005, Huttenrauch et al., 2005). As the results in this 
study suggest that the C5aR is located in a non-lipid raft region and is not distributed into 
such region following stimulation with C5a, this provides further evidence that C5aR is 
endocytosed via a clathrin-dependent pathway as this pathway is lipid raft independent 
(Lajoie and Nabi, 2010).
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6.4.3 Summary
This chapter shows that incubation with simvastatin was able to reduce C5a induced Ca2+ 
release and IL-8 secretion, had no effect on the C5a induced MCP-1 secretion but increased 
C5a induced MMP-9 secretion in the Bt2cAMP differentiated U937PM cell line. We were 
unable to detect C5a induced F-actin assembly, an indicator for chemotaxis in our cells. As 
Chapter 5 has previously shown that simvastatin was able to reduce C5aR expression in 
these cells, this makes it difficult to determine whether the effects observed by simvastatin in 
this chapter are due solely to reduced receptor expression or a combination of reduced 
expression and reduced function.
Although incubation of the U 9 3 7 C 5 a R  cell line with simvastatin was previously shown to 
reduce C5aR expression (Chapter 5) here we found that incubation of these cells with 
simvastatin had no effect on C5a induced Ca2+, MMP-2 or MMP-9 and IL-8 or MCP-1 
secretion. This would suggest that not all the C5aR expressed on these cells is fully 
functional. Results from PBMCs show that incubation with simvastatin or lovastatin had no 
effect on the C5a induced IL-8 secretion in an ex vivo situation which correlated with 
unchanged C5aR expression in these cells, Chapter 5. Despite C5aR expression being 
reduced by fenofibrate in CD14 positive monocytes (Chapter 5), here it was shown that this 
drug had no effect on the C5a induced IL-8 release. However, these differences could be 
attributed to PBMCs being used for the IL-8 ELISAs as opposed to a pure monocytic 
population.
Results from detergent extraction and sucrose gradient floatation suggest that the 
C5aR is unlikely to be associated with lipid raft regions; neither does it move in or out of such 
areas following stimulation with its ligand, C5a.
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Chapter 7
General conclusion
7.1 Summary of findings and conclusions
Complement activation leads to the release of the potent pro-inflammatory anaphylatoxin 
C5a, which exerts its biological actions via the C5aR, a GPCR. Over expression or under 
regulation of C5a and the C5aR has been implicated in a variety of pathologies, including 
atherosclerosis and ischemic reperfusion injury. Cholesterol is an integral component of 
biological membranes and as well as regulating membrane fluidity, it can affect the function 
and expression of numerous GPCR. Statin therapy is widely used to reduce circulating 
serum cholesterol levels, a major risk factor in coronary heart disease.
The principal aim of this thesis was to determine if the C5aR expression and function 
can be modulated by cholesterol. It was hypothesised that statins can exert anti­
inflammatory actions via the C5aR by:
•  Down regulating C5aR expression. Statins may regulate gene transcription of the 
C5aR via transcription factors such as NFkB or PPARs, as is the case for MCP-1 and its 
receptor CCR2 (Veillard et al., 2006, Han et al., 2005, Chen et al., 2005, Yin et al., 2007). 
Alternatively statins may regulate its mRNA stability, as is the case for DAF and eNOS 
(Mason et al., 2002, Laufs et al., 1998, Laufs and Liao, 1998). Furthermore membrane 
cholesterol content may also affect cell surface C5aR expression by regulating receptor 
internalisation via lipid raft dependent endocytosis following interaction with its ligand.
• Reducing functioning of the C5aR. Statins may alter C5aR function by affecting the 
membrane sub-compartmentalisation of the receptor into lipid rafts, as is the case for the 
fMLP receptor whose membrane polarisation and chemotaxis towards its ligand is reliant 
on membrane cholesterol content (Bath et al., 1991, Dunzendorfer et al., 1997, Wolach et 
al., 1992). Alternatively the structural properties of the C5aR may be regulated by 
membrane cholesterol content, as is the case for the rhodopsin receptor whose activation 
is restricted in a high cholesterol environment due to the rigidification of the membrane 
(Albert and Boesze-Battaglia, 2005, Albert et al., 1996). Statins may further reduce the 
signalling capacity of the C5aR by cholesterol independent mechanisms affecting the 
isoprenylation of small GTP-binding proteins involved in down stream signalling 
cascades.
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The findings of this thesis have provided data in several areas:
1. Regulation of basal C5aR expression in the U937 cell; the role of -2Kbp promoter 
region in transcriptional regulation of the gene and the effects of the 3’UTR on mRNA 
stability (Chapter 3).
2. Characterisation of reported inducers of C5aR expression in the U937 cell line; the 
identification and characterisation of two U937 cell lines (Chapter 4).
3. Characterisation of the effects of statins on C5aR expression; inhibition of Bt2cAMP 
induced C5aR expression in the U937 cell line by simvastatin, although statins had no 
effect on basal expression in this cell line or human PBMCs (Chapter 5).
4. Effects of statins on the biological function of the C5aR; simvastatin significantly 
reduced C5a induced Ca2+ release and IL-8 secretion in Bt2cAMP differentiated U937PM 
cell line, although statins had no effect on C5a induced IL-8 secretion in human PBMCs 
(Chapter 6).
5. The sub-membrane localisation of the C5aR; the receptor does not reside in lipid raft 
regions of the plasma membrane, neither does it move in or out of such regions 
following stimulation with C5a, as observed by sucrose gradient floatation (Chapter 6).
As very little was previously known about regulation of the human C5aR expression, it 
was decided to first investigate how basal C5aR expression was regulated. Using the U937 
cell line, it was shown that the majority of the -2Kbp promoter region cloned was dispensable 
for transcriptional activity of the human C5aR (Chapter 3), which is similar to results already 
observed with the mouse C5aR promoter region (Hunt et al., 2005). Using site directed 
mutagenesis the role of three putative promoter elements, NFkB (-238bp to -232bp), CCAAT 
(-123bp to -119bp) and NFAT (-93bp to -87bp), were investigated. In line with results 
already published from the mouse C5aR promoter, it was shown that the CCAAT motif is 
important for the transcriptional control of the human C5aR promoter, as both its mutation 
and deletion resulted in a reduction in promoter activity (Hunt et al., 2005). It was also 
believed that the novel putative NFAT site was identified as critical for the transcriptional 
control of the human C5aR promoter; however these results are still inconclusive (Chapter 
3). Furthermore, site directed mutagenesis of the putative NFkB site resulted in a reduction 
in promoter activity albeit to a lesser extent than the putative CCAAT or NFAT sites (Chapter 
3). As statins have previously been shown to regulate expression of several genes, including 
MCP-1, by regulating activity of NFkB (Veillard et al., 2006, Ortego et al., 1999), it was 
anticipated that this putative site may facilitate a mechanism by which statins could alter 
C5aR expression. However, it was later shown that simvastatin had no effect on the basal 
C5aR expression in the U937 cell line (Chapter 5). Similarly, C5aR expression in human
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PBMCs remained unchanged following incubation with lovastatin or simvastatin (Chapter 5). 
However, incubation with fenofibrate caused a significant reduction in C5aR expression in 
these cells (Chapter 5). Fenofibrate can activate transcription factors belonging to the 
PPARs family. Although statins have also been demonstrated to activate PPARa and 
PPARy which results in reduced IL-ip, TNFa, CCR5 and CCR2 expression (Inoue et al., 
2000, Zhou and Liao, 2010, Han et al., 2005, Chen et al., 2005, Yin et al., 2007), this result 
suggests that the C5aR expression may be regulated by fenofibrate via activation of PPARs 
through a mechanism that was not investigated in the U937 cell line.
As well as transcriptional regulation, this thesis also investigated regulation of mRNA 
stability. Site directed mutagenesis of the two ARE within the C5aR 3’UTR had no effect on 
mRNA stability, suggesting that unlike DAF (Gray et al., 2010), C5aR expression is not 
regulated by the AREs present within the 3’UTR (Chapter 3). Not surprisingly incubation of 
the 3’UTR reporter constructs with simvastatin had no significant effect on EGFP expression, 
suggesting that unlike eNOS (Laufs et al., 1998, Laufs and Liao, 1998), the C5aR mRNA 
stability is not affected by statins (Chapter 5).
To investigate whether statins would have any effect on induced receptor expression, 
the C5aR expression pattern in the U937 cell line following stimulation with various agents 
(including IFNy, IL-6, LPS, TNFa, PMA and Bt2cAMP) was characterised (Chapter 4). 
Although all of these stimuli had previously been reported in the literature to increase C5aR 
expression (Chapter 1, table 1.2 for full details), we found that only the artificial stimuli PMA 
and Bt2cAMP were able to increase C5aR expression and this was only achieved in one, 
U937pm, of the two U937 cell lines obtained for this research project (Chapter 4). 
Furthermore it was shown that although IL-6 and IFNy appeared to increase C5aR 
expression via FACS analysis, this apparent increase was an artefact and due to non­
specific binding of the antibody to Fey receptors (Chapter 4).
Although statins were unable to regulate basal C5aR expression, this thesis has found 
that simvastatin prevents the Bt2cAMP differentiation and up-regulation of the C5aR in the 
U937pm cell line and this effect was mediated by the inhibition of isoprenoid biosynthesis 
(Chapter 5). However, the concentration of statin needed to obtain this effect was more than 
ten times the pharmacological concentration of simvastatin and at this concentration it was 
shown that simvastatin significantly reduced cell proliferation by inhibition of isoprenylation 
possibly involving cell growth regulating proteins (Chapter 5).
Other mechanisms by which simvastatin may regulate Bt2cAMP differentiation and up- 
regulation of the C5aR possibly involve PKA and its down stream signalling components or 
via Epac, a guanine nucleotide exchange factor, which in turn regulates small GTP binding 
proteins. However the exact mechanism was not investigated here.
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Using the -2Kbp promoter, isolated from U937PM cells, and the 3’UTR EGFP reporter 
constructs, it was shown that there were no cis-actin elements responsible for the Bt2cAMP 
induced C5aR expression within these regions (Chapter 4). However the -2Kbp promoter 
region isolated from the U937Ec cells contained a Bt2cAMP responsive element when 
transfected into the U937PM cells (Chapter 4). A possible explanation for the differences 
between these promoters could be explained possibly by 4 SNPs identified between the 
sequences. However further studies are needed to confirm that one or more of these SNPs 
are responsible for these differences.
To investigate further whether statins had any effect on the functioning of the C5aR, 
this thesis monitored changes in the biological activities of the receptor. Although it was 
shown that incubation with simvastatin reduced the C5a induced Ca2+ release and IL-8 
secretion in the Bt2cAMP differentiated U937PM cell line, we were unable to determine 
whether this was due to changes in C5aR expression or both expression and function 
(Chapter 6). Similarly to changes in expression, it was shown that the reduced IL-8 secretion 
caused by simvastatin was due to inhibition of isoprenoid biosynthesis (Chapter 5 and 6).
This thesis has shown that C5a was able to induce MMP-9 secretion in Bt2cAMP 
differentiated U937PM cell line (Chapter 6), which correlates with recent results published by 
Speidl et al. who found that differentiated human monocytes are able to secret MMP-9 and 
also MMP-1 following stimulation with C5a (Speidl et al., 2011). Interestingly, it was shown 
that the C5a induced MMP-9 secretion, in the Bt2cAMP differentiated U937PM cells, increased 
following incubation with simvastatin (Chapter 6). This finding appears to be the first 
reported result that shows statins, which improve plaque stability by reducing MMP secretion 
(Aikawa et al., 2001, Fukumoto et al., 2001, Fujimoto et al., 2008, Sundararaj et al., 2008), 
increasing MMP secretion (Chapter 6).
As expression of the C5aR was altered by simvastatin in the Bt2cAMP differentiated 
U937pm cell line, this thesis investigated the effects of simvastatin on function and expression 
of the C5aR in a U937 cell line previously transfected with the C5aR (Kew et al., 1997). 
Although the majority of the expressed C5aR is not under the transcriptional control of the 
C5aR promoter, incubation with simvastatin significantly reduced the receptor expression in 
these cells (Chapter 5). Furthermore, this reduction appeared to be due to inhibition of 
isoprenoid biosynthesis (Chapter 5). Interestingly, it was shown that simvastatin did not alter 
C5a induced Ca2+ release, MMP-2 or MMP-9 and IL-8 or MCP-1 secretion in these cells 
suggesting that not all expressed C5aR is fully functional (Chapter 6). This thesis also 
showed that incubation of PBMCs with simvastatin, lovastatin or fenofibrate had no effect on 
the biological functioning of the receptor, as the C5a induced IL-8 secretion remained 
unchanged (Chapter 6).
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This thesis also investigated, for the first time, the membrane sub-localisation of the 
C5aR. Results from sucrose gradient floatation suggest that the receptor is unlikely to reside 
in a lipid raft region of the plasma membrane, neither does it move in or out of such regions 
following stimulation with C5a (Chapter 6). The finding that the C5aR does not reside within 
a cholesterol rich region of the plasma membrane makes it less likely that the receptor 
function would be regulated by membrane cholesterol content and thus affected by statins 
via regulation of cholesterol within the membrane.
7.2 Future experiments
The work carried out in the course of completing this thesis has led to a number of questions 
that could be answered by further experimental work: For instance what is the exact 
mechanism by which statins prevent the Bt2cAMP differentiation and up-regulation of the 
C5aR? It would also be interesting to investigate whether statins could prevent the 
differentiation of human primary monocytes to macrophages using more physiologically 
relevant stimuli. It would also be interesting to monitor the effects of statin therapy on C5aR 
expression in an in vivo situation using PBMCs isolated from patients before and after statin 
therapy. Furthermore, it would be interesting to investigate how fenofibrate was able to 
reduce C5aR expression in the human monocytes; as well as investigating whether 
fenofibrate is able to regulate the receptor expression in the U937PM cell line.
As it was shown that incubation of simvastatin increased the C5a induced MMP-9 
secretion in the Bt2cAMP differentiated U937PM cell line; it would be extremely interesting to 
investigate the mechanism by which this is achieved.
Furthermore, it would be interesting to investigate what effects, in any, cholesterol 
and statins may have on the expression of the second C5a receptor, C5L2. This would be 
particularly interesting as it has been suggested that in humans C5L2 acts as a negative 
regulator of C5a by limiting its bioavailability to bind to the C5aR.
7.4 Concluding remarks
Unlike other GPCRs whose function and expression can be regulated by cholesterol and
therefore statin therapy, this thesis has found that statins had little effect on basal C5aR
expression in human monocytes; whereas incubation with simvastatin reduced the Bt2cAMP
induced differentiation and up-regulation of the C5aR in the U 9 3 7 P m  cell line. Although a
reduced C5a induced Ca2+ release and IL-8 secretion function was also observed in these
cells we were unable to determine whether this reduction was solely due to reduced
expression or reduced expression and function. Either way the effects of simvastatin appear
to be due to inhibition of isoprenoid biosynthesis rather than inhibition of cholesterol
biosynthesis. Furthermore sucrose gradient floatation suggests that the C5aR residues in a
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non-lipid raft region of the plasma membrane therefore making it less likely to be susceptible 
to membrane cholesterol content.
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Chapter 9
Appendix
9.1 Alignment o f the U937ECacc C5aR 5' deletion promoter
sequences.
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2kbp EC (-2037
GeneBank (-2035
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1987
GeneBank (-1985
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1937
GeneBank (-1935
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1887
GeneBank (-1885
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1837
GeneBank (-1836
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
50
CCCTTCGCTCATATTACCGCCTGATCTGTCAGATCAGGGGCGGAATTACA 
CCCTTCGCTCATATTACCGCCTGATCTGTCAGATCAGGGGCGGAATTACA 
51 100
TTCTCATAAGAGCGTGAACCCAGGCCGGGCGCAGTGGCTCAAGCCTGTAA 
TTCTCATAAGAGCGTGAACCCAGGCCGGGCGCAGTGGCTCAAGCCTGTAA 
101 150
TCCCAGCATTTTGGGAGGCTGAGGCGGGTGGATCACGAGGTCAGGAGTTC 
TCCCAGCATTTTGGGAGGCTGAGGCGGGTGGATCACGAGGTCAGGAGTTC 
151 200
g a g a t c a g c c t g g c c a a g a t g g t g a a a c c a t g t c t c t a c t a a a a a I t a c a 
g a g a t c a g c c t g g c c a a g a t g g t g a a a c c a c g t c t c t a c t a a a a a | t a c a  
201 250
AAAATTAGCCGGGCGCAGTGGTAGGCACCTGTAGTCCCAGCTACTCGGGA 
AAAATTAGCCGGGTGCAGTGGTAGGCACCTGTAGTCCCAGCTACTCGGGA 
251 300
2 kbp EC (-1787
GeneBank (-1786
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1737
GeneBank (-1736
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1687
GeneBank (-1686
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1637
GeneBank (-1636
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1587
GeneBank (-1586
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1529
2 kbp EC (-1537
GeneBank (-1536
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1490
2 kbp EC (-1487
GeneBank (-1486
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
GGCTGAGGCAGGAGAATCGCTTGAACCTGGGAGGCGGAGGTTGCAGTGTG 
GGCTGAGGCAGGAGAATCGCTTGAACCTGGGAGGCGGAGGTTGCAGTGTG 
301 350
CCGAGATCGTGCCACTGCACTCTAGCCTGGGTGAGAGAGTGAGACTCCAT 
CCGAGATCGTGCCACTGCACTCTAGCCTGGGTGAGAGAGTGAGACTCCAT 
351 400
C T C AAAAAAAAAAAAAAAAAAAAAAAG AG CAT G AAC CCTGTTGT G AAC AG 
CTCAAAAAAAAAAAAAAAAAAAAAAAGAGCATGAACCCTGTTGTGAACAG 
401 450
CGCATGTGAGGGATCTGGGTTGCAAGCTCCTTATGAGAATCTAATGCCTG 
CGCATGTGAGGGATCTGGGTTGCAAGCTCCTTATGAGAATCTAATGCCTG 
451 500
ATGATCTGTCACTGTATCCCATCACCCCCAGATAGGACCATCTCGTTACA 
ATGATCTGTCACTGTATCCCATCACCCCCAGATAGGACCATCTCGTTACA 
501 550
------------ T C AG G GAT T C C AC T GAT T C T AC AT TAT G T T G AAT T GT AT
G G AAAAC AAG C T C AG G GAT T C C AC T GAT T C T AC AT T AT G T T GAAT T GT AT 
G G AAAAC AAG C T C AG G GAT T C C AC T GAT T C T AC AT TAT G T T G AAT T G TAT 
551 600
AAT T AT T T CAT TAT AT AT T AC AAT GT AAC AAT AAT AGAT GGAGATGGT T G 
AAT T AT T T CAT TAT AT AT T AC AAT G T AAC AAT AAT AG AT GG AG AT GG T T G 
AAT TAT T T CAT TAT AT AT T AC AAT GT AAC AAT AAT AGAT G GAGAT G G T T G 
601 650
283
lkbp EC (-994
1.5kbp EC (-1440
2 kbp EC (-1437
GeneBank (-1436
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1390
2 kbp EC (-1387
GeneBank (-1386
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1340
2 kbp EC (-1337
GeneBank (-1336
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1290
2 kbp EC (-1287
GeneBank (-1286
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1240
2 kbp EC (-1237
GeneBank (-1236
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1190
2 kbp EC (-1187
GeneBank (-1186
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5kbp EC (-1140
2 kbp EC (-1137
GeneBank (-1136
lOObp EC (-100
200bp EC (-200
TGGCTTGTGTAGTTGGGGGACAGGGTAGCTCCATTTTCTATTGCCAACTT 
TGGCTTGTGTAGTTGGGGGACAGGGTAGCTCCATTTTCTATTGCCAACTT 
TGGCTTGTGTAGTTGGGGGACAGGGTAGCTCCATTTTCTATTGCCAACTT 
651 700
TATAAC C C TAG AAG G ATG ATTTTTTTC TTTTC TTTTC TTTTTC TTTTC TT 
TATAAC C C TAG AAG G ATG ATTTTTTTC TTTTC TTTTC TTTTTC TTTTC TT 
TATAAC C C TAG AAG G ATG ATTTTTTTC TTTTC TTTTC TTTTTC TTTTC TT 
701 750
t t t t t t | t t t t t g a g a t t g a g t c t t g g t g t t g t c a g c c t g g g c t g g a g t g  
t t t t t t I t t t t t g a g a t t g a g t c t t g g t g t t g t c a g c c t g g g c t g g a g t g  TTTTTTITTTTTGAGATTGAGTCTTGGTGTTGTCAGCCTGGGCTGGAGTG 
751 800
CAATGGTGCAATCTCTGCTCACTGCAACCTCCGCCTCCTGGGTTCCAGCA 
CAATGGTGCAATCTCTGCTCACTGCAACCTCCGCCTCCTGGGTTCCAGCA 
CAATGGTGCAATCTCTGCTCACTGCAACCTCCGCCTCCTGGGTTCCAGCA 
801 850
ATTCTCCTGCCTCAGCCTTCTGAGTAGCTGAGATTACAGGCACCCACCAC 
ATTCTCCTGCCTCAGCCTTCTGAGTAGCTGAGATTACAGGCACCCACCAC 
ATTCTCCTGCCTCAGCCTTCTGAGTAGCTGAGATTACAGGCACCCACCAC 
851 900
CACicCTG G CTAATTTTTG TATTTTTAG TAG AG ATG G G G TTTCACCATAT
CAclcCTGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATAT
CAC|CCTGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATAT
901 950
TGGCCAGGCTGGTGACGATGGTTTTTTTTTTTT«GAGACAGAGTCTTGC
tggccaggctggtgacgatggttttttttttttHgagacagagtcttgc 
tggccaggctggtgacgatggttttttttttttHgagacagagtcttgc 
951 !000
284
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1090
2kbp EC (-1089
GeneBank (-1088
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-994
1.5 kbp EC (-1040
2 kbp EC (-1039
GeneBank (-1038
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-992
1.5 kbp EC (-990
2 kbp EC (-989
GeneBank (-988
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-942
1.5 kbp EC (-940
2 kbp EC (-939
GeneBank (-938
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-892
1.5 kbp EC (-890
2 kbp EC (-889
GeneBank (-888
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-842
1.5 kbp EC (-840
2 kbp EC (-839
GeneBank (-838
lOObp EC (-100
200bp EC (-200
355bp EC (-355
500bp EC (-506
lkbp EC (-791
1.5 kbp EC (-791
2 kbp EC (-790
GeneBank (-789
TTTGTTGCCCAGGCTGGAGTGCAGTGGCGCAATCTTGGCTCACTGCAACC 
TTTGTTGCCCAGGCTGGAGTGCAGTGGCGCAATCTTGGCTCACTGCAACC 
TTTGTTGCCCAGGCTGGAGTGCAGTGGCGCAATCTTGGCTCACTGCAACC 
1001 1050
-----------------------------------------------------------------------------------gggg
TC TG C C TC C C AG G TTTAAG C AATTC TC C TG C C TC AG C TTC C C AAG TH H
TCTGCCTCCCAGGTTTAAGCAATTCTCCTGCCTCAGCTTCCCAAGT^B
TCTG C CTCCC AG G TTTAAG CAATTC TC CTG CC TC AG C TTCC CAAG TBB i 
1051 1100
GGGATTACAGGCACCTGCCACCACACCTGGGTAATTTTTGTATTTTTAGT
GGGATTACAGGCACCTGCCACCACACCTGGGTAATTTTTGTATTTTTAGT
GGGATTACAGGCACCTGCCACCACACCTGGGTAATTTTTGTATTTTTAGT
GGGATTACAGGCACCTGCCACCACACCTGGGTAATTTTTGTATTTTTAGT
1101 1150
AGAGACAGGGTTTCACCATGTTGGCCAGACTCGTCTTGAACTCCTGACCT
AGAGACAGGGTTTCACCATGTTGGCCAGACTCGTCTTGAACTCCTGACCT
AGAGACAGGGTTTCACCATGTTGGCCAGACTCGTCTTGAACTCCTGACCT
AGAGACAGGGTTTGACCATGTTGGCCAGACTCGTCTTGAACTCCTGACCT
1151 1200
CAAGTGATTCATTTGCCTCAGCCTCCCAAAGTGCTGGGATTATAGGTGTG
CAAGTGATTCATTTGCCTCAGCCTCCCAAAGTGCTGGGATTATAGGTGTG
CAAGTGATTCATTTGCCTCAGCCTCCCAAAGTGCTGGGATTATAGGTGTG
1201 1250
AGCCATTGCACCTGGCCCTAGAAGGAAGATTTAACAGTAAAAATATACTT 
AGCCATTGCACCTGGCCCTAGAAGGAAGATTTAACAGTAAAA-TATACTT 
AGCCATTGCACCTGGCCCTAGAAGGAAGATTTAACAGTAAAA-TATACTT 
AG C C A T T G C AC C T G G C C C T AG A A G G AAG A T T T AA C A G T AAAA - T AT AC T T
1251 1300
AAATGCTGGGCTATCTCCGCAGACTAGCTCAGCCTCTTTGGGTCTCAAAT
AAATGCTGGGCTACCTCCGCAGACTAGCTCAGCCTCTTTGGGTCTCAAAT
AAATGCTGGGCTACCTCCGCAGACTAGCTCAGCCTCTTTGGGTCTCAAAT
1301  1350
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5kbp EC 
2kbp EC 
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5kbp EC 
2kbp EC 
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5kbp EC 
2kbp EC 
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
CAGCCTGGCC-GGGAGGCTGAGTGGAGGTTACAGTCTCTGCTTTCTTGAA
CAGCCTGGCC-GGGAGGCTGAGTGGAGGTTACAGTCTCTGCTTTCTTGAA
CAGCCTGGCCCGGGAGGCTGAGTGGAGGTTACAGTCTCTGCTTTCTTGAA
CAGCCTGGCC-GGGAGGCTGAGTGGAGGTTACAGTCTCTGCTTTCTTGAA
1351 1400
TCCCAAGGGAGGGGTTTAAGCCAACTGCATTCCTGAGCTTTTGCCCAGAA
TCCCAAGGGAGGGGTTTAAGCCAACTGCATTCCTGAGCTTTTGCCCAGAA
TCCCAAGGGAGGGGTTTAAGCCAACTGCATTCCTGAGCTTTTGCCCAGAA
TCCCAAGGGAGGGGTTTAAGCCAACTGCATTCCTGAGCTTTTGCCCAGAA
1401 1450
GGCTGGCGTCTTAGGAGGAAAGAGATAGATGGCTCCAGGCCGGGCGCAGT
GGCTGGCGTCTTAGGAGGAAAGAGATAGATGGCTCCAGGCCGGGCGCAGT
GGCTGGCGTCTTAGGAGGAAAGAGATAGATGGCTCCAGGCCGGGCGCAGT
GGCTGGCGTCTTAGGAGGAAAGAGATAGATGGCTCCAGGCCGGGCGCAGT
1451 1500
GGCTCACACTTGTAATTCTAGCACTTTGGGAGGTTGAGGTGGGTGATTGC
GGCTCACACTTGTAATTCTAGCACTTTGGGAGGTTGAGGTGGGTGATTGC
I
1501 1550
------------------------------------------^CGAAACCCCGTC
CTGAGCTCAGGAGTTTGAGTCCAGCCTGGCCAACATGGCGAAACCCCGTC 
CTGAGCTCAGGAGTTTGAGTCCAGCCTGGCCAACATGGCGAAACCCCGTC 
CTGAGCTCAGGAGTTTGAGTCCAGCCTGGCCAACATGGCGAAACCCCGTC 
CTGAGCTCAGGAGTTTGAGTCCAGCCTGGCCAACATGGCGAAACCCCGTC 
1551 1600
TTTACTAAAAATACAAAAAATTAGCCAGGGGTGGTGACACACACGTGTAA 
TTTACTAAAAATACAAAAAATTAGCCAGGGGTGGTGACACACACGTGTAA 
T T T AC T AAAAAT ACAAAAAAT TAGCCAGGGGTGGTGACAC AC ACGTG TAA 
T T TACT AAAAAT ACAAAAAAT T AGCCAGGGGTGGTGACACACACGTGT AA
1601 1650
TCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAGTGCTTGAACCCGGGAGG
TCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAGTGCTTGAACCCGGGAGG
TCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAGTGCTTGAACCCGGGAGG
TCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAGTGCTTGAACCCGGGAGG
286
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
1.5 kbp EC 
2kbp EC
GeneBank
lOObp EC 
200bp EC 
355bp EC 
500bp EC 
lkbp EC
(-440)
1651 1700
1 - 1 0 0 )  ---------------------------------------------------------------------------------------------------------
- 2 0 0 ) -----------------------------------------------------------------------------------------------------------------------------------------
- 3 5 5 )  ------------------------------------ M W im iH IP
- 3 9 2 ) CAGAGGTTACAGAGATCCGAGATTGCACCACTCCACTGCAGCCTGGGCGA 
- 3 9 2 ) CAGAGGTTACAGAGATCCGAGATTGCACCACTCCACTGCAGCCTGGGCGA 
-392) CAGAGGTTACAGAGAGCCGAGATTGCACCACTCCACTGCAGCCTGGGCGA 
-390) CAGAGGTTACAGAGAGCCGAGATTGCACCACTCCACTGCAGCCTGGGCGA
- 3 9 0 )
1701 1750
- 100 ) --------------------------------------------------------------------------------------------------------------------------------------------------------
- 2 0 0 ) ------------------------------------------------------------------------------------------------------------------------------------------
-340) CACAG CAAGAC T C T AT CAAAAAAAAAAAAAAAAAAA - - T GAGAGAGAAG A 
- 3 4 2 ) CACAGCAAGACTCTATCAAAAAAAAAAAAAAAAAAAAATGAGAGAGAAGA 
- 3 4 2 ) CACAGCAAGACTCTATCAAAAAAAAAAAAAAAAAAAAATGAGAGAGAAGA 
- 3 4 2 ) CACAGCAAGACTCTATCAAAAAAAAAAAAAAAAAAAAATGAGAGAGAAGA 
-340) CAC AGCAAGACT C T AT C AAAAAAAAAAAAAAAAAAA- - T GAG AGAGAAGA 
-340) CACAGCAAGACTCTATCAAAAAAAAAAAAAAAAAAA-- TGAGAGAGAAGA 
1751 1800
h 0 0) ------------------------------------------------------------------------------------------
1-2 0 0 ) ------------------------------------------------------------------------------------------------------------------------------------------
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
- 2 9 2 ) GATGGCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCGAGCCTGCAC 
1801 1850
[lOO) --------------------------------------------------------------------------- --------------
[200)  -------------------------------------------------------------------------------------■ B B S
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
- 2 4 2 ) AGGAGCTTCCTCGGTTTTCCGAGCGCCGGCCCCCCTTCTCTGCCTGGGAG 
1851 1900
- 1 0 0 )  ----------------------------------------------------------------------------------------------------------
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
- 1 9 2 ) GAGGTGGTTAGAGTCCCCTGGGTGTGTGCCCCGCAGAGGGAGCTCTGGCC 
|  1901 1950
- 1 0 0 )  ------------------------------------------------------------------------------------------------------ GACGGTCA
- 1 4  2 ) TCAGTGCCCAGTGTGCAGACCAATGAGAGCCCCAGAGAGAAA 
- 1 4  2 ) T CAG TGCCCAGTGTG CAGAC CAAT GAGAG C C C CAGAGAGAAA 
- 1 4  2 ) T CAG T G C C CAG T GT GCAGAC CAAT GAGAGC C C CAGAGAGAAA 
- 1 4 2  ) T CAG TGCCCAGTGT G CAGAC CAAT GAGAGC C C CAGAGAGAAA 
- 1 4  2 ) T CAG T GC C CAGT GT GCAGAC CAAT GAGAGCCC CAGAGAGAAA 
- 1 4  2 ) T CAG T GC CCAGT G TGCAG ACCAAT GAGAGCCCCAGAGAGAAA 
- 1 4 2 ) TCAGTGCCCAGTGTGCAGACCAATGAGAGCCCCAGAGAGAAA
1951 2000  
( - 9 2 )  TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC 
( - 9 2 )  TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC 
( - 9 2 )  TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC 
( - 9 2 )  TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC 
( - 9 2 )  TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC
287
1.5 kbp EC (-92) TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC
2 kbp EC (-92) TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC
GeneBank (-92) TTTCCTCCCTGCATCTTCCCTTGGGGCTTTAAAAACCACAGCCCTTGGGC 
2001 2050
lOObp EC (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAAC--------
200bp EC (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAAC--------
355bp EC (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAAC--------
500bp EC (-42) AG GAG G G AC C T T C GAT C C T C G G G GAG C C C AG GAG AC C AG AAC--------
lkbp EC (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAAC--------
1.5 kbp EC (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAAC--------
2 kbp EC (-42) AG GAG G G AC CTTCGATCCTCGGGGAGCC C AG GAG AC C AG AAC--------
GeneBank (-42) AGGAGGGACCTTCGATCCTCGGGGAGCCCAGGAGACCAGAACATGGTGAG
2051 2100
9.2 Alignment of C5aR 2 Kbp promoter sequence isolated from the U937 
cell lines with human GENEBANK sequence and the chimpanzee 
sequence
GeneBank AC_099491.
1 50
Gerard e t . 
Chimpanzee 
Genebank 
U937 (ECACC 
U937 (PM)
al.
C5aR
1996
prom
(-348)
(-2065)
(-2035)
(-2037)
(-2039)
tcatctg tatttata g ccac g cc^ ^ ^ ^ ^ H I ^ ^ ^ ^ ^ ^ ^ H H H
')
LL/1 1 LvaL 1 LA L A 1 1ALLLLL 1 LA IL1L
-------------------------- CCTTCGCTCATATTACCGCCTGATCTG
-------------------------- CCTTCGCTCATATTACCGCCTGATCTG
51 100
Gerard et. a l . 1996 (-348)
Chimpanzee C5aR prom (-2015) TCAGATCAGGGGCGGAATTACATTCTCATAAGAGCGTGAACCCAGGCCGG
Genebank (-2008) TCAGATCAGGGGCGGAATTACATTCTCATAAGAGCGTGAACCCAGGCCGG
U937 (ECACC) (-2010) TCAGATCAGGGGCGGAATTACATTCTCATAAGAGCGTGAACCCAGGCCGG
U937 (PM) (-2012) TCAGATCAGGGGCGGAATTACATTCTCATAAGAGCGTGAACCCAGGCCGG
Gerard et. a l . 1996 (-348)
101 150
Chimpanzee C5aR prom (-1965)
Genebank (-1958) GCGCAGTGGCTCAAGCCTGTAATCCCAGCATTTTGGGAGGCTGAGGCGGG
U937 (ECACC) (-1960) GCGCAGTGGCTCAAGCCTGTAATCCCAGCATTTTGGGAGGCTGAGGCGGG
U937 (PM) (-1962) GCGCAGTGGCTCAAGCCTGTAATCCCAGCATTTTGGGAGGCTGAGGCGGG
Gerard et . al. 1996 (-348)
151 200
Chimpanzee C5aR prom (-1915) TGGATCACGAGGTCAGGAGTTCGAGATCAGCCTGGCCAAGATGGTGAAAC
Genebank (-1908) TGGATCACGAGGTCAGGAGTTCGAGATCAGCCTGGCCAAGATGGTGAAAC
U937 (ECACC) (-1910) TGGATCACGAGGTCAGGAGTTCGAGATCAGCCTGGCCAAGATGGTGAAAC
LJ937 (PM) (-1912) TGGATCACGAGGTCAGGAGTTCGAGATCAGCCTGGCCAAGATGGTGAAAC
Gerard e t . 
Chimpanzee 
Genebank
al.
C5aR
1996
prom
(-348)
(-1865)
(-1858)
201 250
CACGTCTCTACTAAAAA-TACAAAAATTAGCCGGGCGCAGTGGTAGGCGT
Iffl 11— — B— iiMih'iinniiilnh in i i i ... .
U937 (ECACC) (-1860) GlijTiTCTCTACTAAAA^ATACAAAAATTAGCCGGGCGCAGTGGTAGGCAi
U937 (PM) (-1862) ;TCTCTACTAAAAA/\TACAAAAATTAGCCGGGCGCAGTGGTAGGCAC
Gerard et. a l . 1996 (-348)
251 300
Chimpanzee C5aR prom (-1816) CTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCT
Genebank (-1809) CTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCT
U937 (ECACC) (-1810) CTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCT
U937 (PM) 
Gerard e t .
(-1812) CTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCT
al. 1996 (-348)
301 350
Chimpanzee C5aR prom (-1766) GGGAGGCGGAGGTTGCAGTGTGCCGAGATCGTGCCATTGCACTCTAGCCT
Genebank (-1759) GGGAGGCGGAGGTTGCAGTGTGCCGAGATCGTGCCACTGCACTCTAGCCl
U937 (ECACC) (-1760) GGGAGGCGGAGGTTGCAGTGTGCCGAGATCGTGCCACTGCACTCTAGCC|
U937 (PM) 
Gerard et.
(-1762) GGGAGGCGGAGGTTGCAGTGTGCCGAGATCGTGCCACTGCACTCTAGCC|
al. 1996 (-348)
351 400
Chimpanzee C5aR prom (-1716) GGGTGAGAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAA
Genebank (-1709) GGGTGAGAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAA---
U937 (ECACC) (-1710) GGGTGAGAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAA---
U937 (PM) (-1712) GGGTGAGAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAA
1996
prom
(-348)
(-1666)
(-1662)
(-1663)
401 450
uerara et. a ± .  
Chimpanzee C5aR 
Genebank 
□937 (ECACC)
AAGAGCGTGAACCCTGTTGTGAACAGCGCATGTGAGGGATCTGGGTTGCA
-AGAGCATGAACCCTGTTGTGAACAGCGCATGTGAGGGATCTGGGTTGC|
-AGAGCATGAACCCTGTTGTGAACAGCGCATGTGAGGGATCTGGGTTGCA
289
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
451 500
(-348)
(-1616) AGCTCCTTATGAGAATCTAATGCCTGATGATCTGTCACTGTATCCCATCA
(-1612) Ag c t c c t t a t g a g a a t c t a a t g c c t g a t g a t c t g t c a c t g t a t c c c a t c a
(-1613) AGCTCCTTATGAGAATCTAATGCCTGATGATCTGTCACTGTATCCCATCA
(-1612) Ag c t c c t t a t g a g a a t c t a a t g c c t g a t g a t c t g t c a c t g t a t c c c a t c ^
(-348)
501 550
(-1566)
(-1562) CCCCCAGATAGGACCATCTCGTTACAGGAAAACAAGCTCAGGGATTCCAC
(-1563) |)C CCC AG AT AGGAC C AT C T CGT T AC AGGAAAAC AAGCT CAGGGAT T CCAC
(-1562) CCCCCAGATAGGACCATCTCGTTACAGGAAAACAAGCTCAGGGATTCCAl
551 600
(
(-1516) |GATTCTACATTATGTTGAATTGTATAATTATTTCATTATATATTACAA|
(-1512) TGATTCTACATTATGTTGAATTGTATAATTATTTCATTATATATTACAAT
(-1513) TGATTCTACATTATGTTGAATTGTATAATTATTTCATTATATATTACAAT
(-1512) TGAT T C T AC AT T ATGT T GAAT T GT AT AAT TAT T T CAT TAT AT AT TACAAT
(-348)
601 650
(-1466)
(-1462) GTAACAATAATAGATGGAGATGGTTGTGGCTTGTGTAGTTGGGGGACAGG
(-1463) GTAACAATAATAGATGGAGATGGTTGTGGCTTGTGTAGTTGGGGGACAGG
(-1462) GTAACAATAATAGATGGAGATGGTTGTGGCTTGTGTAGTTGGGGGACAGG
/ O i 1 Q \
651 700
V J 4 0 )
(-1416) TAGCTC||ATlHCTAT|GC|AriCT|C-ira a^^H^HH--TGA^|
(-1412) GTAGCTCCATTTTCTATTGCCAACTTTATAACCCTAGAAGGATGATTTTf
(-1413) GTAGCTCCATTTTCTATTGCCAACTTTATAACCCTAGAAGGATGATTTTT
(-1412) GTAGCTCCATTTTCTATTGCCAACTTTATAACCCTAGAAGGATGATTTTT
(-348)
701 750
(-1369) H ---TTCTTTTSAHIIICTillcriTdUcflF^MH^QA^^l^A^iCT
(-1362) TTCTTTTCTTTTCTTTTTCTTTTCTTTTTTTTTTTTTTGAGATTGAGTCT
(-1363) TTCTTTTCTTTTCTTTTTCTTTTCTTTTTTTTTTTTTTGAGATTGAGTCT
(-1362) TTCTTTTCTTTTCTTTTTCTTTTCTTTTTTTTTTTTTTGAGATTGAGTCT
(-348)
751 800
(-1322) I g g t g t t g t c a g c c t g g g c t g g a g t g c a a t g g t g c a a t c t c t g c t c a c t g
(-1312) TGGTGTTGTCAGCCTGGGCTGGAGTGCAATGGTGCAATCTCTGCTCACTG
(-1313) Ig g t g t t g t c a g c c t g g g c t g g a g t g c a a t g g t g c a a t c t c t g c t c a c t g
(-1312) TGGTGTTGTCAGCCTGGGCTGGAGTGCAATGGTGCAATCTCTGCTCACTG
(-348)
801 850
(-1272) CAACCTCCGCCTCCTGGGTTCCAGCAATTCTCCTGCCTCAGCCTTCTGAG
(-1262) CAACCTCCGCCTCCTGGGTTCCAGCAATTCTCCTGCCTCAGCCTTCTGAG
(-1263) CAACCTCCGCCTCCTGGGTTCCAGCAATTCTCCTGCCTCAGCCTTCTGAG
(-1262) CAACCTCCGCCTCCTGGGTTCCAGCAATTCTCCTGCCTCAGCCTTCTGAG
(-348)
851 900
( - 1 2 2 2 )
( - 1 2 1 2 ) TAGCTGAGATTACAGGCACCCACCACCACGCCTGGCTAATTTTTGTATTT
(-1213) TAGCTGAGATTACAGGCACCCACCACCACACCTGGCTAATTTTTGTATTT
( - 1 2 1 2 ) TAGCTGAGATTACAGGCACCCACCACCACACCTGGCTAATTTTTGTATTT
(-348)
901 950
(-1172) TTAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTGGTCACGATGGTTT
(-1162) |TAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTGGTGACGATGGTTT
(-1163) TTAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTGGTGACGATGGTTt
(-1162) iTAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTGGTGACGATGGTTf
290
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
951 1000
(-348) ---------------------------------------------------------
(-1122) TTTTTTTT-GAGACAGAGTCTTGCTTTGTTGCCCAGGCTGGAGTGCAGTG 
(-1112) TTTTTTTTTGAGACAGAGTCTTGCTTTGTTGCCCAGGCTGGAGTGCAGTG 
(-1113) TTTTTTTTTGAGACAGAGTCTTGCTTTGTTGCCCAGGCTGGAGTGCAGTG 
. . . . ) TTTTTTTTTGAGACAGAGTCTTGCTTTGTTGCCCAGGCTGGAGTGCAGTG 
1001 1050
(-348) ---------------------------------------------------------
(-1072) GCGOGATCTTGGCTCACTGCAACCTCTGCCTCCCAGGTTTAAGCAATTCT 
(-1062) GCGCAATCTTGGCTCACTGCAACCTCTGCCTCCCAGGTTTAAGCAATTCT 
(-1063) GCGCAATCTTGGCTCACTGCAACCTCTGCCTCCCAGGTTTAAGCAATTCT 
(-1062) GCGCAATCTTGGCTCACTGCAACCTCTGCCTCCCAGGTTTAAGCAATTCT 
1051 1100
(-348 
[-1022 
(-1012 
(-1013 
(-1012
-348
-972
-962
-963
-962
-348
-922
■912
-913
-912
-348
-872
-862
-863
-862
-348
-822
-812
•813
-812
-348
-772
-762
-763
-762
•348
-723
-713
-713
-713
-348
-673
-663
-663
-663
CCTGCCTCAGCTTCCCAAGTAGCTGGGATTACAGGCACCTGCCACCACAC
CCTGCCTCAGCTTCCCAAGTAGCTGGGATTACAGGCACCTGCCACCACAC
CCTGCCTCAGCTTCCCAAGTAGCTGGGATTACAGGCACCTGCCACCACAC
1101 1150
CTGGGTAATTTTTGTATTTTTTGTAGAGACAGGGTTTCACCATGTTGGCC
CTGGGTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCC
CTGGGTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCC
CTGGGTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCC
1151 1200
AGACTOGTCTTGAACTCCTGACCTCAAGTGATTCATTTGCCTCAGCCTCC
AGACTCGTCTTGAACTCCTGACCTCAAGTGATTCATTTGCCTCAGCCTCC
AGACTCGTCTTGAACTCCTGACCTCAAGTGATTCATTTGCCTCAGCCTCC
AGACTCGTCTTGAACTCCTGACCTCAAGTGATTCATTTGCCTCAGCCTCC
1201 1250
CAAAGTGCTGGGATTATAGGTGTGAGCCATTGCACCTGGCCCTAGAAGGA
CAAAGTGCTGGGATTATAGGTGTGAGCCATTGCACCTGGCCCTAGAAGGA
CAAAGTGCTGGGATTATAGGTGTGAGCCATTGCACCTGGCCCTAGAAGGA
CAAAGTGCTGGGATTATAGGTGTGAGCCATTGCACCTGGCCCTAGAAGGA
1251 1300
AGATTTAACAGTAAAATATACTTAAATGCTGGGCTACCTCCGCAGACTAG
AGATTTAACAGTAAAATATACTTAAATGCTGGGCTACCTCCGCAGACTAG
AGATTTAACAGTAAAATATACTTAAATGCTGGGCTACCTCCGCAGACTAG
1301 1350
CTCOiGCCTCTTTGGGTCTCAAATCAGCCTGGCC-GGGAGGCTGAGTGGAG
CTCAGCCTCTTTGGGTCTCAAATCAGCCTGGCC-GGGAGGCTGAGTGGAG
CTCAGCCTCTTTGGGTCTCAAATCAGCCTGGCCCGGGAGGCTGAGTGGAG
CTCAGCCTCTTTGGGTCTCAAATCAGCCTGGCC-GGGAGGCTGAGTGGAG
1351 1400
GTTACAATCTCTGCTTTCTTGAATCCCAAGGGAGGGGTTTAAGCCAACTG
GTTACAGTCTCTGCTTTCTTGAATCCCAAGGGAGGGGTTTAAGCCAACTG
GTTACAGTCTCTGCTTTCTTGAATCCCAAGGGAGGGGTTTAAGCCAACTG
GTTACAGTCTCTGCTTTCTTGAATCCCAAGGGAGGGGTTTAAGCCAACTG
1401 1450
CATTCCTGAGCTTTTGCCCAGAAGGCTGGCGTCTTAGGAGGAAAGAGATA
CATTCCTGAGCTTTTGCCCAGAAGGCTGGCGTCTTAGGAGGAAAGAGATA
CATTCCTGAGCTTTTGCCCAGAAGGCTGGCGTCTTAGGAGGAAAGAGATA
CATTCCTGAGCTTTTGCCCAGAAGGCTGGCGTCTTAGGAGGAAAGAGATA
1451 1500
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Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. a l . 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard et. al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
Gerard e t . al. 1996 
Chimpanzee C5aR prom 
Genebank 
U937 (ECACC)
U937 (PM)
348
623
613
613
613
348
573
563
563
563
348
523
513
513
513
348
473
463
463
463
348
423
413
413
413
GATGGCTCCAGGCCGGGCGCAGTGGCTCACACTTGTAATTCTAGCACTTT
GATGGCTCCAGGCCGGGCGCAGTGGCTCACACTTGTAATTCTAGCACTTT
GATGGCTCCAGGCCGGGCGCAGTGGCTCACACTTGTAATTCTAGCACTTT
1501 1550
GGGAGGTCGAGATGGGTGATTGCCTGAGCTCAGGAGTTTGAGTCCAGCCT
GGGAGGTTGAGGTGGGTGATTGCCTGAGCTCAGGAGTTTGAGTCCAGCCT
GGGAGGTTGAGGTGGGTGATTGCCTGAGCTCAGGAGTTTGAGTCCAGCCT
GGGAGGTTGAGGTGGGTGATTGCCTGAGCTCAGGAGTTTGAGTCCAGCCT
1551 1600
GGCCAACATGGCGAAACCCCGTCTTTACTAAAAATACAAAAAATTAGCCG
GGCCAACATGGCGAAACCCCGTCTTTACTAAAAATACAAAAAATTAGCCG
GGCCAACATGGCGAAACCCCGTCTTTACTAAAAATACAAAAAATTAGCCA
GGCCAACATGGCGAAACCCCGTCTTTACTAAAAATACAAAAAATTAGCCG
1601 1650
GGGGTGGTGACACACACGTGTAATCCCAGCTACTCGGGAGGCTGAGGCAG
GGGGTGGTGACACACACGTGTAATCCCAGCTACTCGGGAGGCTGAGGCAG
1651 1700
GAGAATTGCTTGAACCCGGGAGGCAGAGGTTACAGAGAGCCGAGATTGCA
g a g a a g t g c t t g a a c c c a g g a g g c a g a g g t t a c a g a g a g c c g a g a t t g c a
GAGAAGTGCTTGAACCCGGGAGGCAGAGGTTACAGAGAGCCGAGATTGCA 
GAGAAGTGCTTGAACCCAGGAGGCAGAGGTTACAGAGAGCCGAGATTGCA
1701 1750
34 8 ) ------  CTGCAGCCTGGG|GACACA-CAAGACTCTATC--------
373) H CI ^ M CTGCAGCCTGGGTGACACA|CAAGACTCTATCTAAAAAAAAA
3 6 3 )  | H ^ H H CTGCAGCCTGGGl GACACAi CAAGACTCTATC-----------------------
363) CCACTCC|CTGCAGCCTGGG|GACACAlCAAGACTCTATC-----------
363) | ^ H | B H CTGCAGCCTGGGlGACACAiCAAGACTCTATC----------
1751 1800
3 1 7 )  AAAAAAAA A AA AA A AA A AA T G AG AG AG AAG AG AT GG C C C C AAAT AGGG AA 
323) AAAAAAAAAAAAAAAAAAATGAGAGAGAAGAGATGGCCCCAAATAGGGAA 
3 2 3 )  A A AA A AAAAAA AAAAAAAAT GAG AG AG AAG AG AT G GC C CC AAAT AGG G AA 
3 2 3 )  AAAAAAAAAAAAAAAAAAATGAGAGAGAAGAGATGGCCCCAAATAGGGAA 
3 2 3 )  AA A AA AAAAAA AAAAAAAAT GAGAGAG AAGAGAT GGCCCCAAAT AGGGAA 
1801 1850
Highlighted in pink SNP published Barnes et al 2004
-253bp T/C
267) a c c a a g g c c a g g a g a g g g g c I g a g c -t g c a c a g g a g c t t c c t c g g t t t t c  
273) a c c a a g g c c a g g a g a g g g g c | g a g c | t g c a c a g g a g c t t c c t c g g t t t t c  
273) a c c a a g g c c a g g a g a g g g g c I g a g c I t g c a c a g g a g c t t c c t c g g t t t t c  
273) a c c a a g g c c a g g a g a g g g g c I g a g c I t g c a c a g g a g c t t c c t c g g t t t t c  
273) a c c a a g g c c a g g a g a g g g g c | g a g c | t g c a c a g g a g c t t c c t c g g t t t t c  
1851 1900
2 1 8 )  CGAGGCCCGGCCCCCC-TTCTCTGCCTGGGAGGAGGTGGTTAGAGTCCCC
224) C G A G H GGGGCCCCCCCTTCTCTGCCTGGGAGGAGGTGGTTAGAGTCCCC 
223) C G A G H CCGGCCCCCC" TTCTCTGCCTGGGAGGAGGTGGTTAGAGTCCCC 
223) C G A G M CCGGCCCCCC-TTCTCTGCCTGGGAGGAGGTGGTTAGAGTCCCC 
223) c g a g B c c g g c c c c c c -t t c t c t g c c t g g g a g g a g g t g g t t a g a g t c c c c  
1901 1950
1 6 7 )  TGGGTGTGTGCCCCGCAGAGG-AGCTCTGGCCTCAGTGCC-AGTGTGCAG
174) t g g g t g t g t g c c c c g c a g a g g ! a g c t c t g g c c t c a g t g c c |a g t g t g c a g  
174) t g g g t g t g t g c c c c g c a g a g g | a g c t c t g g c c t c a g t g c c | a g t g t g c a g  
174) t g g g t g t g t g c c c c g c a g a g g | a g c t c t g g c c t c a g t g c c |a g t g t g c a g
1 7 4 )  TGGGTGTGTGCCCCGCAGAGGiAGCTCTGGCCTCAGTGCC|AGTGTGCAG
292
Gerard et. al. 1996 (-119)
Chimpanzee C5aR prom (-124)
Genebank (-124)
U937 (ECACC) (-124)
U937 (PM) (-124)
Gerard e t . a l . 1996 (-70)
Chimpanzee C5aR prom (-74)
Genebank (-74)
U937 (ECACC) (-74)
U937 (PM) (-74)
Gerard et. al. 1996 (-24)
Chimpanzee C5aR prom (-24)
Genebank (-24)
U937 (ECACC) (-24)
U937 (PM) (-24)
1951 2000
ACCAATGAGAGCCCCAGAGAGAAAGACGGTCATTTCCTCCCTGCATCT-| 
a c c a a t g a g a g c c c c a g a g a g a a a g a c g g t c a t t t c c t c c c t g c a t c t | t
a c c a a t g a g a g c c c c a g a g a g a a a g a c g g t c a t t t c c t c c c t g c a t c t H
AC CAAT GAGAG C CCCAGAGAGAAAGACG G T CAT T T C C T C C C T G CAT C T M l  
a c c a a t g a g a g c c c c a g a g a g a a a g a c g g t c a t t t c c t c c c t g c a t c t HI
2001 2050
CCTTGGG-CTTTAAAAACCACAGCCCTTGC GGAGGGACCTTCGATCC
c c t t g g g | c t t t a a a a a c c a c a g c c c t t g ^ H g g a g g g a c c t t c g a t c c
c c t t g g g |c t t t a a a a a c c a c a g c c c t t g ^ ^ ^ g a g g g a c c t t c g a t c c
c c t t g g g | c t t t a a a a a c c a c a g c c c t t g ^ B g g a g g g a c c t t c g a t c c
C C TTG G G lC TTTA A A AA C C AC A G C C C TTG B M G G A G G G A C C TTC G A TC C
2051 2077
TCGGGGAGCCCAGGAGACCAGAACATG
TCGGGGAGCCCAGGAGACCAGAAC---
TCGGGGAGCCCAGGAGACCAGAAC---
TCGGGGAGCCCAGGAGACCAGAAC---
TCGGGGAGCCCAGGAGACCAGAAC---
9.3 Human and mouse C5aR promoter aligned
C5aR prom hum tr (-399) 
C5aR Prom mouse (-321)
C5aR prom hum tr (-251) 
C5aR Prom mouse (-273)
C5aR prom hum tr (-210) 
C5aR Prom mouse (-223)
C5aR prom hum tr (-163) 
C5aR Prom mouse (-173)
C5aR prom hum tr (-113) 
C5aR Prom mouse (-125)
C5aR prom hum tr (-71) 
C5aR Prom mouse (-75)
C5aR prom hum tr (-24) 
C5aR Prom mouse (-27)
1 50
GAGAAG-AGATG-GCCCCAAATAGGGAAACCAAGGCCAGGAGAGGGGCCG 
GAAAAGCAGCTGCGTCCCCAAAAGTGAAG— AAGTCCTGGAAATTGCCTT 
51 NFkB  100
AGC C T G CACAG GAG C--------TTCCTCGGTTTTCCGAGC-GCCGGCCC-
TTCCCCTTCTGGGGCCAGAGACTTCCTTCCTTTTCCAAGTTGACATCTCT 
101 150
CCCTTCTCTGCCTGGGA GGAGGTGGTTAGAGTCCCCTGGGTGTGTGC
CCCCTGGCTGGTTGGTACTGGGTGGTGCTGAGGGTGTACTGGGTAAGCAC 
151 200
CCCGCAGAGGGAGCTCTGGCCTCAGTGCCCAGTGTGCAGACCAArGAGAG 
CG-GTGGAGGGAGCCTCAGCTAGGATGGTCAGTGAGT-GACCAATGAGCA
CCAAT binding factor(NFY) 
201 250
CCCCAGAGAGA AAGACGGTCATTTCCTC--------CCTGCATCTTCCCT
C C TC CAGGAGACAAGACAGTCA TTTCCTCT C AGT T GC C T GC AT C T C T T C T 
Nuclear factor of activated T-cells 
251 300
TGGGGCTTTAAAAACCACAGCCCTTGGGCAGGAGGGACCTTCG ATCC
T GAG G GT T TAAAAG GCACAG C C— TGGGTGACAGGGACCTTCAGGCATCC 
301 327
-TCG— GGGAGCCCAGGAGACCAGAAC 
GTCGCTGGT T AC CAC AG AAC C C AG GAG
293
E2F-myc activator/cell cycle regulator -2030 -2014 - 1.000
PAX-4/PAX-6 paired domain biding sites -2027 -2009 + 1.000
TALE homedomain class recognizing TG 
motiffs -2015 -2005 + 1.000
Zinc binding protein factors -2011 -1989 - 1.000
GC-Box factors SP1/GC -2005 -1991 + 1.000
Pancreatic and intestinal homeodomain 
trascription factor -2002 -1982 1.000
Factors with moderate activity to homeo 
domain consensus sequence -2000 -1984 1.000
PAR/bZIP family -1997 -1981 - 1.000
Signal transducer and activtor of 
transcription -1994 -1976 0.807
Octamer binding protein -1993 -1979 - 1.000
PAX-4/PAX-6 paired domain biding sites -1987 -1969 - 1.000
Camp-responsive element binding proteins -1986 -1966 - 0.784
E2F-myc activator/cell cycle regulator -1982 -1966 + 0.847
Metal induced transcription factor -1967 -1953 - 0.949
Selenocysteine tRNA activating factor -1942 -1920 - 1.000
v-ERB and RAR-related orphan receptor 
alpha -1917 -1895 + 0.750
RXR heterodimer binding sites -1916 -1892 + 1.000
E-box binding factors -1909 -1897 + 1.000
v-ERB and RAR-related orphan receptor 
alpha -1909 -1887 + 1.000
RXR heterodimer binding sites -1902 -1878 + 0.888
AARE binding factors -1869 -1861 - 1.000
Vertebrate caudal related homeodomain 
transcription factors -1857 -1839 1.000
Metal induced transcription factor -1833 -1819 - 0.949
myoblast determining factors -1818 -1802 - 1.000
Two-handed zinc finger homeodomain -1817 -1805 + 1.000
Pur-alpha binds both single-stranded and 
double stranded DNA in sequence-specific 
manner -1759 -1747 + 1.000
C/EBP homologous protein (CHOP) -1753 -1741 - 1.000
PAX-3 binding sites -1752 -1734 - 0.780
X-box binding factors -1752 -1734 - 1.000
Nuclear receptor subfamily 2 factors -1729 -1705 - 0.777
Peroxisome proliferator-activated receptor -1726 -1704 - 0.807
PAX-4/PAX-6 paired domain biding sites -1725 -1707 + 1.000
PAX-9 binding sites -1724 -1704 - 1.000
GC-Box factors SP1/GC -1700 -1686 - 1.000
Fork head domain factors -1648 -1632 + 1.000 0.785
Pancreas transcription factor 1, 
heterotrimeric transcription factor -1646 -1626 0.761 0.800
AP4 and related proteins -1627 -1611 - 1.000 0.931
Signal transducer and activtor of 
transcription -1609 -1591 + 0.807 0.876
Octamer binding protein -1606 -1592 + 1.000 0.826
Pancreatic and intestinal homeodomain 
trascription factor -1603 -1583 + 1.000 0.879
PAX-4/PAX-6 paired domain biding sites -1600 -1582 - 0.754 0.758
MAF and AP1 related factors -1589 -1569 - 1.000 0.810
HOX - MEIS1 -1589 -1575 - 1.000 0.806
PAX-5 B-cell-specific activator protein -1582 -1554 + 0.947 0.845
TALE homedomain class recognizing TG 
motiffs -1582 -1572 + 1.000 0.971
GLI zinc finger family -1568 -1554 + 1.000 0.900
Serum response element binding factor -1563 -1545 - 0.757 0.751
GATA binding factors -1559 -1547 + 1.000 0.968
bHLH transcription factor dimer of HAND2 
and E12 -1555 -1541 + 0.758 0.764
Cellular and viral myb-like transcriptional 
regulators -1548 -1536 1.000 0.891
Signal transducer and activtor of 
transcription -1546 -1528 . 0.762 0.783
PAR/bZIP family -1544 -1528 - 1.000 0.862
Signal transducer and activtor of 
transcription -1544 -1526 + 1.000 0.953
X-box binding factors -1544 -1526 - 1.000 0.799
Fork head domain factors -1539 -1523 + 1.000 0.980
Brn POU domain -1511 -1493 - 1.000 0.743
Factors with moderate activity to homeo 
domain consensus sequence -1511 -1495 1.000 0.826
snRNA-activating protein complex -1510 -1492 - 0.892 0.752
Factors with moderate activity to homeo 
domain consensus sequence -1508 -1492 1.000 0.872
SOX/SRY-sex/testis determinig and related 
HMG box -1499 -1483 1.000 0.872
CLOX and CLOX homology (CDP) factors -1498 -1476 + 1.000 0.714
Cart-1 (cartilage homeoprotein 1) -1496 -1480 + 0.750 0.835
PAR/bZIP family -1496 -1480 + 0.800 0.845
Cart-1 (cartilage homeoprotein 1) -1495 -1479 - 1.000 0.832
Homeodomain transcription factors -1495 -1479 + 1.000 0.994
PAR/bZIP family -1495 -1479 - 0.860 0.792
Brn POU domain -1493 -1475 + 1.000 0.906
Brn POU domain -1492 -1474 - 1.000 0.782
Pancreatic and intestinal homeodomain 
trascription factor -1492 -1472 1.000 0.743
NKX homeodomain -1491 -1477 + 0.773 0.845
Tata-bindinq protein factors -1491 -1475 + 1.000 0.826
Factors with moderate activity to homeo 
domain consensus sequence -1490 -1474 1.000 0.854
NKX homeodomain -1490 -1476 - 0.773 0.868
Lim homeodomain factors -1489 -1473 - 1.000 0.932
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Cart-1 (cartilage homeoprotein 1) -1488 -1472 + 1.000 0.940
Homeodomain transcription factors -1488 -1472 - 1.000 0.992
Cart-1 (cartilage homeoprotein 1) -1487 -1471 - 1.000 0.919
Cart-1 (cartilage homeoprotein 1) -1485 -1469 + 0.797 0.888
PAR/bZIP family -1484 -1468 - 0.884 0.847
Tata-binding protein factors -1484 -1468 - 1.000 0.823
Tata-binding protein factors -1482 -1466 - 0.891 0.909
Lim homeodomain factors -1481 -1465 - 1.000 0.828
Special AT-rich sequence binding protein -1478 -1464 - 1.000 0.957
OCT6 binding factors-astrocytes + 
glioblastoma cells -1473 -1461 + 1.000 0.913
PAR/bZIP family -1470 -1454 + 1.000 0.895
SOX/SRY-sex/testis determinig and related 
HMG box -1463 -1447 + 1.000 0.993
Fork head domain factors -1461 -1445 + 1.000 0.879
Brn POU domain -1460 -1442 - 1.000 0.832
CLOX and CLOX homology (CDP) factors -1460 -1438 - 0.960 0.731
CLOX and CLOX homology (CDP) factors -1458 -1436 + 1.000 0.840
Factors with moderate activity to homeo 
domain consensus sequence -1458 -1442 + 1.000 0.875
FAST-1 SMAD interacting proteins -1442 -1426 + 1.000 0.826
human actute myelogenous leukemia factors -1440 -1426 + 1.000 0.870
Basonuclein rDNA transcription factor (Poll) -1422 -1404 - 1.000 0.895
CLOX and CLOX homology (CDP) factors -1412 -1390 + 0.960 0.774
Positive regulatory domain I binding factor -1410 -1392 - 1.000 0.865
Activator/repressor binding to transcription 
initiation site -1410 -1392 + 1.000 0.962
Zinc binding protein factors -1410 -1398 + 1.000 0.858
Pancreatic and intestinal homeodomain 
trascription factor -1395 -1375 + 0.826 0.752
Tata-binding protein factors -1395 -1379 - 1.000 0.908
Vertebrate caudal related homeodomain 
transcription factors -1394 -1376 + 1.000 0.886
HOX - MEIS1 -1394 -1380 + 0.750 0.826
Serum response element binding factor -1385 -1367 - 0.786 0.800
snRNA-activating protein complex -1384 -1366 + 1.000 0.760
HOX - PBX complexes -1373 -1357 + 1.000 0.840
EVI1-myleoid transforming protein -1368 -1352 - 1.000 0.898
Interferon regulatory factors -1364 -1344 - 1.000 0.941
EVI1-myleoid transforming protein -1363 -1347 - 1.000 0.898
Interferon regulatory factors -1359 -1339 - 1.000 0.941
EVI1-myleoid transforming protein -1358 -1342 - 1.000 0.791
CAS interacting zinc finger protein -1352 -1342 - 1.000 0.970
EVI1-myleoid transforming protein -1352 -1336 - 1.000 0.898
Human and murine ETS1 -1349 -1329 - 0.857 0.833
Interferon requlatory factors -1348 -1328 - 1.000 0.941
EVM-myleoid transforming protein -1347 -1331 - 1.000 0.808
Onecut homeodomain factor HNF6 -1324 -1308 - 1.000 0.822
Ccaat/Enhancer binding protein -1286 -1272 + 1.000 0.941
RXR heterodimer binding sites -1285 -1261 + 0.790 0.810
C/EBP homologous protein (CHOP) -1282 -1270 + 1.000 0.923
C/EBP homologous protein (CHOP) -1266 -1254 + 1.000 0.973
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Pur-alpha binds both single-stranded and 
double stranded DNA in sequence-specific 
manner -1260 -1248 1.000 0.985
Signal transducer and activtor of 
transcription -1249 -1231 1.000 0.895
Zinc binding protein factors -1249 -1225 + 0.813 0.788
POZ domain zinc finger expressed in B-cells -1248 -1232 - 0.756 0.772
Signal transducer and activtor of 
transcription -1247 -1229 + 0.759 0.801
MAF and AP1 related factors -1234 -1214 + 0.866 0.857
Growth factor independent transcription 
repressor -1212 -1198 1.000 0.960
Sine oculis (SIX) homeodomain factors -1206 -1198 + 1.000 1.000
Zinc binding protein factors -1199 -1177 + 1.000 0.793
myoblast determining factors -1188 -1172 - 1.000 0.986
Two-handed zinc finger homeodomain -1187 -1175 + 1.000 0.988
Brn POU domain -1185 -1167 + 1.000 0.925
MEF2, monocyte-specific enhancer binding 
factor -1173 -1151 1.000 0.802
CLOX and CLOX homology (CDP) factors -1148 -1126 - 1.000 0.944
AARE binding factors -1147 -1139 + 1.000 0.952
snRNA-activating protein complex -1145 -1127 + 0.892 0.735
CCAAT binding factors -1143 -1129 - 1.000 0.910
SWI/SNF related nucleophosphoproteins 
with a RING finger DNA binding motif -1143 -1133 + 1.000 0.961
PAX-3 binding sites -1135 -1117 - 1.000 0.826
Camp-responsive element binding proteins -1132 -1112 + 1.000 0.945
Camp-responsive element binding proteins -1129 -1109 + 1.000 0.907
EVI1-myleoid transforming protein -1126 -1110 + 1.000 0.973
LEF1/TCF -1093 -1077 - 1.000 0.927
PAR/bZIP family -1067 -1051 - 0.860 0.794
Nuclear factor 1 -1056 -1036 + 1.000 0.834
Nuclear factor 1 -1056 -1036 - 0.750 0.877
C/EBP homologous protein (CHOP) -1047 -1035 + 1.000 0.973
Ccaat/Enhancer binding protein -1027 -1013 + 1.000 0.956
PAR/bZIP family -1027 -1011 - 0.860 0.803
RBPJ-kappa -1005 -991 - 1.000 0.940
Signal transducer and activtor of 
transcription -1004 -986 + 1.000 0.842
Vertebrate homologues of enhancer of split 
complex -981 -967 0.750 0.872
myoblast determining factors -981 -965 - 1.000 0.983
myoblast determining factors -969 -953 - 1.000 0.985
Two-handed zinc finger homeodomain -968 -956 + 1.000 0.981
Brn POU domain -966 -948 + 1.000 0.925
MEF2, monocyte-specific enhancer binding 
factor -962 -940 0.780 0.750
Heterogeneous PAX-4 binding sites -959 -949 - 1.000 1.000
AARE bindinq factors -928 -920 + 1.000 0.952
Vertebrate SMAD family of transcription 
factors -915 -907 1.000 0.991
RXR heterodimer binding sites -905 -881 - 1.000 0.972
v-ERB and RAR-related orphan receptor -902 -880 - 1.000 0.921
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alpha
Camp-responsive element binding proteins -899 -879 + 1.000 0.992
NKX homeodomain -892 -878 + 1.000 1.000
HOX-PBX complexes -887 -871 + 1.000 0.832
Factors with moderate activity to homeo 
domain consensus sequence -886 -870 1.000 0.911
AP1, Activating protein 1 -885 -875 + 0.833 0.946
AP1, Activating protein 1 -885 -875 _ 0.880 0.960
SOX/SRY-sex/testis determinig and related 
HMG box -885 -869 + 0.916 0.906
CLOX and CLOX homology (CDP) factors -864 -842 - 1.000 0.752
Factors with moderate activity to homeo 
domain consensus sequence -858 -842 0.878 0.941
Brachyury gene mesoderm developmental 
factor -853 -833 + 1.000 0.999
C/EBP homologous protein (CHOP) -837 -825 1.000 0.917
Metal induced transcription factor -834 -820 + 1.000 0.900
myoblast determining factors -834 -818 - 1.000 0.984
Two-handed zinc finger homeodomain -833 -821 + 1.000 0.962
Serum response element binding factor -827 -809 - 0.786 0.842
snRNA-activating protein complex -826 -808 + 1.000 0.771
GATA binding factors -814 -802 + 1.000 0.916
PAX-2 binding sites -805 -783 + 0.789 0.780
MYT1 C2HC zinc finger protein -801 -789 + 0.750 0.798
OCT1 binding factor (POU-specific domain) -799 -787 + 1.000 0.864
NKX homeodomain -797 -783 - 1.000 0.976
Tata-binding protein factors -797 -781 - 1.000 0.874
Lim homeodomain factors -796 -780 - 1.000 0.814
PAX-2/5/8 binding sites -796 -784 - 0.800 0.887
NKX homeodomain -794 -780 + 1.000 0.928
Mouse Krueppel like factor -767 -747 + 0.750 0.741
Neuron-restrictive silencer factor -738 -718 - 0.782 0.707
0.782 0.721
E2F-myc activator/cell cycle regulator -737 -721 + 0.809 0.859
Absent in U937PM
NKX homeodomain -726 -712 + 1.000 0.974
Heat shock factors -706 -682 - 1.000 0.864
Neuron-specific-olfactory factor -696 -674 - 1.000 0.922
Neuron-specific-olfactory factor -695 -673 + 1.000 0.882
EGR/nerve growth factor induced protein C 
& related factors -687 -671 + 1.000 0.883
GC-Box factors SP1/GC -687 -673 + 0.876 0.900
Myc associated Zinc fingers -685 -673 + 1.000 0.886
Nuclear factor 1 -683 -663 - 1.000 0.820
PAX-2 bindinq sites -678 -656 - 1.000 0.793
NeuroD, Beta2, HLH domain -672 -660 + 0.767 0.841
Octamer bindinq protein -671 -657 - 1.000 0.816
Cellular and viral myb-like transcriptional 
regulators -670 -658 + 1.000 0.904
TEA/ATTS DNA binding domain factors -665 -653 + 1.000 0.692
Nuclear receptor subfamily 2 factors -662 -638 - 1.000 0.886
Peroxisome proliferator-activated receptor -659 -637 - 0.784 0.872
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Camp-responsive element binding proteins -642 -622 + 0.750 0.834
Winged helix binding sites -638 -628 _ 1.000 0.960
Interferon regulatory factors -626 -606 + 0.774 0.850
Nuclear factor of activated T-cells -626 -608 + 1.000 0.994
CLOX and CLOX homology (CDP) factors -621 -599 + 0.929 0.956
HOX-PBX complexes -621 -605 + 0.833 0.852
PAX-4/PAX-6 paired domain biding sites -614 -596 + 1.000 0.879
Metal induced transcription factor -603 -589 - 0.949 0.947
PAX-3 binding sites -590 -572 + 1.000 0.872
NKX homeodomain -587 -573 - 1.000 0.902
SWI/SNF related nucleophosphoproteins 
with a RING finger DNA binding motif -586 -576 + 1.000 0.985
OCT6 binding factors-astrocytes + 
glioblastoma cells -582 -570 1.000 0.916
GLI zinc finger family -567 -553 - 1.000 0.876
RXR heterodimer binding sites -564 -540 + 0.952 0.809
Zinc binding protein factors -563 -541 - 1.000 0.753
CCAAT binding factors -550 -536 - 0.750 0.838
PBX1-MEIS1 complexes -550 -534 + 1.000 0.797
GC-Box factors SP1/GC -523 -509 - 1.000 0.841
PAR/bZIP family -509 -493 + 0.781 0.849
MEF2, monocyte-specific enhancer binding 
factor -492 -470 + 0.763 0.891
Zinc binding protein factors -474 -452 - 1.000 0.925
Absent in U937EC
Zinc binding protein factors -471 -449 - 1.000 0.943
Absent in U937EC
Activator protein 2 -469 -455 + 0.881 0.925
0.830 0.912
GLI zinc finger family -466 -452 - 1.000 0.981
MAF and AP1 related factors -463 -443 - 0.813 0.924
Brachyury gene mesoderm developmental 
factor -456 -436 + 0.750 0.706
Hypoxia inducible factor, bHLH/PAS protein 
factor -454 -439 + 1.000 0.960
Vertbrate homologue of enhancer of split 
complex -453 -439 1.000 0.968
Hypoxia inducible factor, bHLH/PAS protein 
factor -453 -437 1.000 0.967
E-box binding factors -452 -440 + 1.000 0.988
Vertebrate homologues of enhancer of split 
complex -452 -438 + 1.000 0.961
E-box binding factors -451 -439 - 1.000 0.977
SWI/SNF related nucleophosphoproteins 
with a RING finger DNA binding motif -402 -402 1.000 0.987
RXR heterodimer binding sites -401 -377 + 1.000 0.822
RXR heterodimer binding sites -391 -367 + 0.952 0.820
C/EBP homologous protein (CHOP) -372 -360 - 1.000 0.917
PAX-5 B-cell-specific activator protein -372 -344 - 0.904 0.800
Ccaat/Enhancer binding protein -370 -356 - 1.000 0.960
Selenocysteine tRNA activating factor -361 -339 - 1.000 0.781
X-box binding factors -354 -336 + 1.000 0.939
HOX-PBX complexes -334 : -318 - 0.764 0.801
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EVI1-myleoid transforming protein -300 -284 + 1.000 0.833
Activator/repressor binding to transcription 
initiation site -300 -282 1.000 0.857
bHLH transcription factor dimer of HAND2 
and E12 -294 -280 1.000 0.794
E2F-myc activator/cell cycle regulator -292 -276 + 1.000 0.849
Serum response element binding factor -289 -271 - 0.885 0.870
Serum response element binding factor -288 -270 + 0.888 0.903
RXR heterodimer binding sites -283 -259 + 1.000 0.902
Interferon regulatory factors -279 -259 + 1.000 0.736
Estrogen response element -276 -258 + 1.000 0.890
p53 tumor suppressor -274 -252 + 1.000 0.783
Vertebrate steroidogenic factor -274 -262 + 1.000 0.992
Mouse Krueppel like factor -273 -253 - 1.000 0.796
GC-Box factors SP1/GC -260 -246 + 1.000 0.851
MAF and AP1 related factors -258 -238 + 0.875 0.948
0.750 0.905
CP2-erythrocyte factor related to drosophila -244 -226 + 0.791 0.861
Human and murine ETS1 -244 -224 - 1.000 0.895
Heat shock factors -243 -219 - 0.763 0.768
Nuclear factor kappa B/c-rel -243 -231 + 1.000 0.902
Nuclear respiratory factor 1 -222 -206 + 1.000 0.793
PAX-5 B-cell-specific activator protein -220 -192 - 0.952 0.843
CTCF BORIS gene family, transcription 
regulators with 11 highly conserved zinc 
finger domains -216 -192 0.789 0.805
Autoimmune regulatory element binding 
factor -204 -178 + 1.000 0.860
EGR/nerve growth factor induced protein C 
& related factors -204 -188 + 0.832 0.817
Neuron-specific-olfactory factor -184 -162 + 1.000 0.927
GC-Box factors SP1/GC -176 -162 + 0.750 0.878
Basic and erythroid krueppel like factors -214 -158 + 1.000 0.950
Nuclear receptor subfamily 2 factors -159 -135 - 0.779 0.863
Peroxisome proliferator-activated receptor -156 -134 - 0.784 0.765
RXR heterodimer binding sites -150 -126 - 1.000 0.895
Selenocysteine tRNA activating factor -139 -117 + 1.000 0.830
CLOX and CLOX homology (CDP) factors -129 -107 + 1.000 0.957
CCAAT binding factors -126 -112 + 1.000 0.966
v-ERB and RAR-related orphan receptor 
alpha -105 -83 + 1.000 0.910
Nuclear factor of activated T-cells -102 -84 - 1.000 0.970
Homolog to deformed epidermal 
autorequlatorv factor-1 from D. melangoaster -101 -83 + 0.761 0.761-------------------------W------------------- d.------------------------------------ ------------------------------------------- ** --------------------------
Human and murine ETS1 -99 -79 - 1.000 0.934
TCF11 transcription factor -95 -89 + 1.000 1.000
Neuron-specific-olfactory factor -81 -59 + 1.000 0.972
Tata-binding protein factors -72 -56 - 1.000 0.901
Tata-binding protein factors -67 -51 + 1.000 0.908
human actute myeloqenous leukemia factors -63 -49 - 1.000 0.980
Activator protein 2 -53 -39 - 0.905 0.924
Nuclear receptor subfamily 2 factors -42 -18 - 0.750 0.761
RXR heterodimer binding sites -40 -16 - 0.782 0.700
300
Neron-restrictive silencer factor -32 -12 + 0.782 0.700
X-box binding factors -21 -3 + 0.875 0.957
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9.5 The C5aR 3 ’UTR sequences aligned
3'UTR EC (1)
3'UTR PM (1)
gen 3'UTR (1)
C5aR mRNA HUMC5AAR (1078)
mRNA C5aR NM_001736 (1103)
C5aR mRNA BC008982 (1131)
3'UTR Chimp (1)
Consensus (1131)
3'UTR EC (51)
3'UTR PM (51)
gen 3'UTR (51)
C5aR mRNA HUMC5AAR (1128)
mRNA C5aR NM 001736 (1153)
C5aR mRNA BC008 982 (1181)
3'UTR Chimp (51)
Consensus (1181)
3'UTR EC (98)
3'UTR PM (98)
gen 3'UTR (98)
C5aR mRNA HUMC5AAR (1175)
mRNA C5aR NM 001736 (1200)
C5aR mRNA BC008 982 (1228)
3'UTR Chimp (101)
Consensus (1231)
3'UTR EC (148)
3'UTR PM (148)
gen 3'UTR (148)
C5aR mRNA HUMC5AAR (1225)
mRNA C5aR NM 001736 (1250)
C5aR mRNA BCQ08982 (1278)
3'UTR Chimp (151)
Consensus (1281)
3'UTR EC (198)
3'UTR PM (198)
gen 3'UTR (198)
C5aR mRNA HUMC5AAR (1275)
mRNA C5aR NM 001736 (1300)
C5aR mRNA BC008982 (1328)
3'UTR Chimp (201)
Consensus (1331)
3'UTR EC (246)
3'UTR PM (246)
gen 3'UTR (247)
C5aR mRNA HUMC5AAR (1323)
mRNA C5aR NM 001736 (1349)
C5aR mRNA BC008 982 (1376)
3'UTR Chimp (251)
Consensus (1381)
1131 1180
GCGACAGCC|CATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCC|CATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCClCATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCC|CATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCC|CATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCC|CATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCCGCATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
GCGACAGCCTCATGGGCCACTGTGGCCCGATGTCCCCTTCCTTCCCGGCC 
1181 1230
a t t c t c c — c t c t t g t t t | c a c t | c a c t t t t c g t g g g a t g g 1 g t t a c c t  
a t t c t c c — c t c t t g t t t c c a c t | c a c t t t t c g t g g g a t g g | g t t a c c t  
a t t c t c c — c t c t t g t t t | c a c t | c a c t t t t c g t g g g a t g g | g t t a c c t  
a t t c t c c — c t c t t g t t t | c a c t | c a c t t t t c g t g g g a t g g | g t t a c c t  
a t t c t c c — c t c t t g t t t | c a c t | c a c t t t t c g t g g g a t g g | g t t a c c t  
a t t c t c c — c t c t t g t t t | c a c t | c a c t t t t c g t g g g a t g g | g t t a c c t  
a t t c t c c t t c c t c t t g t t t | c a c t c c a c t t t t c g t g g g a t g g c g t t a c c t
ATTC TC C  CTCTTGTTTTCACTTCACTTTTCGTGGGATGGTGTTACCT 
1231 1280
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
TAGCTAACTAACTCTCCTCCATGTTGCCTGTCTTTCCCAGACTTGTCCCT 
1281 1330
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
CCTTTTCCAGCGGGACTCTTCTCATCCTTCCTCATTTGCAAGGTGAACAC 
1331 1380
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCC|--CACACACCA 
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCCA--CACACACCA
t t c c t t c t a g g g a g c a c c c t c c c a c c c c c c a c c c c c c c | a - c a c a c a c c a
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCC|— CACACACCA
t t c c t t c t a g g g a g c a c c c t c c c a c c c c c c a c c c c c c c | a - c a c a c a c c a
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCC|— CACACACCA 
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCC|CCCACACACCA 
TTCCTTCTAGGGAGCACCCTCCCACCCCCCACCCCCCCC CACACACCA 
1381 1430
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG 
TCTTTCCATCCCAGGCTTTTGAAAAACAAACAGAAACCCGTGTATCTGGG
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1431 1480
3'UTR EC (296)
3'UTR PM (296)
gen 3'UTR (297)
C5aR mRNA HUMC5AAR (1373)
mRNA C5aR NM 001736 (1399)
C5aR mRNA BC008 982 (1426)
3'UTR Chimp (301)
Consensus (1431)
3'UTR EC (346)
3'UTR PM (346)
gen 3'UTR (347)
C5aR mRNA HUMC5AAR (1423)
mRNA C5aR NM 001736 (1449)
C5aR mRNA BC008 982 (1476)
3'UTR Chimp (351)
Consensus (1481)
3 ’UTR EC (395)
3'UTR PM (395)
gen 3'UTR (397)
C5aR mRNA HUMC5AAR (1472)
mRNA C5aR NM 001736 (1499)
C5aR mRNA BC008982 (1525)
3'UTR Chimp (400)
Consensus (1531)
3'UTR EC (445)
3'UTR PM (445)
gen 3'UTR (447)
C5aR mRNA HUMC5AAR (1522)
mRNA C5aR NM 001736 (1549)
C5aR mRNA BC008982 (1575)
3'UTR Chimp (450)
Consensus (1581)
3'UTR EC (495)
3'UTR PM (495)
gen 3'UTR (497)
C5aR mRNA HUMC5AAR (1572)
mRNA C5aR NM 001736 (1599)
C5aR mRNA BC008982 (1625)
3'UTR Chimp (500)
Consensus (1631)
3'UTR EC (545)
3'UTR PM (545)
gen 3'UTR (547)
C5aR mRNA HUMC5AAR (1622)
mRNA C5aR NM 001736 (1649)
C5aR mRNA BC008 982 (1626)
3'UTR Chimp (550)
Consensus (1681)
ATAT T T C CATAT GGCAATAG GT G T GAACAGGGAAC T CAGAATACAGACAA 
ATATTTCCATATGGCAATAGGTGTGAACAGGGAACTCAGAATACAGACAA 
AT AT T T C CAT AT G G C AAT AG G T G T G AAC AG GGAAC T C AG AAT AC AG AC AA 
AT AT T T C CAT AT G GCAATAGG T GT GAACAGGGAAC T CAGAATACAGACAA 
AT AT T T C CAT AT GGC AAT AGG T G T GAAC AG GGAAC T C AGAAT AC AG AC AA 
AT AT T T C CATAT GG CAATAG G T G T GAACAGGGAAC T CAGAATACAGACAA 
AT AT T T CCATAT GGCAATAGG T GT GAACAGGGAAC T CAGAATACAGACAA 
ATATTTCCATATGG C AAT AG G T G T GAAC AG G GAAC T C AG AAT AC AG AC AA
1481 1530
GTAGAAAGATTCTCGCTTAAAAAAA-TGTATTTATTTTATGGCAAGTTGG 
GTAGAAAGATTCTCGCTTAAAAAAA-TGTATTTATTTTATGGCAAGTTGG 
G T AGAAAG AT T C T C GC T T AAAAAAAAT GT AT T T AT T T T AT GG C AAG T T GG 
GTAGAAAGATTCTCGCTTAAAAAAA-TGTATTTATTTTATGGCAAGTTGG 
GTAGAAAGATTCTCGCTTAAAAAAAATGTATTTATTTTATGGCAAGTTGG 
GTAGAAAGATTCTCGCTTAAAAAAA-TGTATTTATTTTATGGCAAGTTGG 
GTAGAAAGATTCTCGCTTAAAAAAA-TGTATTTATTTTATGGCAAGTTGG 
GTAGAAAGATTCTCGCTTAAAAAAA TGTATTTATTTTATGGCAAGTTGG 
1531 1580
AAAAT AT GT AAC T GGAAT CT CAAAAGT T CT T T GGGACAAAAC AGAAGT CC 
AAAAT AT GTAAC T GGAAT CTC AAAAGT T C T T T GGGACAAAAC AGAAGT CC 
AAAAT AT GT AAC T GGAAT CTCAAAAGT T CT T T GGGACAAAAC AGAAGT CC 
AAAAT ATGTAACTGGAATCTCAAAAGTTCTTTGGGACAAAACAGAAGTCC 
AAAAT AT GTAAC T GGAAT C T CAAAAGT T CT T T GGGACAAAAC AGAAGT CC 
AAAAT AT GTAAC T GGAAT CT CAAAAGT TC T T T GGGACAAAAC AGAAGT CC 
AAAAT AT GTAAC T GGAAT CT CAAAAGT T C T T T GGGACAAAAC AGAAGT CC 
AAAATATGTAACTGGAATCTCAAAAGTTCTTTGGGACAAAACAGAAGTCC
1581 . 1630 
a t g g a g t t a t c t a a g c t c t t g t a a g t g a g t t a a t t t a a a a a a § a a a a H a
AT G G AGT T AT C T AAG C T C T T G T AAG T GAG T T AAT T T AAAAAA^AAAAH a
a t g g a g t t a t c t a a g c t c t t g t a a g t g a g t t a a t t t a a a a a a | a a a a H ^
a t g g a g t t a t c t a a g c t c t t g t a a g t g a g t t a a t t t a a a a a a B a a a aH a
a t g g a g t t a t c t a a g c t c t t g t a a g t g a g t t a a t t t a a a a a a I a a a a H a
ATGGAGTTATCTAAGCTCTTGTAAGTGAGTTAATTTAAAAAAAAAAAAAA
a t g g a g t t a t c t a a g c t c t t g t a a g t g a g t t a a t t t a a a a a a I a a a a H a
AT G GAG T T AT C TAAGCT C T T GT AAG T G AGT T AAT T TAAAAAAG AAAAT T A 
1631 1680
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA
A ---------------------------------------------------------
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
GGCTGAGAGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTAA 
1681 1730
GGTGGGTGGATCACCTGAGGTCAAGAATTCCAGACCAGG-CTGGCCAGCA 
GGTGGGTGGATCACCTGAGGTCAAGAGTTCCAGACCAGGGCTGGCCAGCA 
GGTGGGTGGATCACCTGAGGTCAAGAGTTCCAGACCAGG-CTGGCCAGCA 
GGTGGGTGGATCACCTGAGGTCAAGAGTTCCAGACCAGG-CTGGCCAGCA 
GGTGGGTGGATCACCTGAGGTCAAGAGTTCCAGACCAGG-CTGGCCAGCA
GGTC GAGGTCAAGAGTTCCAGACCAGG-CTGGCCAGCA
GGTGGGTGGATCACCTGAGGTCAAGAGTTCCAGACCAGG CTGGCCAGCA
303
1731 1780
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_0017 36 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_001736 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_001736 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_001736 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_001736 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
3'UTR EC 
3'UTR PM 
gen 3'UTR 
C5aR mRNA HUMC5AAR 
mRNA C5aR NM_001736 
C5aR mRNA BC008 982 
3'UTR Chimp 
Consensus
(594) Ig g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g B
(595) Ig g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g g t
(596) t g g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g g t
(1671) t g g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g g t
(1698) t g g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g g t
(1626)
(599) t g g t g a a a c c c c g t c t g t a c t a a a a a t a c a a a a a a t t a a c t g g g c a t g g t
(1731) TGGTGAAACCCCGTCTGTACTAAAAATACAAAAAATTAACTGGGCATGGT
1781 1830
(644) AGTGGGTGCCTGTAATCCCAGCTACTTGGGAGG-CTGAGGTGGGAGAATT
(645) AGTGGGTGCCTGTAATCCCAGCTACTTGGGAGGGCTGAGGTGGGAGAATT
(646) iiii■■ i— inrW— MlrtWI liiniiifliii MMiMrnrriTTiifirii
(1721) AGTGGGTGCCTGTAATCCCAGCTACTTGGGAGG-CTGAGGTGGGAGAATT
(1748) AGTGGGTGCCTGTAATCCCAGCTACTTGGGAGG-CTGAGGTGGGAGAATT
(1626)
(649)
(1781) AGTGGGTGCCTGTAATCCCAGCTACTTGGGAGG CTGAGGTGGGAGAATT
1831 1880
(693) GCTCGAACCTTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
(695) GCTCGAACCTTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
(695) GCTCGAAC-TTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
(1770) GCTCGAACCTTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
(1797) GCTCGAAC-TTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
(1626)
(698)
(1831) GCTCGAACCTTGGAGGTGGAGGTTGTGGTGAGCCATGATCGCACCACTGC
1881 1930
(743) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
(745) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
(744) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
(1820) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
(1846) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
(1626)
(748) AC rF C T AG C C T G G G rP GAG C G AGGG AG GCTCTGTCT C AAAAG C AAAGC AAAA
(1881) ACTCTAGCCTGGGTGACCGAGGGAGGCTCTGTCTCAAAAGCAAAGCAAAA
1931 1980
(793) ^
(795) ACAAAAACAAAAACACCTAAAAAACCTGCAGTTTTGTTTGTACTTTGTTT
(794) ACAAAAACAAAAACACCTAAAAAACCTGCAGTTTTGTTTGTACTTTGTTT
(1870) ACAAAAACAAAAACACCTAAAAAACCTGCAGTTTTGTTTGTACTTTGTTT
(1896) B g a a a a a c a a a a a c a c c t a a a a a a c c t g c a g t t t t g t t t g t a c t t t g t t t
(1626)
(798) \AAACAAAAACACCTAAAAAACCTGCAGTTTTGTTTGCACTTTGTTT
(1931) ACAAAAACAAAAACACCTAAAAAACCTGCAGTTTTGTTTGTACTTTGTTT
1981 2030
(843) TTAAATTATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAATTGTA
(845) TTAAATTATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAATTGTA
(844) TTAAATTATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAATTGTA
(1920) TTAAATTATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAATTGTA
(1946) T T AAAT TAT GCTTTCTATTTT GAGAT CAT T G CAAAC T CAACACAAT T G T A
(1626)
(848) TTAAATTATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAATTGTA
(1981) T T AAAT TATGCTTTCTATTTTGAGATCATTGCAAACTCAACACAAT TGT A
304
3'UTR EC (893)
3'UTR PM (895)
gen 3'UTR (894)
C5aR mRNA HUMC5AAR (1970)
mRNA C5aR NM 001736 (1996)
C5aR mRNA BC008 982 (1626)
3'UTR Chimp (898)
Consensus (2031)
3'UTR EC (943)
3'UTR PM (945)
gen 3'UTR (944)
C5aR mRNA HUMC5AAR (2020)
mRNA C5aR NM 001736 (2046)
C5aR mRNA BC008 982 (1626)
3'UTR Chimp (948)
Consensus (2081)
3'UTR EC (993)
3'UTR PM (995)
gen 3'UTR (994)
C5aR mRNA HUMC5AAR (2070)
mRNA C5aR NM 001736 (2096)
C5aR mRNA BC008 982 (1626)
3'UTR Chimp (998)
Consensus (2131)
3'UTR EC (1043)
3'UTR PM (1045)
gen 3'UTR (1044)
C5aR mRNA HUMC5AAR (2120)
mRNA C5aR NM 001736 (2146)
C5aR mRNA BC008982 (1626)
3'UTR Chimp (1048)
Consensus (2181)
3'UTR EC (1093)
3'UTR PM (1095)
gen 3'UTR (1094)
C5aR mRNA HUMC5AAR (2170)
mRNA C5aR NM 001736 (2196)
C5aR mRNA BC008982 (1626)
3'UTR Chimp (1098)
Consensus (2231)
3'UTR EC (1143)
3'UTR PM (1145)
gen 3'UTR (1144)
C5aR mRNA HUMC5AAR (2220)
mRNA C5aR NM 001736 (2246)
C5aR mRNA BC008982 (1626)
3'UTR Chimp (1148)
Consensus (2281)
2031 2080
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT 
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT 
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT 
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT 
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT
AGTAATGATACAGAGGGATCTTGTGTACCCTTCACCCAGCCTCCCCCAAT 
2081 2130
GGCAACATCTTGCAAAACTACAATGTAGTCTCATAACCAGGATATTGACA 
GGCAACATCTTGCAAAACTACAATGTAGACTCATAACCAGGATATTGACA 
GGCAACATCTTGCAAAACTACAATGTAGTCTCATAACCAGGATATTGACA 
GGCAACATCTTGCAAAACTACAATGTAGTCTCATAACCAGGATATTGACA 
GGCAACATCTTGCAAAACTACAATGTAGTCTCATAACCAGGATATTGACA
GGCAACAT C T T G CAAAAC TACAAT GTAG T C T CATAAC CAG GATAT T GACA 
2131 2180
TTGATACAGTGAAGATACAGGACATTCTCATCACCACAGGGATCCCCAGG 
TTGATACAGTGAAGATACAGGACATTCTCATCACCACAGGGATCCCCAGG 
TTGATACAGTGAAGATACAGGACATTCTCATCACCACAGGGATCCCCAGG 
TTGATACAGTGAAGATACAGGACATTCTCATCACCACAGGGATCCCCAGG 
TTGATACAGTGAAGATACAGGACATTCTCATCACCACAGGGATCCCCAGG
T T GATACAG T GAAGATACAG GACAT T C T CAT CAC CACAGG GAT CC C CAGG 
2181 2230
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTC'CCTAACCCCTGG 
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTCCCTAACCCTTGG 
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTCCCTAACCCCTGG 
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTCCCTAACCCCTGG 
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTCCCTAACCCCTGG
ATGCCCACTTCCCTCCACCCCCACACCCCAGCCGTGTCCCTAACCCCTGG 
2231 2280
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT 
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT 
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT 
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT 
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT
CAACCAGGAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATGT 
CAAC CAG GAATCCACTCTCCATTTCTATAATGTTGTCATTTCAAGAATG T 
2281 2330
TATTCAATGGAATCATATAGTATGTAACCTGTTTTGAGCTTAAAAAAAAA 
T AT T C AAT GGAAT CAT AT AG TAT GTAAC C T GT T T T GAGCT T AAAAAAAAA 
TATTCAATGGAATCATATAGTATGTAACCTGTTTTGAGCTTAAAAAAAAA 
TATTCAATGGAATCATATAGTATGTAACCTGTTTTGAGCTTAAAAAAAAA 
TAT T CAAT G GAAT CATATAGTAT GTAAC CT GT T T T GAG CT TAAAAAAAAA
TATTCAATGGAATCATAAAGTATGTAACCTGTTTTGAGCTTAAAAAAAAA
TATTCAATG G AATCATATAG TATG TAACC TG TTTTG AG CTTAAAAAAAAA
305
2331  2371
3'UTR EC (1193) - G T AT AC AT G AC T T T AAT G AGGAAAATAAAAATGAAT AT T G
3'UTR PM (1195) -GTATACATGACTT T AAT GAG G AAAAT T AAAAT G AAT AT T G
gen 3'UTR (1194) 'AT AC AT GACT T T AAT GAGGAAAAT AAAAAT GAAT AT T G
C5aR mRNA HUMC5AAR (2270) AGT AT AC AT G AC T T T AAT GAGGAAAAT AAAAAT GAAT AT T G
mRNA C5aR NM 001736 (2296) - GT ATACATGACT T TAATGAGGAAAATAAAAATGAATATTG
C5aR mRNA BC008 982 (1 69 6^
3'UTR Chimp (1198) -g t a t a c a t g a c t t t a a t g a g g a a a a t a a a a a t g a a t a t t g
Consensus (2331) GT AT ACATGAC T T T AAT GAGGAAAAT AAAAAT GAAT AT T
306
